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The  Royal  College  of  Surgeons  (RCS)  rat  is  a  well  characterised  model  of 
autosomal  recessive  retinitis  pigmentosa  (RP)  due  to  a  defect  in  the  retinal 
pigment  epithelium  (RPE).  It  is  homozygous  for  a  null  mutation  in  the  gene 
encoding Mertk, a receptor tyrosine kinase found in RPE cells, which is required 
for phagocytosis of shed photoreceptor outer segments.  The absence of Mertk 
results  in  accumulation  of outer  segment  debris.  This  subsequently  leads  to 
progressive loss of photoreceptor cells.  Recently, MERTK has been established 
as a human retinal  dystrophy gene.  Retinal dystrophies are the most common 
cause  of  visual  impairment  in  the  Western  World,  for  which  no  effective 
treatment exists.
In order to evaluate the efficacy of virus mediated gene replacement therapy in 
the  RCS  rat,  we  produced  recombinant  adeno-associated  viruses  (AAV)  and 
lentiviruses  containing  murine  Mertk cDNA.  Vectors were  subretinally  injected 
into the right eye of 10 day old RCS rats; the left eye was left untreated as an 
internal  control.  Animals  were  examined  at  various  time  points  by  light  and 
electron  microscopy,  electroretinography,  and  ophthalmoscopy.  A  detailed 
assessment  of the  duration  and  extent  of the  morphological  rescue  and  the 
resulting functional benefits is presented in this thesis.
AAV-2-mediated  gene  therapy  resulted  in  preservation  of  retinal  function  for 
more than 9 weeks, when there is no activity in untreated eyes.  Photoreceptors 
were  still  present  at  this  time  point  and  debris  layer thickness  was  reduced. 
After subretinal delivery of human immunodeficiency virus type 1   (HIV-1) based 
lentiviral  vectors  carrying  a  functional  copy  of  Mertk  to  the  RCS  rat  eye, 
correction  of  the  phagocytic  defect,  slowing  of  photoreceptor  cell  loss  and 
preservation of retinal function was observed for up to 7 months, the latest time 
point evaluated. Whilst this was an improvement of the rescue compared to that 
achieved  with  AAV-2,  lentiviral  vectors  raise  more  safety  concerns  regarding 
clinical application.  Due to these biosafety issues,  gene therapy vectors based 
on  non-human  lentiviruses  and  integration-deficient  vectors  have  been
2developed. As part of this project, the potential of equine infectious anemia virus 
(EIAV) and non-integrating  HIV-1-based vectors for the management of retinal 
degenerative disorders has been evaluated. The results presented in this thesis 
support  the  use  of  viral  vectors  for  the  treatment  of  retinal  dystrophies. 
However, the development of an efficient therapy depends on the identification 
of patients and characterisation of pathological changes. Therefore,  a panel of 
DNA samples from patients with autosomal recessive and sporadic forms of RP 
was  screened for mutations  in  the  MERTK gene.  A  new  homozygous  frame- 
shifting  deletion  was  identified  in  four affected  members  of a family with  RP. 
Clinical examination of these patients showed distinctive clinical signs that may 
improve the chances of identifying further patients and families in the future.
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1  Introduction
Gene technology is one of the key technologies of the 21s t century and  it will 
soon  have an  influence on  virtually all  sectors  of our  lives.  Basic research  in 
biomedical  sciences  has  already  been  revolutionised.  In  particular  the  vast 
potential  of gene therapy is  prized  because  it establishes a promising tool for 
the development of new and effective treatment strategies for numerous,  so far 
incurable  diseases,  such  as  cancer,  different  infectious  diseases,  inherited 
disorders of the nervous system,  or inherited retinal degenerations.  It may be 
possible,  in  near future,  to  use gene therapy to treat various diseases whose 
genetic defects have been identified.  However,  the capacity and efficiency for 
gene  therapy  in  the  treatment  of  ocular  diseases  has  just  recently  been 
explored.
Since we  perceive  approximately  85  %  of information  about  our environment 
with our eyes, the human eye can be regarded as our major sense organ by far. 
Inherited retina degenerations are one of the most common causes of blindness 
in  the western world,  for which  currently  no efficient therapy exists.  The  best 
characterised form of inherited retinal degenerations is retinitis pigmentosa (RP) 
with  prevalence up to  1:3500 [1].  So far many genes responsible for inherited 
eye disorders expressed within the retina have been  identified,  a pre-requisite 
for the development of efficient therapies.  Furthermore, diseases of the eye are 
prime  candidates  for  gene  therapy  approaches  because  the  eye  has  the 
advantage  of  being  highly  accessible  with  altered  immunological  properties, 
important considerations for easy delivery of virus  and  avoidance of systemic
13immune responses (for more details on  immunological  properties and the eye 
as a target for gene therapy see chapters 1.3.4.1  and 1.3.4.2).
1.1  The eye
1.1.1  Eye development
The  eyes  of all  vertebrates  develop  in  a  pattern  which  produces  an  inverted 
retina, in which the photoreceptor cells are orientated in a way that their sensory 
ends,  the  outer  segments,  are  directed  away  from  incident  light.  The 
differentiation  of  the  retina  during  development  reflects  the  close  interaction 
between  two  cell  types:  the  photoreceptor  cells  and  the  retinal  pigment 
epithelium (RPE) cells.  Both cell types are alternately dependent on each other 
during  different  developmental  stages,  for  example,  they  provide  each  other 
with different survival, growth and differentiation factors. This close interaction is 
not only seen during development but also in the adult eye.  Retinal physiology 
and morphology depends on the close interaction and communication of these 
two  cell  types  and  involves  complex,  cellular  signaling  pathways,  the  most 
important of which will be discussed in more details in the following chapters.
Embryonically, the vertebrate eye develops from an outgrowth of the developing 
brain,  the  optic  vesicle,  which  invaginates  into  the  optic  cup  (see  [2]  for  a 
review).  It  is  derived  from  three  types  of  embryonic  tissue:  the  neural  tube 
(neuroectoderm), from which arise the neuroretina and the RPE; the mesoderm, 
which produces the corneoscleral and uveal tunics;  and the surface ectoderm, 
from which the lens is derived.  In the optic cup the RPE gets thinner, while the 
neural retina thickens into a multicellular epithelium due to its high proliferation 
rate.  The rim  regions develop at a slow proliferation  rate into the iris and the 
ciliary epithelium of the ciliary body.  Furthermore,  it has been known since the 
beginning of this century,  that tissues surrounding the optic vesicle are crucial
14for the eye development. Whilst the developing RPE lies next to the extraocular 
mesenchyme, the neural retina forms from the distal portion of the optic vesicle. 
During  development  there  is  an  active  signalling  between  the  ectoderm 
adjacent to the  distal  part of the  eye that promotes the  neural  retina fate  [3]. 
Members of the fibroblast growth factor (FGF) family [8, 9] and activation of the 
mitogen-activated  protein  (MAP)  kinase  signalling  pathway  [10]  have  been 
shown to be involved in this signal cascade.  Retinal cell types are generated in 
un-equivalent  manner  in  all  vertebrates.  Cone,  ganglion,  amacrine  and 
horizontal  cells  arise  before  bipolar,  rod  and  Muller  cells  [11].  The  ciliary 
epithelium and the iris derive from the rim region of the optic cup [12].  Recently 
it has also been suggested that the  RPE and other cell types within the retina 
might be a source of retinal regeneration.
1.1.2  Anatomy and physiology of the mammalian eye
The  vertebrate  eye  is  designed  to focus  light  onto  specialised  receptors  that 
respond  to  light  and  therefore  provides  the  ability  to  interact  with  the 
environment.  A  schematic  overview  of  the  human  eye  as  an  example  for 
mammalian eye anatomy is shown in figure 1.1.
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Figure  1.1:  Anatomy of the  human eye.  A schematically cross-sectional view of a  human 
eye (left of figure) shows that it is composed of three different layers: the outer layer consists of 
the sclera, and the cornea (white); the middle, vascular layer called uvea (blue), which itself is 
divided into the choroid, the ciliary body and the iris; and the inner neuronal layer (red) including 
the  retina.  The cellular organisation  of the  retina is projected to the  right showing  inter-retinal 
connections  of  different  cell  types  involved  in  the  first  steps  of  light  perception. 
(http://webvision.med.utah.edu)
The retina is the innermost layer of the eye. The retina can be divided into two 
areas,  the neuroretina,  which includes the photoreceptor cells as well  as other 
retinal  neurons and the RPE.  The neuroretina  itself is composed of ten  layers, 
which are shown in figure 1.2 (A).
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Figure 1.2: Structure of the retina. The light micrographs above show a semithin section of a 
mouse retina.  (A) Outside the  retina  lies the vascular choroid  (= C), which connects the outer 
retina with the vascular system. (B) The picture on the right was taken at higher magnification to 
give  a  closer view  of cell types,  namely  photoreceptor and  RPE  cells,  involved  in  the  initial 
processes of vision such as the visual cascade.
Retinal layers:
Retinal pigment epithelium (RPE), a pigmented monolayer,  basally attached to the 
Bruch’s membrane and appically surrounding photoreceptor outer segments 
Layer of photoreceptor outer segments (OS)
Layer of photoreceptor inner segments (IS)
-  Outer  limiting  membrane  (OLM)  which  gives  structural  support  to  photoreceptor 
cells as well as it forms a barrier
Outer nuclear layer (ONL) consisting of nuclei and cell bodies of photoreceptors 
Outer  plexiform  layer  (OPL)  which  contains  the  synaptic  connections  between 
photoreceptor cells and nerve cells
Inner nuclear layer (INL) which is composed of the nuclei of nerve and support cells 
Inner plexiform layer (IPL) which is build up of synapses of nerve cells 
Ganglion cell layer (GC) consisting of ganglion cells
Nerve fibre  layer (NF) which  is  composed  of the  axons  of the  ganglion  cells  and 
astrocytes
Internal limiting membrane (ILM) which forms the border between the retina and the 
vitreous.
171.1.3  The neuroretina
The differing sensory demands of using light to detect environmental space and 
time appear to have provided the selection pressure for the evolution of different 
photoreceptor  systems  in  the  vertebrates.  Photoreceptor  cells  exist  as  two 
different types,  the rods and the cones,  which  share the  same  basic structure 
(figure 1.3) and are one of the most highly metabolic cell types in the body. All 
photoreceptor  cells  have  light-sensitive  pigments  in  their  membranes,  which 
after the absorption of a photon change their structure and thereby initialise the 
phototransduction cascade (see chapter 1.1.4).
Figure  1.3:
Structure  of
photoreceptors.
Although  generally 
similar in structure, 
rods  and  cones 
differ  in  their  size 
and shape, as well 
as  in  the 
arrangement of the 
membranous discs 
in  their  outer 
segments.
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18The light sensitive structures of the photoreceptors are the outer segments, that 
lie  in  the  inter-photoreceptor matrix  (IPM)  between  the  apical  microvilli  of the 
RPE  cells.  Rod  outer segments  contain  a  dense  network of membranes,  the 
discs,  which  are  formed  constantly  and  act  to  enlarge  the  sensory  surface. 
Incorporated  into the disc membrane  is  the  light  sensitive  pigment  rhodopsin. 
The cilium connects the outer segment with the inner segment which contains a 
large  number  of  mitochondria.  The  synapses  hold  vesicles,  which  distribute 
neurotransmitters  after  light  excitement  of the  photopigment,  thereby  passing 
the  signal  on  to  associated  nerve  cells.  The  rod  system  has  a  low  spatial 
resolution  but  is  extremely  sensitive  to  light;  it  is  therefore  specialised  for 
sensitivity at the expense of resolution.  In contrast, the cone system has a high 
spatial  resolution  but is  relatively insensitive to  light;  it is therefore specialised 
for acuity at the  expense  of sensitivity.  In  cones,  discs  are  infolds  of the  cell 
membrane and do not form free discs as they do in rods.  Cones contain cone 
opsins  as their visual  pigments  and,  depending  on  the  exact  structure  of the 
opsin molecule,  are maximally sensitive to either long wavelengths of light (L- 
cones,  red  light),  medium  wavelengths of light  (M-cones,  green  light)  or short 
wavelengths of light (S-cones, blue light). In the human retina, the distribution of 
spectrally  different  cones  varies.  Most  mammalian  species  are  dichromatic 
containing as well as rods only middle and short wavelength sensitive cones in 
their retinae (for reviews see [19, 20]).
In  order  to  maintain  photoreceptor  structure  and  physiology,  a  number  of 
different supporting cells are present in the neuroretina including astrocytes and 
Muller’s  cells.  Muller’s  cells  are  large  cells  that  are  linked  to  each  other  by 
adherent junctions. From them arises a layer consisting of junctional complexes 
between photoreceptor and supporter cells, which is known as the outer limiting 
membrane.  This  barrier  is  essential  for  the  intra-neuroretina  homeostasis. 
Astrocytes  are  known  to  provide  structural  and  physiological  support to  nerve 
cells  throughout  the  nervous  system  [21].  Furthermore,  there  are  several 
classes of neuronal  cells  in the  retina which  are responsible to modulate  and 
forward the signal received from photoreceptor cells.
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cells,  which  themselves  pass  the  signal  on  to  ganglion  cells.  Ganglion  cells 
send  their  axons from  the  eye to  the  brain  via  the  optic  nerve.  Whereas  the 
above  mentioned  neuronal  cells  are  directly  involved  in  the  visual  signaling 
pathway,  horizontal  cells,  amacrine  cells  and  interplexiform  cells  on the  other 
hand modulate the passage of impulses on their way from the photoreceptors to 
the ganglion cells.
The mammalian retina is divided into specialised areas. The axons of the optic 
nerve  exit  from  the  retina  in  an  area  called  the  optic  disc  where  no 
photoreceptor cells are present and therefore a blind spot in the visual field  is 
produced.  Furthermore,  the central  artery and vein  supplying the  inner retina 
exit the  retina at the optic disc.  In  humans  and  primates,  laterally of the optic 
disc is the macula, which is rich in cones (figure 1.4). The centre of this region -  
the fovea centralis -  consists only of cones.  Rods are absent in the fovea but 
dense elsewhere. In the human retina, there are approximately 120 million rods 
and 6 to 7 million cones.
Figure 1.4: Distribution of rods and cones in the human retina. In the human retina, cones 
are concentrated in the macula whereas only few are found outside this region. The fovea is the 
central  area  of  the  macula  and  consists  only  of  cones.  Rod  concentration  peaks  in  a 
submacular ring approximately 20° around the fovea and decreases fast towards the fovea and 
slowly  towards  the  periphery.  Rods  are  absent  in  the  fovea  itself  (http://hyperphysics.phy- 
astr.gsu.edu/hbase/vision/rodcone.html).
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201.1.4  Visual cycle and cascade
Vision  is  a  process  triggered  by  the  absorption  of  photons  by  photosensitive 
pigments  integrated  into the membranous  photoreceptor outer segment discs. 
The  absorption  of  a  photon  results  in  a  conformation  change  of  the 
photopigment. This conformation change initiates a complex intra-photoreceptor 
signaling  pathway,  the  phototransduction  cascade,  which  is  finally  converted 
and  amplified  into  an  electrical  response that  is  passed  on  to  retinal  neurons 
which sent their axons to the brain via the optic nerve.
Unstimulated photoreceptor cells have open cation channels that allow sodium 
and  calcium to  enter and  potassium  ions to exit the cell.  The  steady  influx of 
sodium ions maintains an electrical membrane potential of  -40 mV on the inner 
cell membrane.  At this membrane potential the photoreceptor cell is continually 
releasing neurotransmitters to bipolar cells.  Light stimulates the photoreceptors 
to  trigger  a  sequence  of  biochemical  events  that  change  this  membrane 
potential  and  results  in  a  hyperpolarisation  of  the  receptor.  Changing  the 
membrane potential reduces the amount of transmitters, that is set free into the 
postsynaptic space causing the photoreceptor cell to initiate a neural message 
that is sent to the brain via other neuronal cells of the retina. By this means, the 
photopigments  in  rod  and  cone  outer segments  transduce  light  into  electrical 
signals in the visual cascade.
Even though generally similar in structure and physiology, rods and cones differ 
in their photopigments and enzymes involved in the phototransduction cascade. 
It  has  been  shown  that  cones  express  counterparts  of  many  of  the 
phototransduction enzymes found in rods [36].  It has also been suggested that 
cones  may  have  an  alternative  system  for generation  of their  photopigments 
during the visual cycle [37]. Since rod function is better characterised than cone 
function,  the  following  description  of  the  phototransduction  cascade  and  the 
visual cycle will focus on the physiology of rods.
The light absorbing photopigment of rod photoreceptors,  rhodopsin,  consists of 
the vitamin A-derived chromophore  11-c/s retinal,  and the protein opsin,  which
21is  inserted  into  the  plasma  membranes  of  the  rod  outer  segments.  The 
phototransduction cascade is initiated when a photon strikes the  11 -c/s retinal. 
This causes the isomerisation of 11-c/s retinal to all-trans retinal, which leads to 
a  configuration  change  of  the  photopigment  to  metarhodopsin  II  [23,  24]. 
Metarhodopsin  II  is  the  binding  site  for  regulator  proteins  such  as  rhodopsin 
kinase,  arrestin  and  transducin  [25].  Each  light-excited  photopigment  binds 
several molecules of transducin which results in a 102 to 103 amplification of the 
visual cascade (see figure 1.5 for an overview of the visual cycle). Transducin is 
a  member of the guanosine-5'-triphosphate  (GTP)  binding  protein  (G  protein) 
family  that  connect  receptors  with  their  second  messenger  pathway.  On 
interaction  with  excited  photopigment,  transducin  molecules  exchange  bound 
GDP for GTP, forming an active transducin-GTP complex.  The transducin-GTP 
complex on one hand passes a greatly amplified signal on to another protein, 
cGMP phosphodiesterase (PDE).
During  light,  active  PDE  hydrolyses  cGMP  to  5’-GMP  and  this  results  in  the 
closing  of  cGMP-gated  calcium  channels.  These  channels  are  composed  of 
transmembrane  guanylate cyclase proteins  (retGC).  Their activity  is  regulated 
by  calcium  sensitive  guanylyl  cyclase  activator  proteins  (GCAPs)  [26].  The 
closing  of cGMP-gated  calcium  channels  on  one  hand  interrupts  the  flow  of 
cations  into  the  cell  (reviewed  in  [27])  and  on  the  other  hand  causes  a 
hyperpolarisation  of  the  surface  membrane  along  the  entire  cell.  The 
interruption  of the  ion  flow through  the  membrane  decreases  the  intracellular 
calcium  concentration.  At  low  calcium  levels  GCAPs  bind  to  the  intracellular 
domain of retGC and thereby stimulating the resynthesis of cGMP which is used 
to keep cationic channels open.
During  dim  light and  in  the  dark,  metarhodopsin  II  is  phosphorylated  at its  C- 
terminus by protein kinase C,  which decreases the affinity of metarhodopsin  II 
to transducin while it increases the affinity to another protein,  arrestin. Arrestin 
prevents  further  interactions  between  metarhodopsin  II  and  transducin 
completely.  The  inactivated  photopigment exchanges all-trans retinal to  11 -cis 
retinal  and  releases  arrestin.  All-frans  retinal  enters  the  visual  cycle  to  be 
resynthesised  to  its  photosensitive  isoform,  11 -cis  retinal.  The  synthesis  and
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sensitivity  of  the  visual  system.  The  visual  cycle  takes  place  within 
photoreceptor  and  RPE  cells  and  the  recovered  rhodopsin  starts  the  visual 
cascade again after light stimulation (see [28, 29] for reviews).
The  supply  of  retinoids  to  the  photoreceptors  is  one  of the  crucial  steps  for 
retinal physiology.  Retinoids are supplied as vitamin A (all-trans retinol),  which 
is taken up from food  in the small  intestine by cellular retinol-binding protein 2 
(CRBP2)  and  delivered by serum  retinol-binding  protein  (SRBP,  RBP4)  to the 
target cells via a specific surface receptor. All-frans retinol is then bound to the 
intracellular  transporter  protein  CRBP1.  In  the  RPE  cell,  all-frans  retinol  is 
esterifyed to form retinyl ester by lecithin-retinol acyltransferase (LRAT). The all- 
trans retinyl  ester is converted to  11-c/s retinyl  ester by the  isomerohydrolase 
RPE65 [30, 31].  In this form vitamin A is stored within the RPE cells.  In further 
steps the 11-c/s retinyl ester is converted into 11-c/'s retinal which is oxidised by 
11-c/s retinal dehydrogenase (RDH) to its aldehyde.  In RPE cells,  11-c/s retinal 
is carried by cellular retinaldehyde-binding protein (CRALBP).  In order to cross 
the  subretinal  space,  11-c/'s  retinal  is  bound  to  interphotoreceptor  retinoid- 
binding protein (IRBP) and transported to photoreceptors.  There it is bound to 
the photopigment apoprotein  in the membrane of rod outer segments where  it 
forms part of the visual pigment.  Photons lead to isomerisation of 11 -c/'s retinal 
to  a\\-trans  retinal  that  changes  the  inactive  form  of  rhodopsin  to  the  active 
metarhodopsin  II  form.  For  recovery  of  the  chromophore,  all-trans  retinal  is 
released from metarhodopsin  II to all-trans RDH which catalyses the reduction 
of  all-trans  retinal  to  all-trans  retinol  using  NADPH  as  a  cofactor.  All-frans 
retinol is bound to the ATP-binding cassette transporter ABCA4 and transported 
through  the  cell  membrane  to  the  interphotoreceptor  matrix  [32].  There  it  is 
picked  up  by  IRBP,  which  shuttles  the  chromophore  to  the  RPE  cells.  In  the 
dark it undergoes  isomerisation within the  RPE  cell  to form  11-c/'s retinol  [33, 
34].
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Figure  1.5:  Visual  cycle.  The  capture  of  a  photon  causes  the  isomerisation  of  the 
chromophore  11-c/s-retinal  to  all-frans-retinal  (reaction  a)  of  the  photosensitive  pigment 
rhodopsin in rod outer segment (ROS). All-frans-retinal is hydrolysed and reduced to all-trans- 
retinol (reaction b) by all-frans-retinal specific dehydrogenases (RDH). The all-frans-retinol then 
diffuses to the RPE where it is esterified to all-frans-retinyl esters (reaction c) by LRAT. These 
esters  can  be  hydrolysed  to  11-c/s-retinol  (reaction  d).  11-c/s-retinol  is  isomerised  to  11-c/s- 
retinal  in  a  reaction  (reaction  e)  that  is  catalysed  by  an  isomerohydrolase,  the  RPE-specific 
RPE65  protein.  11-c/s-retinal  diffuses  across the  subretinal space to  be  incorporated  in  ROS 
membranes  (reaction  0-  In  the  dark,  under conditions  of  low  11-c/s-retinal  utilization,  11-c/s- 
retinol  can  also  be  esterified  to  11-c/s-retinyl  esters  by  LRAT  (reaction  g).  With  insufficient 
chromophore levels the hydrolysis of 11-c/s-retinyl esters occurs (reaction h) (picture taken from 
Kim et al [35]).
1.1.5  Retinal pigment epithelium
The  physiological  events  in  the  eye  depend  on  the  cooperation  of  the 
neuroretina  and  the  RPE.  The  importance  of  this  interaction  is  reflected  in 
different  retinal  disorders.  For example,  mutations  in  the  RPE-specific  protein 
RPE65  cause  an  early  onset  type  of retinal  degeneration,  known  as  Leber’s 
congenital  amaurosis  (LCA),  and  vice  versa,  gene  defects  in  photoreceptor- 
specific  genes,  such  as  the  peripherin/rds  gene  that  is  associated  with  RP,
24have been suggested to result in  RPE atrophy [38] (see chapter 1.2 for retinal 
disorders). The RPE fulfils a number of different tasks crucial for vision of which 
the  most  important are  summarised  in  the following  section  (for a  review see 
[39]).
The  RPE  is localised between the neuroretina  and the choroid.  RPE  cells are 
polygonal,  melanin-containing  cells,  which  form  a  single  cell  polarised 
epithelium attached to the  Bruch’s  membrane,  which  separates the  RPE from 
the choriocapillaris. Their apical membrane pointing at the photoreceptor cells is 
folded into microvilli, which surround the photoreceptors outer segment tips, and 
its basal infoldings face towards the choroid (see [40] for a review).  Physically, 
the  RPE  provides structural  support  by attaching the  neuronal  retina and  it  is 
involved  in the  interphotoreceptor matrix (IPM)  production that fills the  narrow 
subretinal space between the RPE and the photoreceptors. The  IPM  mediates 
adhesion  between  the  RPE  and  photoreceptors,  RPE  phagocytosis  and 
nutrients  exchange  (reviewed  in  [41]).  It  also  contains  factors  important  for 
vision,  such  as  IRBP,  FGF-2  and  matrix  metalloproteases  (for  example  the 
tissue  inhibitor  of  metalloproteinase  3,  TIMP3)  [42,  43].  During  embryonic 
development the  RPE  also  provides  trophic factors  necessary for the  correct 
morphogenesis of the retina (see section 1.1.1). Furthermore, the RPE is known 
to produce a variety of growth factors necessary for photoreceptor survival and 
factors for the maintenance of structural integrity of the retina,  such as TIMP3. 
Growth factors secreted by the RPE include ciliary neurotrophic factor (CNTF), 
FGF-2,  members  of the  interleukin family (IL)  and  pigment epithelium  derived 
factor  (PEDF)  [43-47].  The  characteristics  of  some  neurotrophic  factors  are 
discussed in section 1.3.2 in more detail.  The RPE also acts as a blood-retina 
barrier  for  choroidal  blood  circulation,  which  is  necessary  to  regulate  the 
environment  and  homeostasis  of  the  neurosensory  retina.  The  blood-retina 
barrier is maintained by tight junctions which exist between the endothelial cells 
of  the  retinal  vessels  and  similar  tight  junctions  in  the  RPE  (see  [48]  for  a 
review).
The  RPE  increases  the  optical  quality  and  maintains  high  visual  acuity  by 
forming a pigmented  barrier that absorbs scattered  light.  Light is focused onto
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environment  [49].  This  combination  is  ideal  for  photo-oxidation  and  oxidative 
damage,  consequently.  The amount of reactive oxygen  is further increased  by 
disc  shedding  and  phagocytosis  (see  chapter  1.1.6)  [50].  The  RPE  has 
essential defence mechanisms against this damage and toxic substances.  RPE 
cells  contain  various  pigments -  the  main  one of these  is  melanin -  that  are 
specialised  to  absorb  light  of  different  wavelengths  and  supplement  light 
absorption  of photoreceptors  (reviewed  in  [51]).  Melanin  is  a  heterogeneous 
polymer and  serves a  photoprotective role by absorbing  radiation,  scavenging 
free  radicals  and  reactive  oxygen  molecules,  which  arise  during  light 
excitement.  In aged cells, however,  melanin is known to be phototoxic because 
it interacts with oxygen and thereby leads to increased reactive oxygen amount 
within  the  cells.  It  has  been  shown  that  in  aging  RPE  cells,  melanin  forms 
aggregates,  which  increase  the  production  of  radicals.  Consequently,  a 
chemical toxic cellular environment is created which results in RPE cell death, a 
major role in the pathenogenesis of age-related  macular degeneration (AMD), 
the  leading  cause  of  blindness  in  the  population  over  60  years  of  age  [51]. 
Photoreceptors  contain  carotinoids  as  the  most  important  pigments,  which 
mainly absorb blue  light [52].  Blue  light is in particular dangerous for the RPE 
because  it  leads  to  the  oxidation  of  lipofuscin  to  cytotoxic  substances. 
Lipofuscin  is another RPE  pigment that  is  beneficial for visual function  at first 
but  it  accumulates  during  life  and  in  older  eyes  it can  reach  toxic  levels  and 
results  in  a  reduction  in  the ability of the  RPE  to  absorb  light [53].  This  is an 
important factor in the development of AMD.
The  RPE  transports  nutrients  and  ions  between  the  photoreceptors  and  the 
choroid.  Each RPE cell is firmly attached to surrounding RPE cells by adherent 
junctions.  These junctions  limit  any transport across this  cell  layer [54].  Since 
there is no direct blood  supply,  the  RPE  is responsible for regulation  of traffic 
between  the  choroid  and the photoreceptors.  Thus,  the  RPE  cell  actively and 
passively has to manage the bidirectional flow of fluids, molecules and ions into 
and  out  of  the  photoreceptor  layer  of  the  retina.  This  includes  supplying 
nutrients to maintain the high metabolic rate of the photoreceptors, the removal 
of  waste  material,  and  maintaining  ionic  gradients  essential  for
26phototransduction.  The  RPE  cells,  which  surround  the  outer  segments  with 
their  apical  microvilli,  supports  photoreceptor  function  by  the  removal  of 
metabolic end products, such as lactic acid [55]. Photoreceptor cells are among 
the most highly metabolic cells.  Extensive protein and lipid synthesis ensures a 
continuous turnover of new outer segment membranes at the junction with the 
inner segment.  The tips of the outer segments contain the oldest discs,  which 
are  phagocytosed  as  small  packets  of  about  200  discs  by  the  RPE  cell,  a 
process that occurs in a diurnal manner.  Photoreceptors shed approximately 10 
% of the length of their outer segments daily (reviewed  in [40,  56]). The waste 
material  is  cleared  by  RPE  cells  making  them  one  of  the  most  efficient 
phagocytes  in  the  body  (the  process  of phagocytosis  is  described  in  detail  in 
sections  1.1.6  and  1.1.7).  TIMP3  is  a  regulatory  protein  controlling  tissue 
degradation  in  the  eye  by  inhibiting  proteases,  that  breakdown  proteins  from 
ingested  outer  segments  in  the  RPE.  TIMP3  is  also  a  potent  angiogenesis 
inhibitor  that  has  been  shown  to  inhibit  vascular  endothelial  growth  factor 
(VEGF)-mediated  angiogenesis.  Mutations  in  TIMP3  cause  Sorsby  fundus 
dystrophy,  a  macular  degenerative  disease  with  submacular  choroidal 
neovascularisation [57] (see section 1.2.4).
The  RPE  also  stabilises  the  ion  composition  in  the  subretinal  space which  is 
necessary to maintain high excitability of photoreceptors.  RPE cells are apical 
to  basolateral  polarised  cells  which  are  connected  to  each  other  via  tight 
junctions.  The  tight  junctions  between  RPE  cells  make  the  RPE  layer  a 
polarised  barrier  between  the  subretinal  space  and  the  choroid.  This  polarity 
makes transepithelial transport of molecules through RPE cells necessary. The 
polarity is also reflected in RPE cell morphology, in the distribution of organelles 
and  membrane  proteins  [40].  The  Na+-K+-ATPase  is  located  on  the  apical 
surface  and  provides  energy  for  the  transepithelial  transport  [59].  The  high 
metabolic activity of retinal neurons and photoreceptors results in the production 
of large amounts of water that needs constant removal.  In the inner retina, this 
is  accomplished  by  Muller  cells  and  the  RPE  eliminates  water  from  the 
subretinal space [58]. The water transport is mainly driven by a transport of Cl" 
and K* ions and results in an apical  positive membrane potential.  The Na+-K+- 
ATPase,  furthermore,  establishes  a  Na+   gradient that facilitates the  uptake  of
27HCO3'  via  a  Na+-  HC03'  cotransporter  and  K*  and  Cl"  via  the  Na+-K+-2CI' 
cotransporter,  which  in turn  regulates of intracellular Cl‘ concentration.  This  is 
important  for  the  regulation  of  intracellular  pH  (reviewed  in  [60]).  In  order to 
increase  the  intracellular  Cl'  concentration  the  Cl'/  HCO3'  exchanger  on  the 
basolateral  membrane  extrudes  HCO3'.  K*  is transported from the  IPM  to the 
RPE via  Na+-K*-ATPase and  Na*-K*-2CI' cotransporter and can  leave the cell 
via  K +   channels.  In  the  dark,  there  is  a  higher  transport  rate  of  K+   at  the 
basolateral membrane that is leading to the IC flow from the subretinal space to 
the choroid [61 ].
The  transepithelial  transport  is  important  to  maintain  the  homeostasis  in  the 
subretinal  space.  The  RPE  is  also  able  to  compensate  for  fast  occurring 
changes  in  the  ion  composition  that  takes  place  during  light  activation  of 
photoreceptor cells.  Therefore,  the electrical  activity of the  retina  depends  on 
the  RPE.  In the dark,  there  is a  constant influx of Na+   via open  cGMP  gated 
cation channels in the outer segments  and efflux of K* via  K* channels in the 
inner segment [24]. During light activation the efflux of K* is reduced resulting in 
a decrease of subretinal  K" concentration. This change is compensated by the 
RPE.  The low K* subretinal concentration leads to the hyperpolarisation of the 
apical membrane of the RPE [62]. This causes the activation of inward rectifier 
K*  channels  resulting  in  change  of  the  transport  ratio  between  apical  and 
basolateral  membrane.  The  increased  K* transportation  on the apical  surface 
results  in  an  increased  K*  amount  secreted  from  the  RPE  to  the  subretinal 
space [63]. The decrease in subretinal  K+  also decreases the uptake of Cl' via 
the  Na+-K+-2CI'  cotransporter  in  the  late  stage  of  the  apical  membrane 
hyperpolarisation.  Consequently,  the  intracellular  Cl'  concentration  decreases 
and  this  causes  a  change  in  the  Cl'  transport  through  the  basolateral 
membrane,  which  normally  is  high.  The  result  is  a  hyperpolarisation  of  the 
basolateral  membrane  that  further  reduces  the  extruding  rate  of  Cl'  to  the 
choroid [64]. This mechanism can be monitored by the electroretinogram (ERG) 
as the c-wave (see chapter 3.6 for more details on ERG). Light activation closes 
cationic channels  in  the  photoreceptor outer segments  and  thereby increases 
the subretinal Na+  amount, which is compensated by the Na+ /H+  exchanger and 
the  Na+-K+-2CI'  cotransporter  in  the  apical  membrane  of  the  RPE.
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opening  of cationic channels  in the dark.  This  is  compensated  by the  Na+-K+- 
ATPase in the inner segments and the RPE [65].
The  RPE  also  transports  glucose  and  other  nutrients  from  the  blood  to  the 
photoreceptors  [55].  Glucose transporters,  GLUT1  and  GLUT3,  are  localised 
on  the  apical  as  well  as  the  basolateral  membrane  [66].  Another  important 
function  of  the  RPE  is  the  uptake  of  all-trans  retinal  (vitamin  A)  from  the 
bloodstream. The continuous process of light activation and the consumption of 
11 -cis  retinal  during  the  visual  cycle  (see  section  1.1.4)  requires  constant 
regeneration of 11-c/s retinal from all-trans retinal. The regeneration takes place 
in  the  RPE,  where  all  the  necessary  enzymes  to  catalyse  this  reactions  are 
located.  Furthermore, the RPE is the major storage place for vitamin A [67].
291.1.6  Disc shedding and phagocytosis
Because of their close interaction with photoreceptors,  RPE cells play a critical 
role  in vision.  One of the RPE’s  most important tasks  is the phagocytosis and 
the recycling of used rod and cone outer segment membranes [68].  Disruption 
of this phagocytic function may result in clinical disorders leading to blindness, 
which  is  the  case  in  RCS  rats  and  autosomal  recessive  RP  patients  both  of 
whom  carry  mutations  in  the  MERTK gene,  a  key  regulator  protein  of  RPE 
phagocytosis [69].
The  high  level  of  activity  within  rod  and  cone  outer  segments  requires  a 
continual  renewal  of  their  photoreceptive  membranes  [70,  71].  The  renewal 
process occurs in a light-dependent manner at an impressive pace because the 
rate  of  disposal  must  equal  the  rate  of  disc  synthesis  since  outer  segments 
maintain a relatively uniform length throughout life [71]. A normal rod cell sheds 
around 10 % of its oldest outer segment discs daily at its distal ending and the 
outer segment lengthens from the cilium. This process effectively maintains the 
high  sensitivity  of  photoreceptors.  The  renewal  process  can  be  divided  into 
several  main  steps  and  involves  the  synthesis  of  new  membranes  to  form 
photopigment containing discs by the inner segment. These newly formed discs 
displace older discs outwards, towards the tip of the outer segment. The oldest 
discs are disposed  by detachment at the tip,  a process termed disc shedding, 
and are phagocytised by the adjacent RPE cells. The initial step in phagocytosis 
is the recognition of shed outer segments and the binding to the  RPE’s apical 
microvilli,  which  surround  the  outer  segment tips  (figure  1.6).  In  the following 
step, the plasma membrane of the RPE cell invaginates the waste material into 
the  extensive  RPE  phagolysosomal  system.  Finally,  the  waste  material  is 
transported to the choriocapillaries.
30Figure  1.6:  Schematic
diagram of phagocytosis. The
apical  microvilli  of  RPE  cells 
surround  rod  outer  segment 
tips,  which  are  phagocytosed 
by the  pigment epithelium  in  a 
diurnal cycle. There is a burst of 
disc shedding  at  light  onset  in 
the  morning,  judged  by 
increased  numbers  of
phagosomes  in  the  pigment 
epithelium  shortly  thereafter. 
After recognition the  RPE  cells 
internalise  shed  discs  into 
phagosomes  which  are
transported  through  the
cytoplasm  and  degraded. 
IS=inner  segment,  OS=outer 
segment,  MV=microvilli,
Ph=phagosome, N=nucleus.
*
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Disc  shedding  is  a  lighting  cycle  dependent  process  that  follows  a  circadian 
rhythm [71,  72). A burst of rod disc shedding occurs soon after onset of light in 
the  morning.  Apical  processes  of  the  pigment  epithelium  also  phagocytise 
chunks  of  cone  outer  segments  but  at  a  different  time  in  the  diurnal  cycle 
compared with rods at light off-set rather than light-onset [73, 74], The picture of 
RPE phagocytosis is not complete yet. There are still many open questions and 
the  distinct  role  of  many  factors  involved  is  theoretical  and  needs  still  to  be 
elucidated.
311.1.7  Phagocytosis and MERTK function
Phagocytosis is the process in which relatively large particles are ingested into 
vacuoles  by  specific  cells  called  phagocytes.  It  is  of  importance  in  tissue 
remodeling, wound healing,  inflammation and host defence against pathogens. 
One of the key features of programmed cell death or apoptosis is the exposure 
of phosphatidylserine (PS) molecules on the cell surface [75,  76].  Normally PS 
residues  are  localised  in  the  inner  membrane  leaflet  but  are  exposed  on  the 
exterior of dying cells.  It is known that clearance and phagocytosis of apoptotic 
cells  by  different  phagocytes  always  involves  the  recognition  and  binding  to 
these  PS  molecules.  In  the  eye,  the  RPE  cells  specifically  and  selectively 
remove  the  daily  shed  outer  segments  of  the  photoreceptors  in  a  diurnal 
manner. The membrane of the outer segments tips is PS rich and this is thought 
to  be  one  of  the  main  triggers  for  RPE  phagocytosis.  RPE  phagocytosis  is 
poorly  understood  compared  with  the  well-characterized  phagocytosis  by 
monocytes  and  macrophages.  The  main  difference  between  RPE  and 
phagocytosis elsewhere is that the former follows a circadian  rhythm  in  many 
species [72].
The binding and the ingestion of the waste material are independent processes 
in which distinct receptors are  involved.  Receptor tyrosine kinases  have  been 
shown to play a central role in the transduction of extracellular signals into cells 
and thereby enable them to respond to their environment by a variety of cellular 
actions.  So  far  four  plasma  membrane  receptors  of  RPE  cells  have  been 
described  to  participate  in  outer  segment  phagocytosis:  a  mannose  receptor 
[77], MERTK which is a receptor tyrosine kinase [69], avp5 integrin [78-80], and 
the type B scavenger receptor CD36 [81].  Little is known about the function of 
the  mannose  receptor.  There  is,  however,  evidence  that  it  is  involved  in  the 
internalisation  process,  even  though  neither  the  RPE  receptor  nor  the  outer 
segment ligand have been identified [77]. Two animal models -  the RCS rat and 
the  mei*6  mouse  [69,  82]  -   carry  mutations  within  the  MERTK  gene.  Both 
animal  models are deficient in  photoreceptor phagocytosis,  demonstrating the 
crucial  role  that  MERTK  plays  in  the  removal  of  shed  outer  segments.  A
32schematic  diagram  of  phagocytosis  and  the  different  signaling  pathways  is 
' shown in figure 1.7.
Figure 1.7: Signal pathways during phagocytosis. Phagocytosis starts with the recognition of 
different  rod  outer segment  (ROS)  membrane  molecules,  mainly  phosphatidylserine  residues 
(PS),  by four RPE  receptors,  namely  MERTK,  avp5  integrin  receptor,  CD36  and  a  mannose 
receptor.  The  activation  of  these  receptors  results  in  a  variety  of  intracellular  signalling 
pathways leading to cytoskeletal changes necessary for the ingestion and transportation of the 
waste material.
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The  initial  step  in  phagocytosis,  in which  probably several  RPE  receptors  are 
involved,  is the recognition and binding of the shed outer segment by the RPE. 
In  monocytes  the  avp3  integrin  receptor recognises  apoptotic cells  during  the 
early phase of phagocytosis.  RPE cells express another member of this family 
of  receptors,  the  avp5  integrin  receptor  [79].  They  differ  in  the  following 
signaling pathways that are activated upon  receptor binding to its ligand.  avp5 
integrin  forms  complexes  with  the  cytoplasmatic tyrosine  kinase,  FAK,  at  the
33apical  surface of the  RPE  [83].  Activation  of FAK seems to  be critical for the 
integrin function involved  in cytoskeletal  reorganisation  necessary for the cup- 
formation.  Furthermore,  FAK signalling  upon outer segment binding  has  been 
suggested  to  be  required  for  the  phosphorylation  of  MERTK  to  activate  the 
engulfment machinery. That means that the functional interaction between avp5 
integrin and MERTK is via FAK.
Growth arrest specific factor 6 (Gas6) specifically binds PS molecules exposed 
on the outer membrane of the outer segments via its amino-terminal domain in 
a  calcium  dependent  manner.  After  binding  to  the  outer  segment  Gas6 
undergoes a conformation change that is necessary to set its carboxyl-terminus 
free to  act  as  a  bridge  molecule  between  the  PS  residues  and  MERTK  [84]. 
Activation  of  MERTK  by  Gas6  initiates  the  specific  signalling  pathway 
responsible for starting the ingestion of shed outer segments.  In its inactivated 
state MERTK is bound to the guanine nucleotide exchange factor Vav-1. When 
sensing  local  binding  of  apoptotic  material  via  Gas6,  MERTK  auto- 
phosphorylates  specific  tyrosine  residues  thereby  releasing  Vav-1.  The 
released Vav-1  then activates processes leading to selective, local cytoskeletal- 
mediated uptake of outer segments [85].  Furthermore, the activation of MERTK 
results  in  an  increase  in  intracellular inositol-triphosphate  (lnsP3).  It  has  been 
shown  that cells  that do  not  express functional  MERTK,  lack  lnsP3 activation 
which results in the inability to ingest bound outer segments.  The activation of 
the  second  messenger  lnsP3  leads  to  an  increase  in  the  number  of 
phosphorylated  proteins that are required for the initialisation of phagocytosis. 
The increase in lnsP3 also increases the concentration of intracellular free Ca2+. 
Both  the  increase  in  lnsP3  and  in  Ca2+  regulates  phagocytosis.  Whereas  the 
increase  in  lnsP3  on  its  own  activates  phagocytosis,  the  increase  in  Ca2+  
consequently results in an activation of protein kinase C which is thought to be 
a shut-down signal for phagocytosis [83, 86, 87].
Another receptor involved in phagocytosis is a transmembrane glycoprotein, the 
macrophage  scavenger receptor  CD36  [81].  CD36 was found  to  regulate  the 
rate of outer segment internalisation.  Since CD36 is expressed on the apical as 
well as on the basal membrane of RPE cells, it is likely that its function includes
34signalling  during  phagocytosis.  Activation  of  CD36  by  its  ligand  leads  to  its 
dimerisation. The ligand has recently been suggested to be the toll-like receptor 
TLR4.  The  dimerisation  activates  a  cellular  signalling  pathway,  the  target  of 
which  is the internalisation  mechanism of the  RPE  [88].  A second  messenger 
system that acts as a modulator of the rate of phagocytosis is cAMP  [87].  An 
increase in cAMP  reduces the phagocytic activity of the  RPE.  The  lnsP3/Ca2+  
and the cAMP second messenger pathway can interact.  It has been shown that 
the two systems are coregulated by serotonin via protein kinase C [89].
351.2  Inherited retinal disorders
Processes that enable us to see are complex and involve a number of proteins 
encoded by a variety of different genes.  Inherited retinal disorders are a group 
of heterogeneous diseases and are a major cause of blindness in the Western 
world.  The  visual  deficits  are  caused  by  progressive  dysfunction  and 
degeneration of photoreceptor cells, which are triggered by mutations in one of 
over 150 so far identified genes.  Of those,  over  110 genes have been cloned 
(table 1;  RetNet,  up-date September 2005, http://www.sph.uth.tmc.edu/Retnet). 
Many mutations affect proteins that are specifically expressed in photoreceptor 
cells  or  RPE  cells.  These  proteins  are  involved  in  a  wide  range  of functions 
including the phototransduction cascade, the structure of photoreceptors, retinal 
metabolism,  and  photoreceptor  cell-specific  transcription  factors  (table  2).  A 
mutation  in  the  same  gene,  can  cause  a  variety  of  different  diseases.  Even 
though  retinal  disorders  have  been  known  since  the  19th   century,  the 
heterogeneity of the diseases and their complexity present a problem for those 
involved  in counselling patients,  and for the development of efficient therapies 
(for reviews see [1, 90, 92,93]).
This  large  and  diverse  group  of visual  disorders  affects  patients  of all  ages. 
There are many types of inherited retinal degenerations. Their differentiation is 
not always easy since many of them share clinical features. The conditions are 
grouped  into  a  number of broad  categories,  such  as  RP,  cone  and  cone-rod 
dystrophies,  macular  degenerations,  and  Leber  congenital  amaurosis  (for 
reviews see [92, 94, 95]). All these diseases are characterized by degeneration 
of  the  photoreceptor  cells  of  the  retina,  resulting  in  a  loss  of  vision.  The 
mechanisms by which these mutations lead to death of photoreceptor cells are 
not  completely  understood.  However,  it  is  thought  that  in  all  forms  of  retinal 
degeneration, photoreceptors die via apoptosis (see [96] for a review).
36Table 1: Number of retinal dystrophy genes by disease category. The table summarises the 
number  of  identified  and  cloned  genes  that  are  associated  with  different  types  of  retinal 
disorders (RetNet, up-date September 2005).
Disease Number of loci Number of 
cloned genes
Macular degeneration autosomal dominant 13 6
Macular degeneration autosomal recessive 1 1
Leber’s congenital amaurosis autosomal recessive 8 6
Usher syndrome autosomal recessive 11 8
Cone and cone/rod dystrophies autosomal dominant 6 4
Cone and cone/rod dystrophies autosomal recessive 2 0
Cone and cone/rod dystrophies x-linked 2 0
Retinitis pigmentosa autosomal dominant 13 13
Retinitis pigmentosa autosomal recessive 16 11
Retinitis pigmentosa x-linked 5 2
Other retinopathies 84 60
Total number of genes 161 111
Currently, there are no effective treatments for RP.  One of the strategies under 
development is gene therapy, which will be discussed in more details in section 
1.3.4.  Generally,  recessive diseases are easier to approach with gene therapy 
strategies because they “only”  require the addition  of a functional  copy of the 
mutated gene.  Monogenic dominant diseases are more complicated to treat.  In 
many cases (for example peripherin/rc/s) the mutation leads to a gain of function 
that often has cytotoxic effects.  Therefore,  the disease causing allele needs to 
be  removed  from  the  affected  cell  type  and  a  functional  allele  added.  For 
several  reasons,  defects  in  genes  specifically  expressed  in  the  RPE  have 
proven  to  be  more  amenable  to  effective  gene  therapy  compared  to 
photoreceptor-specific defects. Therefore, the following section will focus mainly 
on diseases arising from RPE-specific gene defects.
371.2.1  Leber’s congenital amaurosis
Leber’s  congenital  amaurosis  (LCA)  is  one  of  the  most  frequent  causes  of 
severe  early  onset  retinal  degeneration  with  a  prevalence  of  3  in  100000 
newborn  babies.  It  is  a  clinically  and  genetically  heterogeneous  retinal 
dystrophy presenting in infancy. Classical features of LCA include severe visual 
loss,  nystagmus  (involuntary eye  movements)  and  pigmentary  retinopathy.  In 
the majority of patients,  the inheritance pattern of LCA is recessive autosomal 
and only a few cases of autosomal  dominant  inheritance  have  been  reported. 
The appearance of the retina is initially normal in fundus examinations, however 
little  if  any  retinal  activity  can  be  measured  by  ERGs  early  in  the  disease 
process.  Later various  changes,  including  narrowing  of retinal  blood  vessels, 
pigmentary  changes  of  the  RPE,  and  intraretinal  pigment  migration,  can  be 
found  [97].  To  date  eight  different  genes  are  known  to  be  associated  with 
autosomal  recessive  LCA,  one  of  these  is  also  associated  with  autosomal, 
dominant  LCA.  The  clinical  heterogeneity  of LCA  is  reflected  by the  genetic 
heterogeneity  of  this  disorder  [92,  98,  99].  The  genes  are  predominately 
expressed  in  the  neuroretina  and  the  RPE.  Their  functions  are  diverse  and 
include phototransduction (GUCY2D),  vitamin A metabolism (RPE65,  RDH12), 
retinal  embryonic  development  (CRX),  protein  trafficking  (RPGRIP1,  AIPL1, 
TULP1), and photoreceptor cell structure (CRB1).
Mutations in the RPE65 gene account for 2 % of recessive RP and 15 % of LCA 
cases [100]. RPE65 is an RPE-specific microsomal protein that in its membrane 
bound form binds all-frans-retinyl esters, allowing their entry into the visual cycle 
for  processing  into  11-c/s-retinal  (for  details  on  vitamin  A  metabolism  see 
section 1.1.4) [101-103].  A naturally occurring animal model, the Rpedtf' dog, 
suffers from  early and  severe visual  impairment similar to that seen  in human 
LCA [104]. This dog model has been used to develop an effective treatment for 
LCA.  Using  a  recombinant  adeno-associated  virus  (rAAV)  carrying  wild-type 
Rpe65, it was possible to restore visual function over a long period of time (see 
chapter 1.3.4.4.3) [105].
381.2.2  Cone and cone-rod dystrophies
The  cone-rod  dystrophies  (CORDs)  are  a  clinically  and  genetically 
heterogeneous  group  of  progressive  retinal  disorders.  The  CORDs  usually 
present with  cone  dysfunction  related  symptoms,  including  photophobia,  poor 
colour vision,  and  reduced  central  visual  function.  Night and  peripheral  vision 
are preserved at the beginning but as the disease progresses rods degenerate, 
causing poor night vision,  defective dark adaptation and peripheral vision loss. 
The  onset  and  the  degree  of  visual  impairment  is  variable.  The  inheritance 
pattern of cone-rod dystrophies  is complex and  includes autosomal  recessive, 
autosomal  dominant as well  as X-linked types.  So far  15 genes with  different 
functions (RetNet,  up-date Sep 2005) have been shown to be associated with 
CORDs  including  AIPL1  (retinal  development  [106]),  GUCY2D 
(phototransduction  [107]),  CRX  (transcription  factor  [108]),  ABCA4  (protein 
trafficking [109]), and RDH5 (vitamin A metabolism [110]).
It has been shown that mutations in the 11 -c/s retinol dehydrogenase 5 (RDH5) 
gene are associated with recessive fundus albipunctatus (a type of congenital 
stationary  night  blindness  characterized  by  delay  in  the  regeneration  of 
photopigments,  see  section  1.2.5)  and  recessive  cone  dystrophy  [111,  112]. 
RDH5 is specifically expressed in the RPE and has an important function in the 
visual cycle (see section 1.1.4). After light excitement, the all-trans retinal of rod 
and cone photopigments is recycled to  11-c/s retinal  in  RPE cells.  It has been 
suggested that RDH5 catalyses the conversion of 11-c/s retinol to 11-c/s retinal 
[110].
1.2.3  Retinitis pigmentosa
The  term  retinitis  pigmentosa  (RP)  includes  a  group  of  inherited  genetic 
diseases  leading  to  progressive  photoreceptor  degeneration  and  finally  to 
blindness.  Worldwide  approximately  1.5  million  people  suffer from  this  retinal 
disorder, making RP one of the most common causes of visual impairment [1].
39The clinical features observed in RP patients are variable and are reflected by 
its  genetically  heterogeneous  basis.  The  inheritance  patterns  are  autosomal 
dominant, autosomal recessive, X-linked, mitochondrial and digenic (for reviews 
see [1,  113]). RP may also be either familial (multiplex), affecting multiple family 
members,  or  isolated  (simplex),  affecting  one  individual  only  (see  [114] for  a 
review).  Furthermore,  RP  can  be  classified  as  non-syndromic,  not  affecting 
other organs or tissues, syndromic, affecting other systems such as hearing (for 
example  Usher  syndrome,  see  also  section  1.2.5);  or  systemic,  affecting 
multiple tissues.  Further allelic heterogeneity arises from different mutations in 
the  same  gene.  The  first  mutation  identified  as  a  cause  of  an  autosomal 
dominant form  of RP was a  mutation within the  rhodopsin gene.  Mutations  in 
the  rhodopsin  gene  account  approximately  25%  of  cases  and  therefore 
represent the most common cause of RP [115].
Patients  with  RP  may  present  with  varying  symptoms  (see  [94,  116]  for 
reviews).  The  onset  is  often  gradual  and  many  patients  fail  to  recognize  the 
manifestations  of this  condition  until  it  has  progressed  significantly.  In  typical 
cases, the rods are predominantly affected. The initial clinical symptoms include 
a defective dark adaptation leading to night-blindness at an early age and loss 
of  mid-peripheral  vision  causing  tunnel  vision.  Usually  the  central,  macular 
vision  is  preserved  in the  beginning  of the  disease with  normal  central  vision 
acuity and colour vision. As the degeneration progresses,  cone photoreceptors 
are  also  affected  and  day  vision  and  central  vision  are  compromised.  These 
symptoms  reflect  early  loss  of  rod  photoreceptors,  followed  by  a  slower 
degeneration of cones.
Electron microscopy studies show that in earlier stages of the disease the only 
remaining photoreceptor cells are the cones in the posterior pole and these are 
atypical and fewer in number. The outer segments are connected to abnormally 
wide and shortened inner segments via apparently normal cilia and the nuclei of 
these  cone  cells  appear  to  be  30%  larger  than  their  normal  counterparts. 
Degenerative  changes  in  the  neural  retina  are  very  variable,  with  structurally 
well  preserved  ganglion  cells  and  nerve  fiber  layers  in  some  patients  and
40complete  degeneration  of  these  in  others.  Additional  changes  include  an 
increase  in the size of Muller fibers  and  migration  of these  cells  between  the 
inner nuclear layer and the RPE (reviewed in [117]).
Commonly reported  by many  RP  patients are flashes of light and  a twinkling, 
shimmering  sensation  in  the  mid-peripheral  or  peripheral  field,  which  are 
hypothesised to be aberrant electrical impulses generated by the degenerating 
retina.  Fundus appearance is dependent on the stage of retinal  degeneration. 
The earliest observed change in the fundus  is the  narrowing or attenuation  of 
the retinal arterioles.  Retinal pigmentary changes occur in form of fine spotting 
or  granularity  with  surrounding  areas  of  atrophy.  Later,  star-shaped  pigment 
formations may be noted at perivascular locations in the mid-peripheral retina. 
These  hyperplastic  formations  are  often  referred  to  as  "bone  spicules" 
(reviewed in [94]).
As the  disorder progresses,  general  atrophy of the  RPE  and  choriocapillaries 
ensues, exposing the larger choroidal vessels (see figure 1.8). The optic nerve 
head  is often  normal  in early RP  but may demonstrate a waxy yellow or pale 
appearance later.  RP has a strong correlation with  acquired optic disc drusen. 
The macula, like the optic nerve, is usually unaffected in the early stages but in 
some  forms  of  RP  may  demonstrate  preretinal  gliosis  ("cellophane 
maculopathy"), cystoid macular edema or focal RPE defects. Additional findings 
in  RP  include  pigment  cells  in  the  vitreous  ("tobacco  dust  sign"),  posterior 
vitreous detachment and posterior subcapsular cataracts.
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Figure  1.8:  Fundus  images.  (A)  Fundus  image  of a  normal  subject  and  (B)  of a  patient 
diagnosed  with  RP.  Changes include  narrowing  of blood vessels,  intraretinal  accumulation  of 
melanin (bone spicule), hypopigmentation in the macula area,  pallor of the optic disc (changes 
indicated by arrows).
Findings  on  ophthalmoscopy  include  intraretinal  pigment  around  the  mid­
peripheral  retina  for  which  this  condition  is  named.  Histopathological 
examinations of eyes with advanced stage of RP have shown that loss of vision 
is  due  to  degeneration  of  both  rod  and  cone  photoreceptor  cells.  Retinal 
function is abnormal as determined by light evoked electrical response from the 
retina  that  is  measured  by  electroretinography.  This  abnormality  reflects  the 
loss of photoreceptor function.  Patients with early stage of RP show ERGs with 
reduced  amplitude.  ERG  amplitudes diminish  as the disease progresses  (see 
[118] for a review).
To  date,  five  genes  associated  with  autosomal,  recessive  RP  have  been 
identified that are primarily expressed in the RPE,  namely RPE65 (see sections 
1.1.4  and  1.3.4.4.3)  [103,  119],  LRAT (see  section  1.1.4)  [120,  121],  MERTK 
(see sections 1.2.5,  1.2.6.1  and 5.2) [69,  122], RGR [123,  124] and CRB1 [125] 
(genes  associated  with  autosomal  recessive  RP  and  their  function  are 
summarised  in  Table  2).  The  later  is  also  expressed  in  photoreceptor  inner 
segments [125].  Recent success in the treatment of the Rpe65/' dog suggests 
that  these  genes  are  prime  candidates  for  the  development  of gene  therapy 
approaches [105],
42Table 2: Genes causing autosomal recessive RP. The proteins encoded by retinal dystrophy 
genes show wide spread  diversity  of function.  Nevertheless,  the  interruption  of any  of these
genes by mutations leads to the same clinical phenotype (RetNet, up-date September 2005).
Gene Protein function
ABCA4 ATP binding cassette transporter,  retina specific, transport of molecules across 
extra- and intracellular membranes
CERKL Ceramide  kinases,  convert sphinglipid  metabolites which  are  key mediators of 
apoptosis and survival
CNGA1 Rod cGMP-gated channel a subunit, important role in neuronal function
CNGB1 Rod cGMP-gated channel p subunit, see CNGA1
CRB1 Crumbs  homolog  1   protein,  localized  to  RPE  and  inner  segments,  possibly 
involved in cell-cell interactions and cell polarity
LRAT Lecithin retinol acyltransferase, visual cycle, transformation of vitamin A into 11- 
c/s-retinol
MERTK Receptor tyrosine kinase,  involved in  phagocytosis of shed outer segments by 
the RPE
NR2E3 Nuclear  receptor,  ligand  dependent  transcription  factor,  possibly  involved  in 
development and maintenance of proper cell function
NRL Neural retina lucine zipper,  promotes rhodopsin  and  other genes transcription, 
required for rod development
PDE6A Rod  cGMP  phosphodiesterase  a  subunit,  expressed  in  rod  outer  segments, 
regulates cGMP concentrations and thereby membrane current
PDE6B Rod cGMP phosphodiesterase p subunit, see PDE6A
RGR RPE-retinal G  protein coupled  receptor,  in  RPE and  Muller cells,  bind  all  -trans 
retinal which light converts to 11-c/s retinal
RHO Rhodopsin, transmembrane photosensitive protein of rods
RLBP1 Cellular  retinalaldhyde-binding  protein,  possible  functional  component  of  the 
visual cycle
RP1 Important but unknown role in photoreceptor biology
RPE65 RPE specific protein, necessary for production of 11-c/s-vitamin A
SAG Arrest  in, involved in desensitization of the photoactivated transduction cascade
TULP1 Tubby-like  protein  1,  involved  in  rhodopsin  transport  from  inner  to  outer 
segment, also expressed during development
USH2A Basement membrane  associated,  important for development  and  homeostasis 
of inner ear and retina
431.2.4  Macular degeneration
Macular degeneration (MD) is a term used for different types of retinal disorders 
that are characterised by a degeneration of the macula and a progressive loss 
of central vision (reviewed in [126]). The macula is a small, highly sensitive part 
of the retina temporal to the optic nerve and  is required for central vision.  It is 
the area that provides the most distinctive vision due to its higher concentration 
of cones  compared  to  other  parts  of the  retina.  The  centre  of the  macula  is 
called  fovea.  Here,  there  are  only  cones  present  making  it  the  area  of  the 
highest  visual  acuity.  To  date,  14  genes  associated  with  this  condition  have 
been  identified  (RetNet,  up-date  September 2005).  The  inheritance  pattern  of 
MD  is  autosomal  (apart from  mutations  in  RPGR,  which  is  located  on  the  X- 
chromosome) and may either be dominant or recessive.
Age related macular degeneration (AMD)  is the most common cause of vision 
loss in the elderly. The term refers to a group of late onset conditions that affect 
the macula. AMD has been clinically recognised since more than 100 years but 
since  the  clinical  characteristics  of  AMD  only  partial  overlap,  there  is  no 
satisfying definition for this group of retinal degenerations. However, all types of 
AMD have the accumulation of proteins,  lipids,  and cellular debris between the 
RPE  and the  Bruch’s  membrane  in common.  These accumulations are called 
drusen.  Further  classical  features  of AMD  are  the  patchy  loss  of  RPE  cells, 
known  as  geographic atrophy,  and  an  abnormal  distribution  of the pigment  in 
the  RPE.  Common  is  the  growth  of  blood  vessels  through  the  Bruch’s 
membrane into the subretinal space.  AMD has been shown to be hereditary in 
about  one  fourth  of  the  cases.  There  are  factors  that  increase  the  risk  of 
developing  AMD,  such  as  hypertension,  high  cholesterol,  smoking,  and  high 
exposure  to  sunlight.  The  complement  factor  H  (CFH)  gene  -   a  serum 
glycoprotein that controls the function of the alternative complement pathway -  
has been determined to be strongly associated with the risk of developing MD 
at  older  age.  A  substitution  of  tyrosine  to  histidine  at  codon  402  of  CFH  is 
resulting  in variant of CFH that accounts for up to 50%  of the append  risk of 
AMD [127, 128].
44Sorsby’s fundus dystrophy (SFD) is a late-onset, autosomal dominant inherited 
form of macular dystrophy whose pathological phenotype arises from mutation 
in  the  tissue  inhibitor  of  metalloproteases  3  gene  (TIMP3)  [57].  The  clinical 
characteristics  are  similar to  those  found  in  AMD  patients,  including  drusen, 
accumulation  of extracellular  matrix  material  (including  collagen,  elastin,  and 
glycoaminoglycans)  and  lipids at  the  level  of  Bruch's membrane,  and  colour 
vision deficits. Most commonly, patients suffer from a sudden acuity loss, which 
manifests  in the third  to fourth  decades  of life  and  that  is  due  to  submacular 
neovascularisation  [57].  TIMP3  encodes  an  RPE  endopeptidases  which  is 
involved  in  retinal  extracellular  matrix  remodelling  and  a  component  of  the 
Bruch’s  membrane.  TIMP3  is  an  inhibitor  of  matrix  metalloproteinases  that 
breaks  down  connective  tissue  material  in  the  extracellular  matrix  [129].  The 
mechanisms  that  lead  to  SFD  phenotype  are  not  completely  understood  yet. 
However,  it has been suggested that mutant TIMP3 forms a dimer which is not 
degraded  as  quickly  as  normal  TIMP3  and  may  accumulate  in  the  Bruch’s 
membrane.  Because  the  mutant  TIMP3  is  able  to  inhibit  metolloproteinase 
activity,  it might have an increased inhibition of protease activity, which in turn 
leads to an increased accumulation of extracellular material. The altered elastic 
fibers  in  the  Bruch’s  membrane  might  lead  to  choroidal  neovascularisation 
(CNV) [130].
The  most common form  of juvenile  macular degeneration  is called Stargardt’s 
disease  and  the  onset  of  the  disease  is  between  5  and  20  years  of  age. 
Stargardt’s  disease  is  mainly  inherited  recessively  but  rarely  dominant 
inheritance  patterns  can  be  found.  The  clinical  features  are  similar  to  those 
observed in AMD and SFD patients.  Lipid rich deposit accumulates underneath 
the  RPE,  mainly in the  macula area,  and  subsequently causes atrophy of the 
macula and the RPE, thereby creating a central blind spot in the visual field that 
increases in size as the disease progresses (reviewed in [131]). The phenotype 
is due to mutations in the retinal specific ATP-binding cassette transporter gene 
(ABCA4, ABCR) [109]. The product is a transmembrane protein localised to the 
rim  of rod  outer segments where  it acts  as an ATP dependent flippase for N- 
retinylidine-phosphatidylethanolamine  (N-retinylidine-PE)  [132].  ABCA4  is 
thought  to  translocate  N-retinylidine-PE  across  the  membrane.  In  the
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trans  retinal.  All-frans  retinal  is  then  isomerised  to  all-trans  retinol  by  retinal 
dehydrogenases (see section  1.1.4).  In the absence of ABCA4,  N-retinylidine- 
PE  and  all-trans  retinal  accumulates  within  the  outer  segment.  After 
phagocytosis, the outer segment discs undergo enzymatic digestion resulting in 
the  generation  of  N-retinylidine-N-retinylethanolamine  (A2-E),  a  major 
component  of  lipofuscin.  The  accumulation  of  high  levels  of lipofuscin  has  a 
cytotoxic effect and results in apoptosis of RPE cells [109, 133].
Best’s vitelliform macular dystrophy,  is an autosomal dominant disorder, which 
classically  presents  in  childhood with the  appearance  of lesion  in  the  macula 
[134].  Abnormalities  result  from  a  disorder  in  the  RPE.  Accumulation  of 
lipofuscin  within  the  RPE  cells  and  in  the  sub-RPE  space,  particularly  in  the 
foveal  area,  is  most  commonly found  in  patients.  The  RPE  appears  to  have 
degenerative  changes  and  secondary  loss  of  photoreceptor  cells  has  been 
noted.  In early stages, visual acuity is good but the advancing RPE atrophy and 
possible  development  of  choroidal  neovascularisation  results  in  reduction  in 
visual acuity (reviewed in [135]). The gene mutated in Best’s disease has been 
identified  as the retina-specific  VMD2 gene that encodes for a protein termed 
bestrophin.  The  protein  localises  to  the  basolateral  plasma  membrane  of the 
RPE and functions as a transmembrane,  oligomeric ion channel protein.  VMD2 
mutations  have  been  suggested  to  result  in  reduced  or abolished  membrane 
current  [134,  136].  Lipofuscin  accumulation  may  be  a  secondary  change  to 
abnormal  ion  flux.  Even  though  most  of  the  cases  have  an  early  onset  of 
degeneration, 1   to 2 % of VMD2 mutations might lead to AMD.
1.2.5  RPE defects
The previous section  shows that mutations  in  many RPE-specific genes result 
in different types of retinal degeneration.  Diseases caused by alterations of the 
retinoid  cycle  in  the  RPE  share  characteristics  in  their  fundus  such  as  the 
appearance of yellow to white spots (reviewed in [137]). Such disorders include
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[109],  the  retinol  binding  protein  deficiency  syndrome  (RBP4  gene)  [138], 
fundus  albipunctatus  (RDH5  gene)  [112]  and  retinitis  punctata  albescens 
(CRALBP gene) [139].  Retinol binding protein deficiency syndrome [138] arises 
from  mutation in the RBP4 gene.  RBP4 is produced in the liver,  mobilises and 
transports  vitamin  A  to  the  basolateral  membrane  of  the  RPE.  The  fundi  of 
patients are characterised by small yellowish to white dots in the periphery and 
severe atrophy of the RPE. The impairment of vitamin A uptake and transport to 
the  photoreceptors  results  in  reduced  dark  adaptation  and  scotopic  ERG  is 
unrecordable.  In  fundus  albipunctatus,  white  to  greyish  dots  are  initially 
apparent as a ring around the macula and spread towards the equator as the 
disease  progresses  (see  [137,  140]  for  reviews).  Although  the  dots  are  in 
discrete areas, functional testing reveals global rod dysfunction. This disorder is 
associated with mutations in RDH5 (see chapter 1.2.2), the product of which is 
involved  in the conversion  of  11-c/s retinol  to  11 -cis retinal  in the  RPE  [112]. 
Retinitis  punctata  albescens  is  characterised  by  a  progressive  rod  and  cone 
degeneration.  The fundus typically  shows  distinct dots that sometimes  invade 
the macula, as well as bone spicule.  In late stages the dots disappear and RPE 
atrophy, pigmentary changes and attenuated vessels develop. This disease has 
been linked to defects in the cellular retinaldehyde  binding  protein (CRALBP), 
which is found in RPE and Muller cells.  CRALBP carries  11 -cis retinol and 11- 
cis  retinaldehyde.  In  the  absence  of functional  CRALBP  a\\-trans retinyl  ester 
accumulate in the RPE [124, 141, 142].
Retinal and RPE dystrophies display heterogeneity of genotype and phenotype. 
Variations  have  been  observed  on  inter-  and  intrafamilial  level  and  mutations 
within the same gene can result in different phenotypes.  Besch et al [143] have 
suggested  several  mechanims  that  might  contribute  to  this  heterogeneity, 
including  the  non-homogeneous  shape  and  density  of  RPE  cells,  regional 
differences  in the  photoreceptor ratio  per RPE  cell,  the  uneven  distribution  of 
rod  and  cone  photoreceptors,  accumulation  of  lipofuscin,  and  variation  in  the 
Muller cell distribution.
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metabolism that results in a congenital hypopigmentation of ocular and systemic 
tissues.  Cellular pigmentation is dependent upon the ability of specialised cells, 
called  melanocytes,  to  manufacture  melanin.  This  is  accomplished  within 
organelles  called  melanosomes.  Inside  the  melanosome,  melanin  is 
synthesised  from  the  amino  acid  tyrosine  through  the  actions  of the  enzyme 
tyrosinase [144]. Albinisms are characterized by a reduction or total absence of 
pigment in the hair,  skin, and eyes.  Ocular albinism is a subgroup of disorders 
arising from a reduction of melanin pigment in the RPE (reviewed in [145]). The 
disease  phenotype  has  been  associated  with  mutations  in  the  OA1  gene. 
Retinal  morphogenesis  depends  on  the  organising  influence  of  the  adjacent 
RPE.  The insufficient uveal pigmentation and poor development of the RPE  in 
the albinotic patient provides a developmental^ unstable substrate for normal 
retinal organisation.  Hence, the albinotic macula is always hypoplastic and the 
albinotic  patient  has  secondarily  reduced  acuity.  Pigment  deficits  in  the  RPE 
also lead to a reduction  in the  number and  distribution of photoreceptors  and 
other  retinal  cells  by  affecting  the  mechanisms  controlling  cell  proliferation 
during the early development of the retina.
Failure  of  outer  segment  phagocytosis  by  the  RPE  results  in  retinal 
degeneration, as it is the case in animal models and patients that carry mutation 
in  the  MERTK  (see  sections  1.2.6.1  and  5.2)  and  Myo7A  genes.  Usher 
syndrome  is an  inherited condition  resulting  in  hearing  loss as well  as  loss  of 
vision (see [146,  147] for reviews).  It is the major cause of deaf-blindness in the 
world. The clinical features of the visual impairment are the same as in RP (see 
chapter  1.2.3).  Depending  on  the  hearing  at  birth  three  types  of  Usher 
syndrome are distinguished, with type 1   being the most severe one (bom deaf) 
and type 3 the mildest type (bom with good hearing).  All three types of Usher 
syndrome  are  inherited  in  an  autosomal  recessive  manner.  Mutations  in  the 
myosin Vila gene (Myo7A) are associated with Usher syndrome type 1   (USH1). 
The  absence  of  functional  MY07A  results  in  cytoskeletal  abnormalities 
including  abnormal  organisation  of  microtubules  in  the  connecting  cilium  of 
photoreceptor  cells,  nasal  cilia  cells,  and  sperm  cells,  as  well  as  by  the 
widespread degeneration of the organ of Corti that is responsible for deafness.
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phagocytosis of photoreceptor outer segment discs by the RPE [148]. RPE cells 
display a reduced ability to ingest bound outer segments,  probably due to the 
disturbed vesicle trafficking  and fusion  between  phagosomes  and  lysosomes. 
This suggests that the primary defect responsible for the visual deficits in USH1 
patients is in the RPE rather than in the photoreceptors.
Changes  in the secretory activity of the  RPE  are  associated with  proliferative 
disorders of the retina. An example of a disease in which proliferation is one of 
the key factors is AMD (see chapter 1.2.4). A complication in patients with AMD 
is  the  development  of  choroidal  neovascularisation  (CNV).  The  initial 
mechanisms leading to CNV are not completely understood but are thought to 
involve local  hypoxia,  RPE cell  loss and growth factors.  In all cases the major 
angiogenetic factor,  VEGF,  causes the  development of neovascularisation.  In 
the  eye,  VEGF  is  mainly  produced  by  the  RPE  and  it  has  been  shown  that 
VEGF  secretion  from  RPE  cells  is  up-regulated  in  AMD  patients  with 
neovascularisation. Many extracellular factors, such as insulin-like growth factor 
1   (IGF-1),  have  been  suggested  to  be  involved  in  the  higher  production  of 
VEGF  [149,  150].  IGF-1  is  exclusively  produced  by  photoreceptor  cells  in 
healthy eyes but by RPE and photoreceptor cells in eyes with AMD. Therefore, 
it might contribute as a stimulus for the increased VEGF production.
1.2.6  Animal Models for inherited retinal dystrophies
Inherited  retinal  degenerations  are  the  most  common  cause  of  blindness. 
However,  the mechanisms that lead to photoreceptor cell loss are still  not well 
understood. Hence, a suitable and efficient treatment for most of these diseases 
has yet to be found.  For some types of retinal  degeneration  natural  occurring 
animal  models  exist  (see  [151]  for  a  review).  Over  the  past  few  years,  the 
identification of gene loci for inherited retinal degenerations and the progress in 
genetic  engineering  have  led  to  the  development  of  numerous  transgenic 
animals.  The  successful  development of transgenic animal  models for  human
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development of approaches to diagnosis, treatment,  and intervention of human 
diseases.  Additionally,  the models have clarified our understanding of disease 
mechanisms  and the onset and  course of pathology  associated with  disease. 
These animals,  mainly rodents,  carry constructs that result in the disruption or 
overexpression of specific candidate genes for retinal degenerations that mimic 
the  human  disease.  Animal  models  are  crucial  to  understand  the  processes 
involved in retinal degeneration and have been widely used in visual research. 
They represent a powerful tool to investigate the role of specific gene mutations 
and the resulting cellular defects that finally lead to photoreceptor cell death and 
are required for the development and testing of new treatments.  All vertebrate 
eyes are similar in structure and function. There are, however, some differences 
depending  on  the  life  style  of  different  species  that  play  a  decisive  role, 
particularly when selecting the best qualified animal model for experiments. The 
choice  of  an  appropriate  animal  model  is  crucial  for  the  validity  of  an 
experiment. Whilst animal models are often very valuable they should only be 
seen  as  an  approximation  to  the  morphological,  physiological  and 
pathophysiological conditions of humans.
For  various  reasons,  mice  and  rats  have  been  used  most  extensively  of  all 
species,  including their short gestation  time,  their small  size,  the existence  of 
several  readily  available  retinal  degeneration  mutants,  multiple  inbred  and 
congenic  strains  with  genetic  controls,  and  different  eye  pigmentation  types. 
However,  initial findings need to be validated in larger animal models with eyes 
that more closely resemble human eyes. Any new developed treatment must be 
evaluated for its therapeutic value as well as for its safety before it is applicable 
for  clinical  trial.  Treatment  doses,  duration,  and  timing  must  be  assessed 
thoroughly.
In  most  experiments,  rodents  are  the  animals  of choice.  However,  there  are 
differences  between  rodent  and  human  eyes  that  sometimes  make  an 
interpretation of results obtained from the animal  difficult.  In both humans and 
rodents,  light  passes  through  the  cornea,  which  allows  both  visible  and 
ultraviolet light down to 300 nm to pass through. Then the light passes through
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acts  as  a  filter  to  block  certain  wavelengths  of  light  and  it  is  not  equally 
transparent to  all  colours.  Which  colours  are  allowed  through  differs  between 
species.  Whilst only visible light can  pass through the lens  in  humans,  rodent 
lenses  allow  all  visible  light  plus  almost  50  %  of  ultraviolet  A  light  to  pass 
through.  Once the light hits the retina it is detected by the photoreceptor cells. 
Humans have in addition to rods three different types of cones.  Rodents on the 
other hand  have  only two  types  of cones,  green  and  blue,  and  are  therefore 
unable to see longwave  light.  The distribution  of rods and  cones varies within 
the  retina  in  humans.  At  the  periphery  of  the  retina  are  more  rods  which 
respond to light intensity and cones are concentrated in the optical centre of the 
retina.  The  ratio  of  rods  and  cones  varies  between  different  species  of  all 
vertebrate families.  In humans, 5 % of the photoreceptors are cones compared 
to  only  1-2  %  in  rats  and  mice  (There  are  however  exceptions  [152].  Other 
rodents such as the African mole-rat have despite of its subterranean, nocturnal 
mode of life a high proportion (~ 10 %) of cones). Each neural cell in the rodent 
retina  is  responsive  to  a  larger  number  of  photoreceptors  than  those  of the 
human  retina,  which increases sensitivity at the expense of acuity.  In humans 
and primates,  laterally of the optic disc is the cone-rich macula, whereas cones 
are evenly distributed over the entire retina in rodents.
The small size of the mouse eye,  combined with a relatively large lens, makes 
intraocular  procedures  and  accurate  delivery  of  therapeutic  substance 
extremely difficult. The rat eye is several-fold larger than the mouse eye, which 
simplifies  intraocular  procedures  and  electroretinographic  evaluation.  In 
addition,  rats  breed  as  rapidly  as  mice,  generating  large  litters  in  a  short 
gestational time.
To date, there are a large number of mouse models, both naturally occuring and 
transgenic (see [151,  153,  154] for reviews).  The first natural  occurring animal 
model was discovered 1923 by Clyde E  Keeler.  He discovered a mouse strain 
that has no photoreceptor cells but a lack of interest in the research community 
made  him  abandon  his  work  on  this  mouse  strain.  Almost  30  years  later 
Bruckner and colleagues reported severe retinal degeneration in a wild mouse
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the  most  studied  animal  models  for  inherited  autosomal  recessive  retinal 
degeneration.  Seventy years  after  Keeler discovered  his  mouse  strain,  Pittler 
and  co-workers  identified  the  genetic  defect  underlying  photoreceptor 
degeneration in the rd mouse and demonstrated by polymerase chain reaction 
(PCR) that the defects in Keeler’s mouse and the rd mouse were identical [155]. 
The  gene  mutated  in  the  rd mouse  encodes  the  p-subunit  of the  rod  cGMP 
phosphodiesterase  (p-PDE),  an  enzyme  of  the  visual  cascade  specifically 
expressed in photoreceptors (see chapter 1.1.4) [96, 156].
The  retinal  degeneration  slow  (rds)  mouse  is  a  mouse  model  for  inherited 
autosomal dominant RP [157]. This mouse carries an insertional mutation in the 
rds/peripherin  gene  encoding  for  a  photoreceptor-specific  structural  protein 
expressed  both  in  rods  and  cones.  Peripherin  is  located  in  the  rims  of 
photoreceptors  and  has  an  important  role  in  disc  morphogenesis.  It  is 
hypothesised that peripherin stabilises the membrane fold at the edge of outer 
segments and that lack of peripherin in rds mice disrupts these folds and thus 
proper disc function (reviewed in [91 ]).  Rds mice fail to develop photoreceptor 
outer segments and undergo degeneration of both types of photoreceptors.
The  Royal  College of Surgeon (RCS)  rat,  first described  in  1938  [158],  is an 
example  of a  natural  occuring  model  for autosomal  recessive  RP  caused  by 
RPE dysfunction. The gene that is disrupted in RCS rats is the receptor tyrosine 
kinase  MERTK  [69,  159].  RPE  cells  in  RCS  rats  have  lost  their  ability  to 
phagocytise  shed  outer  segments,  resulting  in  the  accumulation  of  waste 
material  between the  RPE  cell  layer and the photoreceptor cells.  The two cell 
types  lose  contact  and  the  RPE  cells  are  unable  to  provide  nutrients  and 
oxygen to the photoreceptors. The result is a progressive loss of photoreceptor 
cells, which starts at two weeks of age and is completed around three months. 
The RCS rat has been used extensively to assess different treatment strategies 
for photoreceptor degeneration (for more details see chapters 1.2.6.1,  1.3.2 and
1.3.4.4.2).
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cones.  The transgenic pig  model  of RP  expresses  a  rhodopsin  mutation  that 
causes  retinal  degeneration  [160,  161].  Like  RP  patients  with  the  same 
mutation,  transgenic pigs  have  early  and  severe  rod  loss.  Initially,  cones  are 
relatively spared but degenerate over time.  By the age of 20  months,  there  is 
only a single layer of morphologically abnormal cones left and the cone-specific 
ERG  is  markedly  reduced,  resembling  the  pathological  phenotype  in  RP 
patients with rhodopsin  mutations.  Even though the pig  retina  lacks a foveal- 
macular  region,  the  retina  has  a  significant  higher amount  of cones  than  the 
rodent retina.  Therefore,  the pig eye resembles the primate eye more closely. 
Given the strong similarities in phenotype to that of RP patients, the transgenic 
pigs  provide  a  large  animal  model  for  study  retinal  degeneration  (especially 
cone degeneration) found in RP.
In comparison with other animal models of photoreceptor degeneration, the dog 
model offers some advantages.  In the dog,  more autosomal  gene loci causing 
photoreceptor degeneration have been identified than in any other species. The 
canine retina has a similar composition  and distribution of cones,  which  apart 
from the fovea resembles that of humans. The large size of the dog eye allows 
intraocular procedures to be carried out more easily than in rodents and it also 
permits  examination  of different  retinal  regions  of the  same  eye.  The  Briard 
dog (Rpe65A  dog) is a canine model of a recessively inherited retinal  disorder 
characterized  by  congenital  night  blindness  with  various  degrees  of  visual 
impairment under photopic illumination [104].  Along with the visual impairment, 
affected dogs have an abnormal ERG trace and electron microscopy studies of 
the  retina  demonstrate  large,  lipid  inclusions  in  the  retina  as  well  as 
disorientation of outer segment disc membranes.  In Briard dogs a homozygous 
4-bp  deletion  within  the  Rpe65  gene  was  identified.  The  gene  encodes  a 
microsomal  protein expressed  exclusively in the  RPE  (see sections  1.1.4 and
1.3.4.4.3).  Clinical features of the canine disease are similar to those described 
in human. Therefore this form of canine retinal dystrophy provides an attractive 
model of severe early onset retinal degeneration [104,  162,  163]. There are also 
two  mouse  models  that  carry  mutations  in  the  Rpe65  gene:  the  Rpe65A  
knockout  mouse  and  the  natural  occurring  Rd12  mouse  [164,  165].  Both
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result of low levels of photopigment.  Functional  and  biochemical  studies have 
confirmed  that  vitamin  A  metabolism  and  visual  processing  are  disrupted. 
These mouse models can  be  used as initial templates for the development of 
therapies, that can be further evaluated in the Briard dog.
Primate eyes are the most similar to those of humans.  Like humans,  monkeys 
have  a  macula that  is  rich  in  cones.  It  has  been  shown  that  diurnal  species, 
such  as the  rhesus  monkey,  have  a fovea  that  consists  of all  three  types  of 
cones  (red,  green  and  blue).  Macular changes that are similar to that  in  age- 
related  macular  degeneration  in  humans  have  been  reported  in  the  rhesus 
monkey.  Because  of the similarity to  humans,  monkeys  would  be  the  animal 
model of choice to investigate such disorders. However, due the long lifespan of 
monkeys, retinal degenerations occur over a longer period of time compared to 
the  short-living  mice  and  rats,  making  experiments  long  lasting.  Further 
disadvantages are the small  litter size,  long gestational time,  high costs,  great 
housing requirements (space) and ethical problems (see [151] for a review).
1.2.6.1  The Royal College of Surgeon’s rat
The  main  interest  in  the  Royal  College  of  Surgeon’s  (RCS)  rat  and  its 
pathological  condition  relates  largely to  its  potential  value  as  an  investigative 
model of human autosomal recessive retinal degeneration. In RCS rats the RPE 
fails  to  phagocytose  shed  outer  segments  due  to  a  mutation  in  the  MERTK 
gene and photoreceptor cells eventually die [68].
The  RPE of RCS  rats  is  unable to remove the outer segment material,  which 
accumulates  within  the  subretinal  space.  As  a  result  RPE  and  photoreceptor 
cells lose contact and  photoreceptor cells do not get any nutrients or oxygen. 
Consequently,  photoreceptor  cells  undergo  apoptosis  which  finally  leads  to 
progressive  thinning  of the  neuroretina  over time.  An  unusually  phenomenon 
that  is  not  seen  in  any  other  model  of  inhered  retinal  degeneration  is  the 
presents of a great number of pyknotic nuclei  [166]. It is therefore likely that the
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defect  in  this  animal  model.  Some  hemispheric  differences  and  gradients  of 
photoreceptor degeneration have been found between the superior and inferior 
hemisphere,  with  ONL  cell  loss  in  the  inferior  hemisphere  occurring  more 
rapidly than in the superior half. RCS rats also show a distinct central-peripheral 
gradient  of  cell  loss.  Degeneration  of  the  peripheral  retina  is  slowed  by 
approximately  10  days  compared  with  the  degeneration  in  the  posterior  pole 
[167].  Similar observations  have  been  made  in the mer1 ”1   mouse,  a generated 
mouse model that carries a mutation within MERTK [82].  Before photoreceptor 
cell death during retinal degeneration,  RCS rats show failure to phagocytise rod 
outer  segments.  This  deficit  leads  to  the  formation  of  membranous  whorls 
adjacent to the RPE surface.  Furthermore,  longer than normal outer segments 
are present and the rhodopsin content in the eye increases in the beginning of 
degeneration [82,  168,  169].  The membranous whorls consist of disorganised 
outer segment membranes and RPE cell processes. Phagosomes are absent in 
the RPE of the RCS rat providing direct evidence of the phagocytic defect [82, 
167].  Another  characteristic  feature  of  the  degeneration  is  the  presence  of 
vacuoles  throughout  the  retina.  They  are  thought  to  result  from 
interphotoreceptor abnormalities either  in  osmotic composition  or in  abnormal 
transport  and  recycling  of  fatty  acids  [170].  However,  it  remains  to  be 
determined how the gene defect leads to vacuoles in the outer retina and if the 
vacuoles play a role in photoreceptor cell death.
In  RCS  rats,  retinal  abnormalities  are first  detected  at two  to  three weeks  of 
age.  Photoreceptor  cell  loss  is  detectable  histologically  and 
electroretinographically  from  postnatal  day  18  (P18)  onward  and  subretinal 
accumulation of debris is apparent at that time [167,  169,  171]. Both scotopic a- 
and b-waves and photopic b-wave amplitudes decline rapidly over time. Usually 
after P40 neither scotopic nor photopic b-waves are recordable in response to 
bright  stimuli.  From  P25  onwards  invading  macrophages  and  microglia  are 
found  in  retinal  sections  [167,  172].  By  P45  the  whorls,  abnormal  outer 
segments  and  debris  layer  disappears  and  only  a  few  pockets  of  debris 
membranes  are found.  At  late  stages  of retinal  degeneration  the  RPE  shows 
small focal  regions of thinning,  although  some  regions  of RPE  appear thicker
55than normal [167], Depending on pigmentation of the animal the degeneration is 
virtually complete after 2 to 3 months.
Figure 1.9: Time course of retinal degeneration in the RCS rat. The pictures show semithin 
sections of a normal rat eye (8 weeks old;  9A) and RCS rat eyes at the age of 4 (9B), 6 (9C), 
and 8 (9D) weeks. The loss of photoreceptor cells can be seen in the reduction of nuclei in the 
ONL. In normal rat eyes, 12 rows of nuclei are found. After the onset of degeneration the loss of 
photoreceptors is rapid. At the age of 4 weeks only 8 rows of nuclei remain and the formation of 
a  debris  layer in the subretinal  space can  be seen.  Two weeks  later only 4-5  rows of nuclei 
remain until at the age of 8 weeks almost all photoreceptors died (size bar = 50 pm).
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Using  a  positional  cloning  approach  and  sequence  analysis  D’Cruz  and 
collegues  identified  the  gene  defect  in  RCS  rats  as  the  epithelial  expressed 
receptor MERTK that is located on chromosome 3 in rodents [69],  MERTK is a 
member of a family of receptor tyrosine kinases,  which  also include Ax1,  Sky, 
and Tyro3.  All these molecules play an  important role in the development and 
physiology in mammals and are proto-oncogenes, which are involved in several
56types of malignancies (reviewed in [173]).  In RCS rats there is a small deletion 
(409  bp)  of genomic  DNA  that  includes  the  splice  acceptor  site  next  to  the 
second  coding  exon.  This  deletion  results  in  the  production  of  an  aberrant 
mRNA  in  which  the  second  coding  exon  has  been  skipped,  leading  to  a 
frameshift and a stop signal only 20 codons after the start of the open reading 
frame. The aberrant mRNA is incapable of encoding a functional protein [69].
571.3  Therapies for retinal dystrophies
The  clinical  features  observed  in  patients  with  retinal  degenerative  disorders 
reveal a large amount of heterogeneity. The complexity of the diseases makes it 
difficult to counsel patients or to develop efficient therapies. Currently strategies 
for  retinal  degenerations  therapies  include  pharmacological  treatments, 
intraocular  injections  of  factors  that  prolong  photoreceptor  survival, 
transplantation of normal  photoreceptors,  RPE  cells and stem cells,  and gene 
therapy.
1.3.1  Pharmacological agents
Pharmacological  strategies  have  the  advantage  that  the  treatment  can  be 
stopped at any time. Pharmacological agents can compensate for a biochemical 
defect and enhance or inhibit the activity of various effectors.  Pharmacological 
agents usually can be taken orally or applied by injections.  However, they need 
to be constantly administered.  Since their effects are not targeted to a specific 
tissue,  they might result in systemic toxicity and other long-term negative side 
effects.
It  has  been  suggested  that  some  types  of  Ca2+   channel  blockers,  such  as 
nilvadipine, are able to preserve photoreceptor cells in the rd mouse model and 
the  RCS  rat  and  can  potentially  be  used  to  treat  some  RP  patients  [174]. 
However,  caution  needs  to  be  exerted  in  extrapolation  to  the  comparable 
human  forms  of  RP,  as  was  highlighted  by  D-c/s-diltiazem,  another  calcium 
channel  blocker,  that  was  successfully  used  to  slow  degeneration  in  the  rd 
mouse but failed to show any effects  in the rcdl  dog -  animal  models for RP 
due  to  mutations  in  the  PDE  gene  [175,  176].  RPE  cells  and  choroidal 
endothelial  cells  are  important  cell  types  in  the  process  of  choroidal 
neovascularisation  in  AMD.  It  has  been  shown  that  the  antiproliferative  and 
antimigratory  abilities  of  drugs  modulating  calcium-dependent  signal
58transduction  (carboxyamido-triazole)  on  RPE  cells  and  choroidal  endothelial 
cells inhibit important substeps of choroidal neovascularisation.  Therefore, they 
may be of value for the treatment of choroidal neovascularisation in AMD [177, 
178].
Vitamin A has been used as a therapeutic and chemopreventive agent for some 
types of cancer and for the degenerative eye disease such  as  RP  [179,  180]. 
Patients supplemented with a daily oral dose of vitamin A have shown a slightly 
slower  rate  of deterioration  of retinal  function,  if the  intervention  is  continued 
over several years.  Up to 12 years of follow-up in these patients did not reveal 
any signs of liver toxicity as a result of excess vitamin A intake [181].  However, 
it  is  important  to  note  that  treatment  with  high  doses  of  natural  or  synthetic 
retinoids  overrides  the  body's  own  control  mechanisms,  and  therefore  carries 
with  it  risks  of side  effects  and  toxicity.  Additionally,  all  of these  compounds 
have been found to cause birth defects.
1.3.2  Neurotrophic factors
An alternative strategy to treat retinal dystrophies and a type of pharmacological 
treatment  involves  the  use  of  neurotrophic  factors.  In  all  types  of  retinal 
degeneration, photoreceptor cell loss is caused by apoptosis. Apoptosis can be 
manipulated  by  a  variety  of  different  neurotrophic  factors  implicating  that 
photoreceptor  cell  death  can  be  delayed  or  even  -  to  a  certain  degree  -  
prevented  by  the  delivery  of  different  neurotrophic  factors.  This  form  of 
treatment has the advantage that it may be effective  in disease with unknown 
genetic mutation.  Since neurotrophic factors promote photoreceptor survival  in 
general,  this  approach  can  be  used  not  only  for  a  specific  form  of  retinal 
degeneration  but  for  a  wide  range  of  disorders.  To  date  many  neurotrophic 
factors  have  been  tested  and  their  effects  investigated  in  different  animal 
models.  Neurotrophic factors  have  also  been  delivered  by viral  vectors  (see 
section 1.3.4.4) in order to achieve long-term expression and beneficial effects.
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treat retinal dystrophies, was the demonstration that injection of FGF-2 into the 
eye results in long-term survival of photoreceptor cells in the RCS rat [182].  It 
has been reported that FGF-2 slows the loss of rod photoreceptor cells in other 
animal  models for  RP  including  the  rd mouse  [183].  However,  despite  of the 
morphological  preservation,  FGF-2  treatment  did  not  result  in  a  functional 
improvement. FGF-2 is a widely distributed heparin-binding growth factor with a 
diverse  range  of  actions  critical  in  normal  development,  reproduction, 
angiogenesis  and  response  of  the  nervous  system  to  injuries.  A  potential 
disadvantage of FGF-2 is its lack of specificity and its angiogenic activity which 
results in neovascular complications.
Another neurotrophic factor with  similar effects  to  FGF-2  is  interleukin  1   beta 
(IL1-p).  IL1-P  has been tested  in the RCS  rat and  has been  shown to rescue 
photoreceptor  cells  from  degeneration  [184],  In  addition  to  preserving 
photoreceptor cell number,  IL1-p treatment also results in a preservation of rod 
inner  and  outer  segments.  Rescued  photoreceptors  have  been  shown  to  be 
functional and capable of conveying stimulus information. A problem associated 
with  IL1-P  is  its  dose  dependent  effect:  beneficial  effects  on  photoreceptor 
survival were retained at low dosage over a period of a few weeks. However, at 
high  dosage  this  cytokine  has  been  shown  to  be  associated  with  extensive 
disruption  of the  retinal  cytoarchitecture  probably  due  to  its  proinflammatory 
actions.
Glia  cell  derived  neurotrophic  factor  (GDNF)  is  a  neurotrophic factor  that  is 
synthesized  in  the  retina.  Initially,  it  has  been  found  that  GDNF  stimulates 
survival  of mice  photoreceptors  suggesting  possible  beneficial  effects  in  vivo. 
This theory has been proven true by the intraocular delivery of GDNF into eyes 
of different animal  models of retinal degeneration,  such as the rd mouse [185, 
186].  GDNF  delivery  results  in  a  significant  morphological  and  physiological 
rescue of photoreceptor degeneration.
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relatively short lived,  lasting only about a month in animals,  although the effect 
may be much  longer in humans considering the different life span.  Delivery of 
drugs is one of the most significant problems to be solved when contemplating 
survival factor therapy. The survival promoting factors are peptides that do not 
cross  the  blood-retina  barrier.  This  barrier  must  be  bypassed,  which  can  be 
accomplished  with  intraocular  injection.  Repeated  injections  are  not  only 
expensive and time consuming but also raise the risk of retinal detachment and 
endophthalmitis.  In  some  studies  significant  proliferative  response,  including 
epiretinal  membrane formation  has been  reported.  This observation of toxicity 
caused  by  different  survival  factors  pose  another  issue  that  has  still  to  be 
investigated in more detail and has to be resolved before an efficient treatment 
can  be  realised.  Yet,  this  problem  can  be  solved  by  the  delivery  of  growth 
factors via viral vectors (see section 1.3.4.4) or other biological and biochemical 
delivery systems.
Different neurotrophic factors have been delivered to animal models via adeno- 
associated virus (AAV) vectors [186, 231, 232, 244, 245]. CNTF was expressed 
intraocularly using AAV-mediated gene delivery in the rds mouse.  It has been 
shown  that  CNTF  reduces  the  loss  of  photoreceptor  cells.  Visual  function, 
however,  was  significantly  reduced  compared  with  untreated  controls  [231, 
232]. In summary, it has been demonstrated in different studies that the delivery 
of neurotrophic factors via viral vectors can result in a significant delay in retinal 
degeneration.  Whereas  FGF2  and  CNTF  result  in  long-term  morphological 
protection they did not result in a functional improvement. In contrast, GDNF did 
lead to morphological as well as functional improvement [186, 245].
The  effects  of SIV-mediated  subretinal  transfer of pigment  epithelium  derived 
factor (PEDF) has recently been evaluated in RCS rats [246].  Significant delay 
of  retinal  degeneration  up  to  24  weeks  and  functional  preservation  but  not 
prevention  of photoreceptor loss  could  be  shown  by  SIV-mediated  delivery of 
PEDF  in  RCS  rats.  This result suggests the therapeutic value of PEDF.  Even 
though  the  retinal  protection  might  not  be  sufficient  in  humans,  an  additional 
delivery  of  PEDF  in  combination  with  other  strategies,  such  as  gene
61replacement  therapy  or  transplantation,  might  result  in  additional  beneficial 
effects on photoreceptor survival.
Despite the encouraging aspects of these results in animal models, their clinical 
usefulness may be limited, because rescue effects are partial and transient and 
the mechanisms by which they occur are not well known and understood. Yet, 
they  might  be  an  useful  tool  in  combination  with  other  approaches.  Perhaps 
survival  factors  together  with  other  agents  that  exhibit  protective  effects  on 
photoreceptor  cell  survival  in  retinal  degeneration  like  antioxidants  or  anti­
inflammatory agents  might be  more  powerful  and/or longer lasting  than  either 
agent on its own. Another possible use for growth factors is in combination with 
gene transfer approaches. Many specific mutant gene targeted therapies do not 
result  in  a permanent rescue  and  often the expression  of the transgene  is  in 
therapeutical inappropriate levels.  In both cases survival factors may provide a 
better protection due to their cell  death  inhibiting effects when co-delivered to 
the specific transgene.
1.3.3  Cell therapy for retinal dystrophies
The  ultimate  goal  of  cell  therapy  as  a  therapeutic  strategies  for  different 
degenerative  retinal  diseases  is  either  to  replace  lost  photoreceptors  with 
healthy ones and to re-establish the cellular connections with the inner nuclear 
layers or to successfully transplant RPE cells.
1.3.3.1  Transplants
Retinal transplantation was first performed  in  1946 by Tansley et al [190] who 
transplanted  embryonic  ocular  tissue  into  the  brain  of  young  rats  and 
demonstrated  retinal  differentiation  of  the  transplanted  tissue.  However, 
significant  interest  in  retinal  transplantation  was  not generated  until  the  mid-
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the anterior chamber of a  mouse and demonstrated  survival  of both  allografts 
(donor and host from the same species) and xenografts (donor and host from 
different species). These original animal experiments involved transplantation of 
full-thickness  retina.  Over  the  last  15  years,  many  animal  experiments  have 
been carried out to improve transplantation protocols of different cell types into 
the eye and to prolong their life span  in the host [192,  193].  A main  problem, 
that still has to be overcome, is that transplants have a limited ability to integrate 
into the host retina. Animal experiments suggest that visual information may be 
received and transmitted by transplanted retinal tissue to the host brain but the 
quality  of the  transmitted  information is  undefined,  and  vision  beyond  simple 
light perception has not been demonstrated in patients.
Different retinal degenerations affect different layers of the retina.  Mutations of 
the  MERTK  gene  for  example  lead  to  a  malfunction  of  the  RPE  and  to 
degeneration of this cell layer. The loss of photoreceptor cells is secondary. The 
development  of  techniques  to  transplant  retinal  epithelium  cells  that  remain 
viable  and  functional  for  relatively  long  periods  of  time  has  opened  up  the 
possibility  of  correcting  such  genetic  defects  by  transplantation.  In  the  past 
decade,  the  idea  of  replacing  aged  and/or  diseased  RPE  with  healthy  RPE 
allograft  or xenograft  has  been  extensively  investigated  in  the  RCS  rat  [194- 
196].  It has  been  demonstrated that  it  is  possible to transplant normal  retinal 
epithelial cells into the subretinal space of dystrophic,  congenic RCS rats.  The 
host  retina  re-attaches over the transplant and  host photoreceptor shed  outer 
segments  are  phagocytosed  by  the  transplanted  RPE  cells,  thereby  locally 
correcting the genetic defect.  RPE transplants  have been  shown to survive  in 
the  subretinal  space  and  prevent  photoreceptor degeneration to  some  extent. 
These results raise the possibility that some blinding disorders in humans may 
be amenable to treatment by RPE transplantation.  However, currently there is a 
major problem with rejection of transplanted cells.  In most animal studies either 
immune suppression or congenic cells are required for long-term survival.
A  number  of  clinical  trials  involving  transplantation  of  either  RPE  or 
photoreceptor  cells  have  been  carried  out.  A  patient  suffering  from  non-
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the subretinal space with the aim of preserving photoreceptor cells. The patients 
vision,  however,  remained  unchanged  and  fluorescein  angiography  showed 
leakage and staining at the level of the outer retina.  Furthermore, there was an 
immune  response  against  proteins  associated  with  photoreceptors  [197].  In 
another  study,  eight  patients  with  RP  and  one  patient  with  advanced 
neovascular AMD  received subretinal transplants of fetal  retinal  photoreceptor 
suspensions.  Even  though  light  responses  improved  initially,  visual 
improvement disappeared between 3 and 13 months [198].
For transplantation to become a viable therapeutic option for patients with retinal 
degenerations,  a number of different problems will  need to be overcome.  New 
techniques  are  likely  to  be  required to  allow  larger  quantities  of tissue  to  be 
transplanted into the subretinal space in the proper orientation.  Approaches to 
enhance long-term survival of grafted tissue have to be developed. To develop 
a useful transplantation strategy for AMD and some forms of RP the survival of 
transplanted  photoreceptor cells  has  to  be  ensured.  This will  require,  among 
other things, healthy cells forming a layer between the remaining retina and the 
RPE.  More reliable  and  reproducible  methods  of  measuring  visual  function in 
patients with low levels of vision are essential. However, the largest hurdle is the 
establishment of functional  connections  between the graft and the  host retina. 
Currently, experiments are carried out to replace lost or damaged photoreceptor 
cells by implanting sheets of photoreceptor cells grown in tissue culture onto the 
retina  of  animals  [199,  200].  However,  the  transplanted  cells  have  not  yet 
successfully  integrated  effectively  with  the  cells  of  the  host  retina.  In  other 
approaches,  stem  cells  are  being  placed  in  the  retina  in  an  attempt  to  form 
functioning photoreceptors.
1.3.3.2  Stem cells
Recently,  stem  cell  implantation  as  a  regenerative  strategy for treating retinal 
disease has become the object of extensive investigation.  Stem cells are cells
64that self renew and give rise multiple mature cell types. Many experiments have 
employed stem cells or neural precursor cells derived from the developed retina 
or brain [201-204].
Embryonic stem  cells (ES)  are  pluripotent and  can  be  induced  under specific 
conditions to differentiate into almost any cell type including neurons (reviewed 
in [205]).  ES have been shown to cause tumours when introduced into animals 
[206]  and  therefore  it  is  important for clinical  applications  that  ES  undergo  a 
certain degree of differentiation before introduced into the target tissue.  ES can 
be  induced  to  generate  neural  progenitor  cells  in  vitro  that  can  be  used  as 
therapeutic agents. These cells have been injected intravitreally into rd mice,  a 
model for autosomal  recessive  RP  that carries  a  mutation  in the p-PDE  gene 
(see  chapter  1.2.6.).  Cells  have  been  shown  to  migrate  to  the  inner  retina, 
integrate  into  the  neuroretina  and  develop  neuron  like  processes.  However, 
donor cells did not differentiate into photoreceptors, a potential limitation of this 
approach [203].
An  alternative  to  embryonic  stem  cells  are  retinal  stem  cells,  which  are 
multipotent  precursors  that  give  rise  to  the  retina  during  development  (see 
chapter 1.1.1) [207]. While retinal stem cells are present throughout life in lower 
vertebrates, they have little activity after the eye cup formation in mammals [18]. 
However,  it is possible to isolate retinal stem cells from postnatal mouse retina 
and culture them.  Stem cells that are derived from the central  nervous system 
(CNS)  have  been  injected  into the vitreous of RCS  rats.  This  resulted  in  cells 
integrating  into  the  degenerating  retina  and  there  was  some  suggestion  of 
differentiation  into  neurons  [204].  However,  there  is  little  evidence  to  suggest 
that the cells had differentiated into retinal neurons in this or in any other study 
involving transplantation into animal models of retinal degeneration [201, 208].
A major issue facing stem cell therapy for retinal dystrophies is the question of 
functional  integration  of  grafted  cells.  Furthermore,  experiments  need  to  be 
extended to  larger animal  models,  such  as the  pig,  the  dog  and  monkeys,  to 
demonstrate  efficiency  in  settings  more  closely  to  humans.  Studies  of  larger
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and  facilitate  the  development  of  applicable  cell  delivery  strategies. 
Furthermore,  retinal  stem  cells  of  humans  need  to  be  isolated  and 
characterised.  However,  stem  cells  have  a  promising  potential  and  play  an 
important  role  in  the  development  of  strategies  directed  towards  retinal 
dystrophies.
1.3.4  Gene therapy
Gene  therapy  may  be  one  of the  most  important  developments  in  medicine. 
Since gene therapy may be able to correct the underlying genetic defect rather 
than  just  focusing  on  symptoms  it  might  be  able  to  provide  an  effective 
treatment for  otherwise  incurable  diseases.  Nevertheless,  before  this  can  be 
realised  certain  technical  problems  common  to  all  methods  of gene  delivery 
must be overcome.
Gene therapy for other diseases has already moved from the laboratory into the 
clinic.  Severe  combined  immune  deficiencies  (SCIDs)  is  characterised  by  a 
disturbances  of  lymphocyte  development  and  function  resulting  in  immune 
system  disfunction  [209].  Affected  individuals  are  inclined  to  infections  and 
without treatment do not survive beyond the first year of life.  SCIDs comprise a 
group  of  monogenic  diseases  of which  the  main  two  disorders  are  X-linked 
SCID  (SCID-X1) and adenosine deaminase-deficient SCID  (ADA-SCID)  [210]. 
General treatment options for the latter disorder include transplantation of bone 
marrow,  injections  of  synthetic  ADA  and  gene  therapy.  Bone  marrow 
transplants from normal,  histocompatible,  donors would ideally give the child a 
continuous  source  of  ADA+   T  and  B  cells.  However,  even  though  the  child 
cannot reject the transplant because the child has no immune system, T cells in 
the transplant (unless the donor was an identical twin) can attack the cells of the 
child  producing graft-versus-host disease.  ADA injections have been tested  in 
clinic and  have  shown  to  keep  patients  healthy.  ADA  is  currently  conjugated 
with polyethylene glycol (PEG) to delay its breakdown in the blood but,  as it is
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must be repeated frequently [211]. Virus-mediated gene therapy on the contrary 
would  not  result  in  an  immune  response  and  does  not  require  constant 
treatment. The first clinical trial was started in  September 1990 when scientist 
treated  4-year  old  Ashanthi  DeSilva  who  was  born  with  ADA-SCID.  Ashanti 
carried a defective version of the gene that encodes ADA.  In the first attempt to 
treat the disorder,  her own T cells were stimulated to proliferate,  infected with 
retroviral vectors that carried  a functional  copy of ADA and then  injected.  The 
treatment resulted in an improved immune function but the injections had to be 
repeated because T cells live for only 6-12 months in the blood.  However,  she 
was  treated with  PEG-ADA for additional  benefits.  Therefore,  it  is  not  certain 
whether  the  introduction  of  the  therapeutic  gene  into  her  white  blood  cells 
deserves  the  credit  (reviewed  in  [212]).  In  2002,  the  first  successful  gene 
therapy treatment of two young ADA-SCID  patients was  reported.  They were 
treated with their own blood stem cells that had been transformed in  vitro with 
the ADA gene. After a year, both children had fully-functioning immune systems 
and  were  able  to  live  normal  lives  without  any  need  for  additional  treatment 
such as ADA-PEG [213].
SCID-X1  is  due  to  a  mutation  of the  y-c  chain  gene  encoding  a  number  of 
multiple  cytokine  receptors  including  interleukin-7  (IL-7).  IL-7  is  essential  for 
converting blood stem cells into the progenitors of T cells.  Boys with  SCID-X1 
can  make normal  B  cells but because  B  cells  need T-helper cells to function, 
these boys had neither cell-mediated nor antibody-mediated immune responses 
and had to live in a sterile bubble before their treatment.  In October 2002 it was 
reported that 3 out of 15 children suffering from X-linked SCID showed the first 
symptoms  of  a  leukaemia  like  syndrome,  30  months  after  receiving  genetic 
treatment [215, 216].  Later insertional mutagenesis of the viral vectors into the 
oncogene LM02 has been framed to be the cause of the T cell leukaemia [217]. 
However,  now four years after the treatment the other  12  children  live normal 
lives  at  home  instead  of  inside  a  sterile  "bubble",  they  have  normal  T  cell 
numbers, and their antibody production is sufficiently good so that they have no 
need for frequent injections of immune globulin.
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has been made in the basic science of viral and  non-viral vector development 
used  to transfer genes  into  patients  over the  last few years  [218],  In  order to 
further  develop  this  technology  it  is  necessary  to  identify  genes  involved  in 
diseases, to improve the regulation of the transgene expression and to upgrade 
gene delivery systems.  Frequencies and mechanisms of vector integration into 
the host genome have to be understood  better in order to seek a way to gain 
accurate control over the integration process.
Figure  1.10:  Clinical  trials,  (a)  Number  of 
clinical trials world wide,  (b) Clinical trials by 
diseases (http:// 217.215.32.12/trials).
(a)
Continent Number
America 662 (67.1  %)
Europe 277 (28.1 %)
Asia 19(1.9%)
Australia 17(1.7%)
Africa 1  (0.1  %)
(b)
■  cancer diseases
■  monogenic diseases
□  Vascular diseases
□  infectous diseases
■  other diseases
□ gene marking
■  healthy volunteers
Indications Number Percent
cancer diseases 656 66.5
monogenic
diseases 93 9.4
Vascular diseases 80 8.1
infectious diseases 65 6.6
other diseases 29 2.9
gene marking 52 5.3
healthy volunteers 12 1.2
total 987 100
681.3.4.1  Gene therapy and the immune system
One of the main challenges of gene therapy is to circumvent the host immune 
system. When pathogens enter the body an innate immune response develops 
quickly  and  causes  the  generation  of cytokines  and  an  influx  of non-specific 
inflammatory cells such as macrophages and dendritic cells. These non-specific 
cells recognise pathogenic epitopes in the viral capsid or bacterial membranes 
via  specific  receptors.  The  recognition  results  in  the  production  of 
proinflammatory  cytokines  and  a  stimulation  of the  adaptive  immune  system. 
The adaptive immune system  is activated  later on  by antigen-presenting cells 
(APCs)  that  carry  antigens  from  pathogens  to  the  lymph  nodes.  There  they 
evoke a lymphocytes response of CD4+  and CD8+  T cells which consequently 
leave  the  lymph  nodes.  Via  specific  T  cell  receptors  the  specific,  APC- 
presented,  pathogenic  epitopes  are  recognised  and  the  production  of 
proinflammatory cytokines (such as  IL-1  and TNF)  is stimulated.  CD8+  T cells 
eliminate  the  infected  cell  by  secreting  cytotoxic  substances  like  INFy.  The 
interaction of the pathogen with  B cells results  in the  production of antibodies 
(ABs),  which  are able to bind to the  pathogen  and  thereby launch  a  chain  of 
reactions that ultimately neutralise the  microorganismus.  The final  success  of 
each gene therapy approach depends in large part on the ability of the vector to 
deliver the therapeutic gene without evoking an immune response. An immune 
response against the vector would eliminate the vector and the transfected cells 
and  hence  decrease  the  duration  and  intensity  of  transgene  expression. 
Additionally, proinflammatory cytokines have a cytotoxic effect. The activation of 
the adaptive immune system finally results in the generation of a “memory”  that 
renders re-administration of vectors difficult.
Strategies  to  circumvent  immunity  of  vectors,  including  vector  alterations, 
pseudotyping,  immunosuppression,  the  generation  of  “tolerant”   APCs  and 
alteration  of the  vector  structure,  have  been  developed  to  increase  safety  of 
gene  therapy  approaches  (see  [219-221]  for  reviews).  One  of  the  main 
advantages of retro- and lentiviral vectors for gene therapy is that they generally
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transgene  rather that the  recombinant  virus.  However,  retro-  and  lentiviruses 
can  be  inactivated  in  the  serum  by  the  complement  system  and  a  cytotoxic 
response  [222,  223].  Immune  responses  to  other  vectors  are  various  and 
depend on the vector’s characteristics (see chapter 1.3.4.4), the dose,  route of 
administration,  the transgene and  host related factors.  One possible way of a 
non-viral gene therapy approach employs plasmid derived from bacteria. These 
plasmids can -  when delivered on their own or in combination of liposomes or 
electroporation -  evoke an innate immune response.  It has been demonstrated 
that bacterial  DNA includes CpG  motifs more frequently than eukaryotic DNA. 
The  CpG  motifs  have  an  immune  stimulating  character  and  induce  cytokine 
production as well as an activation of the adaptive immune system. The level of 
immune stimulation is dependent on the level of methylation of the CpG motifs. 
Strategies to avoid an immune response against bacterial plasmids include the 
elimination or methylation of these motifs [224, 225].
Another  problem  is  the  immune  response  against the  transgene  itself.  Gene 
replacement therapy  introduces  a gene that  is  normally  not expressed  in  the 
patient.  If APCs present this unknown gene to CD4+  T cells they might respond 
with  the  production  of cytokines.  An  activation  of  B  cells  might  result  in  the 
production of ABs against the therapeutic gene and CD8+  T cells might develop 
a cytotoxic response.  Therefore a specific tolerance has to be induced prior to 
any  contact with  the  transgene.  This  is  possible  by  the  administration  of the 
gene  of  interest  without  any  non-human  sequences  that  could  boost  the 
immune  system.  Without  these  costimulatory  signals  the  transgene  is 
introduced to T cells making them “unresponsive”  to the specific transgene.  In 
this  state T  cells would  not  be  activated  by this  specific transgene  even  with 
costimulation of a virus.
701.3.4.2  The eye as a target for gene therapy
Inherited retinal dystrophies comprise a large number of disorders characterised 
by a slow and progressive retinal degeneration. There is currently no treatment 
by which the primary disorder can be modified. To date much work has been -  
and  still  is  -   done  to  develop  different  therapeutic  approaches  to  solve  this 
problem.  These approaches are based on the  possibility of modulation of cell 
death  by  pharmacological  substances,  growth  factors,  transfecting 
photoreceptor  and  RPE  cells  with  functioning  genes,  or  transplanting 
photoreceptor,  RPE  cells  or stem  cells  into the  subretinal  space.  Most  of the 
strategies so far have been limited in success.  Gene therapy appears the most 
promising approach to date. Conditions or disorders that arise from mutations in 
a  single  gene  are  the best  suited  candidates for gene  therapy  and  there  are 
many monogenic disorders leading to retinal degeneration.
The eye is an attractive target for gene therapy because of its accessibility that 
facilitates an in vivo examination by ophthalmoscopy. Another advantage is the 
immune privilege of the eye, which reduces the risk of stimulating immunocytes 
and  therefore  enhances  the  effectiveness  of  gene  therapy  approaches.  The 
blood-retina and the blood-aqueous barrier concentrate the vectors and reduce 
their spread out of the eye.  Since the eye consists of a variety of tissues,  for 
example endothelium,  epithelium,  muscle and neurons,  it might be used to test 
and investigate the delivery of transgenes to different cell types [226].
The  delivery of the transgene to  a  specific tissue  is of significant  importance. 
There are several possible sites for introducing genes into the eye.  Intravitreal 
injection  is  a  relatively  safe  and  easy  method  of  approach  but  potential 
complications  such  as  vitreous  haemorrhage,  retinal  detachment,  and 
endophthalmitis cannot be ignored.  Furthermore,  studies  using animal  models 
have  found  that while  intravitreal  injections  result  in  efficient  AAV-mediated 
ganglion cell transduction, transduction efficiency is lower for outer retinal layers 
[227]. Therefore,  it is important to deliver the vector as close as possible to the 
target  cell  type.  The  retina-blood  barrier  restricts  the  permeation  of  large
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macromolecules.  The  neural  retina  is  a  multilayer  consisting  of  various  cell 
types.  Among these  layers,  the  internal  and  external  limiting  membranes  and 
the  interphotoreceptor matrix,  which  is rich  in glycosaminoglycans,  might have 
barrier  properties.  Therefore,  subretinal  injection,  which  produces  a  local and 
often  transient  detachment  of the  retina,  has  so  far  been the  most favoured 
means of accessing the photoreceptor layer and the RPE [228, 229].
Recently significant progress regarding in vivo gene transfer to photoreceptors 
using viral vectors to delay photoreceptor loss and prolong and improve retinal 
function  has  been  achieved  in different animal  models of retinal  degeneration 
[105, 230-233].
1.3.4.3  Therapies for monogenic dominant disorders
Monogenic recessive diseases require the functional  gene to be expressed  in 
therapeutically  useful  levels  in  order  to  alter  the  patho-physiological  state. 
Replacing  or  augmenting  a  defective  gene  by  delivering  its  wild-type 
counterpart, thus offers a potential means to correct the pathogenic basis of the 
disease  (see  section  1.3.4.4).  Monogenic  dominant  diseases  are  more 
complicated to treat,  since the addition  of a healthy allele may not be enough 
because its disease causing, malfunctioning counterpart may have a toxic effect 
on the cell. Therefore, the aberrant gene needs to be silenced.
Antisense oligonucleotides have been  used  to demonstrate downregulation  of 
the  expression  of  a  photoreceptor-specific  protein,  rcfs/peripherin  in  vitro. 
However,  oligonucleotides  are  poorly  stable  in  vivo,  have  a  low  intracellular 
penetration  and  are  quickly  eliminated  form  the  vitreous.  Administration  of 
oligonucleotides  are  therefore  repeated.  Although,  antisense  oligonucleotides 
that target VEGF delivered via intravitreal injection have been shown to reduce 
iris neovascularisation in a non-human primate model [234], to date there have
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diseases.
Another  approach  to  address  dominantly  inherited  diseases  is  the  use  of 
ribozymes,  small  RNA  molecules  that  cleave  mutant  transcripts  in  an  allele- 
specific  manner  while  leaving  wild-type  transcripts  intact  [235].  Twentyfive 
percent  of  all  RP  cases  are  due  to  mutations  in  the  rhodopsin  gene.  The 
inheritance  pattern  is  autosomal  dominant.  The  most  common  mutation  is  a 
substitution  of  histidine  for  proline  at  codon  23  (P23H),  resulting  in 
photoreceptor  cell  death  from  the  synthesis  of  the  abnormal  gene  product. 
Ribozymes  can  discriminate  and  catalyse  the  in  vivo  destruction  of  P23H 
mutant  mRNAs  in  a  transgenic  rat  model  of  autosomal  dominant  RP. 
Recombinant  adeno-associated  virus  (rAAV)  vectors  were  used  to  deliver 
ribozyme genes to photoreceptors.  Expression of the ribozyme, slowed the rate 
of photoreceptor degeneration for at least 8 months and resulted in significantly 
greater (93 %) electroretinogram amplitudes in comparison to untreated control 
animals [236, 237].
The most effective way of ablating mRNA is through the use of small interfering 
RNA (siRNA).  siRNAs are small double stranded RNA molecules, which, when 
inserted  into  a  cell,  interfere  with  post-transcriptional  processing  of  the 
endogenous mRNA and thereby specifically turn off the expression of a certain 
gene. siRNA targeted against VEGF has been shown to effectively inhibit laser- 
induced  choroidal  neovascularisation  in  a  mouse  model  and  in  non-human 
primates [238, 239]. These results show the potential value of RNA interference 
for the treatment of retinal diseases that involve abnormal  blood vessel growth 
and  is  now being tested  in  patients with AMD  [240].  In  vitro,  siRNA has  been 
used  to target rhodopsin  in  a  mutation  independent approach.  Degeneracy  of 
the  genetic  code  was  used  to  engineer  a  codon-exchanged  mRNA.  In  these 
experiments,  native  transcripts  are  suppressed  by  a  single  RNAi  molecular 
species, whereas transcripts from genes engineered at degenerate third-codon 
wobble positions are resistant to suppression.  Suppression levels of the native 
transcript were up to 90  %.  The  result was confirmed  in  retinal  explants  [241, 
242].
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mutations in different genes and by the accessibility of the ribozyme or siRNA to 
the  transcript  [243].  In  order  to  overcome  this  problem,  strategies  to  deliver 
neurotrophic factors that promote photoreceptor survival  have been developed 
(see chapter 1.3.4.4).
1.3.4.4  Virus-mediated gene transfer for retinal degenerations
The  ideal  vector should fulfil  different  requirements  that  are  necessary for an 
efficient treatment.  Preparation of this vector would be relatively simple (e.g. not 
involving multiple steps such as attachment of a ligand targeting a particular cell 
type) and result in high vector concentrations.  The ideal vector should be able 
to  deliver  the  transgene  to  a  specific  target  cell  type  without  it  spreading 
elsewhere.  Many viruses  have preferences for specific cell  types,  for example 
the  natural  tropism of HIV-1  to CD4+  cells,  or they  infect a wide range of cell 
types,  like  adenoviruses.  However  it  is  possible  to  change  this  tropism  by 
pseudotyping.  Another regulatory element for tissue specificity is the choice of 
the  promoter.  The  most  frequently  used  promoters  are  viral  in  origin,  often 
derived  from  a  different  virus  than  the  vector  backbone,  for  example  the 
cytomegalovirus  (CMV)  promoter  has  been  used  in  all  vector  systems.  Viral 
promoters  have  the  advantages  of  being  smaller,  stronger  and  better 
understood than most eukaryotic promoter sequences. One of the drawbacks of 
viral promoters is their tendency to be silenced when there is an immunological 
response and that many of them are ubiquitously active in all tissue types [247]. 
A  temporal  expression  of  the  transgene  can  be  controlled  by  inducible 
promoters such as the tetracycline promoter, which has been shown to lead to 
sustained  inducible transgene  expression  in  retinal  ganglion  cells  in  mice and 
rats  [248-250].  Expression  of  the  transgene  should  be  in  appropriate 
therapeutical  levels  and  over  a  designated  period  of  time,  which  in  case  of 
monogenetic  inherited  disorders  would  mean  permanent  expression.  To 
successfully achieve this,  efficient uptake of the virus into the target cell has to
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effects.  To  allow  subsequent  re-administration  and  avoid  undesired  host 
reactions there would be no significant immune response to any component of 
the vector. The lack of an immune response may allow transgene expression to 
be sufficiently prolonged from episomal  systems,  such that re-administration is 
not  necessary.  Alternatively,  integration  into the  host genome,  preferably  in  a 
site-specific  location,  would  ensure  that  the  transgene  is  not  lost  during  the 
lifetime of the cell.  Furthermore,  endocytosis and lysosomal degradation of the 
virus must be avoided [46].
Viruses  can  be  regarded  as  highly  developed  biological  machines  that  have 
successfully evolved a way to gain access to eukaryotic cells.  Once they have 
entered into the host cell they use the host’s innate cellular machinery for their 
own  replication.  For  most  gene  therapy  applications  the  optimal  virus-based 
vector  employs  the  viral  infection  pathway  but  at  the  same  time  avoids  the 
negative  effects  of  a  viral  infection  such  as  viral  replication  of the  virus  and 
toxicity. To accomplish this, coding regions that are normally necessary for viral 
replication and packaging are deleted from the viral genome.  Instead of these 
viral  sequences,  a transgene of choice  is  cloned  into the viral  backbone.  The 
recombinant vector particles are then produced in packaging cell lines,  in which 
the  vector  genome  and  the  packaging  construct  are  co-transfected.  The 
complementing packaging plasmid delivers genes necessary for replication and 
packaging in trans.  Normally, vectors are designed in a way that they share no 
homologous  sequence,  thereby  reducing  the  risk  of  generating  replication 
proficient  wild-type  virus  by  homologous  recombination.  For  gene  therapy 
approaches,  four  main  classes  of  viruses  have  been  used.  These  can  be 
separated into two groups: retroviruses including the family of lentiviruses which 
integrate  their  genome  into  their  host’s  whereas  the  genome  of  adeno- 
associated viruses, adenoviruses, herpes viruses persists as extrachromosomal 
episome.  Initially,  gene  therapy  was  only  targeted  against  monogenetic 
inherited  defects  but to  date  acquired  disorders,  such  as  cancer or  infectious 
diseases,  form  the  main  field  of gene  therapy  research.  The  diversity  of the 
diseases makes clear that no single vector is suitable for all applications.  Each
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(reviewed in [251]).
Gene therapy approaches for ocular diseases have relatively recently started to 
develop. However, many different types of vectors have been successfully used 
to  deliver  reporter  genes  and  therapeutical  transgenes  into  different  animal 
models  of ocular disorders,  suggesting  the  potential  for targeting  the  eye.  To 
date,  experiments  have  shown  that  non-neuronal  cells  of  the  retina  and  in 
particular  RPE  cells  are  efficiently  transduced  by  different  viral  vectors.  This 
data  suggests that  retinal  degenerative  disorders,  which  arise from  mutations 
within  genes  specifically  expressed  in  the  RPE,  are  most  suitable  for  gene 
therapy approaches. A major challenge which still needs to be addressed is to 
further  improve the efficiency  of transduction  of photoreceptor cells  and  other 
neuronal  cell  types  in  the  retina  and  to  reduce  immune  responses  against 
different viruses in order to prolong transgene expression.
1.3.4.4.1  Herpes simplex virus-based vectors
Herpes simplex viruses (HSV) are a family of large,  complex viruses;  of which 
several are known to be human pathogens. The viral genome is a linear, double 
stranded DNA molecule of approximately 152 kb. Since most of the viral genes 
are  dispensable  for  viral  growth  in  tissue  culture,  more  than  half of the  viral 
genome  can  be  deleted  allowing  the  insertion  of  large  transgenes  including 
complex  regulatory  elements.  Further  advantages  are  the  easy  manipulation 
and the production of high titre viral suspensions.  Their episomal  nature in the 
latent  state  also  avoids  problems  of  disruption  or  activation  of cellular genes 
that could occur with vectors, which  integrate into the cellular genome such as 
retroviruses.  To minimise the risk of cytotoxicity all viral gene expression must 
be abolished and the possibility of generating wild-type virus avoided.
Wild type HSV enters its host via epithelia and spreads to neuronal cells where 
latency,  in which the virus persists as an  intranuclear episome,  is established.
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for gene transfer to the nervous system.  Two main types of HSV-based vectors 
have  been  reported  in  gene  delivery  approaches  -  recombinant  viruses  and 
amplicons  [252].  Spencer and  colleagues  [253]  used  a  replication competent, 
attenuated HSV virus.  The virus is deleted for essential in vivo virulence genes 
but retains the ability to be propagated in vitro and limited replication capacity in 
vivo.  Therefore,  the virus can be easily grown to high titres without helper cell 
lines  or  viruses.  The  virus  was  tested  in  rats  and  mice  in  vivo  and  the 
transduction  pattern  was  evaluated  after  different  application  routes.  The 
authors  suggested  that  after  topical  delivery  to  the  cornea,  transgene 
expression  in  the  comeal  epithelium  was  apparent  with  occasional  cells 
expression  in the  iris  pigment epithelium, trabecular meshwork,  and the ciliary 
body. They also claimed that intracameral and  intravitreal  injections resulted in 
transduction  of approximately 75  %  of the  RPE  and weak transduction  of the 
ciliary  body  and  cells  of  the  trabecular  meshwork  as  well  as  the  corneal 
endothelium [253].
While gene transfer to the eye using recombinant HSV have been evaluated in 
several  studies  [253,  254],  the  potential  of amplicons  has  only  recently  been 
explored  [255].  The  HSV  amplicon  contains  bacterial  and  viral  origins  of 
replication,  to allow easy manipulation in  E.  coli,  and a viral  packaging signal. 
After  infection  of the  amplicon  and  HSV  helper  virus  in  eukaryotic  cells,  the 
amplicon is amplified and packed into virions.  Hybrid vectors, which incorporate 
the AAV inverted terminal  repeats  (ITR)  into the amplicon  plasmid  have been 
generated to increase the target cell spectrum.  If in addition the AAV rep gene 
is  present the  virus gains the  ability to  integrate  into the  host genome.  It  has 
been demonstrated that HSV/AAV hybrid vectors can be packaged into HSV-1 
virions,  thereby  exploiting  the  large  transgene  capacity  of  HSV-1.  Moreover, 
upon  infection of human cells,  the hybrid vector genome directs the integration 
of transgenes into the AAVS1  locus. However, the AAV rep gene inhibits HSV-1 
DNA replication, which drastically reduces the titres of HSV/AAV hybrid vectors, 
compared to that of standard HSV-1  amplicons [256-258].
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have been tested in  vitro and in vivo.  In these vectors the gfp gene was either 
under the  control  of the  CMV  promoter  or  the  RPE-specific  rpe65  promoter. 
Transduction  profiles  of HSV amplicons  after subretinal  delivery  into  rat eyes 
have  been  evaluated.  Efficient  transduction  with  both  vectors,  which  was 
restricted  to  RPE  cells  was  observed.  However,  transgene  expression  was 
apparent as early as 24 hr after delivery but was transient and undetectable 6 
weeks  after  injection  [255].  Therefore  it  was  concluded  that  HSV  amplicons 
allow early onset and efficient transfer to the RPE. The transient nature of gene 
expression, however,  limits the usefulness for gene replacement therapy and is 
probably due to an immune response to the HSV capsid.
1.3.4.4.2  Adenoviral vectors
Adenoviruses  (Ad)  are  non-enveloped  viruses,  which  contain  a  linear,  non­
segmented  double  stranded  DNA  genome.  Many  Ad  serotype  strains,  even 
though  not  highly  pathogenic,  are  associated  with  infections  in  humans,  in 
particular of the respiratory tract. The lifecycle of Ad normally does not involve 
integration in the host genome but they replicate as  episomal  elements  in the 
nucleus of the host cell and therefore there is no risk of insertion mutagenesis. 
DNA fragments  up to a  size  of 30  kb  can  be  incorporated  into these vectors. 
The  production  is  easy  and  virus  suspensions  can  be  purified  to  high  titres. 
Whereas  Ad  vectors  have  several  advantages  over  other  vector  systems, 
limitations have become apparent with their use in vivo (reviewed in [259]).
First  generation  Ad  vectors  carry  deletion  of  the  E1  and/or  E3  regions,  viral 
genes  that  are  involved  in  modulation  of the  cell  cycle,  viral  DNA  replication, 
and invasion of the host immune system [260, 261]. The major disadvantage of 
the first generation of Ad is that they evoke immune responses against the viral 
vector capsid  proteins  and  infected  cells  expressing  viral  antigens.  Therefore 
transgene  expression  in  vivo  is  transient  and  disappears  1   to  2  weeks  after 
delivery. To circumvent this problem,  second generation Ad vectors have been
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replication  [262,  263],  in  order to  minimise the  immune  response,  abolish  the 
potential oncogenicity, to make vector replication deficient as well as to expand 
the cloning  capacity of adenoviral  vectors.  Since  E1  proteins  are essential for 
viral  replication,  they  need  to  be  delivered  in  trans  (helper  dependent  Ad 
vectors).  The  third  generation  Ad  vectors,  also  called  gutless  or  mini  Ad 
vectors,  are deleted of more viral  genes.  They only retained the viral  ITR and 
packaging sequences and required helper virus and appropriate complementing 
cells for propagation, followed by careful  purification.  Nevertheless,  there were 
problems associated with these techniques, mainly due to contaminating helper 
virus  and  vector  instability  [264-267].  They  have  been  shown  to  give  less 
immune  response  and  hence  resulting  in  longer  transgene  expression. 
Encapsidated Ad  mini-chromosomes  (EAM)  contain only the  ITR and five c/s- 
acting  Ad  encapsidation  signals  necessary for  packaging  but  no  viral  coding 
sequences.  These  vectors  can accommodate  up to  36 kb  of exogenous  DNA 
and are unable to express viral proteins [268, 269].  EAM vectors are produced 
by  replication  in the  presence  of a  helper virus,  which  provides  all  necessary 
viral proteins in trans. Thereby cytotoxic effects due to de novo synthesis of Ad 
proteins of earlier generations of Ad are reduced [270].  It has been shown that 
EAMs  can  transduce  retinal  cells.  EAM-mediated  delivery  of the  p-PDE  to  rd 
mice  resulted  in  a  prolonged  photoreceptor  survival  up  to  12  weeks  post 
injections [271].
The ability of Ad vectors to deliver and express genes at high levels, especially 
in  vitro,  has  been  demonstrated  over  the  last  two  decades.  However,  the 
immune  response  in  vivo  has  been  a  limiting  factor  in  the  development  of 
vectors for human applications.  It is critical to control or to suppress the immune 
response  to  the  vector  and  the  transgene  where  persistent  expression  is 
needed in the case of supplementing the activity of a faulty gene. However, the 
first lifetime phenotypical correction of a gene defect using Ad vectors has been 
reported recently [272]. Safe and permanent correction of a liver-based genetic, 
autosomal  recessively  inherited  disease  (Crigler-Najjar  (CN)  disease  type  I) 
has  been demonstrated  in  rats for more than 2 years after the delivery of the 
therapeutic gene via helper dependent Ad.
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eye. The virus is able to transduce a wide range of different cell types in the eye 
but  favours  transduction  of the  RPE  as  well  as  Muller  cells  of the  neuronal 
retina  following  subretinal  injections  into  the  adult  mammalian  eye  [273]. 
However,  even in the immune privileged retina,  immune reaction to Ad vectors 
appear to limit its effectiveness to 3 to 8 weeks in mice, suggesting that vectors 
antigens are recognized and responded to relatively normally in the subretinal 
space  [274].  Photoreceptor  cells  are  poorly  transduced  by  the  virus,  but 
transduction  efficiency is  higher if the  photoreceptor cell  are  in the  process of 
development,  as  it  is  the  case  in  neonatal  mice  shortly  after  birth  or  in  the 
process of degeneration, for example in young adult rds mice.  In these cases, 
photoreceptors are more accessible to virus. The former finding is of no clinical 
importance though, because photoreceptor cells in humans are fully developed 
at birth.
An example for the utility of Ads in ocular gene therapy is the rescue of the RCS 
rat.  Recently it was shown by Vollrath et al [233] that 1   month after treating the 
RCS  rat with  rAd  containing  the  MERTK gene,  the  number  of  photoreceptor 
cells was 2 to 3 fold higher in areas of injections and photoreceptor function was 
maintained.  The  authors  show  that  the  phagocytic function  of  the  RPE  was 
restored and that photoreceptor activity one month after injection was higher.  In 
this  study,  however,  the  survival  of the  photoreceptors was  not followed  over 
time  and  it  is  therefore  unclear  how  long  the  improvements  lasted.  These 
experiments provided the formal proof that the MERTK gene is the actual cause 
of the disease in these animals and indicated gene therapy for this form of RP 
may be possible [233],
1.3.4.4.3  Adeno-associated viral vectors
Adeno-associated  viral  (AAV)  vectors  have  generated  considerable  interest 
recently.  AAV  belong  to  the  family  of  parvoviruses,  which  are  among  the
80smallest,  simplest  eukaryotic  viruses.  Essentially,  they  fall  into  two  groups, 
defective  viruses  that  are  dependent  on  helper  virus  for  replication  and 
autonomous,  replication-competent viruses. Their wild-type genome is a single 
stranded DNA molecule. AAVs are not associated with any human disease and 
therefore are considered to be safer than other viruses for the development of 
gene therapy approaches for human disorders. AAV exist in different serotypes. 
They  differ  in  their  cell  surface  receptors,  heparin  sulphate  and  sialic  acids, 
which results in different cell tropism of viruses.  Therefore,  it is possible to use 
different  serotypes  to  target  specific cells  in  vivo.  A  number  of serotypes  are 
currently under development as clinical gene delivery vectors for the treatment 
of human diseases but AAV-2  is the most extensively studied  and used  (for a 
review see [275]). A route to alter the cellular tropism of rAAV is pseudotyping. 
Constructs are employed that encode rep from  one serotype whereas the cap 
gene is derived from the serotype or another virus displaying the cell tropism of 
choice  [221].  The  cellular  tropisms  of  different  serotypes  in  the  eye  are 
discussed in more details in section 3.8.
The main advantages of AAVs are that they are capable to infect both, dividing 
and non-dividing cells and that the wild-type AAV integrates into a specific point 
on  chromosome  19  of the  host  genome  at  a  high  frequency.  However, rAAV 
lacks  the  ability  to  do  this  and  only  a  small  percentage  integrates  into  the 
genome  (1-5  %)  whereas  most  of  the  virus  remains  in  the  nucleus  as  an 
episome.  rAAV  vectors  (see  figure  1.11)  are  deleted  for  all  virally  encoded 
proteins and these sequences are replaced by the transgene of choice.  Since 
all  viral  proteins  are  missing,  their  immunogenicity  is  remarkably  reduced.  In 
contrast to Ad,  AAV do  not induce a  innate  immune response.  However,  they 
induce an adaptive immune response, even though it is much weaker than that 
evoked by Ads (see [276] for a review). A possible reason for this is that AAVs 
different than Ads are unable to infect mature APCs.  AAVs can infect immature 
APCs,  which  would  lead  to  a  specific  T  cell  response  and  in  turn  would 
decrease  transgene  expression.  However,  this  immune  response  would  only 
develop if enough immature APCs would be at the site of infection.  Therefore, 
AAV  usually  does  not  induce  a  sufficient  T  cell  response.  In  some  cases 
however,  a T cell  response can occur against the transgene. Administration of
81Ad and AAV vectors also results in a presentation of viral capsid antigens to B 
cells.  This  induces the  production  of neutralising  antibodies  (ABs)  against the 
capsid,  which  can  prevent  infection  by vectors  and  render readministration  of 
the  vector  difficult.  Another  problem  is  the  pre-existing  immunity  in  humans 
against both Ad and AAV. A majority of the population has specific ABs against 
Ads and AAVs because of viral infections. These ABs are able to neutralise viral 
vectors,  induce an inflammatory response and thereby reduce the efficiency of 
vector infection.
Figure 1.11: rAAV. (A) Schematic diagram of wild-type AAV genome and the rAAV production 
plasmid.  ITR=inverted terminal  repeats;  rep=AAV replication  and  integration  associated gene; 
cap=AAV capsid encoding gene; CMV=cytomegalovirus promoter; transgene=gene of interest. 
(B)  Schematic  diagram  of  rAAV  production.  The  rAAV  plasmid,  which  carries  the  gene  of 
interest, and a helper plasmid providing the rep and cap genes in trans are co-transfected into 
BHK cells; the cells are subsequently infected with HSV (or another helper virus) and after 72 hr 
the rAAV particles are harvested.
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82Transduction by AAV vectors results in an efficient expression of the transgene. 
Interest  in  AAV vectors  has been  due to  the  prolonged  transgene expression 
compared to Ads.  However,  the total length of the insert is relatively small and 
cannot  exceed  ~5  kb,  which  is  approximately  the  length  of  the  wild-type 
genome. Another disadvantage of AAV is a delay in the onset of expression for 
most serotypes  lasting between two and four weeks depending on the treated 
species (see also chapter 3.8).
Recently  AAV  has  been  used  to  specifically  target  genes  [277-280].  This 
reduces  the  potential  risk  of disrupting  essential  genes or  causing  malignant 
transformation  of the target cells  and  ensures  long-term  expression  since the 
viral genome is integrated into the host genome.  It can also be used to switch 
off the expression of certain genes. Gene targeting is the precise alteration of a 
specific chromosomal  site  by  an AAV vector.  Although  this  achievement  is  of 
minor importance for gene therapy applications in the eye, AAV gene-targeting 
vectors are promising vehicles for gene therapy in other disorders [278, 281].
In the eye, AAVs have been shown to efficiently transduce a variety of different 
cells,  including  photoreceptors  and  RPE  cells  after subretinal  injections  [228, 
282]  and  ganglion  cells,  bipolar  cells,  cells  of  the  trabecular  meshwork  and 
Muller cells after intravitreal  injections  [227, 283].  Especially for the delivery of 
transgenes to photoreceptor cells AAVs have been shown to be very promising, 
since rAAV transduces these  cells with  a 2000-fold  higher efficiency than rAd 
vectors [227]. Furthermore, rAAV does not stimulate an immune response in the 
eye [284].
The  potential  of  AAV  vectors  for  ocular  disorders  has  been  extensively 
evaluated in a variety of animal models for dominant (see section  1.3.4.3) and 
recessive diseases.  Many types of retinal  degeneration are due to mutation  in 
genes specifically expressed in photoreceptor cells.  Since other vectors mainly 
transduce RPE cells,  AAVs are a promising tool to deliver a functional copy of 
the mutated gene for this group of disorders.
83Peripherin-2  (Prph2,  rds) is a photoreceptor-specific glycoprotein that localises 
in the outer segments in a complex with rom-1. Peripherin-2 is necessary for the 
stabilisation  of  photoreceptor  outer  segments  where  the  phototransduction 
cascade takes place.  Mutations in prph2 have been shown to result in a variety 
of  photoreceptor  dystrophies,  including  autosomal  dominant  or  recessive  RP 
and  macular  dystrophy.  The  retinal  degeneration  slow  (rds  or  P/p/?2R d2/R d2) 
mouse  is  homozygous for a  null  mutation  in prph2 and  is  characterised  by  a 
complete  failure  to  develop  photoreceptor  outer  segments.  ERG  recordings 
show  diminished  a-  and  b-wave  amplitudes  which  decline  to  virtually 
undetectable  levels  by  two  months.  It  has  been  shown  that  after  subretinal 
delivery  of  an  AAV-2  vector  expressing  a  functional  copy  of  prph2,  stable 
generation  of outer segment  structures occurs  containing  both  peripherin  and 
rhodopsin.  Furthermore,  ERG traces showed an improvement of retinal function 
for  at  least  2  months.  That  was  the  first  successful  in  vivo  gene  therapy 
approach that aimed to correct a photoreceptor-specific defect [230, 285].
Retinitis  pigmentosa  GTPase  regulator  (RPGR)  is  a  photoreceptor  protein 
which is coupled to the connecting cilia via RPGR-interacting protein (RPGRIP) 
[286].  RPGR  is  thought  to  control  the  function  and/or  organization  of  the 
photoreceptor outer segment [287].  Mutations  in  RPGRIP are associated with 
LCA  in  humans  [288].  The  RPGRIP deficient  RPGRIP'7 '  mouse  has  an  early 
onset of photoreceptor degeneration that is virtually completed at the age of 3 
months. The rapid course of the disease in this animal model corresponds with 
the  course  of  the  disease  observed  in  LCA  patients.  Recently,  it  has  been 
shown  that  AAV-2-mediated  expression  of  a  functional  copy  of  the  RPGRIP 
gene  after  subretinal  delivery  results  in  a  restoration  of  retinal  function  and 
prolongation  of  photoreceptor  survival  in  RPGRIP'7 '  mice  for  more  than  5 
months. These data demonstrated the value of AAV-mediated gene therapy for 
photoreceptor-specific defects [289].
Mutations  in  the  human  Rpe65 gene  are  responsible for autosomal  recessive 
early childhood  blindness  including  LCA and  early-onset  RP  [100].  Defects  in 
the Rpe65 gene,  which is selectively expressed in the RPE,  result in blindness 
and gradual photoreceptor cell degeneration [104]. The RPE65'7 ' Briard dog is a
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has  been  used  to  develop  an  AAV-mediated  gene  replacement  strategy. 
AAV.RPE65 vectors,  in which expression of the canine rpe65 gene was from a 
CMV  promoter,  have  been  subretinally  injected  into  dog  eye  [105].  The  gene 
transfer resulted in effective transduction of the RPE and reversed the disease- 
specific phenotype up to 3 years after treatment. ERG recordings demonstrated 
a  remarkable  improvement of retinal  function,  suggesting that a  normal  visual 
cycle was restored by the treatment [105, 290, 291].  However,  in one study 75 
%  of  the  treated  animals  developed  uveitis  in  response  to  the 
immunopathogenic  character  of  the  RPE65  molecule  [290,  291],  a  serious 
complication which still needs further evaluation but may have been due to the 
quality  of  the  viral  preparation  or  surgical  technique.  These  results  laid  the 
cornerstone  for  the  approval  of  a  clinical  trial  of  human  patients  with  retinal 
degenerative diseases that result from Rpe65 gene defects.  In order to further 
evaluate the benefits and study the effects and mechanisms of AAV-mediated 
gene replacement for Rpe65 defects, this approach was also tested in the RpeA  
knockout  mouse.  AAV-2/1 -mediated  gene  delivery  was  used  in  an  in  utero 
approach in this animal model.  In utero treatment has the advantage to correct 
the  defect  before  significant  damage  to  the  retina  has  evolved  [292].  The 
treatment showed beneficial effects on retinal function similar to those found in 
dogs.  However,  AAV-2/2-mediated  gene  therapy  in  adult  Rpe65'/_   mice  has 
been reported to result in an improvement in retinal function but did not lead to 
a slow down of photoreceptor degeneration or apoptotic cell death [293].
AAV  vectors  have  not  only  been  used  for  gene  replacement  approaches  but 
also to deliver neurotrophic and anti-apoptotic factors to the eye. These factors 
are molecules that promote survival of cells. Therefore, once their potential has 
been evaluated they can be used as a supplement for other approaches such 
as gene replacement therapy or transplantations, for a variety of disorders (see 
chapter  1.3.2).
851.3.4.4.4  Retroviral vectors
Retroviruses  are  a  class  of  enveloped,  small  viruses  containing  2  single 
stranded  RNA  molecules  as  the  genome,  which  replicate  through  a  DNA 
intermediate.  Retroviruses comprise many different families but as a group they 
have  been  identified  in  virtually  all  organisms.  Since  retroviruses  are  highly 
pathogenic,  particular attention to safety issues with regard to the development 
of  retrovirus-based  vectors  for  gene  therapy  should  be  paid.  The  general 
advantage  of  retroviruses  for  use  as  vectors  is,  that  they  can  stably  infect 
dividing cells by integrating into the host DNA without expressing immunogenic 
viral  proteins.  The  disadvantage  is  that  most  retroviral  vectors  require  cell 
division  for  stable  infection,  limiting  the  target  tissues  for which  they  can  be 
used.  Retroviral vectors can carry transgenes up to a 7.5 kb which is too small 
for some genes even if the cDNA is used (reviewed in [294]).  The first problem 
can  be  overcome  by  the  use  of  retroviruses  from  the  lentivirus  family. 
Lentiviruses  are  a  subclass  of  retroviruses  that  are  able  to  infect  both 
proliferating and non-proliferating cells efficiently and permanently by integrating 
their genome into their host’s.  Since the discovery that lentiviruses,  in contrast 
to retroviruses,  are able to transduce non-dividing cells,  vectors from a variety 
of  members  of this family  have  been  developed,  like feline  immunodeficiency 
virus (FIV), the human immunodeficiency virus type II (HIV-2), equine infectious 
anaemia  virus  (EIAV),  semian  immunodeficiency  virus  (SIV)  and  bovine 
immunodeficiency  virus  (BIV)  [246,  295-302].  The  most  commonly  used 
lentiviral  vectors,  however,  are  based  on  the  human  immunodeficiency  virus 
type  I  (HIV)  and  so  far  have  dominated  the  research  field  of lentiviral-based 
gene transfer. Wild type HIV has a natural tropism for CD4+  cells.  To increase 
the range of cells,  HIV has been pseudotyped with viral envelopes derived from 
a  variety  of  different  viruses.  For  gene  therapy  applications,  HIV  is  most 
commonly  pseudotyped  with  vesicular  stomatitis  virus  G-protein  (VSV-G) 
because  of  the  broad  cell  tropism.  VSV-G  envelope  protein  recognises  a 
ubiquitous  phospholipid  in  the  cell  membrane  that  enables  the  virus  to  infect 
different cell types.  Since it is possible to target HIV-vectors to a variety of cells, 
the potential use of HIV for different clinical protocols has been evaluated.  Initial
86problems  with  insufficient  vector  titres  could  be  been  overcome  by  the 
improvement  of virus  production  protocols  and  the  use  of ultracentirifugation. 
During  the  clinical  trial  of  SC ID  patients  it  became  clear  that  insertional 
mutagenesis  by  the  vector  (in  the  case  of the  SCID  trial,  a  retrovirus)  as  it 
integrates  into  the  host  genome  is  a  main  problem  which  needs  to  be 
addressed further, in order to increase the safety of integrating viruses in clinical 
applications.  Another  safety  issue,  that  evokes  serious  considerations  in 
particular when  using  HIV-based  vectors,  is the  possibility  of generating  wild- 
type  viruses.  Increased  safety  is  achieved  by  accurate  analysis  of  virus 
preparations  using  long-term  cultures  and  PCR  assays  to  determine  whether 
there is any contamination.
In  the  first  generation  of  HIV-1  vectors,  viral  proteins  such  as  the  HIV  core 
proteins,  enzymes as well as accessory factors for transcriptional signals were 
delivered  in  cis  [303,  304].  In  the  second  generation  HIV-derived  packaging 
components were reduced to the gag, pol,  tat, and rev genes of HIV-1  [305].  In 
either  case,  the  vector  itself  carried  the  HIV-derived  c/s-acting  sequences 
necessary for transcription,  encapsidation, reverse transcription, and integration 
[304,  306-310].  The  biosafety  of a  viral  vector depends  in  part on  how  much 
segregation  of  the  c/s-  and  trans-acting  functions  of  the  viral  genome  is 
achieved by the vector design and is maintained during vector production.  The 
possibility of generating  replication  proficient virus particles through  replication 
has to be abolished because it presents a potential risk in vivo. The likelihood of 
this type of recombination is dependent on residual c/s-acting sequences in the 
packaging plasmid,  allowing  some  level of encapsidation, and on the extent of 
sequence  homology  between  packaging  and  vector  constructs.  In  the  third 
generation  of HIV-1  vectors,  all  HIV sequences  required for encapsidation and 
reverse transcription  [307,  308,  310,  311] are absent.  Third generation vectors 
are  packaged by three non-overlapping  expression constructs:  two expressing 
HIV  proteins  and  the  other  expressing  the  envelope  of a  different virus  (see 
figure  1.12).  To  abolish  transcriptional  activity  of  the  3-prime  long  terminal 
repeat  (3’  LTR)  a  major  deletion  is  included  in  this  region.  Upon  reverse 
transcription  and  integration  the  deletion  is  transferred  to  the  5’  LTR.  The 
resulting  transcriptional  inactive  vector  cannot  be  converted  into  a  full  length
87vector RNA in transduced cells and thereby the risk of regenerating replication 
competent viruses is minimised.  These vectors are also called self inactivating 
(SIN) vectors [312].
Figure  1.12:  Schematic  diagrams  of  wtHIV-1  genome  and  the  3  plasmids  used  in 
recombinant  lentivirus  production.  LNT.SFFV.transgene,  pCMVR8.91  and  pMD.G  plasmids 
are  co-transfected  onto  293T  cells  (human  embryonic  kidney  cells)  for  the  production  of 
lentivirus.  LTR=long terminal  repeats;  gag=capsid  coding gene;  pol=polymerase coding gene; 
cPPT=central  polypurine  tract;  RRE= Rev-responsive  element;  env=envelope  coding  gene; 
3’ALTR=deleted 3’ LTR;
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In  the  eye,  HIV-mediated gfp expression  has  been  shown to  be  limited to the 
RPE,  if the virus is pseudotyped with VSV-G and the transgene is driven  by a 
cytomegalovirus  (CMV)  promoter,  or spleen focus forming virus (SFFV)  [313]. 
However,  reporter gene expression  in photoreceptor cells has been reported  if
88injections are performed in neonatal mice [283, 314] suggesting that the tropism 
of  of  this  vector  depends  on  the  age  of  the  animal.  Gfp  expression  in 
photoreceptor cells has been reported  after subretinal  injection into adult mice 
of  HIV/VSV-G  if the  reporter  gene  is  under the  control  of the  photoreceptor- 
specific rhodopsin  promoter.  However,  the level  of expression is not adequate 
for  efficient  gene  transfer  to  photoreceptors.  SIV-,  FIV-  and  BIV-  mediated 
expression of reporter genes has also been reported to be restricted to the RPE 
in rodents [296, 299, 301].
1.3.4.5  Non-viral gene transfer for retinal dystrophies
An alternative to virus-mediated gene transfer are non-viral vectors. Naked DNA 
and  cationic liposomes  have  been  used to deliver genes to the retina  in  vitro. 
They are considered to be safe and biocompatible with  little risk of inducing a 
host immune response.  In vivo their transfection efficacy has been tested in rat 
and  mouse  retinae  but  it  is  inadequate  and  lower  than  that  of  many  viral 
vectors.  RPE cells have been shown to take up DNA complexes but not naked 
DNA,  if the complexes are directly administered to the RPE.  The inner limiting 
membrane,  the  neuroretina  and  especially  the  interphotoreceptor  matrix  limit 
the access of these complexes significantly because they contain proteins that 
are known to interact with the cationic surface of liposomal complexes of DNA. 
These  natural  barriers  must  be  taken  in  account  in  the  development  of 
strategies  of  non-viral  gene  transfer  systems  targeted  to  RPE.  Liposomal- 
mediated gene delivery to photoreceptors has so far been insufficient.
In  vivo transfer and expression of a reporter gene into adult mammalian retina 
has been achieved using HVJ liposomes [315].  HVJ liposomes are a mixture of 
liposome and expressing plasmid complexed with high mobility group 1   (HMG1) 
chromosomal proteins, which are then coated with the envelope of Sendai virus 
(haemagglutinating virus of Japan,  HVJ). The HMG1  proteins contain a nuclear 
localisation  signal  to  facilitate  nuclear  uptake and  may  also  protect  the  DNA 
from  degradation.  HVJ  induces  membrane fusion  and  cytoplasmic  entry,  the
89encapsulated  plasmid  is  thought  to  bypass  endocytosis  and  lysosomal 
degradation  by  the  host  immune  system.  Expression  up  to  30 days  could  be 
detected in photoreceptor cells after subretinal injections, and neurons and glial 
cells in  the  ganglion  cell  layer after intravitreal  delivery.  However,  the  level  of 
transgene  expression  is  lower  and  the  duration  short  compared  to  virus- 
mediated expression.
The  therapeutic use  of non-viral  gene transfer  is  limited  by  poor transduction 
efficiency to viral vectors and the transient nature of expression compared. The 
blood-retinal  barrier  and  the  neural  retina  are  diffusional  barriers  for 
macromolecules  and  decrease the  penetration  of these molecules.  Therefore, 
different  ways  to  improve  transductions  levels  are  under  development  and 
evaluation.  Lipofectin  has  been  mainly  used  for  gene  transfers  in  vitro. 
Recently,  its ability to promote gene delivery in  vivo has been tested.  Cationic 
lipids  condense  DNA  and  thereby  protect  it  from  degradation  and  facilitate 
endocytosis.  Electric  fields  alter  the  structure  and  permeability  of  cell 
membranes.  Electroporation  uses this  phenomenon  to facilitate  penetration  of 
macromolecules  into  cells.  Both  techniques  have  been  used  to  increase  the 
efficiency  of  non-virus-mediated  gene  transfer  [316].  A  non-viral  plasmid 
containing the  LacZ reporter gene  under the control of either the  RPE-specific 
VMD2 promoter or the ubiquitous CMV promoter was delivered to mouse eyes. 
After  subretinal  delivery,  LacZ  expression  from  the  VMD2  promoter  was 
exclusively  detected  in  the  RPE  whereas  staining  was  also  observed  in 
photoreceptors -  even though  predominately in  RPE cells -  when the reporter 
gene was under the control of the CMV promoter. Expression was evident up to 
28  days  after  treatment  and  could  be  increased  by  repeated  administration. 
These  techniques  hold  promise  for  in  vivo  analysis  of  gene  regulation  or 
promoter  analysis  but  are  inefficient  for  clinical  applications  due  to  their 
transient effect.
In vivo electroporation has also been used to deliver the gfp reporter gene into 
neonatal mouse and rat retinae [317].  A solution of DNA plasmids was directly 
injected into the subretinal space of neonatal mouse and rat pups,  and electric 
pulses  were  applied  by  electrodes.  Five  days  after  the  treatment  expression
90was observed in the developing  outer and inner nuclear layer.  Gfp expressing 
cells were identified as rod photoreceptors,  bipolar cells and Muller glial cells 2 
weeks  after  injection.  Even  though  expression  levels  were  decreasing  over 
time,  expression was still detected at 50 days.  The potential of electroporation 
techniques was further tested in gain and loss of function experiments.  Rax is 
expressed by proliferating retinal progenitor cells and differentiating Muller glial 
cells,  and  its  forced  expression  in  the  P0  rat  retina  with  a  Molony  murine 
leukemia virus (MLV) vector leads to the generation of cells resembling Muller 
glia [108]. The same results were obtained by using a plasmid containing a rax 
expression  cassette.  For  loss  of function  analysis,  DNA-based  RNAi  vectors 
that produce siRNA against the transcription factors Crx and  Nrl were used.  In 
retinae transfected with the RNAi  plasmids,  the numbers of rhodopsin-positive 
cells  were  significantly  reduced  (~  5  %)  compared  to  control  eyes  (~  60  %). 
Consistent with the reported phenotypes of knockout mice,  photoreceptors did 
not have clear outer segment structures [317].
Recently the integrase from the bacteriophage phiC31  was used to confer long­
term  gene  expression  by  means  of  genomic  integration  in  the  RPE  of  rats. 
PhiC31  integrase  mediates  integration  in  to  the  mammalian  genome  by 
recombination  between  a  plasmid  containing  the  attB  sequence  and  pseudo- 
attP  sites  of the  host.  The  potential  of phiC31  integrase to  mediate  long-term 
expression  has first  been  shown  in  mouse  liver [318] and  human  skin  grafted 
onto immune deficient mice  [319].  A phiC31  expression plasmid carrying  both 
reporter  genes  luciferase  and  gfp  and  the  phiC31  integration  sequence  attB 
were  generated  and  injected  subretinally  in  rat  eyes  [320].  Reporter  gene 
expression  was  confirmed  in  injected  eyes  and  was  approximately  1000  fold 
higher in eyes that were electroporated compared to eyes which only received 
subretinal injections but were not electroporated.  In both cases expression was 
restricted to the RPE.  If the phiC31  integrase was provided by another plasmid, 
expression  levels were approximately 85  %  higher than without integrase and 
was detected  up to 4.5  months.  These findings suggest that phiC31  integrase 
may be a simple and  effective tool for non-viral  long-term gene transfer in the 
eye [320].
91The  application  of  viral  vectors  involves  problems,  which  can  be  partly 
circumvented  by  using  non-viral  methods  of gene  transfer.  Most viral  vectors 
induce an immunological response to some degree and have safety risks, such 
as  insertions  mutagenesis,  toxicity  problems,  and  the  reversion  to  a  disease 
causing virus inside a patient. Another problem of virus-mediated gene transfers 
is  that  the  capacity  of  viruses  is  limited  and  large  scale  production  is  often 
difficult to achieve. Non-viral approaches, however, require only a small number 
of  proteins,  have  a  large  capacity,  are  not  infectious  or  mutagenic  and  large 
scale  production  is  possible  by  using  pharmaceutical  techniques.  The  main 
disadvantage  of  non-viral  gene  transfer  approaches,  however,  is  the  poor 
efficacy to date in  vivo.  A number of non-viral gene delivery methods into the 
retina  have  yet  to  be  tested.  One  such  strategy  is  transposon-based  vector 
delivery  system  that  represents  a  promising  new  tool  for  chromosomal 
transgene insertion and establishment of persistent gene expression in vivo.  In 
a  mouse  model  for  hemophilia  B  it  was  possible  to  partially  correct  the 
pathogenic  phenotype  by  delivering  factor VIII  with  transposon-based  vectors 
[321J .
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2 Materials and Methods
2.1  Cloning and plasmid construction
In  order to  create a  recombinant virus,  which fulfils the requirements  of gene 
transfer, most of the viral genome must be replaced with a recombinant genome 
carrying the therapeutic gene  under the control  of an  appropriate  promoter to 
ensure its expression in the right cell type and at an efficient level. To avoid the 
attention of the immune system and as a result the removal of the virus or the 
transduced cell,  viral capsid encoding genes and genes necessary for virus in- 
vivo  replication  should  be deleted.  Since  recombinat viruses are  produced  in- 
vitro,  possible  issues regarding  safety and  purification  need to be considered. 
There should be a minimal risk of the creation of replication competent viruses 
through  recombination  during  production.  In  order  to  minimise  toxicity,  viral 
particles need to be thoroughly purified.
932.1.1  RNA isolation
RNA  of  rat  retinae  was  isolated  using  Trizol  reagent  (Invitrogen  Life 
technologies,  Paisley,  UK). Tissue samples were homogenised in 800 pi Trizol 
and incubated for 5 min at room temperature to disrupt cellular components and 
maintain RNA integrity. To separate nucleic acids from cellular components, 0.2 
ml  of chloroform was added and the sample was shaken for 15 sec.  After a 3 
min incubation step at room temperature, the sample was centrifuged for 15 min 
at 5000xg at 4°C.  Following centrifugation the mixture separates into phases, in 
which  RNA remains  in the  upper most  aqueous  phase.  This  phase was  then 
transferred  into  a  new  tube  and  RNA  was  precipitated  by  adding  0.5  ml 
isopropyl  alcohol.  After  10  min  incubation  at  room  temperature,  RNA  was 
pelleted  by  centrifugation  at  maximum  speed  at  4°C.  The  supernatant  was 
removed  and  the  RNA  pellet  was  washed  with  1   ml  of  75  %  ethanol.  The 
sample was  mixed  by  vortexing  and  centrifuged  again  at  maximum  speed  at 
4°C.  After  removing  of  supernatant,  the  RNA  pellet  was  air  dried  and 
resuspended in RNase free water. The concentration of RNA was measured by 
lightspectroscopy.  Approximately  1   pg  of  total  RNA  was  treated  with  RQ1 
RNase free DNase (Promega,  Madison, Wl) to remove traces of genomic DNA 
that could function as templates in PCR reactions.
2.1.2  MERTK cDNA
The  murine  MERTK cDNA  (see  Appendix for  cDNA  sequence)  was  RT-PCR 
amplified  in  2 fragments from  mRNA  isolated  from  total  murine  retinae.  Both 
PCR fragments were sequenced after cloning into pGem-T (Promega, Madison, 
Wl) and the 2 fragments were combined using a naturally occurring EcoRV site 
to give a full length cDNA clone ranging from nt -1  to nt 3037 in relation to the 
start codon.
942.1.3 Restriction enzyme digests
For cloning  protocols,  plasmid  DNA that carried the sequence  of interest was 
digested  with  appropriate  restriction  enzymes  in  accordance with  the enzyme 
manufacturer's  instructions (New England  Biolabs  Ltd.,  Herts,  UK).  In order to 
ascertain  right orientation after integration of the transgene  into plasmids  non- 
complementary ends were created.
2.1.4  DNA electrophoresis
After  the  restriction  digest  DNA  fragments  were  separated  on  a  1   %  (w/v) 
agarose gel using 1x TBE buffer.  Ethidium bromide (1  pi per 25 ml of gel)  was 
added to visualise nucleic acid bands.  Samples were loaded onto the gel using 
gel-loading buffer (6 x;  0.25 % (w/v) bromophenol blue and 30 % (v/v) glycerol 
in water and a  1   kb  DNA ladder (Invitrogen Ltd.) was run at the same time to 
provide a size marker. The voltage was chosen considering the seperation time 
of  fragments  of  the  expected  size.  Gels  were  then  photographed  on  an 
ultraviolet transilluminator.
2.1.5 Extraction of DNA fragments from agarose gels
The required DNA fragments were excised from the agarose gel and extracted 
using QIAquick™ Gel Extraction Kit (QIAGEN Ltd.) following the manufacturer’s 
instructions.  The  concentration  of  the  eluted  DNA  was  measured  by 
photospectroscopy using a Unicam UV 500 spectrometer. An absorbtion of 1   at 
OD260n m   was  taken  to  equal  the  concentration  of  50  pg/ml  double  stranded 
DNA.
952.1.6 PCR and sequencing
To  ensure  that  the  isolated  fragments  have  the  correct  sequence  they  were 
amplified using appropriate primers and cycling conditions.  PCR reactions were 
performed  in a total volume of 20 pi.  0.2  mM  dNTPs (Promega UK),  25 pM of 
each primer and 1   U of Taq polymerase (Promega UK),  and 8 pi of buffer were 
mixed and DNA was added to a final  DNA concentration of less than  10 ng/pl. 
The amplified fragments were then sequenced (MWG-Biotech).
2.1.7  Ligations
The ligation of gel purified DNA fragments was carried out at 25°C for 3 hr.  T4 
DNA ligase (New England Biolabs Ltd.  UK), the supplied buffer, the viral vector 
backbone  and  the  insert  of  interest  were  added  in  accordance  with  the 
manufacturer’s  instructions.  To check whether the  ligation was  successful  the 
ligated  plasmid  was  transformed  in  bacteria.  Newly  cloned  plasmid  were 
isolated from bacteria and analysed by appropriated restriction enzyme digests 
and gel electrophoresis.
2.1.8  Transformation and recovery of plasmids
For  transformations,  DH5a™  competent  cells  (Invitrogen  Ltd.,  UK)  were 
defrosted  on  ice.  After  the  bacteria  suspension  had  thawed,  the  viral  vector 
solution was added and the transformation mix was incubated on ice for 15 min. 
Samples  were  then  heat  shock  treated  for  90  sec  at  42°C  in  a  water  bath, 
cooled down for 90 sec on ice,  and 750 pi  LB (Luria Bertani,  Merck Ltd,  Leics, 
UK)  medium  was  added.  All  plasmids  used  included  the  ampicillin  resistance 
gene  as  a  selection  marker for  successfully transformed  colonies.  To  ensure 
efficient  expression  of  the  resistance  gene,  transformed  bacteria  were 
incubated for 1   hr at  37°C before they were spread on LB agar plates.  LB agar 
plates were prepared containing  14 g  Bacteriological agar (Oxoid Ltd.) per litre
96of water,  5 g/l yeast extract,  10 g/l tryptone (Oxoid Ltd.),  10 g/l sodium chloride, 
and  50  pg/ml  ampicillin.  Plates  were  incubated  overnight  at  37°C  to  allow 
resistant bacteria to grow.
Bacteria colonies were inoculated into 2 ml  of LB  medium containing 50 pg/ml 
ampicillin (1000x; Sigma Aldrich Company Ltd.) the following day and incubated 
at 37°C overnight to allow growth.  For small scale preparations,  plasmids were 
recovered  using  QIAprep®  Spin  Miniprep  Kit  (QIAGEN  Ltd.,  Sussex,  UK).  For 
large scale preparation 200 pi of the 2 ml culture were used to inoculate 250 ml 
LB  medium  and  bacteria  were  grow  as  described  above.  DNA  was  then 
recovered using a QIAGEN® Plasmid Mega Kit (QIAGEN Ltd.).
2.2  Tissue Culture
2.2.1  Cell lines and culture of cells
Baby  hamster kidney  (BHK)  cells were  grown  in  BHK-21  media.  Ten  percent 
heat inactivated foetal bovine serum (FBS),  5 % tryptose phosphate broth, 5 ml 
of antibiotic and antimyotic solution, 5 ml of 200 mM L-glutamine, and 4 ml of 50 
mg/ml  geneticin  G418  were  added  to  500  ml  of  medium.  293T  cells  were 
cultured in  Dulbecco’s Modified  Eagle’s Medium (DMEM) supplemented with 5 
ml/500 ml of antibiotic and antimyotic solution and  10 % FBS.  HeLa cells were 
grown  in  DMEM.  5  ml  of antibiotic  and  antimyotic solution,  4  ml  of 50  mg/ml 
geneticin  G418  and  10  %  FBS  were  added  to  500  ml  of  the  medium  (all 
reagents were purchased at Invitrogen Ltd.).  Cells were grown in a Sanyo CO2 
incubator at 37°C with 5 % CO2.
972.2.2  Passaging cells
In  order to  keep  cells  at  an  appropriate  density,  they were  split  every 2  to  3 
days. The old medium was removed and cells were washed twice with  1x PBS 
(10 phosphate buffered saline tablets (Oxio Ltd.) dissolved in 1   I sterile ddFfeO) 
before trypsin-EDTA (Invitrogen,  Ltd.) was added dropwise until  all  cells were 
covered.  Plates were then incubated for approximately 10 min at 37°C to allow 
cells to dissociate. The process was stopped by adding FCS containing growth 
medium and cells were split onto new plates in an appropriate ratio, usually 1:6.
2.2.3  Long-term storage
For long-term storage cells were treated with trypsin-EDTA as explained above. 
Cells were  pelleted  by  centrifugation  and  approximately 5 x  106 cells/ml  were 
resuspended  in  growth  medium  with  20  %  FCS  and  10  %  dimethylsulfoxide 
(DMSO;  Invitrogen  Ltd.).  Tubes  were  pre-cooled  on  ice  before  cells  were 
aliquoted.  Tubes  were  then  kept  overnight  at  -70°C  in  a  box  containing 
isopropanol before transferring them to liquid nitrogen for long-term storage.
To re-culture cells,  they were thawed  in a water bath at 37°C.  Cells were then 
pelleted  by  centrifugation,  the  DMSO  containing  medium  was  removed,  and 
cells  were  resuspended  in  the  appropriate  medium  and  left  to  grow  to  the 
desired density in a CO2 incubator at 37°C.
982.3  Adeno-associated viral vectors
The  normal  production  method  of  recombinant  AAV  (rAAV)  requires  the 
cotransfection of two plasmids into a cell  line in the presence of a helper virus. 
The  vector  plasmid  carries  the  rAAV  construct  and  the  packaging  plasmid 
provides the AAV rep and cap gene products in trans (see chapter 1.3.4.4.3 for 
more details) [322].
2.3.1  Constructs
The MERTK cDNA (see section 2.1.2) was cloned between the CMV promoter 
and  the  SV40  poly-adenylation  site  of construct AAV.CMV.GFP  [323]  to form 
construct  pD10/CMV-Mertk.  The  RPE-specific  rpe65  promoter  fragment 
(described in [324]) was amplified from murine genomic DNA (conducted by A. 
Smith) and cloned upstream of the MERTK transgene in construct pD10/CMV- 
Mertk replacing the CMV promoter. The new construct was termed pD10/RPE- 
Mertk.  Constructs  were  used  to  generate  rAAVs,  AAV.CMV.Mertk  and 
AAV.RPE.Mertk,  as described  [323].  As controls,  the plasmids AAV.CMV.GFP 
and AAV.RPE.GFP were used (see chapter 3.2-3.4 for more details).
2.3.2  Production of rAAV
Prior the day of transfection BHK cells were split and plated at 1   x 106 cells/150 
mm  dish  and  incubated  overnight  so  that  they  were  approximately  70  % 
confluent the following  day  (1  x  107 cells).  Recombinant AAV-2  particles were 
produced  using  the  ITR  bearing  plasmids  pD10/CMV-Mertk  or  pD10/RPE- 
Mertk,  a replicating amplicon containing the rep and cap genes,  pHAV7.3,  and 
PS1  HSV  helper  virus.  The  pD10  construct  and  the  pHAV7.3  amplicon  were 
used to co-transfect BHK cells  in a  1:1  ratio.  The transfection solution for four 
150 mm dishes was made by mixing 16 ml (0.1  mg/ml)  Opti-MEM® (Invitrogen,
99Ltd.)  and  150  pi  Lipofectin  (Life Technologies,  Paisley,  UK).  Cyclised  integin 
targeting  peptide 6  ((K16)  GACRRETAWACG)  - a  p-integrin-targeting  peptide 
used to improve the binding of the DNA-containing liposomes to the cells - was 
added  to  the  same  tube.  In  another  tube  16  ml  Opti-MEM®,  100  pg  helper 
plasmid,  and  100 pg plasmid  DNA were  mixed  and this mixture was added to 
the  transfection  solution.  Complexes  were  allowed  to  form  by  incubation  at 
room  temperature  for  1   hr.  Old  medium  was  removed  from  plates  and  cells 
were washed twice with Opti-MEM®.  For transfection,  10 ml of the transfection 
solution was added to each plate and cells were incubated for at 37°C for 4 hr. 
After  incubation,  the  transfection  solution  was  replaced  by  normal  growth 
medium  containing  PS1  HSV helper virus  at a  MOI  (multiplicity of  infection  = 
average number of particles that infect a single cell) of 10 to 20 infectious units 
per  cell.  Cells  were  incubated  at  at  37°C  for  24  to  36  hr,  to  allow  the 
completion of a lytic cycle, the cells were collected by scraping and pelleted by 
centrifugation at 3000xg for 10 min.
2.3.3  Purification of rAAV
Cells from  ten  150  mm  plates were  harvested,  resuspended  in  10  ml  DMEM, 
and  were  then  lysed  by  three  cycles  of freeze  thawing  between  -70°C  and 
37°C.  Genomic  DNA  remaining  in  the  lysate  was  degraded  with  50  U  of 
endonuclease benzonase per millilitre of lysate at 37°C for 30 min. To clarify the 
lysate  cell  debris  was  removed  by  centrifugation  at  3000xg  for  15  min.  The 
supernatant was treated  with  0.5  %  deoxycholic acid for 30  min  at  37°C  and 
filtered through 5 and 0.8 pm syringe filters (Millipore,  USA;  SLSV R25 LS and 
SLAA 025  LS).  After filtration the supernatant was transferred onto a heparin- 
agarose column  (Sigma,  USA)  which  was first  pre-washed with  PBS-MK (1  x 
PBS,  2.5  mM  KCI,  1   mM  MgCI2)  and then with  10 ml  PBS-MK + 0.1M  NaCI. 
Viral particles were eluted with 6 ml PBS-MK + 0.4 M NaCI. The first 2 ml were 
discarded  and  the  remaining  suspension  containing  the  purified  virus  was 
collected. The resulting virus suspension was concentrated by  centrifugation at 
5000xg  for one  hour  using  Centricon  10  columns  (Millipore,  USA).  The  flow­
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centrifugation  step  at  5000xg  for  10  min  to  dilute  out  remaining  salt.  For 
collection  of  the  purified  and  concentrated  virus  suspension,  columns  were 
turned  up side down and spun to elute the virus into a collection tube.  A total 
volume of approximately 100 pi per 10 plates was collected [325].
2.3.4  Viral DNA extraction
To  extract  viral  DNA  from  rAAV  capsid  proteins,  1   and  5  pi  samples  were 
treated  with  100  pg  (10  pi)  proteinase  K  (Promega  UK)  with  100  pi  2  x 
proteinase K buffer (100 mM Tris (ph 7.4),  50 mM EDTA and 0.5 %  SDS) and 
100  pi  dhhO.  After  a  1   hr  incubation  step  at  37°C,  DNA was  precipitated  by 
adding 1/10 volume (20 pi) of 3M sodium acetate, 40 pg (2 pi) glycogen (Sigma- 
Aldrich  Company  Ltd.)  and  2.5 volume  (500  pi)  of 96  %  ethanol  and  left  at - 
70°C for 30 min.  DNA was pelleted  by centrifugation at maximal  speed for 30 
min at 4°C.  Each pellet was washed with 200 pi of 70 % ethanol,  air dried and 
resuspended in 200 pi 0.4 M NaOH + 10 mM EDTA solution.
2.3.5  Titration with dot-blot analysis
The molecular titre of the concentrated virus was estimated by dot-blot analysis. 
A  dilution  series  ranging  from  109  to  1012  molecules  of  plasmid  including  a 
probe DNA of known concentration was used to produce a standard ladder. The 
samples  were  prepared  with  0.4  M  NaOH  +  10  mM  EDTA  solution  in  a total 
volume  of  200  pi.  Samples  from  the  dilution  series  and  recombinant  viral 
genome  samples  in  alkaline  solution  were  first  denatured  at  100°C  for 2  min 
and  then  cooled  for  2  min  on  ice  to  prevent  re-annealing.  Dot-blots  were 
prepared  on  a  pre-wet  0.45  pm  Hybond™-N+  membrane  (Amersham 
Pharmacia  Biotech.,  Bucks,  UK)  -  a  positively  charged  nucleic  acid  binding 
membrane - in a dot-blot manifold (Bio-Rad Laboratories Ltd.,  Herts,  UK).  Each 
well  of the  manifold  was  pre-washed  with  0.2  ml  of dH2 0   and  vacuum  dried
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were empty. Then 0.2 ml of 0.4 M NaOH and 10 mM EDTA was added to each 
well.  Excess  solution was  removed  by applying  a vacuum  and the  membrane 
was air dried between blotting paper.
Meanwhile  the  probe  DNA  was  excised  from  the  plasmid  with  a  restriction 
enzyme as explained in chapter 2.1.3.  In order to label the probe radioactively, 
a  Prime-lt®  II  Randon  Primer  Labelling  Kit  (Stratagene  Europe)  was  used. 
Following  the  manufacturere’s  instruction,  21  pi  H20   and  10  pi  random 
oligonucleotide  primer  supplied  by  the  manufacturer were  added  to  the  DNA 
probe and  incubated  at 95°C for 5  min.  Samples were spun  and  10  pi  of 5 x 
Labelling  buffer,  5pl  32P-dCTP  (3000  Curies/pl)  labelled  nucleotides,  and  1   pi 
Exo-Klenow-enzyme (5 U/pl) were added and incubated at 37°C for 18 hr.
The membrane was then  moistened with dH20,  placed in a hybridisation tube 
and heated to 65°C in a hybridisation rotisserie oven.  The water was replaced 
by Church buffer (0.5 M sodium phosphate buffer, 7 % w/v SDS, 0.01  M EDTA) 
and the membrane was  incubated again for 30 min.  The radioactively labelled 
DNA  probe  was  denatured  for 2  min  at  95°C  and  immediately  added  to  the 
membrane.  The membrane was hybridised for 5 hr and washed twice with 50 
ml  of  sodium  phosphate  buffer  (0.05  M,  pH  7.2)  at  65°C.  Excess  liquid  was 
removed and the membrane sealed in plastic. The membrane was then placed 
in a cassette with a Kodak Scientific Imaging BioMax™ MR-1 film. After an hour 
exposure, the film was developed in a Fuji RG II X-Ray Film Processor and the 
viral titre was estimated by comparison to the standard ladder (see chapter 3.2).
1022.4  Lentiviral vectors
2.4.1  Constructs
The murine MERTK mRNA was isolated from murine total retinal RNA, RT-PCR 
amplified  (see  chapter  2.1.2)  and  cloned  into  a  VSV-G  pseudotyped  HIV-1 - 
based  vector  [313,  326].  The  lentiviral  MERTK  expression  construct, 
LNT.SFFV.Mertk, was generated by cloning the murine Mertk gene between the 
spleen  focus  forming  virus  (SFFV)  promoter  and  the  WPRE  element  of  the 
pHR’SIN-cPPT-SEW  lentivirus  construct.  The  GFP  control  construct, 
LNT.SFFV.GFP,  is identical to the construct pHR’SIN-cPPT-SEW as described 
by Demaison et a! [326].
2.4.2  Production of recombinant lentivirus
Approximately  106 293T cells were  seeded  on  150  mm  plates the day  before 
transfection,  in  order to ensure efficient growth to sub-confluent level  until  the 
following day of transfection.  Routinely,  12  150 mm plates were used for each 
preparation of lentivirus.  Cells were transfected with 50  pg of the recombinant 
construct per plate  in  addition to the  lentivirus  helper constructs  pMD.G  (17.5 
pg) and the packaging plasmid pCMVR8.91  (32.5 pg) [352]. Transfections were 
performed as described using  12 ml Opti-MEM® (Invitrogen,  Ltd.) containing 75 
pi  Lipofectin (Life Technologies,  Paisley,  UK) and 400 pg peptide 6 [323]. After 
5  hr  incubation  at  37°C  the  transfection  mixture  was  replaced  with  complete 
DMEM.  The  following  day,  the  medium  was  exchanged  and  plates  were 
incubated. After 48 hr, the medium was collected and cell debris in the medium 
was  pelleted  by  two  10  min  centrifugation  steps  at  2000xg.  The  supernatant 
was  filtered  through  a  0.45  pm  filter  (Millipore)  and  centrifuged  for  2  hr  at 
maximum  speed to  pellet the virus.  The virus pellet was resuspended  in  Opti- 
MEM®,  spun  at  2000xg  for  10  min  to  remove  remaining  debris  and  frozen  in 
batches at -80°C.  Vectors were titrated  by  infecting 293T and  HeLa  cells with
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postinfection to estimate the transfectious titre (see chapter 1.3.4.4.4).
2.5  In vivo experiments
2.5.1  Animals
Dystrophic RCS rats and non-dystrophic RCS rats were used for this study. All 
animals were cared for in accordance with the Animal Scientific Procedures Act 
1986 and procedures were in accordance with the ARVO Statement for the Use 
of  Animals  in  Ophthalmic  and  Vision  Research.  To  control  for  interanimal 
variability  in the  rate  of degeneration,  the  right eye was treated whilst the  left 
eye remained untreated  in all  animals.  Therefore,  the untreated eyes provided 
an internal control for all experiments.  Each treated eyes received two injections 
of viral suspension or PBS.  Subretinal  injections were usually carried out in  10 
day old animals.  If not stated differently, animals were sacrificed by exposure to 
carbon dioxide.
2.5.2  Anaesthesia
For  intraocular  procedures  animals  were  anaesthetised  by  intraperitoneal 
injections of anaesthetic solution  (0.75 ml  Ketamine,  0.5 ml  Domitor,  and 0.75 
ml  water).  Adult rats  between 250 and  300 g body weight received 0.25 ml  of 
the anaesthetic solution.  For 10 day old animals, the anaesthetic was diluted  1  
in 20 with dH20 and 0.15 ml were injected. To reverse the anaesthesia 0.2 ml of 
Antiseden  and  0.8  ml  dH20 were  injected  intraperitoneal  in  adult animals  and 
0.05 ml of a 1:20 dilution in 10 day old rats.
104For  ERG  recordings,  rats  were  anaesthetised  with  a  single  intraperitoneal 
injection of ketamine (60 mg/kg), xylazine (8 mg/kg) and atropine (0.75 mg/kg).
2.5.3  Subretinal injections
If necessary the  palpebral fissure was opened with  a small  scalpel  blade  and 
pupils  were  dilated  with  1   %  Tropicamide  (Alcon  Labs,  Watford)  topically 
administered.  Surgery  was  performed  under  direct  retinoscopy  through  an 
operating microscope. The eye was protruded by gentle pressure on either side 
of  the  eye  and  held  in  position  by  holding  a  section  of  the  conjunctiva  and 
extraocular muscle with a pair of forceps.  The eye was then covered with 2 % 
hypromellose solution  (Moorfields Eye  Hospital,  London,  UK) and  a cover slip 
was placed over it. The tip of a 1.5 cm, 34-gauge hypodermic needle (Hamilton) 
was guided underneath the cover slip to the sclera of the right rat eye (Figure 
2.1)  and  then  inserted  tangentially  through  it,  causing  a  self-sealing  wound 
tunnel. The needle tip was brought into focus between the retina and the RPE. 
Approximately 4 pi virus suspension containing 4 x 107 particles of rAAV and 4 
x  106  particles  of  lentivirus  were  injected  to  produce  a  bullous  retinal 
detachment  in  the  superior  hemisphere.  A  second  injection  was  performed 
subsequently to produce a similar detachment in the inferior hemisphere.  Each 
injection covered approximately 25 to 30 % of the entire retina [313].
Figure 2.1: Schematic of 
a rodent eye. The route 
of subretinal injection is 
shown [228].
1052.5.4  Electroretinography
ERGs  from  injected  RCS  rats  were  recorded  in  a  standardised  fashion  at 
various  time  points.  All  animals  were  dark-adapted  overnight  (16  hr)  and 
Ganzfeld ERGs were obtained simultaneously from both eyes of each animal in 
order  to  control  for  inta-animal  variations.  All  procedures  for  recording  were 
carried out under dim red light. After anaesthesia as described above the pupils 
were dilated using one drop each of 2.5 % Phenylephrine Hypochlorise and 1   % 
Tropicamide  (both  from  Chauvin  Pharmaceuticals  Ltd.)  to  each  eye.  A  single 
drop  of  2  %  hydroxy-propyl-methyl-cellulose  was  placed  on  each  cornea  to 
keep  it  moisturised  after  dilation.  ERGs  were  recorded  using  commercially 
available  equipment  (Toennies  Multiliner  Vision,  Jaeger/Toennies,  Wurzburg, 
Germany) after placing corneal ring-electrodes (type Henkes, Jaeger-Toennies, 
Germany)  and  midline subdermal  reference and  ground electrodes.  Bandpass 
filter cut-off frequencies were  1   and  300  Hz for all  measurements.  Great care 
was taken to keep electrode impedances symmetrical and low (between 5 and 
8  kOhm).  Single  flash  recordings  were  obtained  at  light  intensities  increasing 
from  0.1  mcds/m2  to  3000  mcds/m2  Ten  responses  per  intensity  level  were 
averaged with  an  inter-stimulus  interval  of 5  s  (0.1,  1,  10,  100  mcds/m2)  or 5 
responses per intensity with  a  17  sec interval  (1000 and 3000 mcds/m2) to try 
and minimise the dark adapted conditioning flash effect. All data was analysed 
using the Toennies Multiliner Vision program.
2.6  Reverse transcription and PCR
RNA of injected and uninjected rat eyes was isolated using Trizol reagent (see 
chapter 2.1.1).  Approximately  1   pg of total  RNA was treated with  RQ1  RNase 
free  DNase  (Promega,  Madison,  Wl)  to  remove  traces  of  genomic  and  viral 
DNA that could function as templates in the PCR reaction.
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42°C  for  30  min  using  M-MuLV  reverse  transcriptase  (New  England  Biolabs, 
Beverly,  MA).  Reactions  without  RT were  performed  to  confirm  the  complete 
removal  of  DNA.  PCR  reactions  on  single  strand  cDNA were  done  with  the 
following  primers:  forward:  5’-TGCTCCATCAATATTCCTAACACA-3’,  nt 324 to 
347  of  the  murine  MERTK cDNA  in  relation  to  the  start  codon;  reverse:  5’- 
GGAGGGGATTACTTTGATGTTGA-3’,  nt  833  to  855  of  the  murine  MERTK. 
PCR reactions consisted of 35 standard cycles with an annealing temperature 
of  49°C.  Both  PCR  fragments  were  sequenced  after  cloning  into  pGem-T 
(Promega,  Madison, Wl) and the 2 fragments were combined using a naturally 
occurring EcoRV site to give a full  length cDNA clone ranging from nt -1  to nt 
3037 in relation to the start codon (see chapter 3.4).
2.7  Histological analysis
2.7.1  Cryosections
At  various  time  points,  rats  treated  with  viral  vectors  carrying  the  egfp  gene 
were  anaesthetised  with  a  single  intraperitoneal  injection  of  ketamine  (see 
Chapter 2.5.2).  The  right  atrium  was  opened  with  a  single  cut  and  periodate 
lysine  paraformaldehyde  (PLP;  2%  paraformaldehyde,  0.05%  glutaraldehyde) 
was injected into the left ventricle for pre-fixation of the tissue.  PLP was injected 
until  most  of  the  blood  was  exchanged.  Eyes  were  taken  and  immediately 
immersion fixed  in  PLP for 4  hr.  After fixation  the eyes were  cryoprotected  in 
10% sucrose solution overnight at 4°C.  Eyes were then embedded in O.C.T. (R 
A Lamb, E. Sussex, UK) and frozen in isopentane which had been pre-cooled in 
liquid nitrogen.  Specimens were stored at -80°C and 12 pm thick sections were 
cut  using  a  Bright  cryostat.  In  order  to  visualise  cell  nuclei,  sections  were 
usually counterstained with propidium iodide.
1072.7.2  Fixation of eyes for semithin and ultrathin sections
At  various  time  points  rats  were  sacrificed  and  their  eyes  were  immediately 
removed and orientated with a nasal stitch. Then eyes were immersion fixed in 
3 % glutaraldehyde and 1   % paraformaldehyde buffered to pH 7.4 with 0.07 M 
sodium cacodylate-HCI buffer (Karnovsky’s; 0.2 M (CH3)2As02Na.3H20 with 0.2 
N HCI). After 12 hr the anterior part of the eye was removed by microdissection. 
The  posterior  segments  were  then  osmicated  for  2.5  hr  in  a  1%  aqueous 
solution  of  osmium  tetroxide,  followed  by  a  dehydration  series  through 
ascending  alcohols  (50 -   100%,  10  min  per  step).  After  3  changes  of  100% 
ethanol,  specimens were passed through propylene oxide (3x 10 min)  and  left 
overnight in a 50:50 mixture of propylene oxide and araldite.  Following a single 
change to fresh  araldite  (5  hr with  rotation) the specimens were embedded  in 
resin and cured for 48 hr at 60°C.
2.7.3  Semithin Sections
Semithin  sections (0.7  pm) were  cut  using  a  Leica  ultracut S  microtome fitted 
with a diamond knife (Diatome histoknife).  Sections were stained with toluidine 
blue  stain  (25  ml  2  %  hydrated  sodium  borate,  25  ml  100  %  ethanol,  0.5  g 
toluidine  blue,  SPI-Chem™)  and  slides  were  mounted  with  DPX  after  the 
sections  had  dried.  Sections were  analysed  using a  Leitz Diaplan  microscope 
for observation and imaged with a Leica DC 500 digital camera.
2.7.4  Ultrathin sections
Ultrathin  sections  (50  nm)  were  cut  using  a  Leica  ultracut  S  fitted  with  a 
diamond  knife for  ultrathin  sections  (Diatome  histoknife for ultrathin  sections).
108Sections  were  taken  of  treated  areas  of  retinae  and  collected  onto  grids. 
Sections were stained with uranyl acetate for 10 min and lead citrate for 7 min 
and then washed with dhfeO. After the sections had dried they were analysed by 
electron microscopy (JEOL 1010 TEM).
2.8  Statistical analysis
The choice of an appropriate statistical method is important to draw conclusions 
from data that are  subject to experimental  error.  Generally,  statistics yield the 
probability value for a  particular result.  In  science,  a  probability (p) of 0.05  or 
less  is  usually  accepted  as  convincing  evidence  that  a  particular  outcome  is 
significant and not due to chance.
A  “Student's  t-test”   can  be  performed  knowing  only  the  mean  and  standard 
deviation of two data sets. The Student's t-test determines a probability that two 
populations  are the  same with  respect to the variable tested.  The  populations 
are  assumed  to  follow  a  normal  distribution  (Gauss  distribiution).  For 
independent  samples,  as  it  was  the  case  for  most  of  the  histological  data 
presented  in this thesis,  an  unpaired  Student’s t-test was  used  (unless stated 
differently). This test compares two small,  independent sets of data that do not 
have to have the same number of data points in each group and are collected 
randomly.  In  order to  evaluate  the  significance  of the  difference  in  number of 
surviving  photoreceptor  cells  and  retinal  layer  thickness  between  either  non- 
dystrohic or dystrophic,  treated or untreated animals, cell counts and thickness 
meassurements were carried  out and on  10 sections  per eye,  in the middle of 
the  superior  injection  site.  Since  the  number  of  animals  for  each  condition 
varied,  the  sets  of  data  should  to  be  regared  as  randomly  collected  and 
independent.  Therefore an unpaired Student’s t-test was applied.
For functional ERG results presented in this thesis, a paired Student’s t-test was 
performed.  A paired t-test can only be applied if the numbers of points in each
109data set are the same,  and if they are organised  in pairs.  Generally,  it is used 
when  measurements  are  taken  from  the  same  subject  before  and  after 
manipulation,  in this case the viral  mediated expression of a transgene.  Since 
ERG  records  electrical  responses  of both  eyes  simultanously,  and  recordings 
can  be  obtained  at  different  time  points  over  a  period  of time  from  the  same 
animal,  a  paired  Student’s  t-test was  used.  For each  animal,  the  height of b- 
wave  amplitude  of  the  ERG  recording  obtained  at  a  flash  intensity  of  100 
mcds/m2 was used for statistical analysis.  The b-wave values (a-wave through 
to  b-wave  peak)  of  the  treated  (right)  eye  were  paired  with  the  untreated 
contralateral  (left)  eye to  provide  an  internal  control.  A paired  Student’s  t-test 
was used to evaluate significance (p<0.05). This method controls for interanimal 
variance and test-retest variance present in rodent ERGs.
2.9  Patient Screen
2.9.1  Patients
A panel  of 96 patients with simplex and  autosomal  recessive retinal  dystrophy 
were  ascertained  from  the  medical  retinal  clinics  at  Moorfields  Eye  Hospital. 
The  study was  conducted  in  accordance with  the tenets of the  Declaration  of 
Helsinki  and  was  approved  by  Moorfields  Hospital  Ethics  Committee.  All 
patients gave written informed consent to be included in the study and provided 
a blood sample for subsequent DNA extraction and DNA analysis.
2.9.2  DNA isolation
Blood  samples  were  collected  in  EDTA  tubes.  DNA  was  extracted  using  a 
Nucleon  Genomic  DNA  Extraction  Kit  (BACC2,  Tepnel  Life  Sciences  pic) 
following manufacturer’s instructions.  Solution A provided by thew supplier was
110added to each sample and samples were shaken for 5 min. After centrifugation 
for  7  min  at  5000xg  the  supernatant was  carefully  removed.  Each  pellet was 
then resuspended in 2 ml solution B, samples were transferred to a new tub and 
mixed with 450 pi of sodium perchlorate. Tubes were inverted several times in 
order  to  mix  the  samples  and  1.5  ml  chloroform  was  added.  After  mixing 
thoroughly 300 pi of Nucleon resin was added and samples were centrifuged for 
5 min at 4000xg. The aqueous phase containing the DNA was transferred into a 
new tube and mixed with 6 ml 100 % ethanol. After a 5 min spin the supernatant 
was removed and DNA pellets were washed with 500 pi 70 % ethanol. Samples 
were  centrifuged  again  at  4000xg  for  5  min,  the  ethanol  was  removed  and 
pellets were air dried. The DNA was resuspended in 400 pi dhhO,  rotated over 
night at 4°C to dissolve DNA, and stored at -20°C.
2.9.3  PCR
Primers  were  designed  corresponding  to  intronic  sequences  for  PCR 
amplification of all 19 exons of MERTK. Sequences of primers used are listed in 
Table 3 (see Appendix). All PCR reactions were performed in a total volume of 
50 pi using 200 pM dNTPs (Promega  UK),  0.5 pM of each primer,  2  pM  DNA, 
magnesium containing Optimase reaction buffer (Transgenomic UK) and 2.5 U 
Optimase  polymerase  (Transgenomic  UK).  Reactions  were  cycled  using  a 
Techne  Touchgene  Thermal  Cycler.  The  optimal  annealing  temperature  for 
each  primer  set  was  calculated  by  using  the  program  PrimerSelect™ 
(DNASTAR Inc.).
Cycling conditions were as followed:
Initial denaturation  5 min at 95°C
Annealing 
Extension 
Final extension
Denaturation 1   min at 95°C 
15 sec at Ta 
1   min at 72°C 
10 min at 72°
> -  35 cycles
111Table 3: Amplification of the human MERTK gene. Primer pairs were designed to cover the 
entire coding sequence and important intronic sequences of the human MERTK gene (see also 
Appendix).  Primer  sequences  and  annealing  temparatures  for  PCR  are  summarised  in  the 
table.
MERTK Forward primer 5’-3’ Reverse primer5-3’ Ta [°Cl
Exon 1 gacaggttcgggaggtccatctg ccctgtggacgcgctccctccccag 60
Exon 2 ggacaccccagtgctctctcttc gctacagaatgatactctgtctc 60
Exon 3 cacagcatatgacaaagaagttg cagagttataaataggcaggc 59
Exon 4 ctttgggctctgtctctgtttt ttgatcctgtccgctattagaga 52
Exon 5 tgtttctctgctgctggtctc cctcaccagctcccagaac 65
Exon 6 gtagctgtagcctgtcatctataa cccacagagagcaccaa 50
Exon 7 tgcctgacattcccaccac tgggaagggtttgttgaatca 65
Exon 8 atgagaatacatctgtgtgtgcttt agttgaaaggagatgactaatcg 50
Exon 9 ctgcagtttgcccagacctc gaccatcacatcctatcagccc 50
Exon 10 tgactatttgttcttccctgttac taacaaccttgtcaataccagtg 50
Exon 11 agtagccctgtttttatagtgaag gtctattgatccttctttgttctc 48
Exon 12 caagtgaaagaaaacacgctg aaactgctaccttcttatcccac 52
Exon 13 tggtcagggaagagtttgc gcacccaatactgaagcaac 52
Exon 14 cccacccactcccctt cacagagcagatcagcagag 60
Exon 15 tggtcacagtaacaaggactc tcacataagccctgagaagt 42
Exon 16 cccccggcagaaact tgcaaagaccaaacacca 58
Exon 17 gtgttttcacctgtgtctga tatgccctcctctttgtg 48
Exon 18 gctttgtggaaaggcttg tgtgtttccgaggtcagtg 50
Exon 19 ggcatggattgcacaaagagatgggtg catcaggtacaattggattctc 60
2.9.4  Gel electrophoresis
Fragment  size  and  purity  of  PCR  reactions  were  controlled  by  gel 
electrophoresis.  Samles  were  loaded  onto  a  2  %  agarose  gel  made with  1% 
TBE buffer and 8 pi ethidiumbromide/200  pi total volume.  The fragments were 
characterised under UV-light.
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2.9.5.1  ExoSapIT treatment
Samples were  processed for direct  sequencing for characterisation.  For each 
sample two reaction -  one for the forward primer and one for the reverse primer 
-  were set up.  DNA fragments were purified by ExoSAP-IT® (Usb Corporation) 
treatment  in  a  total  volume  of  18  pi  using  2  pi  (approximately  10  ng)  of the 
amplified  DNA fragment and 0.5 pi  ExoSAP-IT enzyme with  sterile dhhO.  The 
purification  mix  was  incubated  for  15 min  at  37°C  and  then  the  enzyme  was 
inactivated for 15 min at 80°C.
2.9.5.2  Big Dye
Samples were sequenced using a BigDye® Terminator v1.1  Cycle Sequencing 
Kit  (Applied  Biosystems).  The  Big  Dye  was  diluted  in  2.5  x  Big  Dye  Buffer 
containing 200 mM Tris pH 8, 5 mM MgCh with sterile dH20. To each ExoSAP 
IT treated  sample  1   pi  Big  Dye  v1.1  and  either  1   pi  (0.8  pM) forward  or  1   pi 
reverse primer were added.
Cycling conditions were as followed:
30 cycles:  95°C for 30 sec
50°C for 30 sec 
60°C for 4 min
2.9.5.3  Purification and sequencing
Samples  were  then  purified  using  Millipore  Montage™  Cleanup  Kit  (Millipore 
Corporation).  The  total  volume  of  samples  was  transferred  to  a  Millipore  96 
plate  and  a  vacuum  (15  to  20  psi)  was  applied  for  10  min.  Each  well  was
113washed twice with  25  pi  injection  solution  supplied  by manufacturer.  Between 
and after the washing  steps a vacuum was  applied.  Another 25  pi of injection 
solution was added to each well,  the plate was sealed and shaken for 5 min to 
recover the purified PCR samples.  Samples were then transferred onto an ABI® 
96 plate (Perkin Elmer, Warrington,  UK) for sequencing. Samples were run over 
night on  an ABI  Applied  Biosystems  373A  DNA  Sequencer.  Sequences were 
analysed using the DNASTAR software package (DNASTAR Inc.).
2.10  Clinical assessment
Affected  individuals  in  whom  a  causative  mutation  in  MERTK was  identified 
underwent  detailed  phenotypic  studies.  Clinical  investigations  included 
assessment  of visual  acuity,  colour vision  assessment,  Goldman field  testing, 
slit  lamp  examination,  funduscopy  and  retinal  imaging,  incuding  fluorescein 
angiography  (FFA),  autofluorescent  imaging  with  a  confocal  scanning  laser 
ophthalmoscope (c-SLO-AF) and  optical coherence tomography (OCT). Colour 
vision was  evaluated  using  the  Hardy,  Randy,  Rittler (HRR)  plates  (American 
Optical  Company,  NY,  USA).  Goldman  kinetic  visual  fields  were  determined 
using the V4e and  HVe targets on  a  standard  background.  ERGs assessment 
included  a  full  field  electroretinogram  (ERG)  and  pattern  ERG  (PERG), 
incorporating the protocols recommended by the International Society [327-330] 
for  Clinical  Electrophysiology  of  Vision  Standard  (ICSEV).  Retinal 
autofluorescence  was  recorded  using  the  Heidelberg  Retina  Angiography 
(HRA2;  Heidelberg engineering,  Heidelberg Germany). All clinical examinations 
were  conducted  by  A.  Webster,  G.  Holder  and  colleagues  at  Moorfields  Eye 
Hospital.
1142.11  Buffers and solutions
Ampicillin (1000 x):   50 mg/ml ampicillin (Sigma-Aldrich Company Ltd.) in dH20, 
sterile filtered, stored at -20°C
Big Dye Buffer (2.5 x): 200 mM Tris pH 8, 5 mM MgCI2 with sterile dH20
Church Buffer:   21  g of NaH2P04)  48.55 g  Na2HP04, 70 g of SDS,  0.5 M  EDTA 
and dH20  to 1   litre.
DNA  loading  buffer  (6  x):  0.25  %  (w/v)  bromophenol  blue  and  30  %  (v/v) 
glycerol in water
LB growth medium:   14 g Bacteriological agar (oxoid Ltd.) per litre of water, 5 g/l 
yeast extract,  10 g/l tryptone (Oxoid Ltd.),  10 g/l sodium chloride,  and 50 pg/ml 
ampicillin
PBS (1  x):  85 g NaCI, 4.3 g KH2P04, dH20  to 10 litres, pH 7.2
PBS (tissue culture):  10 phosphate buffered saline tablets (Oxio Ltd.) dissolved 
in 1   I sterile ddH20
PBS-MK:   1   x PBS, 2.5 mM KCI,  1   mM MgCI2
Periodate  Ivsine  paraformaldehyde:  2%  paraformaldehyde  and  0.05% 
glutaraldehyde
Proteinase K buffer:   100 mM Tris (ph 7.4), 50 mM EDTA and 0.5 % SDS 
Sodium cacodvlate buffer (0.07 M):  0.2 M (CH3)2As02Na.3H20 with 0.2 N HCI
115Sodium phosphate buffer: 97.1  g Na2HP04, 43.6 g NaH2P04l pH 7.2
Toluidine blue stain:  25 ml 2 % hydrated sodium borate, 25 ml 100 % ethanol, 
0.5 g toluidine blue (SPI-Chem™)
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3  AAV-mediated rescue of the 
RCS rat
3.1  Introduction
AAV has nowadays reached the central point of prominence in the development 
of  vectors  for  human  gene  therapy  applications  because  of  its  structural 
simplicity  and  its  non-pathogenic  character  in  humans.  Initial  gene  transfer 
studies to the eye showed that AAV-based vectors are the most efficient vectors 
to  target  photoreceptor  cells  after  subretinal  delivery  and  that  long-term 
expression of reporter genes can  be maintained [331].  Over the last few years 
AAV  vectors  were  used  to  rescue  different  animal  models  of  retinal 
degeneration  due  to  photoreceptor-specific defects  [105,  221,  228,  230,  231, 
283,  285,  332].  However,  several  factors  make  retinal  degenerations  due  to 
mutation within genes specifically expressed in the RPE a more attractive target 
for the development of novel gene therapy protocols. The RPE is a tissue that is 
relatively  efficiently  transduced  by  a  variety  of  recombinant  viruses  including 
AAV  [228,  273,  314].  A  single  RPE  cell  is  in  contact  with  a  number  of 
photoreceptor cells and therefore a single transduced RPE cell might protect or 
restore function to  several  photoreceptor cells.  In  conditions,  in which there  is 
an RPE-specific gene defect, photoreceptor cells are primarily both healthy and 
functional,  and  their function  needs  to  be  retained  rather  than  restored.  The 
ability  of  AAV  to  transduce  RPE  cells  has  also  been  evaluated  in  different
117species  including  mouse,  rat,  and  dog  [105,  333,  334].  A  recent  study  has 
shown  the  ability  of AAV  to  restore  vision  in  the  rpe65  null  mutation  dog,  a 
model  for  retinal  degeneration  due  to  an  RPE-specific  defect  [105].  Another 
gene specifically expressed in the RPE is the receptor tyrosine kinase MERTK, 
which  is  mutated  in  the  RCS  rat,  a  well  studied  animal  model  for  retinal 
degeneration,  and  in  patients  afflicted  with  autosomal  recessive  RP  [69,  72, 
159, 335].
The  aim  of the  work described  in  this  chapter was  to determine the  potential 
value  of  AAV-2-based  vectors  for  a  gene  therapy  approach  of  retinal 
degeneration due to a defect in the MERTK gene.
3.2  Transduction of the RPE
Photoreceptor outer segment tips are shed daily to replace used photopigments 
and thereby maintain the high sensitivity of visual perception. The membranous 
waste  material  is  phagocytised  by  RPE  cells  [68,  335].  Many  proteins  are 
involved in the recognition, binding and transportation of this waste material. As 
described in chapter 1.1.6 and 1.1.7, MERTK is one of the key-proteins involved 
in phagocytosis and mutations within MERTK are leading to the inability of RPE 
cells to  remove  the  shed  outer segments  [71].  As  a  result the waste  material 
accumulates  in  the  subretinal  space,  photoreceptors  and  RPE  cells  lose 
contact,  and  the  RPE  cells  cannot  provide  essential  substances  to  the 
photoreceptors, which consequently die [68, 69,  159].
Since it was not known  if RPE  cells express a specific receptor necessary for 
the up-take of AAV or if AAV uses the phagocytosis machinery to enter the host 
cells,  the  first  problem  which  needed  to  be  addressed,  was  whether  the 
phagocytotic defect of the RPE of RCS rats would affect the uptake of vectors. 
Therefore a recombinant AAV-2 (rAAV-2) vector containing the gfp marker gene 
under the control of a cytomegalovirus (CMV) promoter (the recombinant virus
118was named AAV.CMV.GFP) was  injected  into the subretinal  space of four 10- 
day old  RCS  rats.  For the  production  of rAAV,  BHK cells were co-transfected 
with HSV helper virus and two plasmids: the rAAV plasmid pD10 containing the 
reporter  gene  expression  cassette  and  the  replicating  amplicon  providing  the 
rep  and  cap  genes  [323].  The  rAAV  plasmid  is  generally  deleted  of all  viral 
genes  and  is  comprised  of the  viral  terminal  repeats  flanking  the  expression 
cassette (see p81, figure 1.11). The rep and the cap genes, necessary for virus 
replication and packaging [322], are usually delivered on a separate plasmid to 
increase  safety  [323].  Both  constructs  -   the  rAAV  vector  containing  the 
expression cassette (the promoter of choice and the reporter gene or transgene 
of interest) and the complementing vector (containing the cap and rep genes) -  
are  usually  configurated  in  a  way  that  they  share  no  sequence  homology. 
Hence,  contaminating  pseudo-wild-type  virus  can  only  arise  via  non- 
homologous recombination.
Twenty-four hours after infection  BHK cells were assessed for egfp expression 
(Figure  3.1)  and  harvested  by  centrifugation  after  the  completion  of  the  lytic 
cycle (24 to 36 hr).
Figure  3.1:  BHK  cells 
expressing  GFP.
Twenty-four  hours  after 
infection  cells  were 
assessed  for  gfp
expression  to  confirm 
that  the transfection  had 
been  successful.  The 
fluorescent  image  shows
cells  in  which  egfp
expression  is  under  the 
control  of  the  CMV
promoter.
119After  purification,  using  a  heparin  column  purification  protocol  [325]  the 
molecular titre was estimated by dot-blot analysis (Figure 3.2). A serial dilution 
ranging from 109 to 1012 molecules of plasmid including a probe DNA of known 
concentration was  used to produce a standard  ladder.  The dilution series was 
included in the blot.  Usual titres ranged from 101 1  to 1013 particles/pl.
Figure  3.2:  Autoradiogram  of a 
dot-blot.  The  serial  dilution  of  a 
DNA probe of known concentration 
serves  as  a  standard  ladder.  1   pi 
and  5  pi  °f the  virus  suspension 
were loaded and the concentration 
estimated  by  comparing  the 
sample  to  the  dilution  series.  In 
this case it was estimated that the 
virus  suspension  had  a 
concentration of 101 1  particles/ml.
Dilution series 
1012  101 1  1010  109
5 pi  1   pi
•   •
virus suspension
We then  injected  4  pi  of virus  suspension  at a  concentration of 4 x  107 rAAV 
particles/pl subretinally into each hemisphere of the right eye of four dystrophic 
RCS  rats.  The  injections were  performed  under direct retinoscopy through  an 
operating  microscope  [228].  The  needle  tip  was  inserted  into  the  subretinal 
space  causing  a  self-sealing  tunnel  and  the  virus  solution  was  injected.  The 
liquid causes a momentary detachment of the retina, which disappears steadily 
during  the  following  24  hr  (see  figure  3.3).  The  bleb  size  initially  covers 
approximately one third of the retina.
120Figure  3.3:  Rat  fundus 
after  subretinal
injection.  The  injected 
virus suspension causes a 
momentary detachment of 
the  retina.  Detachments 
are  seen  in  the  superior 
and  inferior  hemisphere 
which  together  cover 
approximately two third  of 
the retina.
Four weeks after injections,  eyes were taken and  prepared for cryosectioning. 
Sections were then analysed for GFP fluorescence.  Propidium iodide was used 
as  a  nuclear  counterstain  for  GFP  fluorescence  of  transduced  cells.  The 
enhanced gfp (egfp) used in this project is known to give a brighter fluorescence 
compared  to  common  gfp,  and  has  a  higher  signal-to-noise  ratio  due  to  its 
shifted  emission  fluorescence.  Therefore  areas  of  maximal  transduction  rate 
and  egfp  expression,  appear yellow  in the fluorescent micrograph  (figure  3.4). 
Efficient transduction of photoreceptor cells and RPE cells was observed in the 
treated  areas,  which  covered  approximately  one  third  of  the  retina  for  each 
injection,  of all  animals.  The  size of the  area,  in which  GFP fluorescence was 
observed,  correlated with the  bleb  size generated  by the  injection of the  virus 
solution.  This  result  suggests that the  phagocytotic defect of the  RPE  of RCS 
rats does not prevent the uptake of viral vectors.
superior
retinal 
detachment
inferior
121Figure  3.4:  AAV-mediated  expression  of  egfp  in  the  retina.  Four  weeks  after  AAV-2- 
mediated delivery of the reporter gene egfp under the control of the CMV promoter to the rat 
retina, efficient expression in photoreceptor and RPE cells is observed. Sections were stained 
with propidium iodide, a nuclear counterstain (red). Areas of maximal egfp fluorescence appear 
yellow.  The  size  of  the  GFP  fluorescent  area  correlates  with  the  size  of  the  momentary 
detachment of the retina generated by the virus suspension.
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3.3  Expression pattern of different 
promoters
The  choice  of  the  promoter  has  an  important  role  in  location,  strength  and 
duration  of  expression.  The  CMV  promoter  has  the  advantage  that  it  is 
considered  to  be  a  stronger  promoter than  other common  promoters  used  in 
different  vectors for gene  therapy  approaches  and  that  it  is  highly  active  in  a 
broad range of cell types.
In many gene therapy applications,  however,  a cell-specific promoter would be 
more  appropriate  because  it  provides  the  opportunity  to  restrict  transgene 
expression to the cell type or tissue of interest.  Hence,  possible unwanted side
122effects that might occur if the transgene is expressed  in a non-native cell type 
are abolished and thereby safety of gene therapy increased.  Since  MERTK in 
the eye is predominately expressed in RPE cells,  it was unclear if an additional 
expression of the therapeutic gene in photoreceptor cells - which would be the 
case if driven by the CMV promoter - would cause any unwanted effects.  This 
problem  can  be  circumvented  by  the  use  of  an  RPE-specific  promoter.  The 
rpe65 promoter’s activity is restricted to the RPE and therefore it can be used to 
target  expression  to  the  RPE  [324].  However,  the  rpe65  promoter  is  a 
mammalian  promoter  and  therefore  expression  levels  were  expected  to  be 
lower than those of viral promoters such as CMV.  In order to test the efficiency 
of the rpe65 promoter’s,  another control  construct was designed,  in which the 
egfp marker gene  is driven  by the  murine rpe65 promoter.  The approximately 
650  bp  RPE-specific  rpe65  promoter  fragment  described  by  Boulanger  and 
collegues  was  amplified  from  murine  genomic  DNA  [324]  in  our  group.  It 
contains  an  octamer (ATGCAAAT)  and  two  protein-binding  E-box sites which 
have been shown to be necessary for the RPE-specific activity of the promoter 
fragment.
The rAAV genome is generally comprised of the viral terminal repeats flanking 
the expression cassette of interest. The small size of the wild-type AAV genome 
(approximately 4.7 kb), however, limits the size of the fragment inserted into the 
rAAV plasmid.  It has been shown that the optimal  size of the rAAV vector,  for 
high  post-infection  expression  levels,  lies  between  4.1  and 4.9  kb.  A possible 
reason might be that vectors in this size range are closer to the wild-type size of 
the AAV virus genome. Thus, whenever an expression cassette smaller than 4 
kb is inserted into an AAV vector backbone -  in this case the pD10 vector -  a 
stuffer DNA sequence is cloned  upstream or downstream to reach the optimal 
size range of 4.1  to 4.9 kb [323].  A stuffer DNA is a random sequence that is 
neither  part  of  any  promoter  nor  gene  and  does  not  contain  long  repeats  to 
avoid  non-specific  transcription  or  intra-molecular  recombination  events, 
respectively.  In this case,  the  rpe65 promoter [324] and the reporter gene gfp 
were inserted in between the ITRs of the pD10 expression plasmid.  In addition, 
a  2.3  kb  stuffer  sequence  was  inserted  downstream  the  expression  cassette 
because the total expression cassette size was only approximately 1.8 kb. The
123construct  was  used  to  produce  rAAV  virus  (AAV.RPE65.GFP).  The  virus 
suspension was then  injected  subretinally as described  above into  10-day old 
non-dystrophic RCS rat eyes (4 pi of virus solution at a concentration of 4 x 107  
particles/pl).  Four weeks after injections the eyes were taken and analysed for 
GFP fluorescence (figure 3.5).  Efficient RPE transduction was observed and the 
size of the area showing fluorescence was approximately the same size as the 
area  covered  by  the  bleb  following  injection.  However,  in  contrast  to  the 
expression  pattern  of AAV.CMV.GFP,  expression  in  photoreceptors  was  only 
found in areas of needle trauma.  It is known that the damage to the neuroretina 
due  to  the  surgical  procedure  including  the  degree  of  the  needle  trauma 
following  subretinal  injections  and  the  speed  of injection  of vector suspension 
influences  the  efficiency  of  transduction.  In  these  areas,  transduction  of 
photoreceptor cells by different viruses is commonly found.  Our results suggest 
that the rpe65 promoter is able to drive weak expression in photoreceptors and 
this only becomes in areas of needle trauma.
Figure  3.5:  AAV.RPE65.GFP-
mediated  expression  pattern.  Four
weeks  after  subretinal  injection  of
AAV.RPE65.GFP eyes were analysed
for  egfp  expression.  Cryosections
were  counterstained  with  propidium
iodide  (red).  GFP  fluorescence  was
restricted to the RPE showing that the
rpe65 promoter is specifically active in 
the  RPE.  INL=inner  nuclear  layer, 
ONL=outer  nuclear  layer,  IS  &  OS=
inner  and  outer  segments,
RPE=retinal  pigment  epithelium,
Ch=choroid, size bar=10 pm.
1243.4  MERTK transgene expression
Having established that the cellular defect would not compromise transduction 
by AAV and that the rpe65 promoter is functional,  rAAV expressing the MERTK 
gene driven by either a CMV or an rpe65 promoter were produced.
MERTK  is  a  gene  highly  conserved  between  amniota.  Comparison  of  the 
mouse and rat protein amino acid sequence shows that they are 91  % identical 
and  therefore  it was  assumed  that  a  murine copy of the  MERTK gene would 
express  a  protein  that would  be functional  in  rats  (for alignment of the  amino 
acid  sequences  see Appendix).  Rat  eyes were  collected  and  the  cornea  and 
lens were removed. The retina was immediately homogenised in Trizol reagent 
for total  RNA extraction.  Total  RNA was  then  used  to  specifically amplify the 
Mertk cDNA by RT-PCR. Since it is difficult to amplify large fragments, 2 sets of 
primers  were  designed  to  cover  the  entire  coding  sequence  of  the 
approximately 3600 bp long MERTK mRNA.  The two fragments obtained were 
combined using the naturally occurring EcoRV restriction enzyme site to give a 
full  length  cDNA  clone  of  3038  nucleotides.  The  MERTK  cDNA  was  then 
cloned  into  the  pGMT.Easy  vector  (Promega,  Madison,  Wl).  This  plasmid 
contains a polylinker sequence that facilitates cloning since the PCR product is 
flanked  by  a  variety  of  different  restriction  sites.  The  resulting  plasmid  was 
termed pGMT.Mertk and it was used to sequence the MERTK cDNA to ensure 
that no sequence changes occurred during the isolation and amplification of the 
fragment. After the sequence was confirmed, we used restriction enzymes Sacll 
and Xho\ to excise MERTK (conducted by A. Smith).
After  digestion,  the  sample  was  separated  on  a  gel  by  electrophoresis,  the 
fragment of the  appropriate  size was  excised  and  gel  extracted.  The  MERTK 
fragment was then ligated into the pD10 backbone, which was already digested 
at the same restriction sites. The rpe65 promoter was already cloned into the gt- 
rpe65p2  plasmid.  The restriction enzymes  Sa/I  and  Sacll were used to excise 
the promoter which was then ligated upstream of the MERTK gene in the pD10 
backbone already digested with the same enzymes (figure 3.6).  In this case, no
125stuffer sequence was  needed  since  the  expression  cassette  size  exceeded  4 
kb.  The resulting plasmid was named AAV.RPE65.Mertk (see figure 3.7 for the 
pD10 plasmid map).
Figure  3.6:  Restiriction
enzyme  digest.  The  ~3.1  kb 
MERTK fragment and the ~700 
bp  rpe65  promoter  fragment 
were  isolated  and  cloned  into 
the pD10 backbone to form the 
therapeutic  construct
AAV.RPE65.Mertk (-5 kb).
5000 bp 
3000 bp
750 bp *   —
The  same  enzymes  were  used  to  excise  the  CMV  promoter  from  the 
AAV.CMV.GFP  construct.  The  rpe65  promoter  of  the  AAV.RPE65.Mertk 
construct  was  then  exchanged  against  the  CMV  promoter  fragment  and  the 
resulting construct was termed AAV.CMV.Mertk.  Both constructs were used to 
produce rAAVs.
Figure  3.7:  Map  of the  AAV-2 
pD10  plasmid.  The  transgene 
(either  gfp  or  MERTK)  was 
cloned  downstream  of  a 
promoter fragment  (either  CMV 
or rpe6S). In case of the reporter 
gene  gfp  a  stuffer  DNA  was 
additional  included  downstream 
the  expression  cassett to  reach 
the  optimal  total  vector  size  of 
4.9 kb.
BamHI
promoter
transgene
EcoRV
PmaCI
126The  two  vectors  carrying  the  therapeutic  gene  were  then  injected  into  the 
subretinal space of 10 day old RCS rats (3 animals for each construct).  In order 
to demonstrate that the viruses are functional  and the transgene is expressed, 
rats were sacrificed  nine weeks after injection  and  RNA was  isolated from the 
retina  as  described  previously.  RT-PCR  was  used  to  confirm  expression  of 
MERTK.  In RCS rats, the phagocytotic defect is due to a premature stop codon 
shortly downstream of exon 2 of the MERTK gene.  To prevent amplification of 
the endogenous mRNA, the 5’ primer was located in the region of the gene that 
is  deleted  in  the  RCS  rat  by  the  mutation.  The  samples were  DNase  treated 
before the reverse transcription was carried out to avoid an amplification of the 
transgene present in the recombinant virus.
In  eyes  injected  with  rAAV,  expression  of the  MERTK gene was  detected  by 
RT-PCR,  whereas  full  length  MERTK  mRNA was  not  detected  in  uninjected 
control  eyes  (figure  3.8).  Omission  of  reverse  transcriptase  resulted  in  the 
absence  of signal  in  all  eyes,  confirming  that the  PCR  product  in  the  treated 
eyes was derived from mRNA rather than the recombinant gene.
Figure 3.8:  RT-PCR amplification of MERTK from injected rat eyes. RNA was isolated from 
eyes injected with AAV.CMV.Mertk (lanes 1   and 7) and AAV.RPE65.Mertk (lane 3 and 9) and 
the  uninjected  control  eyes  (lanes 2  and  8  and  lanes 4  and  10,  respectively).  Samples were 
treated  with  DNase  to  remove  genomic  and  viral  DNA  before  reverse  transcription  and 
amplification  of the  transgenic  MERTK mRNA.  A  band  of the  correct  size  (500  bp)  can  be 
amplified  from  the  eyes  treated  with  either  vector  (lanes  1   and  3);  whereas  there  is  no 
transgenic  mRNA detectable  in  the  uninjected  eyes  (lanes 2  and  4).  Lane  5  shows  a  cDNA 
positive  control for the  amplification  of MERTK,  lane  6  is a  marker.  Omission  of the  reverse 
transcriptase results in the absence of signal (lanes 7 to 10).
1   2  3  4  5  6 7  8  9  10
1000
750
500
250
1273.5  Effects  of  MERTK  transgene 
expression on retinal morphology
Since expression of the MERTK transgene could be confirmed by RT-PCR we 
wanted  to  evaluate  the  effect  of  treatment  on  retinal  morphology  and  to 
determine whether we would  be  able to  delay  retinal  degeneration.  For  each 
vector,  five  RCS  rats were  injected  subretinally.  To  increase the treated  area 
and  to  maximise  the  number  of  RPE  cells  reached  by  the  virus,  the  virus 
suspension was not only injected superiorly but the procedure was repeated in 
the inferior hemisphere. With this technique approximately 70 % of the retina is 
exposed to the virus.  For each  construct one eye of the animals was treated; 
the  contralateral  eyes  were  left  untreated  as  internal  controls.  This  was 
necessary because it is known that the pace of photoreceptor cell loss and the 
rate of retinal  degeneration  in  the  RCS  rat  is  influenced  by  many factors  and 
varies  even  between  animals  from  the  same  litter.  If  only  one  eye  of  each 
animal  is treated,  the effect of a treatment can be estimated by comparing the 
treated  with  the  untreated  eye  in  each  animal,  thereby  controlling  for  inter­
animal  variation.  Since degeneration  in  RCS  rats  is  rapid  and  starts at young 
age of the animals (approximately around postnatal day (P) 14 shortly after the 
palpebral fissure opens) injections were performed in 10-day old rats in order to 
achieve transgene expression at a time point when retinal degeneration  is not 
yet too advanced [68].
Animals were  sacrificed  nine weeks  after treatment  and  the eyes were taken 
and processed for semithin sections.  Before fixation and embedding eyes were 
carefully  orientated  in  a  way  that  both  injection  sites  would  be  present  in 
sections taken in areas around the optic nerve head.  For histological analyses 
sections were examined with light microscopy (figure 3.9).  In treated eyes there 
appeared to be less debris deposited between the photoreceptor cell layer and 
the  RPE than  in  untreated controls.  This suggests that after treatment at least 
partial  restoration of RPE  phagocytosis was achieved.  It is known that retinal 
degeneration  in  RCS  rats  is  characterised  by  hemispheric  differences  in  the
128pace of photoreceptor cell loss, with an accelerated pace of degeneration in the 
inferior hemisphere.  Furthermore, there is a gradient in photoreceptor loss from 
the posterior pole to the peripheral retina, with photoreceptors being preserved 
longer close to the ciliary body.  Therefore, pictures of an area approximately in 
the middle of the injection site between the optic nerve and the ciliary body in 
the  superior  hemisphere  were  taken  of  each  eye  and  the  number  of 
photoreceptor cell  nuclei  was  counted  over a  250  pm wide  area of the  outer 
nuclear layer (ONL).  Pictures of untreated eyes were taken of analogous areas 
of the retina. To control for the inter-animal variation in the rate of degeneration, 
a  paired  t-test  was  performed  between  the  number  of  photoreceptors  in  the 
treated  and  untreated  eyes  of  each  animal.  In  the  eyes  injected  with 
AAV.CMV.Mertk,  the  number  of  photoreceptor  cells  was  approximately  2.5 
times higher at this time point than in untreated controls (85 ± 37 versus 33 ± 9; 
p=0.022).  In eyes treated with AAV. RPE65. Mertk the number of photoreceptor 
cells was approximately 2 times higher at this time point compart to untreated 
controls (59 ± 28 versus 31  ± 7; p=0.05). The less efficient rescue achieved with 
AAV.RPE65.Mertk in  comparison to AAV.CMV.Mertk was probably due to the 
difference  in  the  promoter  strength.  The  viral  promoter  CMV  is  a  stronger 
promoter with  higher  expression  levels  than  the  mammalian  rpe65  promoter. 
The  higher  number  of  photoreceptor  cells  in  treated  eyes  confirms  that  the 
photoreceptor  loss  was  reduced.  Furthermore,  in  both  treatment  groups  a 
reduction  in  the  debris  layer thickness could  be observed.  This  indicates that 
the  phagocytic  function  of  the  RPE  was  at  least  partially  restored  after  the 
treatment with the therapeutic constructs.
129Figure  3.9:  Histological  analysis  of  AAV.CMV.Mertk  treated  eyes.  Semithin  sections  of 
AAV.CMV.Mertk treated (a) and the contralateral untreated eye (b) were stained with toluidine 
blue  9 weeks after injection. The amount of debris deposited  between the outer nuclear layer 
and the RPE is lower in the treated eyes than in the untreated eyes, indicative of a restoration of 
the  phagocytic function  of the  RPE.  Furthermore,  the  number of photoreceptor cell  nuclei  is 
higher after injection with therapeutic virus, confirming that the rate of photoreceptor cell loss in 
decreased (size bar = 10 pm).
3.6  Effects  of  MERTK  transgene 
expression on retinal function
After  having  established  that  the  expression  of  the  murine  MERTK  gene  is 
delaying  photoreceptor  cell  loss  in  the  RCS  rat,  we  then  wanted  to  test  if 
transgene  expression  would  also  increase  and/or  prolong  retinal  function. 
Photoreceptor  cells  are  initially  inherited  healthy  and  functional  in  RCS  rat, 
since the primary gene defect is in the RPE cells.  Electroretinography (ERG) is 
a  useful  device  to  examine  retinal  activity  and  follow  the  progress  of 
photoreceptor cell loss over time (see [336] for a review).
The  electrical  response  of the  retina  over time  can  be  separated  in  different 
parts  (see  figure  3.10).  It  begins  with  an  a-wave,  which  polarity  is  negative 
relative  to  the  cornea.  This  signal  is  interrupted  by  a  large  corneal-positive 
potential,  the b-wave.  The a-wave results from the closure of cyclic nucleotide
130gated cation channels in the outer segment of photoreceptor cells in response 
to the capture of photons. The b-wave is generated in Muller and bipolar cells of 
the  inner  nuclear  layer  and  its  amplitude  correlates  with  the  number  of 
functional photoreceptor cells in the eye. At the end of the trace another positive 
signal can be found,  the c-wave.  The c-wave is a sum of potentials generated 
by Muller and  RPE cell which can be used to assess the functional integrity ot 
the  retina.  Oscillatory  potentials  (OPs)  are  a  series  of  rapid  low-amplitude 
potentials  on  the  ascending  limb  of  the  b-wave  of  the  ERG  trace,  usually 
comprising  four  or  more  wavelets  (reviewed  in  [337]).  OPs  are  sensitive  to 
ischemia in the inner layers of the retina.  Therefore OPs are useful  indices for 
clinical application ( for reviews see [327, 338]).
131Figure 3.10:  Oscillatory  potentials  on  the  ascending  limb  of  the  b-wave  are
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3.6.1  ERG intensity series
In  this  experiment  both  therapeutic  vectors,  AAV.CMV.Mertk  and 
AAV. RPE65. Mertk,  as  well  as  the  control  vectors  AAV.CMV.GFP  and 
AAV.RPE65.GFP  were  used.  For each  vector the  right  eye of five  dystrophic 
RCS rats was injected subretinally, whereas the left eyes remained untreated to 
control for inter-animal variations. After dark adaption over night,  scotopic ERG 
recordings  were  obtained  simultaneously  from  the  injected,  right  and  the 
control,  left eye of all  animals.  Retinae were stimulated with bright light stimuli 
with increasing intensity. At an intensity of 10 mcd s/m2, only rod responses are 
measured. At a flash intensity of 100 mcd s/m2 the total response of both rods 
and  cones  was  measured  allowing  us  to  analyse  the  overall  rescue  of 
photoreceptor cells.  The  response  of cones  is  reflected  in  recordings at  1000 
mcd  s/m2.  Figure  3.11  shows  ERG  intensity  series  six weeks  after treatment 
with therapeutic vectors and control injections with the AAV.CMV.GFP virus. At 
all  flash  intensities  b-wave  amplitudes  were  significantly  higher  (see  section
3.6.2  for  statistics)  in  eyes  treated  with  with  either  AAV.CMV.Mertk  (figure 
3.11a) or AAV. RPE65. Mertk (figure 3.11b) than those measured in control eyes 
(figure 3.11 c). Furthermore, there was an improvement in the shape of the ERG
132trace after the treatment. A number of OPs are present on the ascending limb of 
traces from treated eyes.  OPs cannot be seen in recordings taken from control 
eyes.  The  improvement was a direct consequence  of the  MERTK expression, 
since injections of GFP control vectors or (Figure 24c) or PBS did not alter the 
size of the ERG response or the shape of the trace.
Figure  3.11:  ERG  of 0.1,1,10,100, 1000, and 300 mcds/m2.
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MERTK  transgene. 
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1333.6.2  ERG time course
ERG analyses are a non-invasive method and recordings can be obtained from 
individual  animals  at  regular  intervals,  allowing  the  possibility  of following  the 
course  of  photoreceptor  loss  over  time.  Figure  3.12  shows  ERG  traces  at  a 
single flash  intensity  (100  mcd  s/m2)  measured  in the same animal  at various 
time  points  after  treatment  with  AAV.CMV.Mertk.  This  flash  intensity  was 
chosen for further analysis since electrical response of both rods and cones are 
measured. This allows the analysis of the overall rescue of photoreceptor cells. 
Five  weeks  after  treatment,  the  b-wave  amplitude  in  the  treated  eye  was 
substantially  higher  than  in  the  control  eye  (figure  3.12).  This  suggests  that 
more  photoreceptor  cells  were  present  in  treated  eyes  compared  with 
untreated,  control  eyes.  In  the  untreated  eye,  the  amplitude  of  the  b-wave 
decreased  rapidly  over  time  reflecting  the  progressive  loss  of  photoreceptor 
cells,  until the trace was virtually flat after 6 weeks. At this time point there was 
still  an  ERG  response  present  in  the  treated  eye,  suggesting  that  the 
degeneration of photoreceptor cells was slowed by the treatment.
Figure  3.12:  ERG  recordings.  Recordings were taken  from  a  single  animal  at various time 
points following gene delivery. Averaged responses at a flash intensity of 100 mcds/m2  from one 
individual RCS rat are shown over 12 weeks following treatment with AAV.CMV.Mertk. The time 
course clearly reveals the improvement of b-wave amplitude and the shape of the trace. These 
effects  are  present for up to  9 weeks  when  the  b-wave  amplitude  gradually declines  on  the 
treated side.
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134In  order to  show that the functional  rescue we  accomplished  was  significant, 
statistical  analysis  of  the  ERG  recordings  were  carried  out.  Paired  t-tests 
showed that the  average  b-wave  amplitudes  recorded from  eyes treated with 
either AAV.CMV.Mertk  or AAV.RPE65.Mertk  were  significantly  higher than  in 
the contralateral  untreated controls  at all  time points examined  up to  9 weeks 
after treatment (Figure 3.13).  Maximal differences were obtained 7 weeks after 
treatment for both viruses.  At that time point the average b-wave amplitude  in 
the eyes treated with AAV.CMV.Mertk was 2.5 fold higher than in the untreated 
eye  (76  ±  55  pV  versus  29  ± 23  pV;  p  =  0.011).  In  the  animals  treated  with 
AAV.RPE65.Mertk  the  average  b-wave  amplitude  in  the  treated  eyes  after  7 
weeks was 4 fold higher than in the control eyes (73 ± 36 pV versus 17 ± 13 pV; 
p = 0.009).  In the control groups,  injected with  PBS or gfp expressing viruses, 
there was no significant increase in b-wave amplitude at any time point (Figure 
3.13).
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1363.7  Effects of MERTK overexpression
AAV-2  is able to transduce photoreceptor cells and RPE cells in the eye [227] 
and  thus  transgenes  would  be  expected  to  be  expressed  in  both  cell  types 
when  driven  by  a  ubiquitous  active  promoter  like  the  CMV  promoter. 
Consequently,  injections  of  AAV.CMV.GFP  were  leading  to  fluorescence  in 
photoreceptor as well as RPE cells. Accordingly it can be assumed that MERTK 
is also expressed in both cell types after subretinal delivery.  However,  MERTK 
expression is normally restricted to the RPE cells. As mentioned previously the 
CMV promoter is a strong,  viral promoter.  Gene expression from this promoter 
is  known  to  be  at  a  higher  rate  compared  to  mammalian  promoters.  Virus- 
mediated  expression  of  MERTK  under  the  control  of  the  CMV  promoter  is 
leading  to  higher  expression  levels  than  it  would  be  expected  when  the 
transgene  is  driven  by  the  endogenous  promoter  or  other  mammalian 
promoters.  Therefore,  it was necessary to establish if an additional expression 
of MERTK in  photoreceptors and an overexpression in  RPE cells would affect 
retinal function.
Therefore,  AAV.CMV.Mertk  was  injected  subretinally  into  four  adult  non- 
dystrophic  rats  and  ERGs  were  recorded  after  the  treatment  with  the 
therapeutic construct.  In  figure  3.14,  a  representative  ERG  intensity  series  of 
wild-type,  non-dystrophic  rats  is  shown,  eight  weeks  after  treatment  with 
AAV.CMV.Mertk.  The  injection  of the vector and  the  expression  of MERTK in 
the photoreceptor cells did not affect the b-wave amplitude in these animals at 
this time point indicating that an additional MERTK expression in photoreceptor 
cells did not affect retinal activity.
137Figure  3.14:  ERG  intensity series.  Recording  after injection  of AAV.CMV.Mertk into  normal, 
non-dystrophic rat eyes.  No differences were found in  b-wave  amplitude or the shape of the 
trace.  This shows that an additional expression of MERTK in photoreceptor cells has no effect 
on retinal function.
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To confirm that the additional expression of MERTK in photoreceptor and RPE 
cells  does  not  alter  retinal  morphology,  which  was  already  suggested  by  the 
ERG  results,  rats  were  sacrificed  after  the  ERG  recording  and  eyes  were 
processed for semithin sections and light microscope analysis. Wild type eyes 
treated  with  the  therapeutic  vector  did  not  differ from  untreated  eyes  (figure 
3.15) confirming that the additional MERTK expression had no effect on retinal 
morphology.
138Figure  3.15:  Light micrographs of a wild-type  rat retinae. (A)  Eight weeks after subretinal 
injections of AAV.CMV.Mertk into  non-dystrophic rats,  eyes were  analysed  histologically.  The 
additional  expression  of  MERTK  in  photoreceptor  and  RPE  cells  did  not  alter  retinal 
morphology.  (B) The  contralateral  untreated  eye served  as  a  control.  INL=iner nuclear layer, 
ONL=outer  nuclear  layer,  IS=inner  segments,  OS=outer  segments,  RPE=retinal  pigment 
epithelium, size bars=50 pm.3.8  Discussion
In  order  to  achieve  successful  gene  therapy  for  RP  a  number  of  key 
requirements  have  to  be  fulfilled.  The  transgene  should  be  expressed  in  the 
correct cell  type and at an  appropriate level.  Another requirement  is the  long­
term expression of the therapeutic gene to ideally allow a lifelong correction of 
the defect without the need of frequent follow-up treatments. The value of rAAV 
as a vector for gene delivery to the retina has  become apparent over the last 
few years. Most of the studies however are targeted to photoreceptor cells.  An 
example  for  the  successful  treatment  of  retinal  degeneration  due  to  a  RPE- 
specific defect is the rpe65‘~  dog [105]. This chapter describes the use of rAAV 
to  treat  retinal  degeneration  due  to  another  RPE-specific  defect,  namely  the 
phagocytic defect in the RCS rat caused by a mutation in the MERTK gene.
Recently, Vollrath et al. reported a temporary delay of retinal degeneration after 
rAd-mediated MERTK gene transfer into RCS rats. The authors could show that 
one month after injection,  the number of photoreceptor cells in the area of the 
injection  was  2  to  3 fold  higher  in  the  injected  eye  than  in  uninjected  control 
eyes  [233].  They  also  reported  that  they were  able  to  restore  the  phagocytic 
defect of the RPE and that photoreceptor activity was improved one month after 
injection.  However,  they did  not follow the survival  of the  photoreceptors over 
time and it is therefore unclear how long the improvements lasted although it is 
likely to be very short lived due to the host’s immune response against Ad [233]. 
These experiments provided the formal proof that the MERTK gene is the actual 
cause of the disease in these animals and indicated gene therapy for this form 
of RP may be possible [233].  Ad vectors have several disadvantages for gene 
therapy  approaches  including  the  relatively  short  duration  of  transgene 
expression  which  has  been  ascribed  to  the  immune  responses  generated 
against  viral  gene  products  [274,  339].  AAV-mediated  gene transfer  has  the 
advantage over Ad  vectors  in that rAAV is able to transduce  RPE cells with a 
high efficiency [227,  228] and in contrast to rAd vectors,  transgene expression 
mediated  by rAAV vectors  is  maintained over long periods.  After injection  into 
rodents,  expression  typically  lasts  throughout the  lifetime  of the  animal  [340].
140AAV  transgene  expression  studies  in  non-human  primates  have  shown  that 
there is still no notable decrease in transgene expression a year after treatment
[341]. Therefore it is likely that transgene expression in humans will also persist 
for long periods of time.
The decrease in the debris layer thickness suggests that following transduction 
of  RPE  cells  in  the  RCS  rat  with  rAAV  expressing  MERTK the  phagocytotic 
function  of  these  cells  is  at  least  partially  restored.  In  RCS  rats,  rod  outer 
segment tips normally are not removed and accumulate in the subretinal space. 
The  deposition  of  debris  is  slowed  after  treatment,  even  though  it  is  not 
completely  prevented.  As  a  result  of  the  treatment  and  the  reversion  of  the 
phagocytotic defect the rate of photoreceptor cell  loss and retinal degeneration 
is  reduced  and  retinal  activity  prolonged.  Photoreceptor  function  is  still 
detectable  in  treated  eyes  9 weeks  after injection,  whereas untreated  eyes  at 
the same time point provide no recordable activity,  showing that retinal  activity 
was improved after the treatment.
The effect of MERTK expression on photoreceptor survival does not last as long 
as MERTK transgene expression. This may be due to a number of factors.  One 
factor might be the relatively late onset of AAV-mediated transgene expression 
(for a review see [275]). The animals were injected around postnatal day 10. By 
the  time  transgene  expression  started,  2  to 3 weeks  later,  there  already  is  a 
substantial amount of debris deposited in the subretinal space.  ERG recordings 
from  one-month  old  RCS  rats  are  already  lower  than  in  wild-type  animals, 
suggesting that damage to photoreceptors has occurred by the time treatment 
with AAV vectors  may take effect.  The  incomplete  rescue  in this  model  might 
also be explained by the fact that not all the debris between the photoreceptors 
and  RPE  is  cleared.  Not  only  has  debris  accumulated  by  the  time  AAV- 
mediated MERTK expression occurs, the level of transgene expression may not 
be  sufficient  to  clear  the  backlog.  Furthermore,  only  part  of  the  retina  is 
transduced.  We  estimate  that  the  two  subretinal  injections  in  the  rat  cover 
roughly between  50 and 70  %  of the  retina.  Even  if the photoreceptor cells  in 
these areas benefit from  a reduction  in  debris,  degenerating photoreceptors in 
other parts of the retina may have a negative impact on photoreceptor survival
141in  treated  areas  of the  retina.  This  type  of phenomenon  has  previously  been 
described  in  chimaeric animals containing  mutant and wild-type photoreceptor 
cells, in which the rate of photoreceptor cell death for both cell types was similar
[342].  It  was  suggested  that  apoptosis  of  mutant  cells  generated  a 
microenvironment that had a negative influence on the survival of healthy cells. 
Despite the partial nature of the rescue,  loss of function in the treated rats was 
slowed  by  several  weeks.  In  these  experiments  a  murine  MERTK cDNA was 
used to treat the  RCS  rat.  Even though  MERTK is  highly conserved  between 
species there are still some differences in the amino acid sequence. The rescue 
might be increased  and  photoreceptor survival and function  maintained over a 
longer period of time by using the endogenous rat MERTK cDNA.
AAV  exist  in  several  serotypes,  which  differ  in  their  cell  surface  receptors, 
heparin sulphate and sialic acids [221].  In the eye it has been established that 
rAAV-2  and  AAV-2  pseudotyped  with  AAV-5  (AAV-2/5)  efficiently  transduce 
photoreceptor  cells  as  well  as  RPE  cells  after  subretinal  delivery.  Transgene 
expression has been shown to be restricted to the RPE for AAV-2/1  and AAV- 
2/4.  Pseudotyping AAV-2 with either AAV-1  or AAV-4 gives another possibility 
to restrict transgene expression to the RPE  independent of the promoter used. 
The  advantage  of  AAV-2/1  is  the  early  onset  of  expression  which  is  only 
delayed  by  days  compared  to  weeks  if  mediated  by  AAV-2/2.  However, 
whereas  RPE  tropism  for  AAV-2/1  could  only  be  shown  in  mouse,  chimeric 
AAV-2/4 vectors result in a stable,  RPE specific expression of the gfp reporter 
gene in a number of animal  models including mice,  rats,  dogs and non-human 
primates.  Since in  particular AAV-4 has  been shown to  mediate high  levels of 
transgene expression and that the onset of expression  is faster in comparison 
to AAV-2/2  [343],  in  case of the  RCS  rat,  which  has a fast progressing  retinal 
degeneration,  AAV-2/4  might  prove  to  be  a  better  suited  vehicle for efficient, 
long-term transgene expression.  In the experiments presented in this chapter it 
was shown that transgene expression from a CMV promoter is higher than from 
a  mammalian  rpe65  promoter.  With  AAV-2/4  transgene  expression  could  be 
targeted to the  RPE  regardless from  the  promoter used.  AAV-2/4  might be of 
particular relevance in terms of future clinical application since it is important to 
restrict expression of the transgene to a specific tissue or cell type, which in the
142case  of  MERTK  is  the  RPE.  In  addition,  AAV-2/4-mediates  higher  levels  of 
transgene expression compared to AAV-2/2.  However,  more experiments need 
to  be  carried  out  to  define  the  realistic potential  of rAAV-2/4  in  gene  therapy 
approaches.
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4 Lentivirus-mediated rescue of 
the RCS rat
Retroviral  vectors  are  becoming  standard  tools  in  cell  biology  as  well  as 
potential  therapeutic  agents  for  human  diseases.  Lentiviruses,  a  subclass  of 
retroviruses,  have  the  advantage  over  other  viruses  used  for  gene  therapy 
approaches  that  they  are  capable  to  transduce  a  broad  variety  of  different 
dividing and non-dividing cell types.  Long-term expression is ensured because 
lentiviruses  stably  integrated  their  genome  into  their  host’s  genome. 
Furthermore  they  have  a  relatively  large  cloning  capacity,  sufficient for  most 
envisaged  clinical  situations.  Illustrating these  properties,  vectors  derived from 
HIV-1  allow an  efficient  in  vivo delivery and  stable expression  of transgene  in 
different tissues.  Although  this  opens  prospects  for human  gene  therapy,  the 
biosafety of HIV-based  vectors  requires  a  careful  evaluation,  considering  also 
the  pathenogenesis  of  the  parental  virus  and  the  insertional  mutagenesis 
induced by the random integration of the virus.  The biosafety issues connected 
with HIV-based vectors have prompted the development of non-integrating and 
non-primate  based  lentiviral  vectors  as  vehicles for gene therapy approaches 
[295, 298, 300, 301, 344, 345].
Using  AAV-mediated  delivery  of  MERTK we  were  temporarily able  to  restore 
photoreceptor  function  and  improve  retinal  morphology  (see  chapter  3).  The 
partial and temporary rescue we observed was probably due to a combination 
of  factors,  including  insufficient  transduction  of  the  RPE,  inappropriate
144transgene  regulation  and,  perhaps  most  importantly,  the  two-  to  three-week 
delay  in  onset  of  AAV-mediated  transgene  expression.  The  main  potential 
advantage of using a lentiviral rather than AAV vector particularly in the RCS rat 
model,  which  has  a  rapid degeneration,  is the  much faster onset of lentivirus- 
mediated gene expression.  In order to determine whether we would be able to 
prolong  the  rescue  achieved  with  AAV-mediated  gene  delivery,  we  have 
constructed  human  immunodeficiency  virus  1   (HIV-1)  -based  lentiviral  vector 
carrying  a  MERTK cDNA and the  long-term  effects on  retinal  morphology and 
functions were evaluated in detail [283, 313, 314].
Lentiviruses have the ability of genome integration. Thereby the gene of interest 
is passed on by replication and  long-term expression of the gene of interest is 
ensured.  However,  chromosomal  integration  has  its  disadvantages.  Normally 
the insertion occurs randomly and as a result the location of the inserted gene 
varies  enormously.  This  problem  can  be  circumvented  by  the  use  of  non­
integrating  lentiviruses.  Thereofre,  we aimed to assess the value of integration 
deficient HIV-1-based vectors for gene therapy approaches in the eye.
HIV-1-based vectors  are the  most thoroughly  investigated  lentiviral  vectors for 
gene therapy.  Over the last few years significant effort has gone into HIV vector 
development  to  maximise  their  biosafety  and  to  minimize  the  possibility  of 
generating  replication-competent viruses.  However,  many questions about the 
biosafety  of  HIV-based  vectors  for  use  in  human  clinical  trials  remain  to  be 
answered. Due to the biosafety concerns, gene therapy vectors based on other, 
non-human  lentiviruses  have  been  developed.  We  wanted  to  examine  the 
expression pattern and duration of equine infectious anemia virus (EIAV) based 
vectors  [345,  346] after different routes of intra-ocular delivery and to evaluate 
their applicability as gene transfer vehicles for ocular gene therapy.
1454.1  Treatment of retinal degeneration with 
lentiviral constructs
To  determine  whether  we  would  be  able  to  improve  the  rescue  of  retinal 
degeneration  in  the  RCS  rat  model  by  using  lentiviruses,  we  first  produced 
VSV-G  pseudotyped  HIV-1-based  lentiviruses  containing  the  murine  MERTK 
cDNA  under the  control  of the  ubiquitously  active  spleen  focus  forming  virus 
(SFFV)  heterologous  promoter  (figures  4.1  and  4.2)  [312,  313,  326].  VSV-G 
envelope  protein  recognises  a  ubiquitous  phospholipid  in  the  cell  membrane 
enabling for  an  extended  viral  host  range  and  titres  of up to  109  lU/mL  (see 
page 87, figure 1.12) [303, 304].
In  the  third-generation  self-inactivating  (SIN)  vector  used  in  this  experiment 
[347-349],  the  enhancer region  of the  3’  U3 of the  long terminal  repeat (LTR) 
bears  a  deletion,  which  is transferred  to the  5’  LTR of the  proviral  DNA  upon 
reverse  transcription  and  integration  (see  figure  4.2  for  a  vector  map).  This 
deletion  abolishes  the  transcriptional  activity  of  the  LTR.  The  resulting 
transcriptional inactive vector cannot be converted into a full length vector RNA 
in transduced  cells  and thereby the  risk of regenerating  replication  competent 
viruses is minimised [305,  312,  348]. This increases the safety of the virus as it 
renders  vector  mobilisation  impossible  even  upon  infection  of  replication 
competent HIV [350].  Furthermore,  it reduces the likelihood that cellular coding 
sequences  located  next to  the  vector  integration  site will  be  expressed  either 
due to the promoter activity of the 3’  LTR or through an enhancer effect.  The 
final advantage of using a SIN vector is that possible interference between the 
LTR  and  the  internal  promoter that  drives  the  transgene  is  prevented  by  this 
design.  Since  any  promoter  activity  seizes  form  the  LTRs  is  abolished,  an 
internal promoter is needed for the expression of the MERTK cDNA. As it is the 
case  with  all  viral  vector  systems  the  choice  of  an  appropriate  promoter  is 
important to achieve efficient transduction and  expression.  SFFV heterologous 
promoter is derived from a replication-defective retrovirus and allows transgene 
expression levels similar to that of a CMV promoter. Like the CMV promoter, the 
SFFV promoter is a strong viral promoter that is ubiquitously active.  Since HIV-
1461-based vectors have been shown to target the RPE specifically after subretinal 
delivery if pseudotyped with VSV-G and  photoreceptor transduction is normally 
not found apart from areas of the needle trauma,  it was not necessary to use an 
RPE-specific promoter in this experiment.
Figure  4.1:  Restriction  enzyme 
digest.  The  -3.1  kb  MERTK 
fragment  was  isolated  from  the 
pGMT.Easy  vector  and  cloned  into 
the  pHR’SIN-cPPT-SEW  backbone 
between  the  -400  bp  SFFV 
promoter  fragment  and  the  WPRE 
fragment of the vector backbone.
The  central  polypurine  tract  element  (cPPT)  is  a  cis-acting  sequence  that 
mediates the  nuclear import of the  viral  genome  (reviewed  in  [351]).  Although 
not essential, the cPPT element increases the ability of the vector to infect non­
dividing cells and thereby improving transduction efficiency. The MERTK cDNA 
was cloned in a way that its 3’ end is followed by the Woodchuck hepatitis virus 
post-transcriptional  element  (WPRE).  This  cis-acting  transcriptional  regulatory 
element increases  levels of transgene expression in the target cell up to 5-fold 
when included [352] and its action is independent of both the transgene and the 
host cell  [351,  353,  354].  However,  the full-length WPRE has promoter activity 
and  the  potential  to  express  a  60  amino  acid  X  protein-derived  peptide.  This 
peptide  can  activate  or  repress  transcription  of a  number of cellular and  viral 
genes.  It  has  been  suggested  that  X  protein  activity  is  associated  with  the 
generation  of  liver  cancer,  which  is  a  common  consequence  of infection  with 
hepatitis B virus in man  [355,  356], Therefore, we used the safer mutated form 
of WPRE to abolish any promoter activity and expression of the X protein.  We 
termed the therapeutic recombinant viral vector LNT.SFFV.Mertk. As a control, 
a similar vector,  LNT.SFFV.GFP, was constructed, which contained the reporter 
gene gfp cDNA instead of the functional copy of the MERTK gene.
147Figure 4.2: Lentivirus vector map. The HIV-1-based vector pHR’SINcPPT-SEW was used to 
mediate the delivery of MERTK or gfp to the retina.
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In  order  to  optimise  the  effect  of  the  treatment,  the  virus  suspension  was 
injected  subretinally  into  the  superior  and  inferior  hemisphere  of  the  eye  to 
increase  the  size  of  the  treated  area  [228].  For  each  injection  4  pi  of  virus 
suspension containing approximately 4 x 106 viral particles were used. RCS rats 
were treated at the age of 10 days to ensure transgene expression before the 
onset  of degeneration  and  the  appearance of a  debris  layer  in  the  subretinal 
space.  The right eyes of RCS rat were injected whereas the left eyes were left 
untreated  as internal  controls to  balance  inter-animal  variations.  Animals were 
examined  histologically  to  investigate  the  effects  of  the  treatment  on  retinal 
morphology  over  a  period  of  seven  months.  To  follow  the  course  of  retinal 
degeneration functionally,  animals were examined  by ERG at regular intervals 
over this period of time.
1484.2  Restoration of the phagocytotic defect
Rod outer segment disc shedding follows a circadian rhythm in rats and is at its 
peak approximately  1.5 hr after onset of light in the morning [285].  Because of 
the  mutation  in  the  MERTK  gene  of  RCS  rats  [69],  the  RPE  is  unable  to 
phagocytise the shed outer segment tips,  which as a result accumulate  in the 
subretinal space.  Normally, phagosomes are not present at any time in the RPE 
of  RCS  rats  (for  a  schematic  diagram  of  RPE  phagocytosis  see  figure  4.3a) 
[71].  In  order  to  determine  whether  expression  of  a  functional  MERTK 
transgene  leads  to  reversal  of  the  phagocytic  defect,  four  animals  were 
sacrificed  1.5  hr  after  onset  of  light  in  the  morning,  4  weeks  after  subretinal 
injection of LNT.SFFV.Mertk into the right eyes.  It has been shown previousely 
that at this time  point reporter gene expression  mediated  by such vectors has 
reached  its  maximum  levels.  The  contralateral  eyes were  not treated to serve 
as negative controls. Another four animals were treated with LNT.SFFV.GFP to 
show that possible improvements  in  LNT.SFFV.Mertk injected eyes are due to 
MERTK expression  rather then  induced  by the surgical  procedure or the virus 
itself.  As positive controls 4 age-matched non-dystrophic rats were used.  Eyes 
were taken,  carefully orientate with a stitch through the conjunctiva and fixed in 
Kamovski  fixative.  Cornea  and  lens  were  removed  the following  day  and  the 
eyecups were  processed for electron  microscopy (EM).  Semithin sections (0.7 
pm  thick)  were  taken  and  stained  with  toluidine  blue.  Treated  areas  were 
identified by light microscopy and 70 nm thick ultrathin section were then taken 
of these areas and corresponding areas of control eyes.
EM analysis of the retinae of wild-type rats shows that microvilli extend from the 
apical  surface  of  RPE  cells  and  surround  the  outer  segment  tips  of 
photoreceptors.  The  recognition  of  shed  outer  segments,  which  express 
phosphotidylserine residues on their outer leaflet of the cell membrane, involves 
different receptors of the RPE cells. This recognition step leads to the activation 
of  the  receptor  tyrosine  kinase  MERTK  upon  which  the  signal  transduction 
cascade  for  the  cytoskeletal  changes  necessary for the  internalisation  of the 
waste  material  into  phagosomes  is  launched  [84].  Figure  4.3a  showes  a
149schematic diagram of phagocytosis. The first step is the cup formation, in which 
the RPE cell starts to surround the shed outer segment tip. After the up-take of 
the  waste  material  in  phagosomes  it  is  transported  through  the  RPE  cell 
towards  the  choroid  where  they  are  conveyed  to  the  circulation  system. 
Numerous phagosomes containing outer segment debris are found in RPE cells 
of wild-type  rats.  There  is  no  debris  layer  present  between  the  RPE  and  the 
photoreceptors (4.3b).  However,  the mutation in the MERTK gene of RCS rats 
disables the RPE cells to internalise shed outer segments [69,  71].  The failure 
to  phagocytise  shed  outer  segment  tips  leads  to  an  accumulation  of 
membranous  debris  at  the  apical  surface  of  the  RPE.  In  untreated  and 
LNT.SFFV.GFP  (4.3c)  injected  controls,  phagosomes  cannot be found  in  any 
part of the eye [71].  In contrast,  in the RPE of LNT.SFFV.Mertk treated animals 
we  observed  large  round  or  oval  phagosomes  packed  with  structures 
resembling  rod  outer  segment  discs  (4.3d).  Whilst  there  were  fewer 
phagosomes  in  the  RPE  of treated  rats  than  in  the  RPE  of  normal  rats,  the 
phagosomes  appeared  to  be  morphologically very similar to that seen  in wild- 
type animals (4.3b).  This result indicates that we were able to at least partially 
reverse  the  phagocytic  defect  of  RCS  rats  by  delivering  a  functional  copy  of 
MERTK to the RPE cells.
150Figure  4.3:  EM  analysis  of the  RPE.  IS=inner  segment,  OS=outer segment,  MV=microvilli, 
Ph=phagosome, N=nucleus, D=debris.
(a)  Schematic diagram of phagocytosis.  Phagocytosis begins with the recognition of shed 
outer segments  by the  RPE.  This  step  is followed  by the  cup formation  in which  the 
microvilli  surround  the  outer  segment tips.  After internalisation the  waste  material  is 
degraded  in  the  phagosomes  and  transported  through  the  RPE  cells  towards  the 
choroid.
(b)  Non-dystrophic rat retina. Phagosomes are present in the RPE cytoplasm (indicated by 
arrows).
(c)  LNT.SFFV.GFP injected RCS rat retina 4 weeks pi. No outer segments reach the apical 
surface of the RPE, instead a thick debris layer consisting of broken off outer segment 
tips and  membranous waste material  has built up due to the phagocytotic defect. The 
complete  lack  of  phagosomes  indicates  that  injections  of  LNT.SFFV.GFP  have  no 
therapeutic effect.
(d)  LNT.SFFV.Mertk treated  RCS  rat  retina  4 weeks  pi.  In some treated  areas rod  outer 
segment tips  reach  the  surface  of the  RPE.  In these  areas  no  debris  layer could  be 
found  due  to  the  presence  of  numerous  phagosomes.  The  morphology  of  treated 
retinae and RPE resemble that of normal, non-dystrophic animals.
151The restoration of the phagocytotic defect in RCS rats furthermore results in an 
improvement of photoreceptor morphology and a  reduction of the debris layer. 
In  untreated  eyes,  a  thick  debris  layer  is  present  and  the  RPE  microvilli 
therefore  cannot  reach  photoreceptor tips.  The  disruption  of the  nutrition-flow 
from the RPE to the photoreceptors and the transport of waste material towards 
the  RPE  caused  by  the  presence  of  the  debris  layer  induces  apoptosis  of 
photoreceptors.  The  degenerating  retina  in  untreated  animals  has  an 
unorganised  appearance.  Many abnormal  short,  whorl  shaped,  and  broken off 
outer segments are found.  In contrast,  eyes treated with the therapeutic vector 
show  a  reduction  of  the  debris  layer  thickness.  The  microvilli  reach  the 
photoreceptor  outer  segment  tips,  which  are  bound  and  internalised  into 
phagosomes.  Even  though  the  total  length  of  outer  segments  seems  to  be 
diminished compared to wild-type,  the organisation and shape is similar (figure 
4.4).
Figure 4.4: EM analysis of the outer segment layer (x2500 magnification).
(a)  Non-dystrophic  rat  retina.  In  non-dystrophic  animals  there  are  well  organised  outer 
segments which reach the apical surface of the RPE.
(b)  LNT.SFFV.GFP injected  RCS  rat retina 4 weeks pi.  In  LNT.SFFV.GFP treated retinae 
outer segments, that reach the RPE, could not be found. Due to the phagocytic defect, 
shed  outer segments are  not internalised  and  accumulate at the apical surface of the 
RPE, resulting in the formation of a debris layer.
(c)  RCS  rat  retina  4  weeks  after  treatment  with  LNT.SFFV.MERTK.  Areas  with  well 
organised  outer segments could  be found throughout the treated  area  indicating that 
restoration of phagocytosis has a beneficial effect on retinal morphology.
LNT.SFFV.GFP  LNT.SFFV.Mertk
wild type rat  treated RCS rat  treated RCS rat
1524.3  Thickness measurements of retinal 
layers
A characteristic feature of the  RCS  rat is the early accumulation followed by a 
slow disappearance of rod outer segment debris [71,  166, 357].  In RCS rats the 
debris  begins  to  accumulate  at  the  apical  surface  of  the  RPE  at  around 
postnatal  day  14.  The  outer  segment  zone  including  rod  outer  segment  and 
apical debris becomes thicker than in normal  rats between day 14 and 20 and 
remains  thicker  for  up  to  2  months  (18).  To  analyse  the  difference  between 
treated  RCS  rat  eyes  in  comparison  to  controls,  thickness  measurements  of 
different retinal layers were performed on a number of semithin sections.  Since 
the  number  of  animals  from  different  treatment  groups  varied,  an  unpaired 
Student’s t-test was used to calculate the significance of results obtained  (see 
chapter 2.8).  Since the differences were  most obvious 8 weeks after injection, 
all  measurements  were  carried  out  at  this  time  point.  As  the  rate  of 
degeneration  is  known  to  be  slower  in  the  extreme  periphery,  a  picture  of an 
area  between  the  ora  serrata  and  the  optic nerve  head,  approximately  in the 
middle  of  the  superior  injection  site  was  taken  and  measurements  were 
performed  in  a  250  pm  area  using  Zeiss  LSM  5  software.  Figure  4.5 
summarises the mean morphometric values of non-dystrophic, LNT.SFFV.Mertk 
injected  and  untreated  RCS  rat  eyes.  Consistent  with  the  presence  of 
phagosomes,  which  were  packed  with  rod  outer  segment  membrane  waste 
material, in the treated areas we found a reduction in the debris layer thickness 
from  a  mean  of 23  pm  in untreated to a  mean of 15  pm  in treated areas from 
injected  eyes  (p  =  0.05).  There  was  also  a  significant  improvement  in  RPE 
thickness  -  from  a  mean  of  5  pm  in  untreated  to  7  pm  in  treated  areas  of 
injected eyes (p = 0.034).  The RPE is around 9 pm thick in eyes from wild-type 
animals.
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Figure 4.5: Measurements of the absolute thickness of retinal layers. Measurements were 
performed in 7 areas in the  middle of the superior injection site in 4 treated animals 8 weeks 
after treatment  with  LNT.SFFV.Mertk  and  in  corresponding  areas  of 3  untreated  and  3  non- 
dystrophic rats. The SD is indicated for all the results.  Significant differences in the thickness of 
all the  measured  layers could  be found  between  untreated  and treated  areas,  as determined 
with the help of an  unpaired Student’s t-test (indicates p = 0.05 or less). The reduction in the 
debris layer in treated eyes due to the presence of phagosomes indicates that we were able to 
partly restore RPE function in the RCS rat and reverse the phagocytotic defect.  This results in 
an  improvement in  outer and  inner segment morphology and  ultimately in  preservation  of the 
outer  nuclear  layer.  D=debris  layer,  RPE=retinal  pigment  epithelium,  OS=outer  segments, 
IS=inner segments ONL=outer nuclear layer.
The partial  restoration of RPE function also  resulted  in an  improvement in the 
morphology  of the  neuroretina  (figure  4.6).  In  addition  to  an  improvement  in 
outer segment morphology (figure 4.4) we found a significant increase in outer 
segment length with  a mean thickness of the outer segment layer of 25 pm  in 
treated  areas  compared  with  12  pm  in  untreated  eyes  (p  =  0.0074).  It  is 
approximately  30  pm  thick  in  wild-type  rats.  The  degeneration  also  normally 
affects the inner segments. These are reduced by around 75 % (p < 0.0001) in 
dystrophic retinae but in treated areas the mean inner segment thickness was 
not  significantly  different from  wild-type  (p  =  0.35).  Finally,  we found  that the
154ONL  was  around  3  times  thicker  in  treated  areas  compared  with  equivalent 
areas from untreated eyes (p = 0.0002).
4.4  Retinal morphology
In order to analyse the effect of treatment on photoreceptor cell loss over time, 
animals were  sacrificed  at various  time  points  over a  period  of 7  months  and 
semithin  sections  were  taken  throughout  the  eye.  For  each  time  point  and 
vector 3 to 5 animals were  injected.  Photoreceptor cells were found in treated 
areas  of  injected  eyes  for  up  to  30  weeks  following  treatment,  whereas  in 
equivalent areas from untreated eyes and in eyes injected with LNT.SFFV.GFP 
few,  if  any,  photoreceptors  remained  at  12  weeks  (figure  4.6).  It  has  been 
reported previously that in the RCS  rat the disappearance of debris is faster in 
posterior parts of the retina than in the periphery and it is therefore important to 
compare  equivalent  areas  throughout  the  eye  in  order  to  assess  the  overall 
effect of treatment on the rate of degeneration [167].
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Figure 4.6: Light micrographs of RCS rat retinae. Serial sections were taken throughout the eyes of LNT.SFFV.GFP injected RCS rats (upper panel) and 
LNT.SFFV.Mertk treated rats (lower panel) at a number of different time points (4, 8,  12 and 30 weeks) after injection. Pictures were taken of treated areas 
between the optic nerve and the ora serrata of the superior hemisphere (a-h). Photoreceptors were present in treated eyes up to 30 weeks pi indicating that 
the LNT.SFFV.Mertk construct reduces retinal degeneration, whereas no photoreceptor cells could be found in control eyes after 12 weeks. For comparison, 
an image of dystrophic RCS rat retina to compare to the GFP-treated panels (i) and a non-dystrophic rat retina  to compare to Mertk-treated panels (j) are 
included. Control animals were 12 weeks of age. Size bars are 10 pm for (a-h) and 50 pm for (i and j).
156Comparison  of  treated  and  control  eyes  showed  a  reduction  in  the  loss  of 
photoreceptor cells  in  treated  eyes  at  different time  points  (figure 4.6).  Whilst 
the  number  of  photoreceptor  cells  in  treated  eyes  was  approximate  50  % 
greater in the middle of the treated  area than  in untreated ones 4 weeks after 
injection of LNT.SFFV.Mertk,  this difference became more obvious at 8 weeks 
with  a  two-  to  three-fold  increase  in  photoreceptor  number.  It  remained 
significantly higher for the duration  of the study which  lasted 7  months.  At all 
time points a significant difference between either uninjected or LNT.SFFV.GFP 
injected  eyes  and  LNT.SFFV.Mertk  treated  eyes  could  be  found  (p-values 
between  0.004  and  0.0001).  In  contrast,  no  significant  difference  could  be 
found between  untreated  and  LNT.SFFV.GFP  injected eyes at any time point, 
confirming  that  delivery  of  a  non-therapeutic  vector  has  no  influence  on 
photoreceptor survival beyond 4 weeks (figure 4.7).
157Figure  4.7:  Therapeutic  effect.  The  number of nuclei  in  the  ONL,  which  correspond  to the 
number of photoreceptor cells, was determined at a number of points along the vertical meridian 
of eyes from the optic nerve head (ONH) to the ciliary body at different time points (4, 8,12, and 
30 weeks pi). The  number of nuclei was counted  in  both  LNT.SFFV.GFP or LNT.SFFV.Mertk 
injected eyes and the contralateral untreated eyes. For each treatment group and time point at 
least 3  animals were  analysed.  At all  time  points there  was  a  significant difference  between 
control  eyes  and  LNT.SFFV.Mertk  treated  eyes  (p  values  between  0.005  and  0.001).  In 
LNT.SFFV.GFP injected and untreated eyes very few, if any, nuclei could be found at 12 weeks 
pi and time points thereafter, whilst there were still nuclei remaining in LNT.SFFV.Mertk treated 
eyes at 30 weeks pi.
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Even though there were still  some photoreceptors remaining at 30 weeks after 
the  injection  of  the  therapeutic  vector,  the  size  of  the  area,  in  which 
photoreceptors were preserved, was reduced.  It was shown that the size of the 
bleb  generated  by  a  subretinal  injection  correlates  with  the  size  of  the 
transduced  area  and  covers  approximately  30  %  of the  retina.  Thirty  weeks 
after treatment photoreceptors,  however,  are only found in a small area around 
the injection site covering only about  15 % of the retina (figure 4.8). A possible 
explanation for this  is  that changes  in  dying  photoreceptor cells  in  not treated 
areas  generate  a  microenvironment  that  has  a  negative  influence  on  the 
survival  of healthy photoreceptor cells  in treated  areas [342].  This is known to 
be the case in animal models of retinal degeneration and RP patients.
158Figure  4.8:  Light  micrographs  of the  superior  hemisphere  of the  retina.  Pictures  were 
taken  8  (a)  and  30  (b)  weeks  after  injection  of  LNT.SFFV.Mertk.  The  area  of photoreceptor 
preservation (indicated  by arrows) covers around  30 % of the retina at early time points but is 
reduced to 15 % at 30 weeks pi. Only a small island of surviving photoreceptor cell in the middel 
of the preserved  area,  which  is  assumed to  be  around the  injection site,  is found  at this time4.5  Effect of treatment on retinal function
In order to analyse the effect of the treatment on retinal function we performed 
ERG. The ERG trace reflects the activity of several cell types in the neuroretina. 
However,  the  main  part  of  the  trace  is  the  large  corneal-positive  b-wave 
generated  mainly  in  on-bipolar  cells  and  third  order  neurons  but  which 
correlates  well  with  the  number  of  functional  photoreceptor  cells  in  the  eye. 
Before recording the  ERG  animals were dark adapted for 16 hr.  To determine 
whether  a  retention  and  prolongation  of  retinal  function  was  achieved  after 
injections of the therapeutic vector an intensity series of four treated animals 8 
weeks  after  injection  was  recorded.  Figure  4.9  shows  a  representative  ERG 
intensity  series,  obtained  simultaneously  from  the  injected  right  and  the 
untreated  left eye  of an  RCS  rat.  In  the treated  eye,  b-wave  amplitudes were 
significantly  increased  compared with the  untreated control.  Furthermore,  OPs 
could  be found  on  the  ascending  limb  of the  b-wave  of the  ERG  trace.  OPs 
increase in size with brighter stimuli,  in the treated but not in the untreated eyes 
indicating an overall improvement of retinal activity. The pattern of the response 
of the treated eye to a series of increasing stimuli resembled that of the normal 
animal, with increasing b-wave amplitudes and decreasing b-wave latencies.
160dystrophic RCS rat
Figure  4.9:  ERG  intensity
series.  Eight  weeks  after
treatment  of  a  RCS  rat  with 
LNT.SFFV.Mertk  an  ERG 
with  increasing  flash
intensities  was  recorded
simultaneously of the treated, 
right  and  untreated,  left  eye. 
After  treatment  the  b-wave 
amplitudes  were  significantly 
higher  than  those  of
untreated  eyes,  and  the 
shape  of the  traces  showed 
improvement,  resembling  the 
ERG traces of normal rats.
treated untreated
c o
>
T3
>
3 . O
0.1
Q . E
CD
5
CD
I
100
\ 1000
3000
time [20 ms/division]
non-dystrophic RCS rat
c o w '>
>
3 .
8
© |
Q.
E C O
®
> C O
I
time [20 ms/division]
Since both rod and cone responses can be measured at an intensity of 100 mcd 
s/m2,  recordings  of  responses  at  this  flash  intensity  were  measured  in  five 
animals at weekly intervals over a period of seven months.  Figure 4.10 shows 
ERGs  at  a  single  flash  intensity  of  100  mcd  s/m2  obtained  from  one  animal 
treated with LNT.SFFV.Mertk at different time points. The traces were recorded 
simultaneously  from  the  injected,  right  and  the  uninjected,  left  eye.  In  the 
untreated control eye, the b-wave amplitude decreased rapidly over time until it 
was completely gone after 8 weeks.  In the treated eye, the ERG response was 
still  present  at  this  time  and  was  observed  for  more  than  18  weeks  after 
treatment,  suggesting  that  following  treatment  with  LNT.SFFV.Mertk 
photoreceptor  survival  was  prolonged.  The  difference  between  the  untreated 
and treated eye was most obvious at 8 to 12 weeks.
161Figure  4.10:  ERG  time 
course.  ERGs  were 
recorded  of a  single  animal 
at  various  time  points  after 
LNT.SFFV.Mertk  treatment 
at a single flash  intensity  of 
100  mcd  s/m2.  At  this 
intensity  both  rod  and  cone 
responses  are  measured.
The  b-wave  amplitude  is 
substantially  higher  in  the 
right,  treated  eye  compared 
to  the  uninjected, 
contralateral  eye.  The 
difference  is  greatest  at  8
The  average  b-wave  amplitudes  of the  ERG  recordings  were  then  evaluated 
statistically  by  using  a  paired  Student’s  t-test  (see  chapter  2.8).  The 
LNT.SFFV.Mertk  treated  eyes  showed  significantly  higher  b-wave  amplitudes 
than the contralateral untreated eye at time points up to 27 weeks after injection 
(p  =  0.049;  figure 4.11a).  Maximal  differences were obtained  7  and  12 weeks 
after treatment. At these time points the b-wave amplitudes in the eyes treated 
with LNT.SFFV.Mertk were approximately four fold higher than in the untreated 
eye  (median:  93.7  pV versus 22.5  pV;  p  =  0.008).  In  control  animals  injected 
with  LNT.SFFV.GFP,  no  significant  difference  in  b-wave  amplitudes  between 
treated  and  untreated  eyes  could  be  found  at  any  time  point  (figure  4.11b). 
Results obtained with flash intensities of 10 mcds/m2, and 1000 mcds/m2 did not 
differ substantially.
and 12 weeks after treatment. Furthermore, OPs are present in 
treated  eye  up  to  12  weeks  after  injection  indicating  proper 
retinal function.
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162Figure  4.11:  Mean  ERG  b- 
wave amplitudes.
(a)  The  average  b-wave 
amplitudes  (and  standard
deviation)  of  LNT.SFFV.Mertk 
treated  and  contralateral, 
untreated  RCS  rat  eyes  are 
shown at various time points.
(b)  The  mean  b-wave
amplitudes  of  control  animals 
injected  with  LNT.SFFV.GFP 
compared  to  untreated  eyes 
are  shown  as  well.  All  ERG 
recordings were performed at a 
flash intensity of 100 mcd s/m2. 
After  administration  of  the 
therapeutic  vector,  b-wave
amplitudes  were  significantly 
increased  between  6  and  27 
weeks  after  treatment  (p  <
0.05),  whereas  injections  of 
LNT.SFFV.GFP  did  not  alter 
the  electrical  response  of  the 
retina.  3 weeks  after treatment 
a non-significant reduction in b- 
wave  amplitudes  was  found  in 
treated  eyes  which  was 
probably  due  to  an  immune 
response  against  impurities  in 
the virus suspension.
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1634.6  Overexpression of MERTK
Viral  promoters  are  commonly  used  as  regulatory  elements  in  gene  therapy 
vectors because they generally have strong activity in a wide variety of cells of 
different tissues and species. The SFFV promoter is a strong viral promoter.  In 
order to determine if an overxpression of Mertk would affect retinal function, five 
non-dystrophic RCS rats were injected subretinally with the therapeutic vector. 
After  dark  adaption  scotopic  ERGs  were  recorded.  A  representative  ERG 
intensity  series  from  a  wild-type  rat  seven  weeks  after  injection  of 
LNT.SFFV.Mertk is shown  in figure 4.12.  The b-wave amplitudes were normal 
indicating that the delivery of the therapeutic vector was not deleterious.
Figure 4.12:  ERG  intensity series. The ERG was recorded  at different light intensities at a 
single time point of a non-dystrophic RCS rat after injection of LNT.SFFV.Mertk (right eye,  R, 
treated  and  left eye,  L,  untreated).  The traces shown  are  representative,  average  recordings. 
The b-wave amplitude and the shape of the trace were normal.
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After ERG  recordings some animals were sacrificed and their eyes processed 
for  semithin  sections.  The  sections  were  examined  by  light  microscopy  and 
pictures were taken (figure 4.13).  Retinal morphology and histology was normal 
suggesting that the additional MERTK expression in RPE cells had no effects.
164Figure  4.13:  Light  micrograph  of  a  wild-type  rat  after  LNT.SFFV.Mertk  delivery.  The
pictures shows  a  treated  eye  7  weeks  after injection.  Retinal  morphology  did  not show  any 
differences.  INL=inner nuclear layer,  ONL=  outer nuclear layer,  IS=inner segments,  OS=outer 
segments, RPE=retinal pigment epithelium.
1654.7  Non-integrating lentiviral vectors
4.7.1  Introduction
Lentiviruses can  integrate their genome  into the genome of dividing  and  non­
dividing  cells.  Thereby  the  gene  of  interest  is  passed  on  by  chromosomal 
replication  following  cell  division  to  the  progeny  cells  and  long-term  stable 
transgene  expression  is  obtained.  Hence,  gene  therapy  using  this  approach 
may  provide  the  possibility  of  a  cure  for  some  disorders.  However, 
chromosomal  integration  has  its  disadvantages.  Normally the  insertion  occurs 
randomly and  as a  result the  location  of the  inserted gene varies enormously 
from cell to cell. An established complication of retroviral transduction in animal 
models  and  clinical  trials  is  the insertional  mutagenesis  leading to cancer.  An 
integration  event  in  one  of the  many  cells  that  are  targeted  could  disturb the 
normal expression pattern of genes that control cell division or cell proliferation. 
For example,  the  integration  can  cause  activation  of an  oncogene  or  it could 
inactivate  a  tumor  suppressor  gene  or  a  gene  involved  in  apoptosis.  The 
necessity to overcome these  drawbacks  has been  highlighted by reproducible 
induction  of  malignancy  in  murine  models  and  the  development  of 
lymphoproliferative  disease  in  SCID  patients  after  treatment  with  retroviral 
vectors  [217,  358].  Hence,  it  is  crucial  for  successful  clinical  applications  of 
lentiviral  vectors  to  achieve  stable  long-term  transgene  expression  and  to 
minimise the risk of insertional  mutagenesis.  Mutations in the integrase coding 
sequence  can  result  in  integrase  defective  retroviral  vectors.  It  has  been 
demonstrated  in  vitro  that  prolonged  transgene  expression  can  be  achieved 
using non-integrating lentiviral vectors provided that vector episomes are stably 
retained [359].
In  consideration  of  the  justified  concerns  regarding  insertional  mutagenesis, 
HIV-1  integration deficient vectors were produced to evaluate the efficiency of 
transduction in vivo (see figure 4.14a and b for vector maps).  Initially integration
166deficient vectors carrying a gfp reporter gene were tested in vitro (figure 4.14c). 
As for integration proficient vectors the peak of expression has been shown to 
occur at 3 days.  In accordance with the  loss of transgene during cell division, 
gfp  expression  declined  rapidly  in  integrase  deficient  vector  transduced  cells 
between  3  and  10  days,  whereas  the  integrase  proficient  vector-mediated 
expression remained stable (Cloning and in vitro studies were conducted by R. 
Yanez-Munoz  and  colleagues,  Molecular  Immunology  Unit,  ICH.  In  vivo 
experiments were performed by K. Balaggan, Div. of Molecular Therapy,  loO.).
Figure 4.14:  Integration-deficient  lentiviral  vectors,  (a) Schematic representation  of HIV-1 
vectors used in this study. Shown are the double-stranded DNA vector forms after completion of 
reverse transcription. Relevant features are named on L-cSegfpW, and only those differing are 
named  on  the  other vectors.  dLTR  is  the  5'-deleted  LTR  present  in  these  self-inactivating 
vectors. Not drawn to scale.
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167(b)  Schematic
representation  of  linear, 
integrated and circular forms 
of a generic lentiviral vector. 
Solid  lines  are  vector  DNA, 
discontinuous  lines  are 
genomic  DNA  and  white 
boxes  are  dLTRs.  Arrows 
represent  the  transgene 
cassettes  in  the 
corresponding vector forms.
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(c)  Time-course of eGFP expression after transduction of HeLa cells with integration-proficient 
and deficient L-cSegfpW vector at the indicated multiplicity of infection (MOI). A representative 
experiment out of four performed  is shown.  Int-  and  int+  stand  for integration-deficient  and  - 
proficient vectors, respectively.
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1684.7.2  In vivo non-integrating HIV-1 vector-mediated expression
To  determine whether  long-term  expression  could  be  achieved  in  vivo,  either 
integration deficient- or proficient vectors carrying the gfp transgene under the 
control  of  a  SFFV  promoter  were  delivered  to  mouse  eyes  by  subretinal, 
intracameral, or intravitreal injections. Transgene expression was detected by in 
vivo  fluorescence  imaging  and  sections.  With  both  types  of  vectors  similar 
transduction  pattern were found.  Following  subretinal  injection  gfp expression 
was found  in  the  RPE.  Intracameral  injection  led to expression  in the  corneal 
endothelium  and  limited  expression  in  the  trabecular  meshwork.  With  either 
type  of vectors  no  gfp  expression  could  be  found  after  intravitreal  injections 
(figure 4.15).  For both  vectors,  the earliest time point of transgene expression 
was 3 days after delivery. Seven days post injection the expression reached the 
maximum  and  remained  so  until  the  last  time  point  studied,  9  months  after 
injection.  These  results  show  that  long-term  expression  can  be  achived  with 
integration deficient HIV-1  vectors in vivo.
169Figure  4.15:  Gfp  expression  patterns  in  mouse  ocular  tissues.  6  month  pi  GFP 
fluorescence is detectable in mouse retina and cornea. The cryosections were counterstained 
with  propidium  iodide.  In  the  retina,  gfp  is  expressed  within  RPE  cells.  Fluorescence  of the 
neuroretina originates from detached  RPE microvilli.  After intracameral injection of the vector 
GFP fluorescence is mainly present in the comeal endothelium and weak fluorescence is also 
dedected in the trabecular meshwork (gcl=ganglion cell layer, inl=inner nuclear layer, onl=outer 
nuclear layer, rpe=retinal pigment epithelium, cho=choroid, size bar=50 pm).
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4.7.3  Gene therapy with non-integrating HIV-1  vectors
After  it  was  established  that  non-integrating  lentiviral  vectors  are  able  to 
mediate long-term transgene expression in vivo, we evaluated their potential for 
gene  therapy  approaches  for  retinal  degeneration.  Mutations  in  the  human 
rpe65 gene result in a severe form of early onset recessive RP,  known as LCA 
[100],  RPE65  is  an  RPE-specific  protein  that  is  involved  in  the  vitamin  A 
metabolism  [30,  31].  Patients with  mutations  in  RPE65 suffer of severe visual 
impairment from  birth onwards.  Mice homozygous for the rd12 mutation  in the 
rpe65  gene  and  the  rpe65'1 '  dog  have  a  similar  phenotype.  Recently,  these
170animal  models for LCA have been used to successfully restore visual function 
by rAAV-mediated gene transfer [105,  165].
Since  mutations  that  primarily  affect  the  RPE  are  the  most  suitable  for  the 
development  of gene  therapy  protocols  involving  lentiviral  vectors,  integration 
deficient vectors that carry a functional  copy of the  human RPE65 gene were 
designed  and  injected  into  the  subretinal  space  of  one  eye  of  5  weeks  old 
Rperd 12/rd 12  mice.  The  other  eye  was  left  untreated  as  an  internal  control. 
Functional  rescue  was  assessed  by  ERG  (figure  4.16b).  A  significant 
improvement in retinal function was observed three weeks after injection of the 
therapeutic construct with  b-wave amplitudes at  100  mcds/m2 being  almost 6- 
fold greater in  treated  eyes  compared  to  untreated  eyes.  On the  contrary,  no 
significant difference between uninjected and control vector injected eyes could 
be  found  (figure  4.16c).  Furthermore,  rpe65 expression  was  restricted  to  the 
RPE  in  mice after subretinal  delivery as determined  by  immunohistochemistry 
(figure  4.16a).  These  results  suggest  that  integration  deficient  viruses  can 
mediate significant visual restoration in a clinical relevant animal model for LCA.
171Figure 4.16:  Rescue in RpErd12/rd12 mice three weeks after treatment, (a) Subretinal delivery 
of L-cSrpe65W results in efficient rpe65 expression in murine RPE.  Retinal cryosections were 
immunostained  for  RPE65  (green)  and  counterstained  with  propidium  iodide  (red).  RPE65- 
positive  immunohistochemical  labelling  in  the  RPE  layer  of  wild-type  mice  (left)  and  in 
Rpe6&d:2/T d'2   mice  three  weeks  after  subretinal  injection  of  integrase-deficient  L-cSrpe65W 
(centre  left).  RPE65  is  not detected  in  sections from  L-cSrpe65W-injected  RpefiS^1 2 7 ^ 2   mice 
incubated  without  primary  antibody  (centre  right)  nor in  uninjected  Rpee^1 2 ^ 1 2   mice  (right). 
Some background fluorescence from the secondary antibody is visible in the choroid and sclera 
in all sections. (onl=outer nuclear layer, rpe=retinal pigment epithelium, size bar=10 pm)
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173Lentiviral  vectors  are  known  to  show  variations  in  the  cellular  tropism  after 
subretinal  injections  in  different  species.  Like  in  patients  and  animal  models 
carrying mutations in the rpe65 gene,  in humans and animals with mutations in 
the  MERTK  gene  photoreceptor  cells  are  initially  inherited  functional  and 
morphological preserved. Therefore the RCS rat is another animal model to test 
lentivirus-mediated gene therapy protocols. To examine possible differences in 
the transduction patterns using integrase deficient vectors between species the 
mutant  vector was  also  tested  in  RCS  rats.  Integrase  deficient  and  proficient 
vectors that carry a functional copy of the murine MERTK gene were designed 
and  injected  subretinally  into  ten-day  old  rats.  The  functional  rescue  was 
assessed  6 weeks  after treatment.  With  both  vectors  ERG waves  showed  an 
overall  improvement  in  the  shape  form  and  b-wave  amplitudes  were  3-fold 
greater in integration deficient virus treated compared to untreated eyes (figure 
4.17).  The  achieved  rescue was  comparable  between  integrase  deficient and 
proficient viruses, whereas no significant rescue was observed after injection of 
control gfp vectors.
174Figure  4.17:  Functional 
rescue  of  the  RCS  rat.
ERG  recordings  were
carried  out  6  weeks  after 
treatment.
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1764.8  Equine infectious anaemia virus 
(EIAV) vectors
Biosafety  concerns  regarding  HIV-based  vectors  for  gene  transfer  have 
encouraged  the  development  of  vectors  from  lentiviruses  that  are  not 
pathogenic  in  humans.  Several  studies  in  various  animal  models  have 
demonstrated  that,  apart  from  HIV-based  vectors,  also  simian  (SIV),  bovine 
(BIV)  and  feline  (FIV)  immunodeficiency  virus-based  vectors  are  able  to 
mediate  efficient  and  sustained  transgene  expression  in  a  variety  of  ocular 
tissues  after  intraocular delivery  [295,  300,  301,  360,  361].  The tropisms  and 
expression patterns of these vectors are influenced by different factors including 
the natural tropism  of the virus,  vector pseudotype and genome configuration, 
the  transgene  promoter,  and  surgical  technique.  All  lentivirus-based  vectors 
have  been  shown  to  efficiently  target  RPE  cells  after  subretinal  injections, 
however  reports  about  photoreceptor  transduction  rate  and  efficiency  are 
variable [299, 313, 314, 362].
EIAV is another lentivirus that is not associated with any diseases in primates. 
EIAV causes a persistent non-fatal  infection in horses,  donkeys and mules but 
is non-pathogenic in humans (see [363] for a review).  The cellular tropism and 
kinetics  of  ElAV-based  vectors  have  been  evaluated  in  the  central  nervous 
system  of  rodents  [364,  365],  and  these  vectors  have  been  used  to  express 
therapeutic genes in experimental models of human disease [366-369].
We  tested  ElAV-based  lentiviral  vectors  developed  by  Oxford  Biomedica  to 
evaluate  their  in  vivo  expression  profiles  in  different  ocular tissues  and  their 
utility  in  ocular  gene  therapy  approaches.  To  investigate  if  different  viral 
envelope  proteins  influence  the  cellular  tropism  of  EIAV  vectors,  we  tested 
VSV-G  and  rabies-G  pseudotyped  viruses.  Three  EIAV vector genomes were 
used  in  this  study  each  containing  a  CMV  promoter  driven  gfp  expression 
cassette.  The  pONY8.0  genome  has  been  described  previously  [16]. 
Furthermore, we defined the efficiency of a self-inactivating minimal EIAV vector
177(pONY8.4) deleted for all EIAV sequences except essential c/s elements, and a 
further  minimal  EIAV  vector  (pONY8.7)  which  also  incorporates  the  central 
polypurine tract/central termination (cPPT) sequence and the woodchuck post- 
transcriptional regulatory element (WPRE) (figure 4.18). The expression pattern 
and transduction efficiency of all viruses was analysed by in vivo GFP imaging 
and  histology  after subretinal,  intravitreal,  and  intracameral  injections  in  adult 
mice  (In  vivo experiments  were  performed  by  K.  Balaggan,  Div.  of Molecular 
Therapy,  loO.).
Figure  4.18:  Vector  maps.  A  schematic  diagram  of the  genetic  configuration  of the  EIAV 
pONY8.0, pONY8.4, and pONY8.7 expression cassette is shown. The pONY8.4 genome is self- 
inactivating, rev-independent and has been deleted for all EIAV sequences except essential cis 
elements, and is associated with higher expression levels in vitro than pONY8.0 vectors (Wilkes 
et al., manuscript in preparation). The pONY8.7 genome also incorporates the cPPT sequence 
and the WPRE. These elements increase the efficiency of nuclear import of viral pre-integration 
complexes [349], and the export of the unspliced transcripts from the nucleus to the cytoplasm 
[352], respectively.
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4.8.1  Subretinal injections
With  in  vivo  GFP  imaging  gfp  expression  was  detected  first  by  3  days  after 
injection  of  EIAV  vectors.  Expression  increased  by  7  days  and  reached 
maximum  levels  at  14  days  with  all  vectors  tested.  Higher expression  levels 
could  be  found  with  pONY8.4  and  pONY8.7  compared  to  pONY8.0  (figure
4.19).
178Figure 4.19:  In vivo visualisation of 
retinal eGFP expression. Colour and 
fluorescent  retinal  images  of  eyes 
receiving  subretinal  injections  of 
PONY8.0  EIAV.VSV-G  (1.4  x  101 0  
TU/ml),  pONY8.0  ElAV.rabies-G  (1.0 
x  101 0  TU/ml),  pONY8.4  EIAV.VSV-G 
(8  x  108   TU/ml)  or  pONY8.7 
EIAV.VSV-G  (1.5  x  109   TU/ml) 
vectors.  The  injected  retina  is  clearly 
identifiable  as  a  paler  area  using 
colour slit lamp biomicroscopy.  eGFP 
fluorescence  is  detectable  at  3  days 
post  injection  in  pONY8.0  injected 
eyes  and  is  already  efficient  at  this 
stage  in  pONY8.4  and  pONY8.7 
injected eyes. Expression continues to 
increase with time achieving  maximal 
levels  between  7  and  14  days. 
Despite their lower titre, pONY8.4 and 
pONY8.7 vectors are able to mediate 
higher levels of eGFP expression than 
pONY8.0 vectors at all time points.
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179To  investigate which  cell  types were  transduced  by  EIAV vectors,  cryosections 
were taken of eyes after injection. Sections revealed that up to 100% of RPE cells 
were transduced in  injected areas.  In addition,  variable gfp expression,  that was 
not  restricted to the  injection  site,  could  be  detected  in  photoreceptor cells with 
either  pseudotype.  The  transduction  pattern  of  RPE  and  neuroretina  was 
irrespective  of  vector  pseudotype,  age  of  animals,  and  titre,  and  could  be 
observed up to 10 months (ElAV.rabies-G) and  16 months (EIAV.VSV-G) (figure
4.20).
pONY8.0 VSV-G  pONY8.0 rabies-G
16 months 10 months
Figure 4.20:  Cryosections of eyes after subretinal delivery of EIAV.  In order to visualise cell 
nuclei,  sections were  counterstained  with  propidium  iodide  (red).  In  eyes  injected  with  vectors 
pseudotyped with either VSV-G or rabies-G GFP fluorescence (green) is first observed at 7 days 
post  injection  and  remains  evident  up to  16  months  (gcl=ganglion  cell  layer,  inMnner  nuclear 
layer, onl=outer nuclear layer, rpe=retinal pigment epithelium, cho=choroid, size bar=50 pm).
180With  pONY8.4  and  pONY8.7,  gfp  expression  was  restricted  to  RPE  cells  in 
approximately half of the eyes treated. However, GFP fluorescence was observed 
in photoreceptor cells in the remaining eyes and with greater efficiency than with 
pONY8.0  vectors  (figure  4.21).  No  gfp  expression  could  be  found  in  ganglion 
cells, optic nerve or brain following subretinal injection of EIAV vectors.
Figure 4.21:  Retinal cross sections,  (a) Limited  photoreceptor cell transduction in the anterior 
retina is observed in eyes injected with pONY8.0. (b) The transduction is not limited to the site of 
injection trauma  but  extends  across the  injected  area  after injection  of pONY8.4.  Efficiency  of 
transduction varied from occasional  (c) to significant (d) proportion of photoreceptors within the 
injected area, (e) Long-term high levels of gfp expression lead to outer retina atrophy. At 6 months 
and later time points a loss of RPE and scattered areas of RPE hypertrophy (arrowheads) within 
the injected areas are observed. Following the loss of RPE cells, photoreceptor cells degenerate 
which is shown by the absent of the outer nuclear layer. (gcl=ganglion cell layer, inl=inner nuclear 
layer, onl=outer nuclear layer, rpe= retinal pigment epithelium, cho=choroid, scl=sclera).
181Inflammatory  infiltrates  were  observed  in  the  subretinal  space  1   week  after 
injection  but  were  not  found  at  later  time  points.  At  6  to  16  months  following 
subretinal delivery of vectors carrying the gfp reporter gene, outer retinal atrophy 
was observed  in approximately 70% of the treated eyes.  These findings comply 
with  previous reports of outer retinal  atrophy  after gfp administration  due to the 
long-term high level gfp expression.
1824.8.2 Intravitreal administration
EIAV vectors pseudotyped either with  VSV-G or rabies-G were injected  into the 
vitreous  cavities of adult  mice.  No fluorescence was detected  in  any  cell  types 
after  intravitreal  delivery  of  vectors.  There  was  no  inflammatory  cell  infiltrate 
evident in the tissues examined at any time point.
4.8.3 Intracameral delivery
To  investigate the transduction  and  expression  pattern  in  the  anterior chamber, 
EIAV  vectors  pseudotyped  with  either  VSV-G  or  rabies-G  were  injected 
intracamerally in  adult mice.  Efficient expression  levels were  reached at 7 days 
post administration and were maintained up to 10 months. The cellular tropism of 
EIAV vectors was depended  on  the  pseudotype.  EIAV.VSV-G vectors mediated 
efficient  gfp  expression  in  corneal  endothelium  cells  and  limited  expression  in 
trabecular  meshwork  cells  (figure  4.22).  In  contrast,  no  GFP  fluorescence  in 
comeal  endothelium  cells  or  trabecular  meshwork  cells  was  detectable  in 
EIAV.rabies-G  vectors  injected  eyes.  However,  this  vector-mediated  variable 
transgene  expression  in  linear  configurations.  GFP  fluorescence  was  found  in 
radial  orientation in  corneal  stroma  and  in  an  axial  orientation  in the  epithelium 
consistent with  the  pattern  of neuronal  innervation  in  the  cornea.  Fluorescence 
was also present in the anterior iris and within the ciliary body in some eyes.
183Figure  4.22:  Croysections  of  eyes  after  intracameral  injection.  EIAV.VSV-G  (a,  b)  and
ElAV.rabies-G (c-g). (a) GFP fluorescence is present in corneal endothelium cells 10 months post 
injection,  (b)  Cells  of the  trabecular meshwork and  corneal  endothelium  are transducted,  (c-e) 
Axial  orientated  fluorescence  is  observed  in  the  comeal  epithelium  and  in  a  radial  orientation 
within  the  anterior  and  mid-corneal  stroma  after  ElAV.rabies-G  administration.  Fluorescence  is 
also  observed  along  the  anterior  border  of  the  iris  (e)  and  within  the  ciliary  body  (f). 
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1844.9  Discussion
In  this  chapter  a  detailed  assessment  of  the  duration  and  extent  of  the 
morphological  rescue  and  functional  benefit  following  HIV-1-mediated  gene 
replacement  therapy  in  the  RCS  was  presented.  The  preservation  of  retinal 
function  and  morphology  was  observed  up  to  seven  months.  This  is  the  most 
significant rescue of a severe retinal degeneration to date. The results presented 
provide further evidence to support gene therapy approaches for the treatment of 
RP.  For  clinical  protocols,  however,  HIV-based  vectors  have  several 
disadvantages. Wild type HIV-1  is highly pathogenic in humans. A primary safety 
concern  therefore  is  the  generation  of  a  replication-competent  lentivirus  by 
recombination  events.  To  circumvent  this  risk  we  tested  non-human  lentivirus 
vectors, based on EIAV, and assessed the potential for gene therapy protocols.
The ability of lentiviruses to integrate their genome into their host’s, implicate both 
asset and drawback.  On the one hand,  integration ensures long-term expression 
of the transgene, which is a prerequisite for successful gene therapy approaches 
to cure many genetic disorders. On the other hand, the integration events occur at 
random  genomic  locations  and  thus  there  is  also  the  risk  of  insertion 
mutagenesis.  Integration-deficient lentiviruses are unable to integrate into the host 
genome and therefore might be better gene transfer vehicles for the development 
of clinical protocols. To investigate transduction and expression profiles we tested 
integrase  deficient  HIV-based  vectors.  These vectors were  also used to  rescue 
two animal models of retinal degeneration.
1854.9.1  Gene replacement in the RCS rat using HIV-1-based vectors
Gene replacement therapy using AAV-2 vectors is more effective in comparison 
to Ad vectors mainly due to their low immunogenidty. As described in chapter 3, 
photoreceptor degeneration could be delayed and retinal function improved in the 
RCS rat up to 9 weeks after treatment with AAV-based vectors. However, the late 
onset of AAV-mediated expression compromises its efficacy. Whilst AAV vectors 
are  much  less  immunogenic  than  Ad  vectors  and  AAV  vector-mediated  gene 
transfer is generally maintained over a long  period of time,  by the time maximal 
transgene expression is attained,  retinal  degeneration  in the  RCS rat is already 
well  advanced  [227,  275].  In  RCS  rats,  retinal  degeneration  is  rapid  and  starts 
around  postnatal  day  14  depending  on  the  eye  pigmentation  [71,  167,  357]. 
Lentiviruses, as vehicles for transgene delivery, have the advantage that onset of 
transgene  expression  occurs  within  24  hr  after  administration  [313].  Therefore, 
they are more suitable for a gene replacement approach in the RCS rat than AAV- 
2-based vectors.
Following treatment with an HIV vector, an improvement of retinal function for up 
to  27  weeks  after treatment  was  achieved,  compared  with  treatment  using  an 
AAV-2  vector,  which  showed  an  improvement  in  the retinal  response in  treated 
eyes  over a  period  of 9  weeks,  b-wave  amplitudes were  significantly  higher in 
eyes  treated  with  LNT.SFFV.Mertk  compared  to  untreated  or  LNT.SFFV.GFP 
injected eyes. The presence of OPs on ERG traces of treated eyes implies proper 
retinal  function.  After treatment  with  the  therapeutic vector,  the  pattern  of the 
ERG response to a series of increasing stimuli resembled that of normal animals, 
with  increasing  b-wave  amplitudes  and  decreasing  b-wave  latencies  indicating 
successful  functional  rescue  at  this  time  point.  Since  ERG  recordings  reflect 
changes  in  the  inner  as  well  as  the  outer  retina  that  occur  during  retinal 
degeneration this data suggests an overall improvement of the retina. At 3 weeks 
b-wave  amplitudes were  lower in  treated  eyes than  in  untreated.  However,  this 
effect was only of short duration and disappeared at 6 weeks after the treatment.
186Since  purification  protocols  for  lentiviruses  are  not  optimal  yet,  this  temporary 
decrease was probably due to an immune response against impurities of the virus 
preparation. The improvement in function did not last as long as the improvement 
in retinal morphology.  Since an ERG is an average response from the whole eye, 
contributions  to  this  response  from  a  decreasing  area  of  rescued  retina  will 
eventually be masked by the global response from areas that have degenerated. 
Treated areas covered approximately 50 to 70 % of the entire retina initially.
Whilst retinal degeneration was not completely prevented, photoreceptor loss was 
significantly  delayed.  Eight weeks  after treatment,  there were two- to three-fold 
more photoreceptor cells in treated areas than in equivalent untreated areas and 
photoreceptor cell survival was prolonged for up to 30 weeks after treatment, 23 
weeks longer than that following treatment with an AAV-2 vector. One reason why 
treatment did not result in better photoreceptor cell protection might be that 50-70 
%  RPE  transduction  is  insufficient to  ultimately  prevent degeneration  in  treated 
areas.  Degenerating  photoreceptor cells in  other parts of the retina may  have a 
negative  impact  on  photoreceptor  survival  in  treated  regions  [342].  Several 
studies have suggested that retinal metabolism is altered within the RCS rat retina 
and also in patients with RP [370, 371].  Changes in degenerating photoreceptors 
are likely  to  generate  a  microenvironment that  has  a  negative influence on  the 
survival of healthy cells [342, 372, 373].  Therefore it will probably be important to 
treat as much of the retina as possible in the RCS rat and eventually in patients.
4.9.2  Non-integrating HIV-1-based vectors
Lentiviruses,  as  vehicles for gene  transfer,  have  the  advantage of efficient cell 
transduction of a broad range of cell types including post-mitotic cells, the absent 
of an  immune  response,  and  long-term,  high  level  transgene expression due to 
the integration of their genome into their host’s.  Integration events,  however,  are
187random and bear the risk of insertional mutagenesis. This can be avoided by the 
use  of  gene  therapy  vectors  that  do  not  integrate.  Existing  non-integrating 
systems are often limited  by inefficiency or immunogenicity.  Lentiviruses can be 
altered to integration deficient by mutation of the viral integrase. Following reverse 
transcription,  integration  deficient vectors form stable episomal  double  stranded 
DNA  genomes  in  the  target  cell  nucleus  [359].  In  this  study  we  tested  non­
integrating  HIV-1-based  vectors  and  defined  their  potential  for  gene  therapy 
approaches for retinal degeneration.  It was shown that these integration deficient 
vectors are  effective templates for gene  expression  in  vivo and  that expression 
levels and the duration of transgene expression are similar to those achieved with 
integration  proficient  vectors.  These  results  suggest  that  integration-deficient 
lentiviral vectors are attractive tools for human gene therapy approaches.
4.9.3  EIAV vectors
Different from HIV,  EIAV is a non-human lentiviral pathogen and thus ElAV-based 
vectors  might  be  more  suitable for clinical  gene  therapy  approaches than  HIV- 
based vectors. The cellular tropism and kinetics of ElAV-based vectors have been 
tested in rodents CNS.  In order to evaluate the potential of EIAV vectors for gene 
therapy in the  eye,  ElAV-based  vectors with  different expression  cassettes and 
pseudotypes  were  designed  and  tested  in  vivo  for  their  transduction  and 
expression capability after different administration routes into the mouse eye.
In  this  study  it  was  demonstrated  that  EIAV  is  able  to  mediate  efficient  and 
sustained  transgene  expression  in  different  ocular  tissues.  After  subretinal 
delivery GFP fluorescence in RPE cells was first detected at 3 days post injection 
and  persisted  until  at  least  16  months  regardless of the vectors pseudotype.  In 
contrast to  HIV-mediated reporter gene expression,  variable gfp expression was
188also  detected  in  photoreceptor cells and  extended  throughout the treated  area. 
The  persistence of gfp expression  in  photoreceptor cells for 16 months suggest 
that  photoreceptor  cells  are  indeed  transduced  by  viral  particles  and  that  GFP 
fluorescence is not due to the transfer of GFP protein during vector manufacture 
(pseudotransduction). The transduction of photoreceptor cells was independent of 
the vector pseudotype or titers.  However, it was influenced by the configuration of 
the  EIAV genome with  elevated  expression  levels after pONY8.4 and  pONY8.7 
administration compared to expression levels obtained with pONY8.0. The rate of 
photoreceptor  cell  transduction  is  often  influenced  by  the  stage  of  retinal 
maturation  at the time of vector delivery.  In this study,  however,  no age related 
effect was observed.
Intracameral  administration  of EIAV vectors resulted  in a pseudotype-dependent 
gfp expression profile.  Conforming with our experience with VSV-G pseudotyped 
HIV-1  vectors,  VSV-G  pseudotyped  EIAV  vectors  transduce  the  corneal 
endothelium and trabecular meshwork.  In contrast, vectors pseudotyped with the 
rabies-G  envelope  did  not  result  in  expression  in  the  trabecular  meshwork  or 
comeal  endothelium  instead  expression  was  detected  in  the  corneal  stroma 
consistent with the pattern of neuronal innervation and epithelium as well as in the 
iris and  ciliary  body.  The ability  of EIAV vectors  pseudotyped with the  rabies-G 
envelope to transduce comeal neurons is consistent with the enhanced neuronal 
tropism previously described for these vectors in other neuronal populations [364, 
365].  Consistent  with  previous  reports  of  HIV-based  lentiviral  vectors  [313], 
intravitreal  delivery  of  EIAV  vectors,  did  not  result  in  detectable  transgene 
expression in any cells, irrespective of pseudotype.
We  demonstrate  that  intraocular  delivery  of  minimal  non-primate  EIAV  vectors 
pseudotyped with either VSV-G or rabies-G envelope proteins can mediate rapid 
and  stable  highly efficient transgene expression in a variety of ocular cells.  The 
favourable  cellular  tropism  and  expression  kinetics  of  optimised  EIAV  vectors
189make  them  attractive  for  delivering  therapeutic  genes  in  the  management  of 
inherited and acquired retinal and anterior segment disorders.
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5 Screening retinitis pigmentosa 
patients for mutations in MERTK
5.1  Aim
The role of MERTK in human  retinal disease has recently been established with 
the finding  of  mutations  in  autosomal  recessive  RP  patients  [122].  The  results 
presented  in  chapter 3 and  4  suggest that defects within this gene  are  suitable 
targets for the development of gene therapy approaches in patients. However, the 
potential  for an  effective  therapy  in  humans  depends  upon  the  identification  of 
patients with  MERTK mutations.  Since the complexity of RP makes it difficult to 
counsel  patients or to  assess the effects of treatments,  more about the specific 
clinical characteristics of this form of RP has to be established. To date, only four 
patients with  mutation  in  the  MERTK gene  have  been  identified  [122,  374].  In 
order to  identify  more  patients  and  characterise the  clinical  features associated 
with this defect, a panel of 96 patients was screened for mutation in MERTK.
1915.2  Patients with mutations in MERTK
To  date,  four  unrelated  patients  with  autosomal  recessive  RP  and  pathogenic 
mutations in the MERTK gene have been identified in two studies [122,  374].  Of 
these only one has been clinically characterised in detail. The mutations found in 
the first screen include a 5 bp deletion in exon 15, a splice acceptor site mutation 
in intron  10,  and a premature termination codon in exon  14. All patients suffered 
from  poor vision  and  night blindness  since childhood.  Over time  visual  acuities 
declined and  peripheral vision was lost until only a small  island of central vision 
remained [122].  In a second screen,  another patient with MERTK mutations was 
identified. The patient was compound heterozygote for three sequence changes: 
a premature termination codon in exon 16 and two missense substitutions in exon 
19 [374].  In vitro expression studies of the wild-type and MERTK variants showed 
a reduction in the level of mutant protein. It has been shown that the expression of 
mutant  MERTK  variants  reduces  the  receptors  autophosphorylation  which  is 
necessary  for  MERTK  function  [374,  375].  The  patient  suffered  from  visual 
problems from the age of three onwards and was diagnosed with advanced and 
progressive rod-cone dystrophy at the age of eight. At this age, the patient had no 
colour  discrimination,  the  fundus  showed  disc  pallor,  macular  atrophy  and 
presence of bone spicule  pigments.  ERG showed a total  loss of response to all 
rod  and  cone  stimuli.  At  the  age  of fifteen  both  fundi  showed  a  bull’s  eye  like 
pattern of macular atrophy with widespread  RPE thinning  in the  periphery [374] 
(All mutations found so far and their locations are shown in figure 5.3).
All  four  patients  were  reported  to  have  relatively  severe  disease,  with  onset  in 
early childhood  and  rapid  progression to extensive  peripheral  visual  loss by the 
late teenage years.  However, a detailed clinical description of the phenotype has 
only  been  reported  for  the  last  identified  of  these  patients.  The  recessive 
inheritance  pattern  of retinal  degeneration  associated with  MERTK mutations in 
humans  and  in  the  RCS  rat,  suggests that  pathenogenesis  is due to  a  loss  of
192function [69,  122, 357, 374].  In contrast to the mutation in the RCS rat,  however, 
the location of all  mutations found in humans are within the region that encodes 
the cytoplasmatic domain of the protein.  This leaves open the possibility that the 
human mutations do not result in a complete loss of MERTK function.
Table  4  summarises  the  identified  disease  causing  mutations  and  common 
polymorphisms.
Table 4: Mutation and polymorphisms in the MERTK gene. The table summarises the known 
mutations  and  polymorphisms  in  MERTK.  (adapted  from  Retina  International’s  Scientific
Newsletter)
Mutation
Polymorphism
Exon Change Remark Ref
ARRP Intron 10 A ^G Aberrant splicing, homozygous 1,2
ARRP? 14 1951C-»T, R651Stop Premature termination, 
heterozygous, no 2n d  mut found
1
ARRP 15 2070de!AGGAC Frameshift, premature 
termination, homozyous
1
ARRP 16 2164C-»T, R722X Nonsense mutation, Together 
with R844C and R865W
3
ARRP 19 2530C-»T, R844C Together with R722Xand 
R865W
3
? only in patients 11 1628G-M, E540K Uncommon missense 
substitution, compound in cis 
S661C
1
? only in patients 15 1982C-»G, S661C Uncommon missense 
substitution, compound in cis 
E540K, single
1
? only in patients 19 2612T-»C, 1871T Uncommon missense 
substitution, heterozygous
1
Polymorphism 1 R20S Equally found in patients and 
controls
1
Polymorphism 2 N118S Equally found in patients and 
controls
1
Polymorphism 5/6 A282T Equally found in patients and 
controls
1
Polymorphism 6 R293H Equally found in patients and 
controls
Polymorphism 9 R466K Equally found in patients and 
controls
1
Polymorphism 10 N498S Equally found in patients and 
controls
1
Polymorphism 10 1518V Equally found in patients and 
controls
1
Polymorphism 19 2593C-»T, R865W Polymorphism 3
Polymorphism 19 V870I Equally found in patients and 
controls
1
1935.3  Results
5.3.1  Patient screen and sequencing
In a programme of work to identify patients and families with potentially treatable 
retinal  degenerations,  a  panel  of  96  unrelated  probands  with  simplex  and 
recessive  rod-cone  dystrophy  were  screened  for mutations  in  MERTK.  Patients 
were ascertained from the  medical  retinal  clinics at  Moorfields Eye  Hospital  and 
gave written  informed  consent to  be included  in the  study and provided  a  blood 
sample  for  subsequent  DNA  extraction  and  DNA  analysis.  PCR  primers  were 
designed in a way that the entire coding sequence of all 19 exons and the intronic 
sequences important for splicing were covered.  The primer sequences are listed 
in  table  3  in  chapter  2.8.3  (see  also  Appendix).  The  19  coding  exons  of  the 
MERTK  gene  were  amplified  and  the  PCR  products  were  checked  by  gel 
electrophoresis.  Figure 5.1  shows a picture of a DNA gel on which PCR products 
of exon 11  were loaded. After it was established that all samples showed a clean, 
specific single band of the predicted size, they were analysed by sequencing.
Figure  5.1:  Gel  electrophoresis.  After  amplification  all  samples  were  analysed  by  gel 
electrophoresis. As an example, PCR samples of exon 11  are shown. The primers were designed 
to cover the entire coding sequence as well as important intronic sequences. In case of exon 11  a 
fragment of -  200 bp was expected. (M=marker, 1- 18=patient samples)
^   \   'b   t*  < 0< Q  A   Q)
^ 5 0 0
^"250
194A total  of 19  exons from  96  patients were  screened for mutations in the coding 
and splice site sequences of the MERTK gene and 11  variants from the Genbank 
sequence  (accession  number  NT022135  -  build  35  version  1)  were  detected 
(summarised  in table  5),  including  one  mutation.  This was a  novel frameshifting 
single  base  deletion  (2214delT)  within  exon  17.  Both  alleles  contained  the 
deletion. The sequence chromatograms of the patient, the unaffected mother and 
a  control  are  shown  in  figure  5.2.  The  2214delT  sequence  change  cause  a 
frameshift  and  a  premature  stop  codon  (TGA)  31  codons  downstream  of  the 
mutation.
/
Figure  5.2:  DNA  sequence  chromatograms.  A  novel  mutation  was  identified  in  patients with 
severe retinal degeneration. The homozygous deletion 2214delT was found in affected individuals 
(top). The sequence of an unaffected carrier (middle) and an unaffected control are shown as well 
(bottom).
heterozygous sequence
RP patient with homozygous deletion
t g n t t g g [ n ] g t t g c g g a
Normal human control sequence
C   T   G   T   C   T   G   l~T~l  GTTGCGGA
2214T
c t g t c t gQ gttgcgga
Unaffected carrier with
195A  schematic  overview  of  the  MERTK  gene  structure  and  the  corresponding 
functional domains of the protein is given in figure 5.3. The mutation found in this 
study and mutations found in previous screens are indicated by arrows.
Figure 5.3: MERTK gene structure and mutations. The 19 coding exons and various encoded 
functional  domains  are  shown  (GenBank AF2605  14-529).  Mutations  identified  in  the  present 
study (bold) and in previous studies are indicated by arrows. * compound heterozygous mutations 
found, horn =  homozygous,  het =  heterozygous,  Ig = immunoglobulin like, FN = fibronectin like, 
TM = transmembrane, TK= tyrosine kinase.
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If translated, the resulting protein would contain 31 foreign amino acids and would 
lack 262  aminoadds from the  carboxyl  end  of the  999  amino  add-long  protein. 
This would indude a large portion of the highly conserved tyrosine kinase domain. 
Furthermore,  the  frameshift  results  in  a  loss  of the  major  autophosphorylation 
sites  of the  receptor,  which  are  the  three  tyrosine  residues  in  the  IYSGDYYR 
amino add sequence  (aa748-aa755).  It has been shown that the kinase activity 
correlates  with  the  phosphorylation  level  and  that  mutations  of these  tyrosine 
residues  significantly  reduce  the  kinase  activity  [376].  Amino  add  sequence 
alignment of MERTK shows,  that the  mutation is located in a region that is fully 
conserved  between  the  human,  chimpanzee,  mouse,  rat,  and  chicken  proteins
196(figure 5.4).  The  amino  add  sequence of this  region  is also  highly  conserved 
between other members of the human axl subfamily of tyrosine receptor kinases, 
namely Axl and Tyro3.
Mertk sequence of different species
chicken  MTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADR 
rat  MTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADR 
mouse  MTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADR 
human  MTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADR 
mutation MTVWLRTSASLRRFTVAIITAKAALLRCLLNGSPStop
C 7 3 8 W
Members of the human axl family
Mertk  MTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADR 
Axl  MSVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLADR 
Tyro3  M7VCVADFGLSRKIYSGDYYRQGCASK1PVKW1ALESLADN
Figure 5.4: Amino acid sequences. Sequences were aligned using SDSC Biology WorkBench. 
(A)  Amino  acid  alignments  of  different  species  show  that  the  mutation  occurred  in  a  highly 
conserved domain of MERTK.  The predicted sequence caused by a single base pair deletion of 
the  affected  probands  is  shown  in  the  lowest  line.  The  mutation  leads  to  a  frameshift  and  a 
premature  translation  termination  signal  within  the  tyrosine  kinase  domain  of the  protein.  (B) 
Amino add sequence comparison of different members of the human axl tyrosine kinase receptor 
family  shows that the  region,  in  which  the  mutation  occurred,  is  highly  conserved  between  all 
members. This suggests that the sequence is important for proper function.
197The  mutation  segregated  with  disease  in  the  family;  all  three  affected  siblings 
were  homozygous for the  deletion,  as was the  affected  cousin;  their unaffected 
mother and father were  both  heterozygotes.  The pedigree structure is shown  in 
figure 5.5.
Figure 5.5: Family 
pedigree
structure.  Circles 
represent  females 
and  squares 
represent  males: 
unaffected = open, 
affected  =  filled. 
Double  lines 
indicate  inter­
related marriages.
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The other sequence changes found in the screen include four variants that would 
not be expected to change the sequence of the encoded protein, being intronic or 
synonymous in  nature.  None of these,  however,  have been reported  previously. 
Six base changes causing  missense substitutions were found.  Of these five had 
been  reported  previously;  the  prevalence in  96  control  Caucasian samples was 
not  significantly  different  to  that  of  the  96  samples.  The  remaining  missense 
change,  R20T was detected in both  MERTK alleles of a 54 year old patient with 
severe autosomal  recessive  RP.  Sequence alignments show that at amino acid
198position 20, arginine is a fully conserved residue in all members of the human axl 
protein  subfamily  but  is  not  conserved  between  different  species  (figure  5.6). 
Furthermore,  R20S is a known  polymorphism in the human MERTK gene [122]. 
Since  serine  and  threonine  are  structurally  identical  apart from  a  single  methyl 
group,  it is likely that this change is a rare polymorphism rather than a disease- 
causing change.  However,  the substitution was not found in 96  Caucasian and 
41  Pakistani control DNA samples. Changes are summarised in table 5.
199Figure  5.6:  Missense  change  R20T.  (A)  DNA sequence  chromatograms.  The sequence  of an 
autosomal  recessive  RP  patient who  carries the  R20T  change  (top)  and the  control sequence 
(bottom)  are  shown.  (B)  Amino  acid  alignment.  Comparison  of  the  amino  acid  sequence  of 
different species shows that the change did not occur in a conserved area. (C) Molecular structure 
of threonine and serine.  The two amino adds are structurally similar apart from a single methyl 
group.
(A)  i ' jf~  (B)  Chicken L  LCAL  PL  PjRC  GAAE  F  GGAG 
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Mertk 
Axl  1 
Tyro  3
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■MAWRC  PRMGR----
MALRRS-MGRPGLP
(C)
N -H I
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H -C -O K
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200Table  5:  MERTK  sequence  variants.  Sequence  variants  in  MERTK  were  identified  by 
sequencing DNA from individuals affected by RP. The table summarises all changes found in the 
present study. Blue=identified in this screen, Black=known from previous screens.
Mutation/Polymorphism Exon Change Remark
ARRP 17 2214delT,
C738W
Frameshift, premature 
termination before 
position 770
Substitution 1 R20T Only found in 1  ARRP 
patient
Polymorphism I VS 1   +19 G->A Equally found in patients 
and controls
Polymorphism’ 2 N118S Equally found in patients 
and controls
Polymorphism IVS3+13 T->C Heteroz., homoz. equally 
found
Polymorphism’ 9 R466K Equally found in patients 
and controls
Polymorphism 9 Q451Q Not found in controls
Polymorphism’ 10 N498S Equally found in patients 
and controls
Polymorphism* 10 1518V Equally found in patients 
and controls
Polymorphism I VS 15 
+11
T ->C Heteroz., homoz. equally 
found
Polymorphism 19 V870I Equally found in patients 
and controls
2015.3.2 Clinical examination
The  dinical  characterisation  of  disease  due  to  MERTK  is  important  for 
assessment  of any  future  therapies.  Clinical  assessment of affected  individuals 
induded  fluorescein  angiography,  electrophysiology,  Goldmann  perimetry,  OCT 
and  autofluorescent  imaging.  Clinical  examinations  were  conducted  by  A. 
Webster, G. Holder and colleagues at Moorfields Eye Hospital.
5.3.2.1  Visual acuity and visual fields
Visual acuity is the spatial resolving capadty of the visual system, which means it 
is a measure of the ability of the eyes to resolve details. Visual acuity is commonly 
examined by asking the patient to read a Snellen eye chart. The Snellen fractions, 
20/20, 20/30,  20/40,  etc.,  are measures of the sharpness of sight. They relate to 
the  ability  to  identify  a  letter of a  certain  size  at a  specified  distance.  "Normal" 
vision is considered to be 20/20.  Different factors induding photoreceptor density 
throughout the eye limit visual acuity.
Patient  IV:6 was first seen in  2001  at the age of 16 years.  Her corrected visual 
acuities  then  were  20/30  OD  (oculus dexter,  right  eye)  and  20/40  OS  (oculus 
sinister,  left eye) and did not dedine until the age of 19 years.  The two younger 
siblings (IV:7 and  IV:9) also showed well preserved visual acuities. The 2214delT 
deletion was also found in an older affected maternal  half-cousin (IV:4).  He was 
unavailable for examinations but gave a detailed history of the disease progress. 
His visual acuities were normal until the age of 15 years. From then onwards they 
started to dedine  until  at the age  of 46 years only  his perception  of light vision 
remained.
202The term “visual field”  refers to the total area in which objects can be seen in the 
peripheral  vision  while  the  eye  is  focused  on  a  central  point.  Visual  fields  are 
commonly  measured  by  using  a  Goldmann  perimeter with  the  patient  looking 
directly at a small spot in the center of the perimeter while an object is presented 
to the periphery. A normal field of vision is nearly 180° horizontally and about 120° 
in  the  vertical  axis  and  the  nasal  fields  of each  eye  show  significant  overlap. 
Visual field testing  maps the visual field  of each eye and can be used to detect 
pathological  changes  ([377],  reviewed  in  [378]).  The  limits  of  the  visual  field 
depend  on  the  intensity  and  the  size  of the target  presented. In figure  5.7  the 
visual fields from patients are shown.  Visual fields of patients were tested using 
Goldmann V4e and  Il4e targets,  which differ in size,  on a standard background. 
The expected  normal  visual field  meassured with the target V4e is described as 
being  60°  superiorly,  75°  inferioriy,  60°  nasally,  and  95°  temporally.  In  a  visual 
field examination, the term isopter describes a line that connects all test locations 
from the same  stimulus.The  blue  isopter reflects visual  fields obtained  by  using 
the V4e target whereas the red isopter reflects the visual fields of the Il4e target. 
The  blind  spot  of  the  visual  field  is  depicted  by  the  red  spot.  The  macula  is 
thought to be the  centre  of each  chart and  each  concentric circle on the graph 
represents  10°. With both targets,  visual fields from patients were well preserved 
(figure 5.7).
203Figure 5.7:  Goldmann  visual fields. Monocular Goldmann perimetry targets V4e (blue isopter) 
and Il4e (red isopter) were used on standard background to obtain visual fields. With both targets 
visual fields from patients IV:6 (A), IV:7 (B), IV:9 (C) were well preserved.
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2045.3.2.2  Clinical ERG
ERG records the light induced activity of the retina.  It is used to assess the status 
of the retina and to precisely map regions of abnormally changed retinal activity. 
The Ganzfeld ERG records the overall electrical  response of the retina after light 
stimulation.  Principally two parameters are important to interpret ERG recordings 
-   the  amplitude  of  a-  and  b-waves  and  the  peak  times.  A-waves  reflect  the 
general physiological  state of photoreceptors whereas b-waves reflect the health 
of the inner retinal  layers including  bipolar and third order neurons.  Pathological 
conditions  in  most  retinal  disorders  are  indicated  by  an  attenuation  of  the 
amplitude and changes in the implicit time. Rods and cones differ in number, peak 
colour  sensitivity,  threshold  and  recovery.  This  characteristics  can  be  used  to 
isolate  rod  and  cone  activities  by  changing  adaptation  levels,  background 
illumination, the use of filters, flash intensity, colour and rate. Using different rates 
of stimuli  (flicker  ERG,  routinely  used  is  a  30  Hz  flicker)  allows  to  specifically 
measure  cone  responses  since  cones  recover  faster  than  rods.  A  multifocal 
pattern ERG allows the detailed examination of the macular area [338, 377, 379, 
337,  380,  381].  Electrophysiology  (figure  5.8)  showed  significant  attenuation  of 
rod and  cone  ERG  amplitudes from  an  early age (8 years). The ERG  results of 
patient  IV:6  are  those  of  a  severe  rod-cone  dystrophy  with  severe  macular 
involvement. The rod-specific ERG and pattern ERG (PERG) were not detectable 
and the bright flash "mixed" ERG was severely reduced. Single flash cone ERGs 
(photopic) and 30 Hz flicker ERG showed reduced and delayed amplitudes. The 
younger siblings (patients  IV:7 and  IV:9) showed severe rod system dysfunction. 
However,  there is better preservation of generalised cone function than in patient 
IV:6  but  still  with  marked  delay  and  amplitude  reduction.  There  is  some 
preservation of macular function shown  by the very low amplitude but detectable 
PERGs.
205Figure 5.8:  Representative electrophysiological traces.  ERGs from three patients showing a 
rod-cone pattern of abnormality.  Patient IV:6 shows no detectable rod-specific ERG,  a severely 
reduced  bright flash "mixed" ERG,  profoundly  reduced and delayed 30Hz and single flash cone 
ERGs and an undetectable pattern ERG (PERG). Patients IV:7 and IV:9 also show no detectable 
rod-specific ERG.  Mixed ERGs,  30 Hz flicker and photopic ERGs were better preserved than in 
patient IV:6 but still with marked delay and amplitude reduction. The PERGs were just detectable 
suggesting some degree of macular function preservation.
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2065.3.2.3  Fundus Imaging, Fluorescein Angiography and Scanning Laser 
Ophthalmoscopy (SLO)
Retinal blood vessel morphology is an important indicator for many diseases. The 
detection  and  measurement  of  blood  vessels  can  be  used  to  characterize  and 
quantify the severity of disease.  Retinal blood vessels have changes in diameter, 
branching  angles,  and  length  in  different  pathological  conditions.  Fluorescein 
angiography  is  an  established  technique  for  examining  the  circulation  of  the 
human retina.  After colour images of the fundus have been taken, fluorescein is 
injected  rapidly  into  a convenient vein to increase the  contrast of blood vessels 
against the background and photographs are taken at different time points.
Fundus examination of patient IV:6 showed attenuated vessels as well as a pale 
reflex from  the  RPE.  Furthermore,  a  bulls-eye  lesion  was  seen  at the  macula. 
However,  intraretinal  pigmentation  or  bone  spicules,  which  are  typical 
characteristics of RP, could not be found in this patient. FFA from patient IV:6 was 
performed  at the age  of  16  years.  A region of hypofluorescence  could  be seen 
throughout the central macula (figure 5.10b). Fundus examination of patients IV:7 
and IV:9 showed a similar fundus appearance compared to IV:6. In addition, there 
were  fine crystals present at the central macula present (figure 5.9).
207Figure 5.9:  Fundus  photographs from the three affected siblings.  (A) Fundus photograph of 
patient IV:6 showing attenuated vessels, a pale reflex form the RPE, and a bulls-eye lesion at the 
macula. (B) Fundus photograph of patient IV:7 showing fine crystals present at the central macula. 
(C) Fundus photograph of patient IV:9. IV:7 and IV:9 showing a similar appearance compared to 
IV:6, although with additional  fine crystals present at the central macula.SLO is a routine technique for imaging of the fundus and has the advantages over 
conventional  fundus  imaging  using  a  fundus  camera  of  lower  levels  of  light 
exposure,  improved  contrast  by  the  selection  of appropriate wavelength for the 
laser,  and  direct  digital  imaging.  In  SLOs  a  laser  beam  is  scanned  over the 
surface of the retina and a detector captures the reflected light. By using infra-red 
light visualisation of pathological conditions, such as choroidal neovascularisation 
and  pigmentary  changes  in  the  RPE,  which  are  often  blocked  by  overlying 
haemorraghe,  lipids,  or pigments  in  normal  fundus images  otherwise,  becomes 
possible  [382-385].  In  RPE  cells  autofluorescent lipofuscin  granules accumulate 
with  age  in  the  lysosomal  compartment as  a waste  product of phagocytosis of 
shed outer segments.  The RPE plays a key role in the pathogenesis of different 
degenerative  diseases.  The  confocal  SLO  (cSLO)  can be  used to examine  and 
visualise topographical variations in the RPE autofluorescence [386].
Fundus  autofluorescence  imaging  of  patient  IV:6  showed  an  area  of  hyper­
autofluorescence surrounded by an area of hypo- autofluorescence in both eyes. 
This  area  is normally  relatively  hypofluorescent because of the presence  of the 
pigment  lutein  which  absorbs the  incident  blue  light.  The central  macula  lesion 
was seen  in  all  three affected  individuals,  which  masked choroidal fluorescence 
on  angiography  but  appeared  brightly  hyperautofluorescent  on  SLO  imaging 
(figure 5.10).
209Figure 5.10:  Fundus autofluorescence and  FFA . (A) Fundus autofluorescence of patient IV:6 
showing a bilateral area of increased autofluorescence encircled by an area of relative decreased 
signal.  (B)  FFA  from  patient  IV:6  performed  at  the  age  of  16  years  showing  a  region  of 
hypofluorescence throughout the transit at the central macula. Fundus autofluorescence of patient 
IV:7 (C)  and  of patient  IV:9  (D)  were similar to  patient IV:6 showing the  central  macula lesion 
which appeared hyperautofluorescent on SLO imaging.
2105.3.2.4  Optical Coherence Tomography (OCT)
OCT  is  an  imaging  technique  that  produces  high  resolution  cross  sectional 
imagines  of  optical  reflectivity.  Time  delays  in  reflected  signals  are  used  to 
measure  the  distance  between  different  ocular  tissues.  The  high  level  of 
resolution achieved with OCT imaging is particularly suitable for retinal thickness 
measurements.  Histological data of many human ocular disorders is rare and so 
far was only obtained from retinal  biopsies and  post-mortem tissues.  OCT gives 
the  possibility  of  in  vivo  histological  examinations  and  can  be  either  used  to 
generate  topographical  maps  or  cross-sections  through  specific  areas  of  the 
retina [381, 385].
OCT imaging did not demonstrate debris layer (The data could not be presented 
due to a technical failure of the OCT).
5.3.2.5  Summary of clinical examination and patients history
The  proband  (IV:6;  figure  5.5),  a  19  year old  girl  of  Middle-Eastern  origin,  the 
oldest of 5 siblings of a first-cousin marriage, was diagnosed with RP at the age of 
12  years.  She  had  no  significant  history  of systemic disease  and  no  history  of 
medication  or drug  use.  She  had  become  symptomatic at the time of diagnosis 
with nyctalopia but complained of no other symptoms by the age of 19 years.  She 
did not experience any problems with navigation but found reading and discerning 
fine detail difficult, although she did not require the use of magnifying aids.  When 
first  examined  at  the  age  of  16  years,  her  best  corrected  visual  acuities were 
20/30  OD  and  20/40  OS.  Three  years  later,  at the  age of  19  years,  her visual 
acuity had not changed. There was no nystagus and the anterior segments were 
normal.  Fundus examination  showed  attenuated  vessels,  a pale reflex form the 
RPE,  and a bulls-eye lesion at the macular (figure 5.9) There was no intraretinal 
pigmentation (bone spicules), or macular oedema evident on biomicroscopy.
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(figure  5.7).  Colour vision  assessment with  HRR  plates  showed  both  red-green 
and  blue-yellow  defects.  Autofluorescent  imaging  of  the  RPE  layer  showed  a 
relatively  homogeneous signal from the posterior pole but was unusual in that it 
demonstrated a central  area of hyper-autofluorescence of approximately 500 pm 
in  diameter  at  the  central  macula  (figure  5.10)  encircled  by  an  area  of relative 
decreased autofluorescence. This region is usually relatively hypofluorescent due 
to  the  lutein  pigment  which  absorbs  the  incident  blue  light.  Fluorescein 
angiography,  performed  at  the  age  of  16  years  showed  a  region  of 
hypofluorescence  throughout  the  transit  at  the  central  macula  (figure  5.10b). 
There was no retinal edema.  OCT imaging did not demonstrate a debris layer, the 
central  retina being of normal  thickness.  Electrophysiology performed at the age 
of  16  showed  a  significant  reduction  of both  scotopic and  photopic responses. 
The  attenuated  30  Hz  flicker  showed  significant  delay.  The  pattern  ERG  was 
unrecordable (figure 5.8).
The proband’s affected younger sister (IV:7) had been diagnosed with RP at the 
age of 10 years. By the age of 14 years, she experienced difficulty navigating and 
discerning  colours in  the  dark but did  not have  problems  reading.  Her acuities 
were  20/30  OU  best-corrected  and  she  was  mildly  myopic  (-2D  spheres  OU). 
Fundus  examination  revealed  a  similar appearance  to  her sister,  although  she 
had fine crystals present at the central macula (figure 5.9).  Her visual fields were 
relatively  well  preserved.  Colour vision  assessment with  HRR  plates  showed  a 
marked  red-green  and  blue-yellow defects.  Autofluorescent imaging  of the  RPE 
showed  a  bilateral  central  area  of increased  autofluorescence at  both  maculae 
(figure 5.10).  OCT imaging was unremarkable.  ERG testing performed at the age 
of  10 years  showed  attenuation  of rod  and  cone  responses,  delay  of the cone 
implicit times and the pattern ERG was just recordable (figure 5.8).
The youngest affected sibling (IV:9) had noticed nyctalopia by the age of 10 years 
but  otherwise  had  no  symptoms.  At  age  7  years,  when  examined  as  part of a
212family  survey,  his  retinal  examination  was  reportedly  normal.  At  10  years,  his 
acuities  were  20/20  OU  (oculi uterque)  unaided.  Fundus  examination  revealed 
some pallor of the RPE in the peripheral retina and some fine crystalline deposits 
near the fovea. His visual fields (Goldman, V4e) were well preserved (figure 5.7). 
Colour  vision  testing  with  HRR  plates  showed  moderate  red-green  and  blue- 
yellow  defects.  Autofluorescent  imaging  of  the  RPE  layer  showed  a  similar 
appearance to his two older sisters,  although the area of hyper-autofluorescence 
was  larger  (figure  5.10).  OCT  imaging  was  unremarkable.  Electrophysiology 
showed  an  absent  scoptic response,  a  severely  attenuated  maximal  response, 
and delayed  and attenuated  reponses to photopic stimuli. The pattern  ERG  P50 
was just recordable (figure 5.8).
An older affected  maternal  half-cousin of the proband (IV:4) was unavailable for 
examination.  However,  he was  able to  give  a  detailed  history  at the  age  of 46 
years.  He first started  experiencing  problems seeing in the dark at the age of 9 
years.  At that stage, his corrected visual acuities were normal. He was examined 
extensively in his early teens but was not diagnosed with  RP until the age of 15 
years.  He learnt to drive,  although he was advised to stop driving by the age of 
18 years.  For the next few years he managed well,  attending University without 
assistance.  At this stage, he began to find reading and writing challenging and by 
the age of 24 benefited from the use of a closed-drcuit TV monitor. At the age of 
34 years,  he required a permanent guide for navigation.  By the age of 38, he no 
longer  found  use  for  his  monitor  due  to  further  deterioration  of  vision  and 
presently, at the age of 46 years only has perception of light vision.
Retinal  examinations  of  one  other  unaffected  twin  male  sibling  (IV:8)  and  the 
mother (III:3) were both normal.
2135.4  Discussion
RP is highly heterogenous genetically,  with at least 16 specific genes shown so 
far  to  cause  autosomal  recessive  disease,  13  causing  autosomal  dominant 
disease and 5 genes causing X-linked disease (retnet September 2005). Many of 
these  genes  are  specifically  expressed  in  photoreceptors  or  RPE  cells,  whilst 
others  have  a  ubiquitous  expression  pattern.  The  fundus  appearance  in  RP  is 
most typically characterised by a pigmentary degeneration of the retina indicated 
by the presence of bone spicules,  attenuation and narrowing of the retinal blood 
vessels, and optic disc pallor (for a review see [387]).  However, the presentation 
of RP  is clinically  variable;  a  factor that  reflects the  genetic heterogeneity.  The 
onset of the symptoms of RP usually begins with a loss of dark adaptation (night 
blindness) followed  by  a  progressive reduction  in the mid-peripheral  visual field. 
The  primary  pathological  observation  of  the  retina  is  degeneration  of  the  rod 
photoreceptors,  followed  by  secondary  changes  in  cones,  RPE  cells  and  other 
cells of the neuronal retina.
Currently  there  are  no  effective  treatments  for  patients  suffering  from  retinal 
degeneration,  although  there  has  been  much  success  with  various  therapeutic 
strategies  using  animal  models.  Current  strategies  include  transplantation  of 
normal  photoreceptors and  RPE  cells  [388],  intravitreal  injections of factors that 
prolong photoreceptor survival  and promote function [182,  389], gene delivery to 
mutant  photoreceptor  and  RPE  cells  using  viral  vectors  [105,  228,  233]  and 
liposomes  [315].  The  RCS  rat  has  been  widely  used  as  a  model  for  such 
strategies,  including  subretinal  transplantation  of  RPE  cells and  cell  lines  [182, 
390],  treatment with growth factors such  as  bFGF  [182],  and gene replacement 
therapies  [233]. The latter has also been successfully tested in another model for 
RP,  the  rpe65'l~   dog  [105].  The  MERTK  protein  in  the  eye  is  predominately 
expressed  in  the  RPE.  Like  rpe65,  mutations  in  MERTK primarily  cause  RPE
214defects  whereas  photoreceptor  cell  are  inherited  functional  and  morphological 
preserved.
Patients  with  autosomal  recessive  RP  arising  from  mutations  within  genes 
expressed in the RPE may be predetermined to create a group that is a promising 
target for gene replacement approaches.  However,  in order to improve both the 
effectiveness of existing  strategies and the development of novel therapies,  it is 
crucial to understand and characterise the histopathological changes in individual 
patients with RP.
This  study  presents  the  first  detailed  clinical  and  molecular  report  of  multiple 
family  members  affected  by  RP  due  to  mutation  in  the  MERTK  gene  and 
describes a novel  mutation.  Common to other reported surveys, the disorder is 
likely to be a rare cause of autosomal recessive RP (ARRP). Only one family was 
identified in a screen of 96 probands suggesting that mutations in MERTK count 
for approximately  1% of all ARRP.  One previously unreported missense change, 
R20T was detected in this study on both alleles in one person of Pakistani origin 
with  ARRP.  The  fact  that  this  residue  is  polymorphic  in  the  human  population 
(R20S) and that it is not conserved in other species suggests that it is likely to be 
a non-disease causing variant although a rare one.
Childhood onset nyctalopia,  preserved visual fields,  relatively mild RPE changes 
with a bulls-eye lesion  at the  macula,  absence of pigment migration to the RPE, 
and recordable autofluorescence within the RPE were all consistent and defining 
features of the disorder within the family.  In addition, the age difference between 
the affected members enables some insight into the rate of visual decline of the 
disorder,  at  least  in  this  particular  family,  which  may  prove  useful  when 
determining a time scale for preventative intervention.  The time span of 10 years 
proved little in the way of detectable difference in fundus abnormalities,  although 
functional decline was observed.
215One clinical finding was a hyperfluorescent area, situated at the central macula, of 
up to half a disc area in size,  in the three affected siblings.  It was smaller in older 
individuals  and  showed  hypofluorescence  on  fluorescein  angiography.  One 
possibility  is  that  this  represents  debris  from  non-phagocytosed  photoreceptor 
discs  lying  between  the  RPE  and  neurosensory  retina  with  inherent 
autofluorescence but which masks choroidal fluorescence during angiography.  In 
support,  the  debris  characteristic of the  degeneration  in  RCS  rat retina  is  also 
autofluorescent  to  light  of a  comparable  wavelength  (figure  5.11).  However,  no 
such debris layer could be detected on OCT examination. This sign may be useful 
in the clinical  identification  of MERTK-deficient disease when  examining families 
with RP.  It should be emphasised that the appearance of this ring is much smaller 
than  that reported  by  Robson  et al and  others  [391] which  can  occurs in  some 
patients  with  RP.  The  homogeneous  autofluorescence  elsewhere  implies  that 
phagocytosis  of  outer  segments  is  not  completely  deficient  and  in  this  regard 
would be different from the RCS rat.
Figure 5.11: Fluorescence micrograph. The picture was taken of a 5 week old dystrophic RCS 
rat.  Due to the  phagocytotic defect  of the  RPE cells,  a  debris  layer consisting  of broken  outer 
segment and membranous waste material has build up.  Photoreceptor outer segments and RPE 
cells show strong autofluorescence, a characteristic feature of the degenerating retina. INL = inner 
nuclear layer, OPL = outer plexiform layer, ONL = outer nuclear layer, IS = inner segments, D = 
debris layer, RPE = retinal pigment epithelium, C = choroid
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216The decline of retinal function as measured by electrophysiology,  appears at an 
early stage in this family with early loss of both macular and scotopic function at 
the age of 5 years (IV:9) and loss of photopic function soon after. By the age of 16 
years all responses were severely attenuated and delayed. This early loss of the 
ERG, in which scotopic function is predominantly affected, is similar to that seen 
in  the  rat  and  mouse  models.  The  preserved  visual  acuity  and  field  into  the 
second decade suggests that the visual  system develops normally,  an important 
consideration  given  the  prospect  of  therapeutic  intervention.  The  detailed 
description of the phenotype exhibited by the human MERTK mutation described 
here might assist the identification of eligible patients and families from amongst 
the many molecular types of RP.
The  disease  observed  in  the  three  affected  members  reported  here,  appear 
milder than  those  previously  described  for a  patient  of comparable  age with  a 
different MERTK genotype (R722X/R844C) who had vision reduced to 20/200 at 
13 years and  restricted visual fields [374].  In contrast the oldest member of the 
present  sibship  maintained  acuites  of 20/20  at  the  age  of  18  years  with  more 
extensive  visual  fields.  Interestingly,  a  common  feature  is the  appearance  of a 
ring  of  RPE  depigmentation  in  a  'bull's  eye'  pattern  on  fundoscopy  in  all  four 
photographed  patients  which  in  our family  corresponded  to  the  area  of hyper- 
autofluorescence.  The  deletion  2214delT  and  the  substitution  R722X,  result  in 
premature termination signals. Whilst a proportion of the resulting mRNAs is likely 
to succumb to nonsense-mediated decay (NMD; for reviews see  [392, 393]),  the 
remaining  mutant  mRNAs  would  be  expected  to  be  translated  into  truncated 
proteins. Since the premature termination signal caused by the mutation R722X is 
located further up-stream to the deletion 2214delT, the truncated MERTK protein 
would  lack  a  larger  portion  of  its  intracellular domain.  This  missing  part  might 
include recognition or binding sites for other proteins involved in the phagocytosis 
signaling  pathway  that  are  still  present  on  the  2214delT  truncated  protein.  In 
addition,  the  R722X  substitution  was  found  together  with  the  missense
217substitution  R844C  as  compound  heterozygeous.  This  substitution  has  been 
shown  to  be  at  a  fully  conserved  position  in  different  species,  and  has  been 
shown  to  abolish  MERTK  tyrosine  phosphorylation  necessary  for  phagocytosis 
[374]. The presence of these two different mutant proteins might be one possible 
explanation for the difference in severity observed in the two MERTK genotypes, 
R722X/R844C  and  2214delT/2214delT.  Another  explanation  might  be  the 
influence of other genetic or environmental modifiers on the expression of MERTK 
deficiency.
The clinical  characterisation  of disease due to MERTK is important to allow the 
interpretation of any future therapies. The specific macular appearance may allow 
the identification of further patients through ophthalmic screening, and the rate of 
visual decline might allow preventative intervention.
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6 Discussion
Inherited  retinal  degenerations,  including  RP,  lead  to  a  progressive  loss  of the 
visual  field  and  in  some  cases finally  to  blindness.  The  last twenty  years have 
seen  enormous  growth  in  the  understanding  of  the  molecular  and 
histopathological  changes that occur during  retinal  degeneration. The constantly 
improving  knowledge  and  understanding  of  RP  increases  the  prospects  for 
developing  new  and  effective  strategies  to  delay  photoreceptor cell  death  and 
prolong  retinal  function.  With  major  advances  in  molecular-biological  research, 
numerous  retinal  dystrophy  genes  have  been  identified.  Thus,  a  fundamental 
requirement for the development of gene therapy for these type of diseases has 
been  achieved.  One  recently  identified  gene  is  the  receptor  tyrosine  kinase 
MERTK  [122].  The  resulting  autosomal  recessive  disease  in  patients  with  a 
mutation in the MERTK gene is characterised by night blindness at a young age, 
with progressive loss of peripheral vision until only a small island of central vision 
remains [69]. The RCS rat provides a good animal model for this type of RP and 
has been used widely to test different therapeutic strategies, including subretinal 
transplantation  of  RPE  cells  and  cell  lines  [182,  390],  treatment  with  growth 
factors such as bFGF [182], and gene replacement therapies [233, 394, 395].
AAV-2-based vectors have already been tested in a wide range of tissues.  Since 
AAV-2-mediated gene  replacement had  already been established as an efficient 
approach for a restoration of the rpe65 defect in RPE65_ /' dogs [105], we aimed to
219evaluate its therapeutical potential in the RCS rat.  In this study we demonstrated 
that  subretinal  injection  of rAAV-2  expressing  a functional  copy  of the  MERTK 
gene can significantly slow retinal  degeneration in the  RCS rat.  ERG analysis of 
treated eyes showed that functional photoreceptors were still present at 9 weeks, 
when there is virtually no activity in untreated control eyes. Histological analysis of 
treated eyes revealed a decrease in the amount of debris in the subretinal space, 
suggesting that RPE function was restored. Moreover, nine weeks after treatment 
the number of photoreceptors was 2.5 fold higher in treated compared with control 
eyes.  Since  AAV-2  transduces  RPE  and  photoreceptor  cells  and  the  CMV 
promoter is ubiquitously active, the rpe65 promoter was used to restrict transgene 
expression  to the  RPE.  With  both  promoters comparable levels of rescue were 
achieved. This is important in view of future clinical trials,  since gene expression 
should be limited to the cell type that carries the defect in order to avoid possible 
side  effects  induced  by  an  additional  expression  of the  transgene  in  other cell 
types.
Whilst AAV-based vectors are very effective, they do have some disadvantages. 
Firstly, they have a relatively small cloning capacity and therefore they cannot be 
used to deliver transgenes bigger than approximately 5 kb.  Secondly, AAV-2 has 
a delay in onset of transgene expression of about 2 weeks and finally,  they can 
evoke  an  immune  response  that  renders  re-administration  difficult.  It  has  been 
shown that infections by the non-pathogenic AAV-2 virus are common and lead to 
a  pre-existing  immunity  against AAV-2  [396].  Different  studies  have  suggested 
that anti-AAV antibodies have a neutralising effect that decreases the efficiency of 
in vivo vector delivery in different organs [397,  398].  However, the development 
of anti-AAV antibodies is minimal or not existent after dilivery of AAV to the brain 
or  retina  [399,  400].  Since  other serotypes  are  less  common  than  AAV-2,  pre­
existing  immunity  in  humans  is  rare  and  pseudotyping  would  be  an  option  to 
circumvent this problem. Although this is of minor importance for gene delivery to 
the eye because of its  unique immunological  environment,  it is a major concern 
for other disorders. The delay in expression can be avoided by the use of chimeric
220vectors.  AAV-2  has been  pseudotyped with AAV-1  and this chimeric vector has 
an onset of expression within 3 to 4 days after delivery. A fast onset of expression 
is  particularly  desirable  in  testing  therapeutic  approaches in  models  of disease 
with rapid retinal  degeneration as is the case in the RCS rat.  In consideration of 
the different life span and therefore the pace of photoreceptor loss of humans and 
rats,  the delay  in  onset  of AAV-2-mediated  expression  should  not be  a  limiting 
factor for effective treatment of RP patients with MERTK mutations.  Furthermore, 
AAV-2/1  and  AAV-2/4  have  been  recently  shown to  specifically  transduce  RPE 
cells  in  different  animal  models  including  rats  and  dogs.  Chimeric vectors  are 
promising  vehicles  for  targeted  transgene  expression,  even  though  the 
therapeutical value of these vectors still needs to be evaluated [221, 343].
Lentiviral vectors have three outstanding features in regard to their use in human 
clinical  trials:  the  ability  to  transduce  non-dividing  cells  in  vivo,  the  ability  to 
efficiently deliver large  genes  (~8 kb)  and the abilitiy to  mediate long-term,  high 
level transgene expression.  In order to evaluate the efficacy of lentivirus-mediated 
gene  replacement  therapy  in  the  RCS  rat,  we  produced  recombinant  VSV-G 
pseudotyped  HIV-1-based  lentiviruses containing a  MERTK cDNA driven by the 
ubiquiteous SFFV promoter.  After subretinal delivery of the therapeutic construct 
animals were examined at various time points over a period of 7 months by light 
and electron microscopy,  and electroretinography. A correction of the phagocytic 
defect,  slowing of photoreceptor cell  loss and  preservation of retinal function for 
up to 7  months was observed.  Comparing the different rates of degeneration of 
humans  and  rats  a  similar  approach  in  patients  might  delay  degeneration  for 
years rather than months.
Lentiviral vectors based on HIV-1  have been used widely to develop efficient gene 
therapy protocols for a variety of disorders. A major concern of employing HIV-1- 
based  vectors  in  clinical  trials  however  is  the  possibility  of  generating 
recombination-competent viruses  during  vector production due to  recombination 
events between vector plasmids or in vivo due to mobilisation of proviral DNA by
221infectious retroviruses. Replication-competent viruses would be able to spread the 
therapeutic  vector  to  non-target  tissues.  To  address  this  concern,  a  class  of 
vectors was designed to undergo self-inactivation.  Self-inactivating vectors (SIN), 
which were also used in the experiments presented in this thesis [305,  349], will 
delete some of the c/s-acting elements needed for replication upon delivery (see 
section  4.1).  Therefore,  even  in  the presence  of a  replication-competent  virus, 
these vectors cannot be transferred to other target cells efficiently. The generation 
of  a  replication-competent  virus  involves  either  recombination  between  the 
defective helper plasmid and the vector encoding the gene of interest, or they can 
be produced through  recombination  between an endogenous retrovirus (present 
in the host genome) and the helper construct or the vector. SIN vectors efficiently 
infect  and  integrate  into  the  target  cell  but  generation  of proviral  transcripts  is 
inhibited.  Hence, they are less likely to be mobilised by other human retroviruses. 
However, the long-term persistence of viral  DNA could result in the generation of 
recombination-competent  viruses  at  any  time  after  in  vivo  administration. 
Therefore,  patients  should  be  monitored  for  vector  mobilisation  and  sensitive 
assays  including  PCR-based  protocols  to  detect  recombination  competent 
lentiviruses are being developed.
Lentiviral vectors have the potential to infect both dividing and  non-dividing cells 
and  they  have  the  ability  of  genome  integration  thereby  ensuring  long-term 
expression  of  the  gene  of  interest.  However,  chromosomal  integration  occurs 
randomly  and  as  a  result  the  location  of the  inserted  gene  varies  enormously 
(reviewed  in [401]).  It has been shown that random integration carries the risk of 
insertional mutagenesis [217,  358].  Studies of integration preferences of different 
viral  systems  provide  new  insight  in  the  integration  process.  It  has  been 
demonstrated  that  differences  exist  between  different types  of retroviruses  and 
that  both  vector and  host factors  are  important for integration.  Results  suggest 
that  integration  preferences  might  be  cell-type  specific and  different  in  dividing 
and non-dividing cells [402-404]. These problems can be circumvented by the use 
of  non-integrating  lentiviruses.  As  part  of  this  project,  the  potential  of  non­
222integrating  HIV-1-based  vectors  for  retinal  degeneration  has  been  investigated. 
We have shown that these integration-deficient vectors are effective templates for 
gene expression in vivo and that expression levels and the duration of transgene 
expression are similar to those achieved with integration proficient vectors.  These 
results suggest that  integration-deficient lentiviral  vectors are attractive tools for 
human gene therapy approaches with increased biosafety features.
HIV-1  vectors  have  proven  to  mediate  long-term  and  efficient  transgene 
expression in vivo.  However,  HIV-1  is a lethal pathogenic virus that causes AIDS 
raising some safety concerns for the use of HIV-1-based vectors in clinical trials. 
Due to these biosafety issues,  gene therapy vectors based on other lentiviruses 
have been developed. SIV [300], BIV [301] and FIV [295, 360, 361] based vectors 
have already  been tested  in the eye and show sustained expression in different 
ocular  tissues  after  intraocular  delivery.  We  aimed  to  assess  the  potential  of 
another,  non-primate  lentivirus  vector,  namely  an  EIAV vector  [345,  346].  The 
expression  patterns  and  the  duration  of  expression  after  different  routes  of 
intraocular delivery were  evaluated and their utility  as gene transfer vehicles for 
ocular  gene  therapy  determined.  Subretinal  vector  delivery  resulted  in  efficient 
and stable transduction of RPE cells and variable transduction of photoreceptors 
up to 16 months post injection.  Retinal trauma facilitated the local transduction of 
neurosensory retinal cells.  Intracameral administration of VSV-G but not rabies-G 
pseudotyped vectors produced stable gfp expression in comeal endothelial cells 
and  trabecular  meshwork.  These  results  suggest  the  potential  of  ElAV-based 
vectors  as  vehicles  for  delivering  therapeutic  genes  in  the  management  of 
inherited and  acquired retinal  and anterior segment disorders. Vectors based on 
non-primate lentiviruses have the advantage that they are only distantly related to 
HIV-1. This minimises the risk of recombination or other interactions between the 
vector  and  human  endogenous  retroviruses.  Non-primate  lentiviruses  have  no 
known  human  pathogenicity.  However,  they  are  also less well  understood  than 
HIV-1.  Possible  pathogenic features would  probably only  be revealed by clinical 
study. Other factors that should be considered are toxicities of viral gene products
223and  host immune  responses to various lentiviral  vectors,  in particular in view of 
clinical applications.
The  results  presented  in  this  study  demonstrate  the  potential  of gene  therapy 
approaches for the treatment of retinal degenerations caused by defects specific 
to the RPE and support the use of lentiviral vectors and the development of AAV- 
mediated  gene therapy for the treatment of such  disorders.  Pre-clinical  trials of 
gene therapy for LCA due to mutations in the RPE-specific rpe65 gene have been 
particularly  successful  [105,  290,  291]  and  highlight the utility  of AAV-mediated 
gene therapy to  target  RPE-specific defects.  RPE65  deficiency  is characterised 
by an  unusual feature,  which  is the dissociation of retinal function and structure. 
Despite  the  visual  impairment,  RPE65  deficient  animals  retain  photoreceptor 
structure, which is normally lost in other types of retinal degeneration.  It has been 
suggested that the relatively preserved retinal morphology is the main reason for 
the  success  of  pre-clinical  studies  in  RPE65  deficient  animals  and  that  the 
success  rate  is  dependent  on  the  level  of  preservation  [405].  Clinical 
examinations of  RPE65  patients  show  regional  preservation  of retinal  structure 
similar to that observed in animal  models. Therefore gene therapy might prove to 
be  an  adequate  strategy  to  restore  rod  and  cone  function  in  such  patients.  In 
contrast,  MERTK  deficiency  results  in  photoreceptor  cell  loss  with  disease 
progression.  Gene therapy might be more efficient for RPE65 deficiencies rather 
than  MERTK deficiencies  as  indicated  by  pre-clinical  animal  studies.  However, 
the  results  presented  in  this  thesis  suggest that  patients with  MERTK mutation 
might  still  benefit.  The  necessity  of  structural  preservation  for  efficient  rescue 
levels also highlights the importance of treating patients at early stages of disease 
progress.
Theoretically,  gene therapy targeted  at the causal  mutations represent the most 
promising approach to treat inherited retinal degeneration, especially for diseases 
in  which  photoreceptors  are  primarily  healthy  and  their  loss  occurs  as  a 
secondary  consequence.  The  assessment  of risk to  benefit  ratio  is  the  central
224issue for human gene therapy approaches. Although over the last few years there 
have  been  major  advances  in  lentiviral  vector  production  with  regard  to 
purification  and  biosafety  [406],  the  use  of AAV  vectors  raises fewer concerns 
about  safety.  Recombinant  AAV  efficacy  has  been  demonstrated  in  numerous 
gene therapy pre-clinical  studies.  As this vector is increasingly applied to human 
clinical trials,  it is a priority to evaluate the risks of its use for workers involved in 
research  and  clinical  trials as well  as for the  patients and  their descendants.  A 
critical  aspect of in  vivo gene delivery is the possible transmission of exogenous 
DNA to the germ line.  Different studies that aimed to explore the risk of germ line 
transmission of rAAV have shown that there is a dose-dependent increase in the 
likelihood  that  vector  sequences  can  be  detected  in  gonadal  DNA  using  a 
sensitive  PCR technique in  mice and  rats (see [407] for a review).  However,  no 
vector  sequences  could  be  dedected  in  DNA  extracted  from  semen  saples  of 
rabbits  and  dogs  after  intramuscular  or  hepatic  atery  delivery  [408].  In  clinical 
studies human subjects that received intramuscular injected of AAV vectors have 
shown no evidence of vector sequences in semen.  In addition, direct exposure of 
mouse  spermatozoa  to  AAV-2  vectors  has  shown  no  evidence  of  germ  line 
transduction  [409].  These results suggest that there is no significant risk of germ 
line transmission after different routes of delivery. Viral vectors that can integrate 
into  the  host  genome  have  a  potential  higher  risk  of  entering  the  germ  line. 
Especially when using HIV-1-based vectors precautions must be taken since HIV- 
1   interacts  with  biological  function  of  human  endogenous  retroviruses. 
Biodistribution  studies  of  different  rAAV  serotypes,  which  were  delivered 
intraocularly in rats and dogs, failed to detect vector sequences in liver or gonad 
samples.  However,  vector sequences were detected  along the visual  pathway 
after  subretinal  and  intravitreal  delivery  of AAV-2.  These  findings  raise  safety 
concerns regarding intraocular delivery of AAV-2-based vectors and highlight the 
importance of tissue-specific transgene expression [410].
Whilst the results presented  in this thesis of the rescue of the  RCS rat are very 
encouraging, the  potential for therapy in humans depends upon the identification
225of patients. We therefore screened a panel  of DNA from patients with autosomal 
recessive  and  sporadic forms of RP for mutations in the MERTK gene.  A novel 
frame-shifting  deletion  and  a  number  of  polymorphisms  within  the  gene  were 
identified. The deletion allele was detected on both chromosomes of four affected 
members  of  a  family  with  autosomal  recessive  RP.  Patients  with  MERTK 
mutations  suffered  from  early  loss  of  scotopic  and  macular  function  on 
electrophysiology  with  later  loss  of  photopic function.  Acuities  and  fields  were 
preserved into the second decade but only perception of light vision was present 
in the fourth  decade.  A 'bull's eye'  appearance  on funduscopy  and  an inherent 
hyper-autofluorescent  lesion  at  the  central  macula  were  consistent  clinical 
findings.  These  are  distinctive  clinical  signs  that  may  improve  the  chances  of 
identifying further patients and families in the future and distinguishing this from 
the  many  other  cause  of  human  retinal  degeneration.  The  study  extends  the 
phenotypic  characteristics  of  retinal  dystrophy  associated  with  human  MERTK 
mutation.  However,  the  phenotype  in  these  patients  appears  milder  than  that 
previously  described  for  a  patient  of  comparable  age  with  a  different  MERTK 
genotype (R722X/R844C) suggesting variability in the degree of disease severity 
[374].  In  order  to  develop  an  efficient  therapeutic  protocol,  it  is  necessary  to 
identify  more  patients with  MERTK mutation  and  to  gain  a  better knowledge  of 
their clinical features.
The results presented in this study added weight to the prospect of applying gene 
therapy to the treatment of retinal degeneration.  However,  much research has to 
be done before gene therapy is routinely used in clinics. One of the main limiting 
factors  for  a  fast  progression  into  clinical  trials  is  that  any  new  therapeutical 
strategy  must be  shown  to  be  efficient in  an eye  similar to that of humans.  For 
several  reasons,  including  that  they  are  cheap  and  easy  to  keep,  rodents  are 
most  commonly  used.  Nevertheless,  fundamental  differences  between  rodents 
and humans limit the rodent from being the best model for many human diseases. 
For instance, the rodent eye lacks specific characteristics of the human eye such 
as the macula (see section 1.2.6). The advantage of large animal models has also
226become  evident  during  this  study.  The  RCS  rat is  a valuable  animal  model  for 
retinal degeneration due to RPE-specific defects. The null mutation in the MERTK 
gene makes  it an  attractive  model  for early experiments [69].  Different from the 
RCS rat, the mutations identified in human patients are all located in the tyrosine 
kinase domain within the last third of the ORF [122, 374]. The resulting truncated 
protein is unlikely to lead to a complete loss of function as is the case in the RCS 
rat. The bulls-eye appearance on funduscopy and the hyperautofluorescent lesion 
at the central  macula observed in  patients with  MERTK mutations are important 
clinical  characteristics.  Functional  assessments  and  visual  testing  in  these 
patients  also  showed  an  involvement  of  cone  photoreceptors  in  the  disease 
course.  These findings  differ from clinical  findings in  the  RCS  rat since  rodents 
have  no  macula  and  a  different  cone  distribution.  Furthermore,  the  difference 
between  the  rate  of  degeneration  between  rat  and  human  is  significant.  The 
differences  may  also  be  caused  by  genetic redundancy  or altered  biochemical 
pathways in rodents.
The  availability  of  natural  occurring  large  animal  models  is  limited  and  their 
production  difficult.  Non-human  primates  closely  parallel  humans with  regard  to 
genetic, anatomic,  and cognitive characteristics.  Hence they are considered to be 
one  of  the  best  models  for  understanding  human  physiology  and  diseases. 
Transgenic technology in biomedicine has opened a new era for animal modeling, 
which  accelerates  model  development  and  results  in  better  understanding  of 
diseases  as  well  as  development  of  therapies  for  patients.  Over  the  last  few 
years,  transgenic  animals  with  genetic  alterations  that  lead  to  human  genetic 
diseases  have  been  created.  This  has  a  major impact on  the  understanding of 
disease  development  and  the  development  of  cures.  In  particular  non-human 
primates  mimic  patient  conditions.  The  major  difficulty  in  producing  transgenic 
non-human primates so far was the low efficiency of the gene transfer protocols. 
Apart from other designs,  the development of replication defective retroviral  and 
lentiviral  vector systems  [348,  411-413]  have led  animal  biotechnology to  broad 
applications  and  relatively  high  rate  of efficiency.  Recently  the  first  transgenic
227non-human  primate  animal  has  been  created  by  using  a  retroviral  vector [414]. 
These  models  will  provide  a  more  accurate  representation  of  the  human 
condition.  However, the use of large animal models will increase the cost and the 
duration of experiments.  Whilst large animal models for MERTK deficiency might 
help to better understand the pathways underlying the disease progress, they are 
not indispensable for future  clinical  gene therapy trials.  Experience gained from 
pre-clinical  studies  for  rpe65  defects  involving  dogs  and  non-human  primates 
have  shown  the  potential  of  gene  therapy  for  RPE-specific  defects  [105,  343, 
415]. Taken together all results obtained from gene replacement studies on RPE 
specific  defects,  a  benefit  from  this  type  of  therapy  for  patients  with  MERTK 
mutations is suggested.
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AAV adeno-assodated virus
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Ad adenovirus
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ADP adenosine-5'-di phosphate
AMD age related macular degeneration
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APC antigen-presenting cell
ATP adenosine-5'-tri phosphate
p-PDE p subunit of the rod cGMP phosphodiesterase
BHK cells baby hamster kidney cells
BIV bovine immunodefidency virus
bp base pair
cAMP cydic AMP
cDNA complementary DNA
CFH complement factor H
cGMP cydic GMP
CMV cytomegalovirus
CMZ dliary margin zone
CNS central nervous system
CNTF dliary neurotrophic factor
CNV choroidal neovascularisation
CORD cone-rod dystrophy
cPPT central polypurine tract element
CRALBP cellular retinaldehyde binding protein
CRBP cellular retinol-binding protein
DNA deoxyribo-nudeic add
EIAV equine infectious anemia virus
ELM external limiting membrane
ERG electroretinography
ES embryonic stem cell
FGF fibroblast growth factor
FIV feline immunodefidency virus
Gas6 Growth arrest spedfic factor 6
GC ganglion cell layer
GDNF glia cell line derived neurotrophic factors
GDP guanosine- 5'-diphosphate
GFP green fluorescent protein
GLUT glucose transporter
GMP guanosine 5'-monophosphate
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MAP
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Mertk
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mRNA
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NAD+, NADH 
NADP+, NADPH
NF
nt
ONL
OP
OPL
ORF
guanosine-5'-triphosphate 
human immunodeficiency virus 
high mobility group 1  
hour
herpesvirus
insulin-like growth factor 1  
interleukin
internal limiting membrane
inner nudear layer
inositol-triphosphate
inner plexiform layer
interphotoreceptor matrix
interphotoreceptor retinoid-binding protein
inner segments
inverted terminal repeats
infectouse units
kilobases
kilodalton
litre
E. coli lactose operon gene Z = p-galactosidase 
Leber’s congenital amaurosis 
ledthin-retinol acyltransferase 
long terminal repeat 
micro­
metre 
milli-
mitogen-activated protein 
macular degeneration 
mer-receptor tyrosine kinase 
minute
micropthalmia transcription factor 
molony murine leukemia virus 
multiplicity of infection 
messenger ribonudeic add 
microvilli 
myosin 
nano­
oxidized and reduced nicotinamide-adenine dinudeotide 
oxidized and reduced nicotinamide-adenine dinudeotide 
phosphate 
nerve fibre layer 
nucleotide 
outer nudear layer 
osdllatory potential 
outer plexiform layer 
open reading frame
248OS outer segments
p postnatal day
Pax paired-box transcription factors
PCR polymerase chain reaction
PDE phosphodiesterase
PEDF pigment epithelium derived factor
PEG polyethylene glycol
Ph phagosome
Pi post injection
PS phosphatidylserine
rAAV recombinant AAV
RBP retinol binding protein
RCS rat Royal College of Surgeon rat
rd retinal degeneration
RDH retinal dehydrogenase
rds retinal degeneration slow
RNA ribonucleic acid
RNAi RNA interference
RP Retinitis pigmentosa
RPE retinal pigment epithelium
RPGR retinitis pigmentosa GTPase regulator
RPGRIP RPGR-interacting protein
RT reverse transcription
SCID Severe combined immune deficiency
SFD Sorsby’s fundus dystrophy
SFFV spleen focus forming virus
SIN self inactivating vector
siRNA small interfering RNA
SIV semian immunodeficiency virus
SRBP serum retinol-binding protein
TGF transforming growth factor
TIMP3 tissue inhibitor of metalloproteinase 3
TNF tumor necrosis factor
U unit
USH1 Usher syndrome type 1
V volt
VEGF vascular endothelial growth factor
VSV-G vesicular stomatitis virus G-protein
WPRE Woodchuck hepatitis virus post-transcriptional element
w/v weight/volume percent or mass/volume percent
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Murine MERTK mRNA sequence (NM_ 008587)
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12
18
24
30
36
42
48
54
60
66
72
78
84
90
96
102
108
114
120
126
132
138
144
150
156
162
168
174
180
186
192
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306
312
318
324
330
336
342
348
354
tggatacgtg 
cccactgcta 
gtgggaagag 
caaccacagg 
tggaagatca 
cctacctcct 
tgtcaaattt 
atggtggaaa 
tgatgaggaa 
caatgggtcg 
atacgtggaa 
cagaaacaca 
cttctgggtt 
aaccgtacct 
actgacggtg 
agtccatatc 
tggctactcc 
tggctcagtc 
gcaagccctg 
agtaagccct 
catcactgtg 
aattaagcgg 
agggacttac 
tgtccaaatc 
cgggcccttc 
accctcgtca 
ctgtggattc 
ccaggaaaca 
tagagcgaag 
gagcgaggag 
cggcaaagtt 
agatgggact 
ggagatcgag 
catccgactt 
ga  ttttaccc 
cacaggaccc 
gggaatggag 
catgttgcgg 
cagtggtgat 
cgagagcctg 
catgtgggaa 
gtacgactac 
gtatgacatc 
gttgaggctg 
catcatctac 
actcacgggg 
cgctgccgtc 
catcttgaat 
cacacctgaa 
gtctcaccat 
tgactccttg 
accaagcaaa 
aaaacatcat 
ggggttagag 
atctttaaga 
cctcaaagcc 
caaacaattc 
ttaagcaaac 
agagttcatg 
ccaaggtctt
catctgtccg 
ctggggctgc 
accgagctag 
ccattctctg 
catccagcac 
gttgcgttta 
aattgctcca 
gatggaaagg 
ggggtatcaa 
tacttctgta 
gttcaaggac 
gccttcaacc 
caaaatagca 
ggtctgacag 
tccaagggtg 
ctcaacagta 
ccacttcaga 
atggttttta 
gctaattaca 
tggattctgg 
tttctgaacg 
caggatgggg 
aaagagcttt 
cacaatgcca 
agtgagccag 
accccagccc 
attttaatcg 
aagtttgggg 
aagtccttct 
ctgcagaata 
ctgggtgaag 
tctcagaagg 
gagtttctca 
ctaggcgtgt 
ttca  tgaaat 
aagtacattc 
tatctgagca 
gatgacatga 
tattaccgcc 
gcggaccgag 
ataacaacac 
cttctccacg 
atgtactctt 
cagctggaaa 
atcaataccc 
ctagacatga 
agcgtggtca 
gggggcaatg 
aaggatggtg 
agtacactac 
gaagactctg 
tacagcttcc 
gaccaaggca 
tctatgattg 
gcaagcagga 
tgctcccagt 
caccaactgg 
cactacactg 
gccggacagc 
gagagctcgt
gagagaactg 
tgctgctacc 
atcagctatt 
ctcctcactc 
acacagccgc 
atcacaccat 
tcaatattcc 
aattgctcgg 
taattgcatt 
agatgaaggt 
tcccttactt 
tcacctgcca 
gccgtgttaa 
agacagcagt 
tacatatcaa 
cagcacacag 
actgcagcat 
atacctctgc 
gcatcgctgt 
ccagcacaac 
aa  tctaacaa 
aactggtggg 
ctgaagaagt 
cctgcacagt 
tgaatatcat 
ctggcaacac 
ggttaatttt 
gagcattctc 
gccggcgagc 
agctggaaga 
gagagtttgg 
tggcagtgaa 
gcgaagcagc 
gtatagaact 
acggagacct 
acctgcagac 
acaggaattt 
ctgtctgcgt 
aaggccgcat 
tctacacaag 
ggggaatgac 
gccacaggct 
gctggagtgc 
agctctccga 
agttgctaga 
acattgaccc 
cggcagaagt 
aggaatggga 
tcttaccgga 
ccttggggag 
aagttctgat 
tgggatctgg 
atcttcaaga 
cagaaggaag 
gacagagagc 
gacaaaagtc 
agaccaaaca 
gttatacctg 
accaggtgaa 
gccg
ccagatccgc
cgcgctctgg
ttcagggcct
cagccgggac
tccccaggtg
tggacacata
taacacatac
ggcacatcat
gttcagcata
gaacaataga
tattaagcag
ggccgtgggc
tgaaaaaccg
cttcagctgt
catcaaagta
catcctggtc
tcaggtcaag
ttcgccacat
gtcctgtcgg
agaaggagct
tatcctggat
ctaccggata
cagccagaat
gagaatcgcg
cattcctgaa
cgactctatg
gtgtatttct
tgaggaggat
catcgagctt
tgttgtgatt
gtctgtaatg
gaccatgaag
atgcatgaaa
gagctctcaa
ccacaccttc
actactgaag
tcttcatagg
ggcagacttt
tgccaaaatg
caaaagtgac
tccctatccc
gaagcagcct
tgatcccttg
gagtttgcct
gagctgcgag
tgactccatc
tcacgagaac
agatgtgtcc
ggacagactc
cccatcacca
gtgaagccag
tggtcttaga
gaaagtgttt
ttatgatggc
actctgggaa
cttcaacagg
ttcaaatgta
aggttttggt
agctgtcaag
ggccccgcga
agtggaggca
ttaccaggga
cagctgccac
acctccacag
gtactgtcgg
caagaaacag
tcaatcacac
gccagtgtgc
gagattgtat
cctgagagtg
cctcctgagc
gaaaggtccc
gaggcccaca
atcccctccc
tcctgggtcc
gaagctgacc
ctgtatgaga
aatgagattg
ccatctgtag
attagatgga
tctcacgtgt
ggcagctggg
gccattacta
cacagtaagg
ttcatcatcc
ctggccctca
tcccaactgg
accttgcaga
gacagaaacc
gaaggaaatt
ttggacaact
gacttcaacc
ggcatcccga
ctgttatatt
ttcatgatgg
gatttggcag
ggcctctcaa
cctgtgaagt
gtgtgggctt
ggagttcaga
gaggactgct
gatcgaccca
gatgcgcagg
ggcatagcca
attgcctctt
aaccttcgtg
tccactcctt
accaaaaatg
gatgaacttt
ctgagaggag
tactttgtta
aactaggttt
aggaacagct
atggcaccta
ccatacctcc
tgcgcgtatt
acttgttttc
tcaggtttgc
tggttctggc
ctgccgagaa
gactcccagt
caccccagac
catcaaagct
aacataaaaa
ctggcatttc
agttttatcc
agcgctcaga
ctgatcccat
tgaatgtcac
ccgtcaatat
cgtctgtcct
atgacaaagg
cgcccactga
ctggttttga
ggctgagtaa
tccagcagct
gctggtctgc
cacctttaaa
cgaagcctcc
gggaaagcgc
ctcagattcc
aagggggcat
tagattacgc
tcggctgctt
gaaggagagt
tcgtaaatta
gcctgggagt
ttctggttct
tgaagcaaga
tttctcaacg
acccaaatgt
agcccatggt
cccgattaaa
aeattgccca
ctcgaaactg
agaagattta
ggatcgccat
ttggcgtgac
accatgagat
tggatgaact
ccttctctgt
acaaagaatc
atgggccctc
gcacaccagg
aggaaagata
ttgctgcagt
gcgtctcctg
tatttgtaga
gcatgagaga
ttgctctgat
actgtttcag
gagtgcttat
tcttttgaaa
taatccttcc
ggggccattc
cttaccaagt
aaatacataa
251MERTK amino acid sequence alignment (Biology WorkBench)
BWB1040  human 
BWB1104  mouse 
BWB1148  rat
* - single, fully conserved residue 
: - conservation of strong groups 
. - conservation of weak groups 
- no consensus
BWB114 8  MVLAPLLLGL-LLLSALWNGGTAEKEEEIKPDQPFSGPLPGSLPADHRPFF-APHSSGDQ
BWB1104  MVLAPLLLGL-LLLPALWSGGTAEKWEETELDQLFSGPLPGRLPVNHRPFS-APHSSRDQ
BWB1040  MGPAPLPLLLGLFLPALWRRAITEAREEAKPYPLFPGPFPGSLQTDHTPLLSLPHASGYQ
*  ***  *  *  *.*_***  _   .*  **  •   *_**.**  *  ;*  *;  **.*  *
BWB1148  --------LSPSQTGRSHPAHTATPQMTSAASNLLPPVAFKNTIGRIVLSEHKSVKFNCSINIP
BWB1104  --------LPPPQTGRSHPAHTAAPQVTSTASKLLPPVAFNHTIGHIVLSEHKNVKFNCSINIP
BWB1040  PALMFSPTQPGRPHTGNVAIPQVTSVESKPLPPLAFKHTVGHIILSEHKGVKFNCSISVP
I.*.*.**.*..:.*  **;**.  *•  ***«**j   • * • * • * • * * * * * #* * * * * * *   .*
BWB114 8  NVYQETAGISWWKDGKEL LGAH H SITQFYPDEEGV  SIIALFSITSVQRSDNGSYICKMKV
BWB1104  NTYQETAGISWWKDGKELLGAHHSITQFYPDEEGVSIIALFSIASVQRSDNGSYFCKMKV
BWB1040  NIYQDTT-ISWWKDGKELLGAHHAITQFYPDDEVTAIIASFSITSVQRSDNGSYICKMKI
*  * * . * .   * * * * * * * * * * * * * * * . * * * * * * * . *   _.***  * * * . * * * * * * * * * * .* * * * .
BWB114 8  NDREWSDPIYVEVQGLPYFTKQPESVNVTRNTAFNLTCQAVGPPEPVNIFWVQNSSRVN
BWB1104  NNREIVSDPIYVEVQGLPYFIKQPESVNVTRNTAFNLTCQAVGPPEPVNI FWVQNSSRVN
BWB1040  NNEEIVSDPIYIEVQGLPHFTKQPESMNVTRNTAFNLTCQAVGPPEPVNI FWVQNSSRVN
* .  _ * . * * * * * * . * * * * * * . *   * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
BWB114 8  ENPERSPSVLTVAGLTETAVFSCEAHNDKGLTVSKGVQINIKVIPSPPTEVHILNSTAHS
BWB1104  EKPERSPSVLTVPGLTETAVFSCEAHNDKGLTVSKGVHINIKVIPSPPTEVHILNSTAHS
BWB104 0  EQPEKSPSVLTVPGLTEMAVFSCEAHNDKGLTVSKGVQINIKAIPSPPTEVSIRNSTAHS
* .**.*******  ****  ******* ** * * * ** * * * * ** * * * *   ********  *  ******
BWB114 8  ILVSWVPGFDGYSPLQNCSIQVKEADQLSNGSVMVFNTSASPHLYEVQQLQALANYSVTV
BWB1104  ILVSWVPGFDGY  S PLQNCSIQVKEADRLSNGSVMVFNTSAS PHLYEIQQLQALANY SIAV
BWB1040  I L I SWVPGFDGYS PFRNCSIQVKEADPLSNGSVMIFNTSALPHLYQIKQLQALANYSIGV
* * . * * * * * * * * * * * . . * * * * * * * * * *   * * * * * * * * * * * * *   * * * * . . . * * * * * * * * * .   *
BWB114 8  SCRNEIGWSAVSPWILASTTEGAPAVAPLNITVFLNESSNNLEIRWTKPPIKRQDGELVG
BWB1104  SCRNEIGWSAVSPWILASTTEGAPSVAPLNITVFLNESNNILDIRWTKPPIKRQDGELVG
BWB1040  SCMNEIGWSAVSPWILASTTEGAPSVAPLNVTVFLNESSDNVDIRWMKPPTKQQDGELVG
* *   * * * * * * * * * * * * * * * * * * * * *  * * * * * *  * * * * * * * *   •   . . * * *   * * *   * . * * * * * * *
BWB114 8  YRISHVWESAGTSKELSEEVSQNGSWAQVPVQMHNATCTVRIAVITKGGIGPFSEPVDVA
BWB1104  YRISHVWESAGTYKELSEEVSQNGSWAQIPVQIHNATCTVRIAAITKGGIGPFSEPVNII
BWB1040  YRISHVWQSAGISKELLEEVGQNGSRARISVQVHNATCTVRIAAVTRGGVGPFSDPVKIF
* * * * * * * * * * *   * * *   * * * _ * * * *   * ;; m * * . * * * * * * * * * * _ . * • * * • * * * * . * * _  .
BWB114 8  IPEHSRVDYAPSSTPAPGNTESMLIILGCFCGFVLMGLILYLSLAIKRRVQETKFGGAFS
BWB1104  IPEHSKVDYAPSSTPAPGNTDSMFIILGCFCGFILIGLILCISLALRRRVQETKFGGAFS
BWB1040  IPAHGWVDYAPSSTPAPGNADPVL11FGCFCGFILIGLILYISLAIRKRVQETKFGNAFT
* *   *_  * * * * * * * * * * * * * ; ; _ ; ; * * ; * * * ♦ * * ; * ; * * * *   ; * * * ; ; ; * * * * * * * * ^* * .
BWB114 8  EEDSQLWNYRAKKSFCRRAIELTLQSLGVSEELQNKLEDVWDRNLLILGKVLGEGEFG
BWB1104  EEDSQLWNYRAKKSFCRRAIELTLQSLGVSEELQNKLEDWIDRNLLVLGKVLGEGEFG
BWB1040  EEDSELWNYIAKKSFCRRAIELTLHSLGVSEELQNKLEDWIDRNLLILGKILGEGEFGBWB114 8 
BWB1104 
BWB1040
BWB1148
BWB1104
BWB1040
BWB114 8 
BWB1104 
BWB1040
BWB114 8 
BWB1104 
BWB1040
BWB114 8 
BWB1104 
BWB1040
BWB114 8 
BWB1104 
BWB104 0
SVMEGNLKQEDGTSQKVAVKTMKLDN FSLREIEEFLSEAACMKDFNHPNVIRLLGVCI EL 
SVMEGNLKQEDGTSQKVAVKTMKLDNFSQREIEEFLSEAACMKDFNHPNVIRLLGVCIEL 
SVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFSHPNVIRLLGVCIEM
SSQGIPKPMVILPFMKYGDLHTFLLYSRIESVPKSIPLQTLLKFMVDIAQGMEYLSSRNF 
SSQGIPKPMVILPFMKYGDLHTFLLYSRLNTGPKYIHLQTLLKFMMDIAQGMEYLSNRNF 
SSQGI PKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNF 
**********************.*****...  **  *  ********.***  ******^***
LHRDLAARNCMLRDDMTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADRVYTS
LHRDLAARNCMLRDDMTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADRVYTS
LHRDLAARNCMLRDDMTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADRVYTS
KSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDDLYEIMYSCWSA 
KSDVWAFGVTMWEITTRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYDIMYSCWSA 
KSDVWAFGVTMWEIATRGMT PYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRT 
* * * * * * * * * * * * * * • * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . * * . * * * * * *
DPLDRPTFSVLRLQLEKLSESLPDAQDKESIIYINTQLLESCEGLANRSSLAGLDMNIDP 
DPLDRPTFSVLRLQLEKLSESLPDAQDKESIIYINTQLLESCEGIANGPSLTGLDMNIDP 
DPLDRPTFSVLRLQLEKLLESLPDVRNQADVIYVNTQLLESSEGLAQGSTLAPLDLNIDP 
******************  *****_...  •**.*******'**•*•  **.****
DSIIASCTAGAAVSWMAEVHENNLHEERYILNGGNEEWEDVASTPFATVTAGKDGVLPE 
DS11ASCT PGAAVSWTAEVHENN LREERYILNGGN EEWEDVS ST P FAAVT P EKDGVL PE 
DSI IASCTPRAAIS  W T  AEVH D S K PH EGRYILN GGSE EWED LT S  AP S  AAVTAEKN S  VL PG 
********m   **.***  ****._.  .*  ******* '*****  .*  *.**'  *.+**
BWB114 8 
BWB1104 
BWB104 0
DRLTKNGISWSHHSTLPLGSPSPDELLFADDSSGDSEVLM
DRLTKNGVSWSHHSTLPLGSPSPDELLFVDDSLEDSEVLM
ERLVRNGVSWSHSSMLPLGSSLPDELLFADDSSEGSEVLMHuman MERTK exon 1-19 nucleotide sequence
AF260514-AF260529, AF3666903 
Coding sequences: bold 
Primer binding site: underlined
Exon 1   (<142..202)
1  c ttg g c tc c g   c c a c tc g g c a   c tc a c tg c c c   gggccgcccg  gacagggagc ttc g c tg g c g
61  c g c ttg g c c g   gcgacaggac  a g g ttc g g g a   c g tc c a tc tg   tc c a tc c g tc  cggagagaaa
121  tta c a g a tc c   gcagccccgg  g atg gg g ccg   g c c c c g c tg c   c g c tg c tg c t g g g c c tc ttc
181  c tc c c c g c g c   tc tg g c g ta g   a g g tg a g tg c   g cccggctgg  gggccaggcg agggggtggg
241  g g ctcccag g   aggaagcagg  g g c c tctq g q   qaqqqaqcqc  qtccacaqqq gcgcgcctgg
301  c tg c tg g a c a   a g tttg c a a a   c a c c c tc c a c   c c a c tg c g g t  gccagaggag ggggcgtagg
361  c g a a c c ta c c
Exon 2 (179..599)
1  acg aa tg a a c   tg g tg a a ta a  g a a ta tg tc c   a g a tg tg tg t  g tta a tg a a t t c t g c t ta tc
61  t t ttc c tg g g   gcacagagga c a c c c c a g tg   c t c t c t c t t c   ttg g c c ta a g   aag ttg g g a a
121  c c ta c ttg g g   a a a c tc tt c t ta ttta a a a g   g c ta a a a ttt  g g a t g t t t t t   tt t t a c a g c t
181  a tc a c tg a g g   caagggaaga a g c c a a g c c t ta c c c g c ta t  tcccg g gacc  ttttc c a g g g
241  a g c c tg c a a a   c tg a c c a c a c  a c c g c tg tta  tc c c ttc c tc   acgccagtgg g ta c c a g c c t
301  g c c ttg a tg t  tttc a c c a a c  c c a g c c tg g a  a g a c c a c a ta   cag gaaacg t a g c c a ttc c c
361  c a g g tg a c c t  c tg tc g a a tc  a a a g c c c c ta  c c g c c tc ttg   c c ttc a a a c a  c a c a g ttg g a
421  c a c a ta a ta .c   tt tc tg a a c a  ta a a g g tg tc  a a a t t t a a t t  g c tc a a tc a g   tg ta c c ta a t
481  a ta ta c c a g g   a c a c c a c a a t t t c ttg g tg g  aaag atg gg a  a g g a a ttg c t  tg g g g c a c a t
541  c a tg c a a tta   c a c a g ttt ta  tc c a g a tg a t g a a g tta c a g   c a a ta a tc g c   ttc c ttc a g g
601  t a t g t g t t c t   t t c t t c c t t t  t t t a t t t t t t   t a g t t t t a a t   a t t t a t t t a t   t t a t t t a c t t
661  a t t qaqacaq  a q ta tc a ttc  tq ta q c ccaq
Exon 3 (183..283)
1  g ta c c ttc a c   a g c a a c a tc t a g g c ta g g g t  ttg a c c a a a c   a a c tg c g ta c   a a tg g c c ta g
61  c c a a g c tg a c   a ta t a a a a t t a a c ta tcaca  q c a ta tg a c a   a a g a a g ttg a  a g a a g tttc c
121  a tc c t a ta a t  a g g a a c tc a a  a g g g ta g tc a   c tg ta a a ta t  c ttc a tg tg t t t t t c t t t g c
181  a g c a ta a c c a   g tg tg c a g c g  ttc a g a c a a t g g g tc g ta ta   tc tg ta a g a t g a aaataaac
241  a a tg a a g a g a   tc g tg tc tg a   tc c c a tc ta c   a tc g a a g ta c   a a g g ta a g tc  cacagaccag
301  a g tc c c a ttg   c c a g a g a a c t  g t t t g t t t t a   g g g c c tg tg t  t a a a t g t t t t  g tg ta ta a ta
361  c tc ta g a g tt  t t q c c tq c c t  a t t t a t a a c t   c tq ta tg c a a   a c c ttg c a a a  tc ta tc a g c a
421  c t g a a a t t t t   a c a a g g ta c t  c c a c tttg ta   g tc ta ta a g t  a a ta a tg a a a  tg a a ttc a a t
481  tc c tg a a g tt  tg a g c tc ta t  ta ta g g c a tt  acaggtgaga  taaaaagaga t t t t g g a c t t
541  c c ttg tc c a c   a g a tta ttg a   c
254Exon 4 (96..269)
1  c ta ttg c c a a   g ttc ta g tc c   a g t t t c c a t t  
61  c tg a a a c a tt  c t t t t g t g t a   a c g t t t t c t c  
121  tg a g a g c a tg   a a tg tc a c c a   gaaacacagc 
181  g c c tg a g c c c   g tc a a c a tt t  tc tg g g ttc a  
241  a a a a tc c c c c   tc c g tg c ta a   c tg ttc c a g g  
301  tc t c ta a ta g   cg q acag g at  c a a a a g tttg  
361  g tg g ag acag   a tg a a a a ta c   a g g tg tg g c a
Exon 5 (180..266)
1  c c tt g g g ttt  a a tc c c a g g t  t t g t t t c t c c  
61  c a c ta a tg c c   c a a a a g c c a t  gaaccaagaa 
121  g ta g tg a a c a   gcagcct g t t   tc tc tq c tq c  
181  c ctg acg g ag   a tg g c g g tc t  tc a g ttg tg a  
241  aaag g g ag tg   c a g a tc a a c a   tc a a a g g ta a  
301  tq q q a g c tg g   tg a q g q ta c a   g c a tg a g c tt 
361  t t t c t c a c t g   tc tc a a g g tt  c tttg tg a c c  
421  a g g g ttc
Exon 6 (71..186)
1  q ta g c tg ta g   c c tg tc a tc t  a t a a t t g t g t  
61  t t t t a t g c a g   c a a ttc c c tc   c c c a c c a a c t 
121  a g c a ttc tg a   tc tc c tg g g t  t c c t g g t t t t  
181  a ttc a g g ta a   a g ttc c a g g g   tgaagaggga 
241  a g g a t t t t t c   ttc c ttc c a a   g g a tg g g c a t 
301  c c c c tg a c c t  c c c tg c ttc a   g tg tc c a g c a
Exon 7 (88..271)
1  cc a c g tg c a c   cg aatg c a c a   cag g ccccg t 
61  c g g tc c tc a t  g t t t a c t c t t   c g ttta g g tc  
121  g t c a t g a t t t   tta a c a c c tc   tg c c tta c c a  
181  c tg g c ta a tt  a c a g c a ttg g   t g t t t c c t g c  
241  c c ttg g a ttc   ta g c c a g c a c   g actg aag g a 
301  c c c c c a a tg a   c a tg tq a ttc   a a c a a a c c c t 
361  t g c t t t g t t t   g g a c tttg tc   tc tg g a g g a g  
421  a a a g a ta ttt  c c tc c a ta c t  g ta a a a g c a t 
481  agg
Exon 8 (134..285)
1  g tg c ta ta a g   tc t t g g t c t c   a tttg a g tg c  
61  tg a a a a c c c a   qa tq a q a a ta   c a tc tq tq tg  
121  t t t t c t t t t g   ta g c c c c a tc   a g ta g c a c c t 
181  a g tg a ta a tg   tg g a c a tc a g   a tg g a tg a a g  
241  g tg g g c ta c c   g g a ta tc c c a   c g tg tg g c a g  
301  agaagagcac  q a tta q tc a t  c tc c tttc a a  
361  t c a t t t g g t t   ttg a a a a g a c   c tg g tg tg a t
cccc tttg q q   c tc t g t c tc t  q t t t t c a q a t 
c g c a g g a c tt  c c tc a c ttta   ctaag cag cc 
c ttc a a c c tc   a c c tg tc a g g   c tg tg g g c c c  
aaacag tag c  c g tg tta a c g   aacag cctg a
ta a g tc c g a g   c tg tg g g c tt  a t t g a t t t a t  
g c g a c c c ttg   c tg tg c a c c a   ctag cag gca 
g c a a a g tta t  gggaccaggt  agac
a ta g c ta g c a   c a c c tttta a   a tt a a c t t t g  
a ta a a a ta a t  acaaagacaa  c c a ta g a a tt 
tg g tc tc a tq   a g tc tc c ttc   c a ttc c a g a g  
g g c c c a c a a t  gacaaagggc  tg a c c g tg tc
gcagcaaggc  ta g g c tc c c c   a tg c a tg ttc  
g c a g c tg g c t  g c c tg g g tg t  g g a tc c tg g c  
ttg g a c a a c t  c a c ttc tc c t  c tttg g tg tc
t t g t g t g t g t   a tg tg tg tg t  g t g t g t t t t g  
g aa g tc a g c a   tc c g ta a c a g   c a c tg c a c a c  
g a tg g a ta c t  c c c c g ttc a g   g a a ttg c a g c
a g ta g c tg tt  tg g tg c tc tc   tg tg g g t t t a  
g g a g g g c a tt  tc tc c a tc tc   tg ta c a g a g t 
tg c a tg c a c t  a ttc c a tg tc   c a tg c
q c c tg a c a tt  cccaccacc t  ta c ta a tg c c  
aag g aag ctg   a tc c g c tg a g   ta a tg g c tc a  
c a tc tg ’ta c c   a a a tc a a g c a   g ctg caag cc 
a tg a a tg a a a   ta g g c tg g tc   tg c a g tg a g c
g g ta a ttc c t  g g g g ttcag a  a tg ta t a ttg  
tc c c a g tg g c   c tg a c tg a g a   g ttg a a a c tt 
a a a a tta ttg   aggcgactga  tg aaaatg g g  
tc a g tg a c a a   a a c tta g c c g   t g t t a t g t a t
t t t t c a t a g a   g c a tttg a a a   a ccaaacact 
t q c t t t g tg g   t t c t t c a t t c   t t c t c t c c t t  
tt a a a tg tc a   c t g t g t t t c t   g a a tg a a tc t 
c c tc c g a c ta   agcagcagga  tg g a g a a c tg  
agtg cagg g a  tttc c g ta a g   tc ta a a c c c t 
c tt g c t g g tt  ta c t tc a g tt  tta g a a g c tt 
tg a g tta g g c   aaggcaccExon 9 (293..446)
1  g tg c a tc tg c   ta c g tg c tc c   c tc tc ttc c a  g a a g c ttc tt  ta g g a c c a c t c ta a g tg c c a
61  tg c c c tc a tg   g c c c ta g c tt  g ccaa tg c c c  c c c a a a a c tt  g a tg tta c a t c c tg tc c c ta
121  c c t g a c t t t t   g g ttc c a ttg   g c c a tg g c c t gagtgacaaa  g g a a tg c tg t g gaag tg tg g
181  c ttc tg g c c t  cg gacgtggg  c g g g a tg g c t tc c c tc a g a a   g g aactg tag  a tg c a c c tg c
241  a g tttg c c c a   g a c c tc a g tg   t t t t c a t t t c  c t c t c t t c c t   c tc tg tc tc c  ag aaagag ct
301  c ttg g a g g a a   g ttg g c c a g a   a tg g cag ccg  a g c tc g g a tc   tc tg ttc a a g  tc c a c a a tg c
361  ta c g tg c a c a   g tg a g g a ttg   c a g c c g tc a c  cagaggggga  g ttg g g c c c t tc a g tg a tc c
421  a g tg a a a a ta   t t t a t c c c t g   c a c acg g tg a g a g c ta ta c c   c a g ta a gggc tg a ta g g a tg
481  tg a tg g tc ca  g g cag tg cac  a g a ttg c c a g  a a a g t
Exon 10 (146. .299)
1  ta c a c a a a g t  g a g acctg cc  t a t a t t t g t a   g a tta ta a a a   g a ttta a c tg  a g ttc tg a a a
61  g c t t tg a c ta   t t t g t t c t t c   c c tg tta c aa  g c c a g tg ttt  c t c a t a ta tt tc a a a c c c a t
121  g a c tg g tc ta   t t g g t a t c t c   a c c a g g ttg g   g ta g a tta tg   c c c c c tc ttc  aactccg g cg
181  c c tg g caacg   c a g a tc c tg t  g c tc a tc a tc   tt tg g c t g c t  t t t g t g g a t t  t a t t t t g a t t
241  g g g tt g a t tt  ta t a c a tc tc   c ttg g c c a tc   agaaaaagag  tccaggagac a a a g tttg g g
301  ta a g tc tc c c   a g c ta a a a a t  g tttg c c cac  tg g ta ttg a c   a a g g ttg tta  ta c c a a g tg a
361  t t a t g c c t t t   c c tg ttg g g c   c a g c tg c tta   c a ttg c tc c c   a g atg g ctg c c c tg c c tta t
421  g c a ta c c c tg   g gctcag g ca  g c ttc c tg a c   tta c g c c a tg   g tc ta c a g a a  gcagctgcca
481  gcaaaagcca  g g c c tg a a a a   g g g tt c c ttt  acagagaaga  g ta tc a g ta g  g c c tttg c t
Exon 11 (182..267)
1  c a a ta ttg c c   a a g ta a g tc t  a a a a ta a a tc   aaaggaaaga  a a c a c g tttc  ttc ta g g g g g
61  a a a g c ttttg   ttg ta g a a g a   g c c c a ttg a a   aagcggaagc  tc tg ta g c a t c c ttg tg g a a
121  tc a g tg c c tg   cc c c a g ta q c   c c t q t t t t t a   ta q tq a a q ta   t c t t t g t t t t  c a ttc a c c c a
181  g g a a tg c a tt  cacagaggag  g a ttc tg a a t  ta g tg g tg a a   tta ta ta g c a  a a g a a a tc c t
241  tc tg tc g g c g   a g c c a ttg a a   c tta c c tg ta   a g ttg a c tt t  c a t t t c c c t t  tttg g c a a a a
301  g tta a a a ta g   t t qagaacaa ag aagg atca  a ta g a c a q a t  ttc ta a c a a a  ag ccaaag at
361  g tcg aagaag   a a tg g a ta tt t t t a a t g t a c   a a a a tg tc tt  taaaag cag c a a g ta g a ta g
421  ccag
Exon 12 (99.. 194) and 13 (911..991)
1  g g a a t g t ttt  a tta ta c a g g   a c t t t a t t t c   a t t t t a a t t a   t caag tg aaa gaaaacacqc
61  t g a c a a t t t t   tg ta c a ta c t  a tg tta c tc c   t t t t t c a g t a   c a ta g c ttg g  g a g tc a g tg a
121  g g a a c ta c a a   a a ta a a c ta g   a a g a tg ttg t  g a ttg a c a g g   a a tc ttc ta a  ttc ttg g a a a
181  a a ttc tg g g t  g aag g taag c  a a ttta a a g t  a a t t c t t t t a   a a a tqtgqga ta a g a a g q ta
241  g c a g tttaga  a t a a t t c t t t   a a c a ta ta t t  ta tta a a ta a   a a ta g c a tc t c a g g a c tc tg
301  a g tta ta c ta   tg g a ta g tta   t a t t t t a t t a   ttta a a a tg a   ta g a c ta ttg  a tt tttg a a a
361  c tc a g a tc tg   g c a c a tg a a a   a g a t t c t c t t   c a a tg c c ta g   cacatacag g  tc c ttg a a a a
421  a t a t t a a t t t   t c t t t c t t c a   ttg a a a a g c a   t g t a a t t c a t   tg a g ta g ttt c c ta tg ta c t
481  t t a a g t t t a t   t c c t c t a g t t   c tta a g ttc a   t t g t t c t t g g   c a c c tttc ta  a tta g g a a c a
541  a a a a tg a a a a   t a c g t a t t t a   a c ttg tta a g   t t g t t c t t a g   g a tg a a tg a t a a tg g ta tta
601  a a a g tttg tg   c ttta a a a a c   tt c a a ta a ta   t t t t t c a t g t   t c t c t t c t a a  g tg tc ttg g a
661  tt g g t t a t a a   tg c tta a ta a   a g tg a tg a g c   aaaggtaggc  ccaagccacc c a a g c tc g tg
721  acaagcagga  g actag agcg   tg g c g c a tc a   c c c tg g tttg   c g a tg tg g g t ggcctgggca
781  g g c tc tg c c t  g g c tg c c c g t  g g g tg a g ttg   c tc tc a ta c c   acatg aaacc a g c a g c tc tg
841  g c a c tg ta g c   a t t t c t q tg g   tcag g gaaq a  g ttt q c acaq  tg tc c a ta c a  g g t g t t c t t t
256901  c a c ttc a c a g   g a g a g tttg g   g tc tg ta a tg  gaagg aaatc  tta a g c a g g a   ag atg gg acc
961  tc tc tg a a a g   tg g c a g tg a a   g accatg aag  tg tg a g tta t  c a g tg a tg a a   t c c c a t t c t t
1021  cta g g g tg g g   cag ttg c tt c   a g ta ttg g g t g c tc c a tg a g   g c c a ta tg tc   a c a a tc tc a g
1081  ttc c c a g tg g   gccagaaggc  a a tg tg g a a c  a
Exon 14 (184..276)
1  c tg tttg c c c   c t c t c t t a t c   tc c c c ta g c c   c ta c ta g c c c   ctg acaacca c t c a t c t g t t
61  t c c t g t c t c t   a t a c t t t c a t   c tc ttc c tg a   c c tg g g tttt  agagaacaga a c tg c tg ttg
121  ccc a c c c a c t  c c c c tta a tt  g a g ta a a tta   tc c a ta c tta   a c c t t t t c t a  t t t t c t c c t c
181  ta g tg g a c a a   c tc ttc a c a g   cg g g ag atcg   a g g a g tttc t  cagtgaggca g c g tg c a tg a
241  a a g a c ttc a g   c c a c c c a a a t  g tc a ttc g a c   ttc ta g g ta c   ttc c g a g a a a  tg c a g g a g tg
301  ggtggccaag  agggc tc tq c   tg a tc tg c tc   tg tq ccaaag  g a a a a a a tc t c tg g tg ta g a
361  ta a g ttta c
Exon 15 (144..262)
1  c a g a g tg tg a   g tta g g c g c t  c t t g a t t t t t  tc a a a c tg tt  a a c ttg g ta a  c a c a c g g c tt
61  c a g t t t t t c c   a g tg g tc c a c   g a g g g c tttt c tg g tc a c a q   taacaag g ac t c t t t g t a a t
121  tg a tg c tg tg   t t t g t a a t t t   c a g g tg tg tg  ta ta g a a a tg   a g c tc tc a a g  g c a tc c c a a a
181  g c c c a tg g ta   a t t t t a c c c t   tc a tg a a a ta  cggg g acctg   c a ta .c tta .c t t a c t t t a t t c
241  c c g a ttg g a g   acaggaccaa  a g g ta a tg a t c tc c t tg tg t  ta c c c c tg a a  ca c ttc tc a g
301  g g c tta tg tg   a c tta g c c a g   g acaaccaaa tc a tc ta a tc   ttg a a a g tg a  agccaggaag
361  gagaggacgt  t g a c t t t t g t   tc a g tg c tc c  c tg tg tg
Exon 16 (292..401)
1  g g a tc a c g tt  tg a c c tc a ta   c c ttc ta a a a   ag aaacaatg   tc a ttc a c tg  t a a a t a c t t t
61  ta a a g a tg g g   gaaaagagaa  t a t g a t g t t t   g ccaagaag t  t t a a g g t t t t  t c t c a t t c c t
121  tt tta a a a a c   c t t a t t t g t g   a ta tta g tg a   ta g g g a a a ta   a a a g a tttg t t t c c t t a t t t
181  c a tc a c ta c a   c tg ta a ta a a   tta a a g c a tc   c ta a a c c c c c   cccggcagaa a c tg c ttg c a
241  a g t t t t c c t t   ttta a a a g a t  a g t c t t t c t t   c t t g t t t c c t   c ta tc a tc ta  g c a ta ttc c t
301  c tg c a g a c a c   ta t t g a a g t t   c a tg g tg g a t  a ttg c c c tg g   g a a tg g a g ta  tc tg a g c a a c
361  a g g a a ttttc   ttc a tc g a g a   t t t a g c t g c t   cgaaacbgca  tg ta a g a g tc  c tc g g c ta tc
421  ctg g aag g g t  ttg g a c c tc a   tg g tg tttg g   t c t t t g c a gg  g tta g tg a g a  g g a c c tg ttc
481  c tg tt ta g a t  aggcaaggaa  g c tg c a g tc a   gcgggggatg  g tg tg g c ttg  c tc c g a a g a t
541  g g aaat
Exon 17 (159..318) and 18 (995.. 1131)
1  g c tc tg c c a t  tg g tc c c a a t  g c a g c a tg c t  cacaggctgg  tg g tg tc tc t g t g t t c t t t t
61  g g tc a a tta t  c a ta a g t g t t   ttc a c c tg tg   tc tg a ta c a g   a c c a g ta a tt ta a g g c a ttg
121  c c tc tg a c g c   tg c tg a a g a c   g ta a c c tg c t  c tc tg ta g g t  tg c g a g a tg a  c a tg a c tg tc
181  tg tg ttg c g g  a c ttc g g c c t  c tc ta a g a a g   a ttta c a g tg   g c g a tta tta  ccgccaaggc
241  c g c a ttg c ta  a g a tg c c tg t  ta a a tg g a tc   g c c a ta g a a a   g tc ttg c a g a  c c g a g tc ta c
301  a c a a g ta a a a   g tg a tg tg g t  a tg ta c a c a g   c t t t g a t t c a   ggggtcccac agcacaaaga
361  qgagqgcata  ttg a a a g a a a   tg a c c tc a g c   tg g ta tg g c a   a g a c a tttta  c t c t ttg a ta
421  a a c tg a g g g t  tg g c a g c ttg   c tc a g a tc tc   t t t t a t a t c t   ta c c a tc a g a  t a c t t t a a t t
481  caag tg gaac  a g ta g a ttc t  g a tg a a g tg t  c c tg a c a ttc   a g a a g a tg tg  tg c tttg c a a
541  a a g c c c tta a   t t t c t t c c c a   t t t t t c c t t g   ccg tcaaag g   a tg a c tc a tt g cccacaact
601  a g g a ta tttc   a ta g tc a c a t  ta a a ttg a a t  g a g ttc a tc c   a c tg g c tc tt g gaacctaga
661  tg c ta ta tg a   a a g g tg c tg t  g ta a tta c g c   c c ttg a c c c g   ag ataag gaa aaaaaagcac
257721  ctcacag caa  cagtggagga  g ag cactaag   c a g a tg tg tg   acg a g g c tg t t t c t g c c t t t
781  g c c a g a tttc   ccagaacagc  t t ttg ta g a a   g tg g g g aact  g tg a c a c tc c  aacc c c a c g t
841  ta ttg c c g c g   ttgg g agag c  a g tg c g tc tc   a c a c a ta a tt  g c c a g c tttg  tg c a tg a tc a
901  tc a g tg tt ta   aggaaatgac  c tttc c c a g t  g aaaaagtcc  a ttc a g g c tt tg tg g a a a g g
961  c tt q c a tc c t  a a c ttg ttg t  t g c t t t g t t c   ccagtgggca  tttg g c g tg a  c c a tg tg g g a
1021  a a ta g c ta c g   cggggaatga  c tc c c ta t.c c   tg g g g tcc a g   aaccatg ag a tg ta tg a c ta
1081  t c t t c t c c a t   ggccacaggt  tg aag cag cc  cg aag actg c  c tg g a tg a a c  tg tg a g tg g g
1141  c t t c tc tg tc   tc c c ttc c a t  a c tc tg c a tg   gggcagccac  c tg g c tc tg c  a c tg a c c tc g
12 01  gaaacacaqc  catgggaggg  gaaagg g act  g c tg tta g c c   an g tg g g cat gtgcagaggg
1261  gtggaaccca  cagacacccc  agcccaggag  c c a ttc c tg a   tg tg g g a g a t a g tg tg tg g t
1321  a tc tc c a g tg   ag
Exon 19 (234. >747)
1  a c tg c c a c a t  a tg tg c tc tt  c c ta g a a a c a   g a a tc a c ttt  tt tg tc a a a t accatg g aac
61  a ttta c a a a a   g ttg ta ta a a   ta tta g g c c a   ccaa a a a a g t  c tc a a ta a tt ttta ta a a a a
121  g ta g a a tg a a   tg c tg a tta a   a a tg tg a ta a   a g a ttc tg ta   aaaacaaagg c a tg g a ttg c
181  acaaag agat  qgqtqc c a tq   ctg g g ag aca  a tc c a c ttc t  t t t t a a c t t t  c a g g ta tg a a
241  a ta a tg ta c t  c ttg c tg g a g   a a c c g a tc c c   tta g a c c g c c   c c a c c ttttc  a g ta ttg a g g
301  c tg c a g c ta g   a a a a a c tc tt  a g a a a g tttg   c c tg a c g ttc   ggaaccaagc a g a c g tta tt
361  ta c g tc a a ta   c a c a g ttg c t  g g a g a g c tc t  gagggcctgg  cccag gg ctc c a c c c ttg c t
421  c c a c tg g a c t  tg a a c a tc g a   c c c tg a c tc t  a ta a ttg c c t  c c tg c a c tc c  ccg cg ctg cc
481  a tc a g tg tg g   tc a c a g c a g a   a g ttc a tg a c   a g c a a a c c tc   atg aag gacg  g ta c a tc c tg
541  aatgggggca  g tg a g g a a tg   g g a a g a tc tg   a c ttc tg c c c   c c tc tg c tg c  a g tc a c a g c t
601  gaaaagaaca  g t g t t t t a c c   gggggagaga  c ttg tta g g a   a tg g g g tc tc  c tg g tc c c a t
661  tc g a g c a tg c   tg c c c ttg g g   a a g c tc a ttg   cc c g a tg a a c   t t t t g t t t g c  tg a c g a c tc c
721  tc a g a a g g c t  c a g a a g tc c t  g a tg tg a g g a   gaggtgcggg  g a g a c a ttc c  a a aaatcaag
781  c c a a ttc ttc   tq c tg ta g g a   g a a tc c a a tt  g ta c c tg a tg   t t t t t g g t a t  t t g t c t t c c t
841  ta c c a a g tg a   a c tc c a tg g c
258